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Abstract 
 A three-part project was devised to investigate the origins of and potential 
methods to reduce the risk of occupational exposure to cytotoxic drugs. The first phase 
involved researching the current decontamination methods applied in UK hospital 
pharmacies, which manipulate cytotoxic drugs. The second phase evaluated practical 
decontamination methods, and the third phase investigated one intervention aimed at 
reducing or preventing contamination occurring in an isolator.  
 
 A questionnaire was sent out to ASU managers in NHS hospital pharmacies to 
gain information about the disinfection and decontamination procedures and products 
used. The practical decontamination methods investigated were mechanical removal and 
degradation by detergents (pH range from 1.7 - 13.2) and cleaning agents, and 
degradation by vaporised hydrogen peroxide. Analytical methods were developed and 
validated to recover and quantify the amount of cytotoxic marker drug remaining after 
the decontamination tests carried out in phase two, and to recover and quantify cytotoxic 
surface contamination from various surfaces in phase three of this work. This composed 
an attempt to evaluate the effectiveness of a closed-system e.g. PhaSeal® device for 
fluid-transfer, in reducing contamination produced from the compounding of cytotoxic 
drugs in an isolator. 
 
 The detergents and cleaning agents were effective in removing or reducing 
cytotoxic surface contamination. Alkaline detergents caused degradation of doxorubicin 
(maximum 81% at pH 13.2 after 1 hour exposure); the other detergents tested did not 
 xix
degrade the cytotoxic drugs investigated. Exposure to vaporised hydrogen peroxide (1.6 
g min-1 for 2 hours) caused the degradation of cyclophosphamide (98.9%), 5-
Fluorouracil (29.3%), doxorubicin (71.0%) and epirubicin (65.9%) when exposed in 
pharmaceutical diluents. The closed-system (PhaSeal®) device was effective in reducing 
contamination produced in an isolator from the compounding of cytotoxic drugs.  
 
 The risk posed by handling and manipulation of cytotoxic drugs and products to 
the operator and the environment may be reduced, if not eliminated by considering 
additional approaches to the methods already in place. Firstly, the application of 
effective decontamination methods; and secondly, by using an effective closed-system, 
for example the PhaSeal® drug transfer device in a controlled environment. 
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1.  Literature Review 
1.1  Literature Search Strategy 
 The references for the following literature review were retrieved as a result of 
searching databases from the Web of Science, Pubmed, Embase and Science Direct. 
A variety of search terms were used alone and in combination, to build a database of 
references for the study. 
 In general, there were plentiful references in this area of study. Additional 
information was gathered from various sources other than peer-reviewed journal 
literature, including textbooks, conference abstracts and posters, technical data files, 
monographs and the World Wide Web. Personal communications are also referred to, 
where their inclusion is of importance. All sources are referenced. 
1.2  Cytotoxic Chemotherapy 
Cytotoxic drugs are the only systemic treatment for cancer, and are used either 
as a single modality treatment, or in combination with adjuvant therapy i.e. radiation 
or surgery. The approaches of radiation and surgery often eradicate localised disease 
but may fail if the cancer has metastasized to other areas of the body. Surgery or 
radiation, or both combined with chemotherapy, have increased survival rates for a 
number of solid tumours.1 The clinical use of cytotoxic drugs is a paramount necessity 
in the successful treatment of cancer and the number of patients being cured of cancer 
successfully is increasing gradually every year.2 These drugs are also effective in the 
treatment of non-cancer disease. Effective chemotherapy may considerably improve 
the quality of life, and extend the life of the patient, even when there is a poor chance 
of survival. Patients receiving chemotherapy have lead almost normal lives due to 
relief from some of the symptoms of the disease, when previous treatment with 
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radiation or surgery has been unsuccessful, highlighting the immense benefit of 
chemotherapy as a palliative therapy.2 A more recent approach is to combine 
cytotoxic therapy with monoclonal antibodies (MABs) e.g. the addition of 
trastazumab to anthracyclines for the treatment of breast cancer. Direct administration 
of MABs has had limited success, but adjuvant chemotherapy with anthracyclines 
have been demonstrated to be superior with respect to disease-free and overall 
survival from breast cancer.3  
Cytotoxic drug use has increased gradually over time due to more agents being 
synthesised/discovered, the use of ambulatory infusion devices, combination and 
adjuvant chemotherapy and improved supportive care. However, cytotoxic drugs are 
not just selective for cancer cells and cytotoxic effects are also directed at the growth 
and reproduction of healthy cells. Single agents can be effective but it is more 
common to use drug combinations, increasing the possibility of inflicting cell damage 
in all stages of the cell cycle (see Figure 1 below).  
 
Figure 1. The Cell Cycle and the Relationship of Cytotoxic Drug Action to the Cycle 
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The only reason chemotherapy is feasible is that normal tissues may recover 
more rapidly, and the life of the patient is prolonged. The risk of adverse effects 
however, is not justifiable to healthy personnel; an estimated number exceeding 5.5 
million may be exposed to sub-therapeutic levels of these drugs in their occupational 
environment e.g. pharmacists, medical and nursing staff.4  
Cytotoxic drugs are classified according to pharmacologic action or effect on cell 
reproduction and encompass a diverse range of chemical structures: 
1.2.1  Covalent DNA-Binding Drugs 
 The covalent DNA-binding drugs are highly reactive compounds. They act as 
DNA cross-linkers by binding covalently to nucleophilic groups on cellular 
constituents. The nucleophilic groups of proteins or nucleic acids e.g. amino, 
carboxyl, sulfhydryl or imidazole moieties are substrates for chemical attack by the 
covalent DNA-binding drugs. They may also be referred to as alkylating agents, as 
the nucleophilic group which binds to the DNA is an alkyl group.1 Bifunctional 
alkylators are the most reactive as they are able to form more cross-linkages with 
DNA than monofunctional alkylators. These linkages can occur during any stage of 
the cell cycle. In general, they attack exocyclic oxygens and ring nitrogens.1 Some of 
the most damaging agents are those which methylate the O-6 position of guanine, 
producing a mutagenic and carcinogenic lesion if not repaired.2 There are six major 
groups of covalent DNA-binding drugs, five of these groups are alkylating agents.  
The covalent DNA-binding drugs are grouped as follows: 
 
Nitrogen Mustards 
The nitrogen mustards are cyclophosphamide (CP), ifosfamide (IFOS), 
chlorambucil, melphalan and mechlorethamine (nitrogen mustard gas).1 The proposed 
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mechanism of action is a multi-step mechanism: at neutral or alkaline pH, the β-
carbon of the chlorethyl chain undergoes intramolecular nucleophilic attack by the 
nitrogen, releasing a chloride ion.5;6 The aziridinium ion intermediate formed (a 
strained three-membered aziridine ring) is highly reactive and is subject to 
intermolecular attack by nucleophiles, causing opening of the ring and alkylation of 
the nucleophile.5;6 Typically, a covalent bond is formed between the drug and the N-7 
group of guanine.6 The nitrogen mustards are bifunctional alkylators. They contain 
two chlorethyl chains and can undergo another cyclization, forming a second covalent 
bond with another nucleophilic group. The biological effect observed depends on the 
result of cross linking between strands of DNA or between bases on the same strand 
of DNA.1 
The chemical structure of CP is shown in Figure 2 below. Both CP and IFOS 
(a structural analogue of CP), are oxasophosphorine pro-drugs and require metabolic 
activation in the liver by cytochrome P-450 mixed function oxidase before they can 
alkylate cellular constituents.1 
 
Figure 2. Chemical Structure of Cyclophosphamide 
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Nitrosoureas 
Carmustine, lomustine, semustine and streptozotocin are the nitrosoureas. They 
all contain one chlorethyl side chain; except for carmustine, which contains two 
chlorethyl chains (see Figure 3 below). They are bifunctional alkylators and are also 
carbamoylators.1 
 
Figure 3. Chemical Structure of Carmustine 
 
 
Aziridines  
The aziridines are thiotepa (see Figure 4 below) and triethylenemelamine.1 
They both contain a three-membered aziridine ring which is analogous structurally to 
the aziridinium ion intermediate formed by the nitrogen mustards.1 Mitomycin is an 
antibiotic aziridine, which acts as a bifunctional alkylator through a unique 
mechanism.1 
 
Figure 4. Chemical Structure of Thiotepa 
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Alkane Sulfonates 
The alkane sulfonates busulfan and myleran are both bifunctional alkylators. 
Busulfan (see Figure 5 below) reacts with nucleophiles through a rate-limiting 
reaction depending upon both the concentrations of the drug and the nucleophile.1 
 
Figure 5. Chemical Structure of Busulfan 
 
 
Platinum Compounds  
 The platinum compounds include oxaliplatin, carboplatin and its analogue 
cisplatin (see Figure 6 below). They act as DNA cross-linkers, forming strong 
covalent bonds to produce platinum abducts. Antineoplastic activity results from an 
interaction with DNA, forming both intra-strand and inter-strand cross-links by the 
displacement of nucleophilic atoms, particularly the highly reactive 7-nitrogen atoms 
of guanine and adenine.1 Cross-links between adjacent guanines on the same strand of 
DNA are the most readily demonstrated.1 
 
Figure 6. Chemical Structure of Cisplatin 
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Methylating Agents  
The methylating agents are dacarbazine and procarbazine. These drugs cross-
link DNA by methylation, not by alkylation. Dacarbazine (see Figure 7 below) is a 
prodrug which undergoes cytochrome P-450-mediated oxidative N-demethylation in 
the liver before becoming an active species.1 After elimination of the 
methyldiazonium cation, 5-aminioimidazole-4-carboximide is the active methylating 
agent, which favours 7-guanine.1 
 
Figure 7. Chemical Structure of Dacarbazine 
 
 
1.2.2  Antimetabolites 
The antimetabolites structurally resemble natural metabolites necessary for 
cellular function. They inhibit de novo synthesis either directly by substitution as 
structural analogues of nucleotides and direct incorporation into nucleic acids, or 
indirectly by acting as substrates for cellular enzymes inhibiting nucleoside 
triphosphate production. In both cases DNA and RNA synthesis is inhibited.1   
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Pyrimidine Analogues  
The pyrimidine analogues are 5-Fluorouracil (5-FU), fluorodeoxyuridine, 
CB3717 and azacytidine. They act as direct inhibitors of the enzyme thymidylate 
synthase (TS).1 5-FU (see Figure 8 below) is a fluorine-substituted analogue of uracil 
and clinically is a very important member of this group. Within the cell, 5-FU is 
phosphorylated to a nucleoside derivative (5-fluoro-2’-deoxyuridine 5’-
monophosphate or 5dUMP) that competes with the natural deoxyribotide of uracil 
(deoxyuridine 5’-monophosphate or dUMP) for TS. Normally, TS methylates dUMP 
which is used for the synthesis of thymidine and cytosine in a multi-step process. 
When 5dUMP is the analogue substrate for TS, the catalysis process becomes frozen 
at an intermediate step, 5-FdUMP cannot be methylated, and the enzyme, the 
analogue substrate and the 5,10-methylene tetrahydrofolate cofactor become ‘locked’ 
in a stable covalent ternary complex. The trapped enzyme is then inhibited from 
catalysing thymidine monophosphate synthesis.1;7  
 
Figure 8. Chemical Structure of 5-Fluorouracil 
 
 
Purine Analogues  
 The purine analogues are mercaptopurine (6-MP), thioguanine (6-TG), 
tiazofurin, chlorodeoxyadenosine and pentostatin.1 6-MP and 6-TG are analogues of 
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hypoxanthine and guanine, respectively.1 6-MP (see Figure 9 below) inhibits multiple 
sites in de novo purine synthesis and interferes in the purine salvage pathway by 
substituting for hypoxanthine as a substrate for hypoxanthine-guanine phosphoribosyl 
transferase.7 
 
Figure 9. Chemical Structure of Mercaptopurine 
 
 
Folate Analogues 
 The folate analogues are methotrexate (MTX), aminopterin and 
trimetrexate.1;7 They are analogues of dihydrofolate and competitively inhibit the 
action of dihydrofolate reductase, the enzyme responsible for the conversion of 
dihydrofolate to tetrahydrofolate in the presence of NADPH.7 Tetrahydrofolate is 
further converted via TS to a coenzyme involved in one carbon transfers to form 
deoxyuridylate from deoxythymidylate, which is needed in abundance by rapidly 
dividing cells for the synthesis of DNA.7 MTX blocks the regeneration of 
tetrahydrofolate, preventing the synthesis of deoxythymidylate and ultimately halting 
DNA production. MTX (see Figure 10 on the following page) kills proliferating cells 
whether they are malignant or not, and as a result can cause significant toxic side 
effects.8  
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Figure 10. Chemical Structure of Methotrexate 
 
 
Sugar-Modified Analogues 
Sugar-modified analogues have an altered sugar moiety, rather than a base 
portion, and are derived from nucleoside analogues.1 Cytarabine, a nucleoside 
analogue from a Caribbean sponge1 (see Figure 11 below), and fludarabine are both 
sugar-modified analogues.  
 
Figure 11. Chemical Structure of Cytarabine 
 
 
Ribonucleotide Reductase Inhibitors  
Ribonucleotide reductase converts ribonucleoside diphosphates to 
deoxyribonucleotide diphosphates, and is the only enzyme whose activity is involved 
in the de novo synthesis of all the precursors required for DNA synthesis.1 This 
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enzyme is comprised of two protein subunits, one that contains a tyrosyl radical 
essential for the catalytic activity of the enzyme. Hydroxyurea (see Figure 12 below) 
is a ribonucleotide reductase inhibitor. Its action is to destabilise the iron centre 
needed to generate and stabilise the tyrosyl radical, thereby inactivating the enzyme.1 
 
Figure 12. Chemical Structure of Hydroxyurea 
 
 
1.2.3  Non-Covalent DNA-Binding Drugs 
 Non-covalent DNA-binding drugs bind to double stranded DNA forming a 
tight drug-DNA interaction. They all have characteristic planar regions that stack in-
between (intercalate) the base pairs, causing them to separate and the double helix to 
uncoil. The intercalators in routine clinical use are the anti-tumour antibiotics, the 
anthracenediones, the dactinomycins, bleomycin and pliamycin.1 
 
Anti-Tumour Antibiotics (anthracyclines) 
Doxorubicin (DOX), daunorubicin, idarubicin and epirubicin (EPI) are 
anthracycline anti-tumour antibiotics, which are isolated from different species of 
Streptomyces.1 They consist of a characteristic four-ring structure linked via a 
glycosidic bond to an amino sugar. EPI is an isomer of DOX. Daunorubicin and DOX 
are identical structurally, except for the presence of a hydroxyl group or hydrogen at 
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the 14 position of the anthracycline ring.1 See Figures 13 and 14 below for the 
chemical structure of DOX and EPI, respectively. The anthracycline antibiotics also 
interfere with DNA strand breakage and the reunion reaction of topoisomerase II.1 
Furthermore, they can be reduced to a semi-quinone form by NADP and NADPH, 
generating free radicals that can attack cell membranes and DNA, halting cell 
growth.1;8 
 
Figure 13. Chemical Structure of Doxorubicin 
 
 
Figure 14. Chemical Structure of Epirubicin 
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Anthracenediones  
 The anthracenediones lack of the sugar moiety of the anthracyclines, but retain 
the planar polycyclic aromatic ring structure that permits intercalation into DNA. 
Mitoxantrone (see Figure 15 below) is an example of an anthracenedione; 
 
Figure 15. Chemical Structure of Mitoxantrone 
 
 
Dactinomycin 
 Dactinomycin (see Figure 16 below) is an antibiotic from the actinomycin 
family. Amongst this family dactinomycin is the only drug which is used clinically.1 
 
Figure 16. Chemical Structure of Dactinomycin 
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1.2.4  Inhibitors of Chromatin Function 
 There are two main groups of chromatin inhibitors, the microtubule inhibitors 
and the topoisomerase inhibitors. The anti-tumour effects of these drugs are thought 
to be due to the disruption of chromosomal dynamics.1 
 
Microtubule Inhibitors  
 The microtubule inhibitors are the vinca alkaloids i.e. vinblastine (see Figure 
17 below), vincristine, (derived from the periwinkle plant), vindesine and vinorelbine, 
and the taxenes i.e. paclitaxel (sourced from the bark of the Pacific yew tree), and 
docetaxel.1 
 
Figure 17. Chemical Structure of Vinblastine 
 
 
 
 Microtubules are polymers comprised mainly of the protein tubulin and are 
responsible for cellular morphology and movement. The vinca alkaloids bind to 
tubulin and disrupt the balance between microtubule polymerization and 
depolymerization. This results in dissolution of the microtubules, destruction of the 
mitotic spindle and arrest of cells, ultimately inhibiting mitosis in metaphase.1 
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Paclitaxel (see Figure 18 below) disrupts the equilibrium between free tubulin and 
microtubles by shifting the equilibrium towards polymerization, forming abnormal 
bundles of microtubules.1 
 
Figure 18. Chemical Structure of Paclitaxel 
 
 
Topoisomerase Inhibitors  
 Topoisomerases are enzymes that are required to break and reseal strands of 
DNA, permitting selected regions of DNA to become unwound and relaxed to allow 
transcription and replication. There are two types of topoisomerases: topoisomerase I, 
which breaks one strand of DNA, and topoisomerase II, which breaks two strands of 
DNA. The inhibitors of topoisomerases I are amsacrine and camptothecin, and the 
inhibitors of topoisomerase II are the epipodophyllotoxins i.e. teniposide and 
etoposide.1  
 The enzyme topoisomerase II interacts with DNA, forming a non-covalent 
complex. It then cuts both strands of DNA and forms a covalently bound complex 
between each protein subunit and the 5’-phosphate end of the DNA. Inhibitors of 
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topoisomerase II, such as etoposide, stabilise this complex and prevent it from 
returning to the non-covalent complex. In the absence of enzyme inhibitors the 
complex may be subject to topological changes by strand passage or rotation, the 
breaks are resealed and the enzyme dissociates from the DNA.1 See Figure 19 below 
for the chemical structure of etoposide. 
 
Figure 19. Chemical Structure of Etoposide 
 
 
 As shown in Figure 1 (page 2), some cytotoxic drugs are phase-specific i.e. the 
antimetabolites and inhibitors of chromatin function, and cytotoxic effects are exerted 
within a specific phase of the cell cycle. Cytarabine and hydroxyurea are S-phase 
specific, MTX and mercaptopurine are S-phase specific (self-limiting), and vincristine 
and vinblastine are M-phase specific. The alkylating agents and anti-tumour 
antibiotics are cell cycle-phase non-specific and can kill cells in any phase of the cell 
cycle. Even so, they are usually more effective against proliferating cells and may 
show enhanced activity in a specific phase of the cycle.1;2  
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1.3  Health Effects/Occupational Exposure Risk 
 The International Agency for Research on Cancer (IARC) monographs 
represent the most authoritative and scientific series of chemical carcinogenesis 
information. The purpose of the monographs is to evaluate the carcinogenicity of 
agents, or environmental exposures, by evaluating the strength of published scientific 
data. The information provided by the monographs is used internationally to provide 
a scientific basis for cancer prevention. According to the IARC, at least nine 
alkylating agents have been classified as carcinogenic to humans (Group1); several 
have been classified as probably carcinogenic to humans (Group 2A i.e. the anti-
tumour antibiotics) and possibly carcinogenic to humans (Group 2B). A few (the 
antimetabolites and mitotic inhibitors) have been classified as not being carcinogenic 
to humans (Group 3) but are mutagenic and teratogenic.8;9  
 A risk of exposure of healthcare workers to cytotoxic drugs was first reported 
in the 1970s, when urine samples taken from nurses tested positive for mutagenic 
substances compared with non-exposed workers.10 Since then, increasing knowledge 
of cytotoxic drug toxicity has resulted in growing concern about the potential of 
cytotoxic drugs to produce adverse effects in healthcare staff handling these agents.  
 The acute health effects that have been associated with exposure to cytotoxic 
drugs include direct effects on the mucous membranes, eyes and skin.11 Symptoms of 
rashes, dizziness, nausea, vomiting,11;12 shortness of breath and hair loss have been 
reported and contact with skin cuts or needle-stick injuries can lead to severe soft 
tissue injury.11  
 An increase in the number of working mothers in recent decades has resulted 
in an affect on reproductive health and it is recommended that pregnant women do not 
work directly with cytotoxic drugs. However, pregnancy is often not acknowledged 
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until after the first trimester. Within the first 3-month period of the pregnancy, the 
handling of cytotoxic drugs may still be routine, posing a potential risk to the unborn 
child. There are 45 cytotoxic drugs listed as Pregnancy Category D by the Food and 
Drug Administration.13 Category D includes drugs where there is evidence of risk to 
the human foetus, but in the therapeutic setting, benefits may outweigh the risk for 
pregnant women who have a serious condition that cannot be treated effectively with 
a safer drug. Five drugs are listed as Category X where there is clear evidence that the 
medication may cause abnormalities to the foetus, but the risks outweigh any potential 
benefits for women who are or may become pregnant.13 MTX is one of the five drugs 
classified as Category X by the FDA.13 In a study of the effects of the handling of 
cytotoxic drugs by health workers, menstrual cycle changes among nurses have been 
reported.14 Further studies have suggested that women exposed to cytotoxic drugs 
during or shortly prior to pregnancy are at an increased risk of miscarriage,15;16 
premature delivery and low birth rate.17 However, no effects on pregnancy outcome 
have been reported.18   
 Evidence of the effects on the health of staff handling cytotoxic drugs is 
conflicting; the studies reported vary in design, the level of exposure and the scale of 
measurement. Many of the studies were conducted in the 1970s prior to the 
implementation of safety standards, and do not reflect current working practice. To 
standardise the results, a meta-analysis was conducted that combined and reviewed 14 
studies carried out between 1996 and 2004 in the U.S and in Europe. Of these 14 
studies, the 7 that were eligible for pooling concluded that insufficient evidence was 
available to estimate the risk of cancer or acute cytotoxic effects. No significant 
association between exposure and stillbirths or congenital malformations were 
measured, but a small increased risk of spontaneous abortion was identified.19 This 
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review highlights the lack of data for statistical pooling, and the need for more recent 
health studies carried out to evaluate the latest safety measures. Studies are required 
that assess the health effects among humans from exposure to non-therapeutic, 
environmental levels. 
 The chronic effects due to long-term repeated exposure to small quantities of 
these drugs are more concerning, and the actual risks from skin contact, inhalation or 
dermal penetration are not fully known.20 There are no data correlating the number of 
declared symptoms with, for example the frequency of exposures, the drugs exposed 
to, or the extent of personal protection adopted. Although various adverse health 
effects have been documented,18;19 the effect of regular exposure to several drugs over 
long periods is difficult to quantify.  
 The effects of long-term exposure can only be assessed over time, thus the 
results of most studies are based on the occurrence of secondary cancers from chronic 
exposure. Many cytotoxic drugs, and some drug combinations, have been associated 
with the development of secondary malignancies, most commonly leukaemia and 
bladder cancer in patients undergoing potentially curative chemotherapy.21 In terms of 
occupational exposure, a significant increase in the incidence of leukaemia among 
oncology nurses has been reported.18 As a result of limited available exposure data to 
assess the cancer risk, animal data, and primary and secondary tumour occurrence in 
patients receiving CP was modelled.22 From the available dose-response data and 
excretory amounts of the drug in urine, a theoretical increase in the risk of leukaemia 
and bladder cancer exceeding the ‘target risk’ (no more than one extra cancer case per 
million per year for one compound) from exposure to this one agent was calculated.22   
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1.4  Cytotoxic Reconstitution Services  
 Changes have occurred in the last few decades concerning the way cytotoxic 
drugs are prepared in hospital pharmacies. Cytotoxic reconstitution services allow for 
the preparation of drugs, under controlled conditions, by appropriately trained staff. 
These services not only improve occupational safety but also patient safety.23 The 
type of cytotoxic reconstitution service is defined locally. The service may be situated 
close to hospital wards involved in cancer treatments as a satellite to the main hospital 
pharmacy, or it may be centralised in the main hospital pharmacy, or cytotoxic drugs 
may be supplied by a single commercial unit to several hospitals within an area.24 
 Many European countries have made significant moves towards specially 
designed centralised units for cytotoxic drug preparation, usually Centralised 
Intravenous Aseptic Services (CIVAS) within the pharmacy. Drug reconstitution in 
these facilities, is an aseptic pharmaceutical procedure that is carried out under the 
direct control of a pharmacist, away from the patient. This leads to a minimal amount 
of activity on the ward, a reduction of medication errors and centralisation of the risk 
to occupational exposure in the hospital.23 In the UK, the Medicines and Healthcare 
products Regulatory Agency (MHRA) regulate this practice, and health and safety 
aspects are regulated by the Health and Safety Executive (HSE). In these facilities, 
pharmacists are less likely to be trained in cytotoxic drug preparation i.e. pharmacy 
technicians and assistants are usually trained ‘in-house’ to manipulate cytotoxic 
drugs. Issues concerning the safe handling of cytotoxic drugs are therefore of 
particular importance to these personnel.  
1.5  Routes of Exposure 
 Despite the implementation of collective protective measures, many 
international studies have demonstrated evidence of exposure to workers.25-31 To 
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reduce the risk it is necessary to consider all possible sources of the exposure. 
Workplace contamination and subsequent worker exposure may result from several 
sources during cytotoxic drug preparation and administration. The sources and routes 
of exposure resulting from cytotoxic drug preparation and administration are shown 
schematically in Figure 20 on the following page. 
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Figure 20. Schematic Diagram Showing the Routes of Exposure from the Preparation and Administration of Cytotoxic Drugs 
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 Exposure through inhalation and skin absorption are the primary sources,4 and 
are likely to occur from actions taken during the preparation process and from pre-
contaminated sources such as the outside of drug vials.  
1.5.1  The Preparation Process and Routes of Contamination 
Cytotoxic doses can be harmful to the patient if they are not prepared 
correctly. Prior to administration to the patient, cytotoxic dose preparation involves 
reconstitution, as many are supplied as lyophilized powders because they are unstable 
in solution, volume adjustment and dilution.  
Inhalation has been attributed to the airborne contamination of drug particles 
or droplets.8 The employment of fluorescent markers has been used to identify routes 
of contamination, as the majority of cytotoxic drugs are colourless and odourless and 
are not visible to the naked eye. Spiking a solution with a dye is a useful tool to 
demonstrate drug leakage into the environment during simulations of preparation and 
administration.32 Using this method, the production of aerosols was observed from the 
aseptic transfer of a dye solution to occur in the following ways; by withdrawing a 
needle from an over-pressurized drug vial; the withdrawal of a needle from the port of 
an IV bag; the simulated drug administration and the push of the solution into an IV 
port; transferring drugs using syringes and needles; crushing tablets; breaking open 
ampoules; expelling air from a drug-filled syringe and connecting and disconnecting 
to infusions.32;33  
 Drug particles may also become airborne after contamination on surfaces e.g. 
surfaces inside the isolator or biological safety cabinet (BSCs), gloves, vials or trays 
has dried. It has been reported that carmustine, IFOS, thiotepa and CP may vaporise 
from surfaces at room temperature, and the vapour pressure of CP is three times 
higher at 40ºC compared to 20ºC.34 Certainly, temperatures higher than room 
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temperature may be reached under normal working conditions, where cytotoxic drugs 
are manipulated. This may be due to the continual running of isolators and BSCs, or 
the use of ancillary equipment e.g. lighting and the running of pump motors. Particle 
size also influences the rate of vaporisation and small drug particles may vaporise 
within seconds or minutes.34 Aerosols or drug particles may settle on immediate 
surfaces in the environment and be picked up i.e. on gowns, gloves or shoes and 
transported to other areas, contributing towards surface contamination. 
 Inhalation alone cannot explain the levels in urine found in operators and 
evidence suggests that dermal contact and consequently skin absorption may also be a 
major route of exposure.20;30;35-37 Dermal exposure may occur through glove 
penetration, where direct contact with contaminated material may transfer 
contamination onto gloves.38 Successive use of the same syringe has also been 
implicated as a source of contamination. CP was shown to infiltrate onto the plunger 
of syringes, not after first usage but after several and increasing plunges of the 
syringe.39 This would contribute towards glove contamination and hence dermal 
contact, even in the absence of any manipulation errors. 
  Oral ingestion or accidental dermal exposure from needle-stick injuries, 
spillages or breakages are also potential routes of exposure.4 These events happen less 
frequently but contribute towards airborne contamination and long-term 
contamination of the workplace.  
1.5.2  Pre-Contaminated Sources 
Pre-contaminated sources may also contribute towards glove contamination 
and consequent dermal contact. It has been demonstrated that the external surface of 
drug vials are contaminated with the corresponding drug.40-42 In a study measuring 5-
FU contamination on vials available commercially in Belgium, 27 out of 90 vials 
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were found to be contaminated with traces of 5-FU.40 The levels found varied 
according to origin. Three of these vials were contaminated with quantifiable amounts 
of 5-FU, one as high as 18.1 ug mL-1.40 External contamination of the corresponding 
drug ranging from 0.5 to 24 µg per vial was also recovered on all vials filled with 5-
FU, etoposide, CP, IFOS, DOX and docetaxel.41 Quantities varied between drug 
batches supplied by the same manufacture, and between manufacturers.41 Carboplatin, 
cisplatin and MTX contamination have also been reported on the corresponding vial, 
and vials of CP have been reported to be cross-contaminated with IFOS.43 It is 
feasible that drug contamination on vials could also contaminate any corresponding 
external packaging. Certainly, 5-FU contamination has been recovered from the 
corresponding vial packaging, and as the vials themselves were also contaminated 
with 5-FU, they were implicated as the source.41  
A pre-contaminated source taken into an environment prior to any 
manipulations being carried out will contaminate gloves, and any surfaces the vials 
are placed or stored on. This may include surfaces in the preparation area such as 
bench tops, shelves, trays or the base of the isolator or BSC. The manufacturers’ of 
the drug have control over this source of contamination. Contamination during 
manufacture may occur during the vial filling process where splashing, foaming or 
dusting can occur. Accidental breakage of vials during freeze-drying, collisions on 
conveyor belts or turntables, and accidents during transportation can also happen.44 
Variations in the levels of contamination found on vials from different manufacturers 
indicate that any precautionary measures taken are not standardised.40;41 A study has 
shown that contamination can be reduced after the filling process, by cleaning the 
vials with a vial washer, and subsequent application of a protective sleeve. This was 
demonstrated on cisplatin vials, which were washed using a powerful stream of water, 
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which also decontaminates the base of the vial. Sleeves were then shrunk tightly 
around the vials to contain any remaining contamination and to serve as a form of 
protection. The effectiveness of this procedure was demonstrated when levels of 
platinum contamination on vials of the corresponding drug were reduced by 90%.45 
1.6  Control Measures/Risk Management/Safe Handling 
There appears to be little monitoring data in the UK on potential cytotoxic 
exposure to staff, albeit the considerable routine quality control test data for product 
sterility and patient protection.26 The handling of cytotoxic drugs occurs in a range of 
surroundings throughout the life cycle of the drug. It is not just restricted to the 
hospital pharmacy but extends to other populations through a complex chain; from 
production to transport and distribution; preparation and administration in hospital; 
nursing homes and home care environments; laundering; disposal and waste 
treatment. This involves many workers - production workers, transport personnel, 
pharmacists, pharmacy technicians and assistants, nurses, physicians, home carers, 
waste disposal personnel, transport staff and cleaning staff. It can also be extended to 
vets and researchers.46 These populations are potentially at risk from exposure to 
these drugs contributing a risk of toxicity to healthy cells.  
The interaction of various personnel with cytotoxic drugs from drug discovery 
through to waste disposal is illustrated in Figure 21 on the following page. 
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Figure 21. Life Stages of the Cytotoxic Drug and Identification of Personnel at Risk 
during the Various Stages of Drug Manufacture, Transportation, Storage, 
Compounding and Administration 
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Many countries have introduced statutory controls to protect the worker from hazards 
in the workplace: 
- COSHH (Control of Substances Hazardous to Health) UK; 
 
- HSE (Health and Safety Executive) UK: 
 
- OSHA (Occupational Health and Safety Administration) USA; 
 
- NIOSH (National Institute for Occupational Health and Safety) USA; 
  (an arm of the better-known OSHA); 
 
 
Non-statutory guidelines have been drawn up to provide recommendations on good 
practice: 
- OSHA Work Practice Guidelines 1986,47 199548 and OSHA Technical Manual;49 
 
- ASHP (American Society of Health-System Pharmacists) Handling Cytotoxic 
Drugs in Hospitals;50 and Technical Assistance Bulletins on Handling of 
Cytotoxic and Hazardous Drugs;51  
 
 - ISOPP (International Society of Oncology Pharmacy Practitioners) Standards of 
Practice. Safe Handling of Cytotoxics;52  
 
- HSE Personal Protective Equipment at Work Regulations 199253 and HSE 
information sheets;54;55 
 
- SHPA (Society of Hospital Pharmacists of Australia) Standards of Practice for the 
Safe Handling of Cytotoxic Drugs in Pharmacy Departments;56  
 
- RCN (Royal College of Nursing) clinical practice guidelines (1998); the 
administration of cytotoxic chemotherapy;  
 
- The MARCH (Management and Awareness of the Risks of Cytotoxic Handling) 
Guidelines.57 
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The MARCH guidelines were developed in acknowledgement of an absence 
of guidelines specific to chemotherapy pharmacy practice. They are in the form of an 
internet on-line service and cover all aspects of pharmacy cytotoxic services.  
 Although the specific recommendations of the guidelines vary between 
countries, the general principles are the same; controlled handling procedures, a high 
level of staff training and, if possible, CIVAS with working areas specially designed 
for cytotoxic containment. 
 Challenging the traditional assumptions about the safe handling of cytotoxic 
drugs is universal. Despite the implementation of collective protective measures 
many international studies have still demonstrated cytotoxic contamination in the 
surrounding environment,26;43;58-68 and in the urine of operators.25-31;69 So great is the 
concern in the U.S that NIOSH issued an alert in March 2005, to educate healthcare 
workers of the risk, and to provide guidance on implementing the best measures 
possible to protect their health.4  
There are no acceptable safe levels of exposure to cytotoxic drugs, therefore 
all the necessary measures possible should be employed to keep the levels to a 
minimum. The effects on health are specific to the drug, the route and amount of 
exposure and individual physiological variation. Published guidelines (as mentioned 
previously) have contributed greatly to increased awareness and have provided advice 
on the recognised risks at the time. One recent study reported a decrease in CP, 
although still detectable, in the urine of nurses since the introduction of guidelines in 
1997.69 Although many advances have been made, new improved methods to monitor 
employee risk are needed. Practical steps to prevent harm to the employee should be 
implemented and should include: identification of the hazards; procedures for 
emergency spillages including documentation of events; periodic evaluation and 
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updates of work practices to ensure safe procedures are being followed and that staff 
are regularly updated; written safe policies and procedures; and the provision of 
information and training in the occupational health aspect of manipulating and 
disposing of these drugs.11  
1.6.1  Engineering Controls (Biological Safety Cabinets and Isolators) 
There are two different workstation containment technologies used for the 
compounding of cytotoxic drugs. The design of these workstations is to contain 
hazardous materials as well as maintaining a high quality aseptic work area to protect 
the product. Isolators and BSCs are the main choice of use for the aseptic 
manipulation of cytotoxic drugs.  
 
Biological Safety Cabinets 
 In the 1980s, cabinets with horizontal laminar flow were in widespread use. 
However, it was strongly recommended that they were replaced with vertical laminar 
air flow, as the horizontal flow of air was thought to direct airborne contamination 
into the breathing zone of the operator.70-72 
 BSCs are a type of vertical laminar flow cabinet. Air channelled downwards 
through the vents at the front and back of the cabinet creates a curtain of air, which 
protects the operator. Figure 22 on the following page shows a diagram of a BSC 
(front and side view) with arrows indicating the airflow pattern. The large opening in 
the front fascia allows access into and out of the cabinet and movement of the 
operator’s arms working within. The effectiveness of the air barrier may be measured 
using the KI discus test method, as accepted by the European standard for 
Microbiological Safety Cabinets, EN 12469. This method involves applying a fine 
mist of potassium iodide droplets into the cabinet and measuring the portion of 
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escaped aerosol.73 However, this test is not suitable for hazardous drugs, which may 
vary in physical state i.e. solid, liquid, or gas, and particle size.24 BSCs are widely 
used in the United States and Germany.73  
 
Figure 22. Airflow Diagram of a Biological Safety Cabinet (front and side view) 
 
(reproduced with kind permission from Envair Ltd) 
 
 
Isolators 
Isolators are of a rigid or a flexible structure and are fully enclosed systems. 
They are designed to provide protection for the cytotoxic reconstitution and 
manipulation process from the outside environment. Operator access is via the front 
sleeve/glove port system, and introduction/removal from the isolator is via transfer 
hatches with interlocking doors. Isolators have built-in alarm systems warning of any 
system leakage or failure. See Figure 23 on the following page shows a diagram of an 
isolator (front and side view) with arrows indicating the airflow pattern. 
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Figure 23. Airflow Diagram of an Envair Model CDC-F Isolator (front and side view) 
 
(reproduced with kind permission from Envair Ltd) 
  
   
 Isolators are designed to operate under either positive or negative pressure. 
Negative-pressure will protect the operator in the event of a leak, and is favoured by 
the HSE,24 as opposed to a positive environment which favours product protection 
and is supported by the MHRA.74 The preferential pressure is debatable depending on 
favoured protection of the operator or the product.55 A study comparing positive with 
negative-pressure isolators was not definitive regarding operator exposure.26  
 Isolator technology is used widely in Europe and Australia and significant 
integration has been seen into French and UK hospital pharmacy practices. 
Integration of the isolator was initially slow but it has superseded the conventional 
BSC,74-76 and now approximately 90% of hospitals pharmacies use isolators in the 
UK.75 Current practice in the UK favours the use of negative-pressure isolators.24  
 The air in both isolators (including hatches) and BSCs is exhausted and re-
circulated via high-efficiency particulate air (HEPA) filters. These are glass fibre 
filters and are designed to trap particulate material of ≤2 µm from an air stream.77 
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However, levels of CP have been measured in the air while admixing in a BSC and in 
subsequent periods when no preparation was taking place.34 The authors hypothesize 
that drug particles retained on the HEPA filter or present on surfaces within the BSC 
may be acting as a reservoir, thus, providing a source from which the molecules may 
vaporise slowly.34 If this was a common occurrence, these filters would not be 
effective in retaining molecules of cytotoxic vapour, which would be smaller than the 
pore size of the HEPA filter. As a result, any cytotoxic aerosols generated would pass 
through the filter and re-enter the workroom, or in the case of air which is ducted 
externally, be released into the outside environment. It is therefore paramount to 
operator protection that whichever source is used, the air is exhausted externally away 
from the working environment.4  
 BSCs with vertical laminar flow were introduced as a superior measure of 
protective intervention, but with the development of more sensitive analytical 
methods it has been demonstrated that exposure is still apparent.58;61;71 The downside 
of BSCs is that they are very sensitive to changes in air turbulence e.g. operator arm 
movements may disrupt the air barrier compromising operator and product protection. 
Removal of the operators gloved hands after working in the BSC is a potential source 
of contamination to the external environment. CP, 5-FU and MTX have been 
quantified in the air, on the floor and on workbenches in drug preparation areas when 
work had been carried out in a BSC.28;58;61;64;66;71;78 Logically, isolator technology 
offering containment and either product or operator protection would appear to be 
more favourable. However, there is no firm evidence to support the superiority of 
isolators over BSCs. Isolators have limitations and there is the potential for 
contamination to pass through hatches from the main chamber to the outside 
environment. Cytotoxic contamination has been reported in both isolators and 
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BSCs.61 In a comparative study, 83% of wipe samples taken from isolators tested 
positive compared to 8.3% from BSCs. Contamination on the finished product was 
also measured with the result that 35 out of 72 samples, compared to 3 out of 72 
tested positive for cytotoxic contamination when prepared in isolators compared to 
BSCs, respectively.61 These findings may reflect increased difficulty in cleaning 
isolator workstations. 
1.6.2  Effectiveness of Personal Protective Clothing 
Gloves 
 Gloves are the first line of protection against contact with cytotoxic drugs; 
therefore, it is important that the glove material is tested for permeability to these 
agents. The OSHA guidelines for the safe handling of chemotherapy agents 
concerning personal protection advise against the use of polyvinyl gloves and 
recommend the use of latex gloves.47;79 However, issues have arisen over sensitivity 
to natural rubber latex with a possible allergic response.80 The nitrile polymer is more 
resistant chemically, and is stronger than the latex polymer, but gloves made of latex 
are thicker.38 Thick gloves may result in more discomfort during wear, whereas 
thinner gloves are preferable for dexterity and comfort. 
 Static permeability tests concluded that most gloves are impermeable or 
minimally permeable to cytotoxic drugs after certain periods of time.38;81 Carmustine 
and paclitaxel were the only 2 of the 18 drugs tested which permeated through glove 
material. Of the 864 glove samples tested, only 3 showed evidence of permeation, one 
through a latex glove permeated by carmustine at 90 min, and two by paclitaxel, 
which permeated a polyurethane glove at 60 min and a neoprene glove at 120 min.38 
Alcohol 70% v/v, which is used regularly and sprayed liberally onto gloves did not 
aid the permeability of six cytotoxic drugs in commercially available brands of latex 
  35
and nitrile gloves.82 Initially, these studies were encouraging. However, static tests 
are likely to underestimate the risk, and a study simulating latex glove usage 
demonstrated permeation, measured as breakthrough onto the cotton glove worn 
underneath when double gloving. CP easily penetrated the gloves after 10 min, 
followed by MTX after 62 min. The longer penetration time of MTX was attributed 
to its higher molecular weight (454.44 for MTX compared to 279.1 for CP).30  
 More rigorous tests using a device designed to subject the gloves to the 
dynamic conditions of rubbing, stretching and tension were carried out on 13 
different gloves and 13 cytotoxic drugs. Permeation was related to exposure, and 
increased with time. The highest resistance to permeation was observed generally in 
latex gloves with a thickness of at least 0.24 mm.83 The rate of drug permeation may 
be influenced by the thickness and composition of the glove, molecular weight and 
lipophilicity of the drug, the solvent into which the drug is dissolved, and the inactive 
ingredients in the drug formulation.24 In actual practice, factors such as temperature,84 
humidity and pH of the skin may also have an influence.83  
 Glove materials vary between manufacturers and it is impossible to test every 
cytotoxic drug with every glove on the market. It is recommended that low-protein 
(<50 µg/g) powder-free gloves are used,85 and double gloving carried out if it doesn’t 
interfere with dexterity. Gloves should be changed every 30 min and replaced 
immediately if torn or punctured.79 Special precautions to minimise glove contact 
should be adopted when working with low-molecular weight or lipophilic cytotoxic 
drugs i.e. nitrile gloves should not be used with etoposide,57 as some sources have 
demonstrated permeability.81 This may reflect the solubilisation aids present in the 
etoposide (vepeside) formulation. 
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Gowns 
 Gowns should be worn closed at the front with tight-fitting cuffs, which tuck 
underneath the gloves. They should be disposable, lightweight, low-lint and offer low 
permeability. The visible penetration (using fluorescein) and splash protection 
(beading on the gown surface) of six disposable gown materials with either water-
based or non-water based cytotoxic drugs was investigated.86 Polypropylene spun 
gowns were found not to be a sufficient barrier to the cytotoxics tested. Polyethylene 
or Saranax® (ethylene/vinyl acetate copolymer) gowns laminated with Tyvek® 
(spunbound polyethylene) were found to be the most protective barriers garments. 
The Saranax®/Tyvek® gown provided adequate splash protection and prevented 
penetration during a 1 min observation period of all 15 drugs tested.86 The 
impermeability of this gown was also supported by another study which studied 
absorbance of 6 drugs after a 4 hour exposure time.87 However, the least protective 
gowns were found to be more comfortable than those with polyethylene or vinyl 
coating. As protective garments increase in thickness, heat exchange by sweat 
evaporation is impeded leading to general discomfort - a factor that is important to 
ensure the gown is worn properly. Data are lacking to support the integrity of seams, 
and the protection provided during the preparation of large chemotherapy batches. 
1.7  Methods for Monitoring Exposure to Cytotoxic Drugs 
To identify the main exposure routes and to quantify potential health risks, 
biological and environmental monitoring are paramount to assess the occupational 
exposure risk to hospital personnel involved in the preparation and administration of 
cytotoxic drugs. The methods available to monitor exposure to cytotoxic drugs have 
been reviewed.8;88;89 They can be divided into biological effect monitoring, biological 
monitoring and environmental monitoring. 
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1.7.1  Biological Effect Monitoring 
Biological effect monitoring studies genotoxic, biological endpoints. Included 
in these methods are the cytogenetic methods sister chromatid exchange, 
chromosomal aberrations and micronuclei. These cytogenetic methods are non-
selective, laborious and expensive, and the results of studies are conflicting. Several 
authors have found an increase in the frequency of these endpoints,90-93 while others 
have failed to find a significant difference between workers and controls.94;95 
 Methods to detect DNA damage include point mutations and the Comet 
Assay.96 A limited number of studies have been reported using these methods to 
detect DNA damage, so it is difficult to assess the usefulness of these tests. The 
Comet assay has been suggested as being a potential tool to measure for early 
genotoxic effects caused by exposure to cytotoxic drugs.97 The first study reported 
using the Comet Assay to probe for induced DNA damage from cytotoxic drugs, 
showed nurses with an increase in DNA damage from the controls and less DNA 
damage in nurses using the required protection.96 
1.7.2  Biological Monitoring 
Biological monitoring methods can be either non-selective or compound 
selective.  
 
Non-Selective Methods 
Non-selective methods, for example urinary mutagenicity or thioether 
excretion, rely on the common properties of a group of chemicals to take 
measurements. Pharmacy personnel have tested positive for urinary mutagenicity, 
with the highest results recorded during the working week and subsiding to control 
levels when the exposure period decreased.70 Another study found negative results.98 
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Many studies have been carried out using variations of the urinary mutagenicity test. 
In a review of 29 studies, 14 were found to be positive, and 15 negative for urinary 
mutagenicity associated with cytotoxic drug handling.8 
The Ames test is used commonly to measure urinary mutagenicity by testing 
for mutagenesis in bacteria. Screening bacteria is a useful alternative to animal 
studies, but chemicals, which induce mutations in bacterial DNA, may not do so in 
human cells, therefore the test it is not a reliable predictor. The test is easy and not 
expensive to carry out, but lacks the sensitivity that would be required to detect the 
levels which may be absorbed by drug handlers occupationally, thus the suitability of 
the assay is questionable.99  
Studies measuring thioether excretion in urine are contradictory. An increase 
in urinary thioether concentration was observed in nurses handling cytotoxic 
drugs.100;101 Whereas another study of nurses concluded there was no relationship.90 
 The urinary mutagenicity and thioether excretion tests are limited as they can 
only be applied during the excretory period, generally 1 to 2 days.8 Furthermore, 
positive results are not fully conclusive due to background genotoxic levels i.e. 
smoking, diet and environmental factors. In conclusion, these methods may not be 
sensitive enough or interpreted correctly. A negative test result indicating no exposure 
could be due to the lack of sensitivity of the method, whereas positive results may 
occur due to the lack of specificity of the method, creating unnecessary anxiety to the 
employee.88;89 
 
Compound Selective Methods 
Compound selective methods include sensitive chemical-analytical methods, 
which are used to quantify the parent drug or its metabolites typically from urine, 
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blood or environmental samples. These methods assure the sensitivity and specificity 
that has been lacking in biological methods. Typically, these methods are developed 
to quantify one analyte. A HPLC method for the simultaneous analysis of five 
cytotoxic agents was developed which could be applied to measure airborne levels 
and surface contamination.102 Simultaneous analysis enables a broader risk evaluation 
to be carried out in a single analysis, although there is the risk of compromising of the 
sensitivity of the method.  
Instrumentation used for this work includes; high-performance liquid-
chromatography (HPLC) with either UV or fluorescence detection, often coupled or 
tripled with mass-spectroscopy to further improve the sensitivity; gas-
chromatography coupled with nitrogen-phosphorus electron capture or mass- 
spectrometry; voltammetry inductively coupled with plasma mass-spectrometry (used 
commonly to determine urinary platinum).66;103 Sensitivity is enhanced with liquid-
liquid or solid-phase extraction which pre-concentrates and cleans-up the sample.65 
Derivatisation methods may also be used to increase the sensitivity and improve the 
selectivity of the method for the drug of interest.104 
Using chemical-analytical methods, metabolites of cytotoxic drugs have been 
identified in blood and urine. α-fluoro-β-alanine, a metabolite of 5-FU was assayed 
for to measure 5-FU,44 6α-hydroxypaclitaxel and 3’-p-hydoxypaclitaxel were used to 
quantify levels of paclitaxel105 and 4-hydroxycyclophosphamide was used as a 
measure for CP in plasma and urine.30;106 CP (maximum concentration 0.76 µgL-1), 
IFOS (maximum concentration 1.90 µgL-1), DOX, EPI and platinum were found in 
the urine of 40% of pharmacy and hospital personnel in a German hospital,27 and 5-
FU and MTX tested positive in the urine of pharmaceutical plant workers for these 
two cytotoxic drugs.44;107  
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 Given the large number of drugs used in cancer chemotherapy, testing has 
been limited to a few marker drugs, typically those in frequent use and for which 
validated assays are available. All conclusions reached so far are based on the 
capabilities of the experimental conditions and the limit of detection (LoD) or limit of 
quantification (LoQ) of the analytical method.  
1.7.3  Environmental Monitoring 
 Environmental monitoring of cytotoxic drugs measures airborne 
contamination and contamination of surfaces, usually in the immediate environment. 
Chemical-analytical methods are used to quantify the levels of cytotoxic 
contamination after recovery from these areas. 
 
Air Sampling 
Air concentrations in cytotoxic drug preparation and administration areas have 
been measured by drawing environmental air through a filter and extracting the drug 
from the filter for analysis. The first data published on ambient air concentrations in 
preparation areas tested positive for environmental contamination of CP and 5-FU.71 
Studies have been carried out by means of filters of different materials i.e. PTFE, 
glass-fibre or filter papers, different filter pore sizes, and varying flow rates.29-31;72 
However, the concentration levels of the airborne contaminants, when present, were 
low in these studies, and may be due to the inefficiency of the method4 or the 
vaporisation of one of the marker drugs i.e. CP from the filter.35 Airborne CP was 
measured in a study where solid or liquid aerosols of CP were trapped by a glass fibre 
particle filter, and gaseous CP was frozen out in a cyrotrap.34 This setup demonstrated 
that the air in the workroom contaminated with gaseous CP was higher than 
particulate CP. This may be due to the possibility that particles are sporadically 
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released and are therefore distributed less homogeneously in the air compared to 
gases.35 It may also explain low levels of airborne particles found in previous studies. 
 
Surface Wiping 
 Wipe sampling coupled with analysis by chemical-analytical methods has 
been widely used to measure contamination on a range of different surfaces. 
Typically, these methods employ a collection matrix and a solvent system to aid 
recovery of the drug. Pre-wetted and dry wipes, filters pre-moistened with ethyl 
acetate, cellulose pads moistened with water and cotton wool have all been applied as 
the collection matrix. Aqueous sodium hydroxide, aqueous ammonium acetate, water, 
ethyl acetate, methanol and hydrochloric acid have been used to aid collection of the 
drug from the surface, or as a desorbing solution in which to recover the 
drug.20;28;29;42;58;66;108;109  
 Considerable amounts of contamination have been recovered from surfaces in 
pharmacy drug preparation areas (75% of samples) and in drug administration areas 
(65% of samples) in a six site study carried out in Canada and the United States.58 
The levels of cytotoxic drug contamination, and the areas in drug preparation and 
administration where various studies have confirmed contamination, are documented 
in Table 1 on the following page. The reporting of the widespread contamination of 
surfaces makes the possibility of skin contact more likely. 
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Table 1. Levels of Cytotoxic Drug Contamination Recovered from Surfaces in Drug 
Preparation and Administration Areas 
 
Area     Drug and Reference   Amount of Surface  
           Contamination 
 
Preparation Areas 
Inside the BSC   CP 28   1 - 160 ng cm-2  
     MTX 28    2 - 623 ng  cm-2 
 top side of BSC airfoil  5-FU 58   110 ng cm-2 
 bottom side of BSC grill 5-FU 58   209 ng cm-2  
     CP 58    66 ng cm-2 
     IFOS 58    459 ng cm-2 
 tray of BSC   MTX 109  0.02 - 6 µ g  m-2 
 
Floor in front of BSC  5-FU 28    48 - 236 µ g  cm-2 
 
Gloves    5-FU 28   5 - 980 ng cm-2 
     CP 26   100 - 5993 ng per glove  
     IFOS 26   99 - 1159 ng per glove  
     MTX 26   24 - 890 ng per glove  
     MTX 109  20 - 1900 µ g per glove 
 
Floor in preparation room  5-FU 58   40.8 ng cm-2 
Floor outside preparation room  5-FU 58    2.31 ng cm-2 
 
Floor in preparation room where Pt 26   5 - 130 ng cm-2 
an isolator was used for  CP 26   625 - 1596 ng  cm-2 
preparation    IFOS 26   61 - 1503 ng  cm-2 
     MTX 26   20 - 674 ng  cm-2 
 
Sink    CP 20    <0.005 ng cm-2 
     5-FU 20    <0.98 ng cm-2 
 
Fridge door handles   CP 20    <0.002 ng cm-2 
     5-FU 20   < 4.3 ng cm-2 
 
Waste bin    CP 66   1286 pg cm-2 
     Pt 66   2700 pg cm-2  
     IFOS 66   28 pg cm-2 
 
Storage shelves   CP 66   5106 pg cm-2  
     Pt 66   2700 pg cm-2  
     IFOS 66   1860 pg cm-2  
 
Telephone    MTX 108  11 µg m-2 
 
  
Administration Areas 
Floor    CP 8   <0.02 - 4.5 µ g cm-2 
 
Tables    CP 8   0.2 - 4.5 µ g  
     5-FU 8   4.9 - 22 µ g 
 
Pt = platinum from platinum-containing compounds i.e. carboplatin and cisplatin 
  43
Immersion/Rinsing Techniques 
The application of immersion techniques, coupled with analysis by chemical-
analytical methods, has enabled cytotoxic residues on the surfaces of cytotoxic drug 
vials to be quantified.41-43 Typically, this involves rinsing the object or immersing it 
in a suitable solvent, with agitation for a defined period of time, followed by 
collection and analysis of the solution. Immersion and rotation of stoppered vials in 
water for 30 sec was adequate to remove and measure 5-FU, etoposide, CP, IFOS, 
DOX and docetaxel contamination on the external surface of drug vials. This same 
method was effective in measuring cytotoxic contamination on packaging.41 
Potassium hydroxide (0.01 M) has also been used as a rinsing/immersion solution to 
recover the external surface contamination of 5-FU on vials of the corresponding 
drug.40  
Immersion techniques are also applied to measure cytotoxic contamination on 
gloves. Typically, the gloves are placed into a container of desorbing solution and 
agitated for a defined period of time, followed by collection and analysis of the 
solution.28;68  
Solvents selected to aid collection of the drug from a surface and desorption 
of the drug into a suitable desorbing solution are likely to be drug specific. The 
solvent chosen depends on the solubility of the drug, pKa values, solvent pH, stability 
in the solvent and solvent compatibility with the analytical method. 
1.8  Removal of Contamination and Degradation/Inactivation of Cytotoxic Drugs 
The effectiveness of removing cytotoxic residues from surfaces during 
cleaning is not often considered. Ideally, cleaning after the manipulation of cytotoxic 
drugs should involve the physical removal of drug contamination from a non-
disposable surface to a disposable surface and drug breakdown into less toxic 
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compounds.35 NIOSH recommends that all surfaces are cleaned according to a 
protocol that includes an appropriate detergent if available, which may be a 
deactivation agent.4 The agent used should preferably remove/breakdown biological 
and chemical contamination,4 and be compatible with the surfaces to which it is 
applied.110  
Cytotoxic drugs represent a diverse range of chemical structures and OSHA 
recognises that there is no single accepted method of chemical deactivation for all 
cytotoxic drugs used currently.79 Previous methods have involved the use of acid and 
strong oxidising agents,111;112 at concentrations which are too harsh for use on 
sensitive equipment in the hospital environment.113 In 1985, the IARC included 
cytotoxic drugs in its program for the treatment of contaminated waste.114 Studies 
carried out to investigate the efficacy of oxidising agents at acceptable concentrations 
i.e. sodium hypochlorite (5.25%), liquid hydrogen peroxide (≤30%) and Fenton 
reagent (30%) were suggested as part of a program to assess the efficacy of oxidation 
in degrading 36 cytotoxic agents.113 Sodium hypochlorite (5.25%) was efficient at 
degrading CP, melphalan, idarubicin, DOX, EPI, aclarubicin and daunorubicin to 
non-mutagenic residues above the LoD.113;115;116 Liquid hydrogen peroxide (≤30%) 
was also efficient in degrading CP, but less efficient in degrading DOX.113;115 
Treatment of DOX with sodium hypochlorite and Fenton reagent was more 
successful with >99.96% efficiency achieved in the same experiment.115  
1.9  Closed-System Containment Device 
Prevention of the primary contaminating event is more effective than 
removing the contamination once it has occurred, and will also prevent the transfer of 
secondary contamination.20 To prevent the primary contaminating event, NIOSH 
recommends the use of a closed-system drug transfer device to prepare cytotoxic 
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drugs. It defines a closed-system device as “a transfer-device which mechanically 
prohibits the transfer of environmental contaminants into the system and the escape of 
hazardous drug or vapour concentrations outside the system”.4 This is also supported 
by ISOPP, which includes in its guidelines (awaiting publication) that the system 
should be ‘leak-proof’ and ‘airtight’.52  
There are a number of products available commercially that declare safe drug-
transfer i.e. the Alaris Smart Site®, the Tevadaptor Vial™ Adaptor System, the Chemo 
Mini-Spike Plus™ Dispensing Pin, the Chemoprotect Spike®, and the PhaSeal® 
Protector 50 and Injector Luer-Lok. These five devices were tested to determine how 
effectively they contained vapour produced from the over-pressurization of a drug 
vial. Titanium tetrachloride gas generates a visible smoke and expands when it comes 
in contact with moisture in the air, thus moist air was injected into vials containing 
titanium tetrachloride to simulate gas-containing active drug into the 
environment.117;118 In comparison with the four other drug-transfer systems, the 
PhaSeal® system was the only one to prevent titanium gas leakage, concluding that it 
was the only device to offer a closed-system.117;118 Titanium tetrachloride was used in 
this study to simulate drug reconstitution as it has a molecular weight similar to 5-FU 
and CP.118 However, there has been some debate between the manufacturers’ of the 
Tevadaptor Vial™ and the supervisor of the study, regarding the validity of the study 
and the effectiveness of titanium tetrachloride as a substitute for a cytotoxic drug 
vapour.119-121 The Tevadaptor™, Alaris® System and PhaSeal® system were tested 
further for containment (unpublished work) when simulating cytotoxic preparation 
and administration using a fluorescent dye solution. No leakage was observed when 
using the PhaSeal® device, but it was observed when using the Tevadaptor™ and the 
Alaris® System.122 In-house testing by Teva (unpublished work) using wipe sampling 
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and radioactive analysis of possible leakage demonstrated the Tevadaptor™ to be 
effective.123 Regardless of these various studies, the effectiveness of only one closed-
system device - the PhaSeal® device in reducing surface contamination has been 
published in peer-reviewed scientific journals.20;67;78;124;125  
A number of studies have been carried out comparing usage of the PhaSeal® 
device with standard reconstitution procedures.32;62;67;124 As a result of the findings of 
surface contamination in six cancer treatment centres in the United States and 
Canada58 the PhaSeal® device was evaluated in the a Cancer Center (U.S.), which at 
the time had been completely rebuilt with new equipment. The study demonstrated a 
significant reduction in surface contamination of CP and IFOS.78 The device has been 
investigated in research centres worldwide, including the MD Anderson Cancer 
Center, Houston, USA,78 Uz-Gent University Hospital, Belgium,67 University 
Hospital of Utah, Salt Lake City, USA126 and Japan.64 All these studies have 
supported a significant reduction of contamination when using the PhaSeal® device, 
i.e. in the Belgium hospital a 10-fold decrease in environmental contamination was 
observed when comparing the traditional method.67  
 A long-term study carried out in an outpatient oncology clinic in a Swedish 
hospital showed virtually no detectable environmental contamination after using the 
PhaSeal® device to prepare and administer CP and 5-FU over a period of 1 year.20 
The study was designed so that the drugs were prepared outside of a clean-room 
environment i.e. on the bench top in the drug preparation room without the use of a 
BSC. The staff involved in the study considered the PhaSeal® device easier and more 
efficient to use on the bench top than in a BSC. The turnover for preparation and 
administration of the cytotoxic drug was shorter due to the reduction of personal 
protective measures required to work in a clean-room, which are time consuming to 
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don and are expensive.20 However, this lack of protection in the form of ventilation 
would not be acceptable under UK standards of practice, which require that sterile 
dosage forms are manufactured providing optimal operator and product protection.  
The prevention of drug leakage into the environment has been observed 
visually when using the PhaSeal® device and a fluorescent marker for the following 
phases of drug handling: reconstitution of a dry powder, drug transfer from the vial, 
simulated drug administration, and IV push administration through an IV port.32  
The design features of the PhaSeal® device that creates a closed-system are an 
expansion chamber that neutralizes over and under-pressure in the drug vial, and a 
double membrane that forms dry connections when the components are fitted 
together.  
More than 500 cancer centres, oncology practices and speciality pharmacies in 
the United States use the PhaSeal® device for the handling of cytotoxics.127 The 
device appears to be an effective answer to the containment of hazardous drugs as 
referred to in the NIOSH alert. It is designed not only to maintain asepsis, but also to 
protect the operator and personnel who administer the drug. The benefits of the 
closed-system are also maintained during the process of waste handling, as the device 
is disposed of in the normal chemotherapy waste, without dismantling the 
components.   
1.10  Selection of Cytotoxic Marker Drugs 
For the purpose of this work, some of the cytotoxic drugs used most widely 
and clinically were selected to be used as marker drugs. Marker drugs should be 
drugs of high significance and of frequent use, to provide an initial estimation of the 
risk. Personnel working with cytotoxic drugs may be exposed to a cocktail of 
different drugs, all of differing levels of toxicity. Therefore, marker drugs from 
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different chemical classes were selected. The results of all determinations with these 
drugs are influenced strongly by the LoD of the analytical method applied. 
CP, 5-FU, MTX, DOX and EPI were the marker drugs selected for studies 
reported in this thesis. More in-depth studies of these drugs have been made, 
reviewing the chemical properties, for the purpose of including them in the 
experimental part of this thesis.  
1.10.1  Cyclophosphamide 
CP (2-[bis(2-chloroethyl)amino]-perhydro-1,3,2,oxaza-phosphorine-2-oxide 
monohydrate) is one of the most used common bifunctional alkylating agents.8 The 
chemical structure of CP is shown in Figure 2 (page 4). It is supplied as a white 
powder for reconstitution with water for injections (WFI). It may be infused in 0.9% 
normal saline (NS) or 5% glucose.24 The degradation of CP occurs primarily by 
hydrolysis with temperatures above 30ºC accelerating this breakdown. Consequently, 
it is recommended that CP products are not stored above 25ºC.128 The rate of 
decomposition is independent of pH over the range of 2 to 10. Outside of this range 
acidic and basic catalysis may occur.128 Under acidic conditions, the pathway and 
breakdown products formed depend upon the pH of the solution, either route will 
produce phosphoric acid, propanolamine and nor-nitrogen mustard.5 Under basic or 
neutral conditions, hydrolysis occurs by an initial intra-molecular alkylation, forming 
hydrochloric acid and a bicyclic compound.5 However, this compound is very labile 
in aqueous solution and may breakdown to further products.5 
Contamination of CP in pharmacy preparation and administration areas has 
been reported to a large extent26;58;62;63;67;68;78;124;125 - see Table 1 (page 42). This is of 
great concern, as CP has been classified by the IARC as Group 1 i.e. carcinogenic to 
humans.9 CP is an oxasophosphorine prodrug which undergoes enzymatic oxidation 
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in the liver to form 4-hydroxycyclophosphamide and its tautomeric form, 
aldophosphamide.128 4-hydroxycyclophosphamide is further converted to 4-
ketocyclophosphamide, and aldophosphamide to carboxyphosphosphamide, both are 
non-cytotoxic in vivo or in vitro.1 A β-elimination reaction converts aldophosphamide 
to phosphoramide mustard, which is a bifunctional alkylator of DNA, and acrolein 
which has been associated with bladder toxicity.8  
Structurally, CP does not possess a strongly conjugated chromophore,129 
therefore some analytical methods are not very sensitive, and it is necessary to 
monitor at low UV wavelengths where there might be the possibility of other 
compounds absorbing and interfering with the assay. 
 Potassium hydroxide, in methanol (0.2 M) solution for 1 hour, or sodium 
hypochlorite (5%) solution for 24 hrs is recommended for the chemical degradation 
of CP.24  
1.10.2  5-Fluorouracil  
5-FU (5-fluoro-2, 4(1H, 3H) pyrimidine-dione) is a six-membered fluorinated 
pyrimidine of the antimetabolite family - see Figure 8 (page 8) for the chemical 
structure of 5-FU. 5-FU is stable at acidic pH,24 although precipitation may occur at a 
pH of less than 8.0, depending upon the concentration.128 It may be subject to alkaline 
hydrolysis, the rate increasing above pH 9.0, therefore it is formulated within the pH 
range of pH 8.0 - 9.0 by the addition of sodium hydroxide.24 5-FU may be 
administered undiluted, or diluted as an infusion in NS, WFI or 5% glucose.24 When 
prepared in these diluents, thermal and photochemical exposure may cause the 
breaking of the chemical bonds of the pyrimidine ring between N3 and C4, and N1 
and C5 to produce urea.24 Moreover, the most likely method of degradation is 
alkaline hydrolysis, which is slow. This leads to the production of barbituric acid, 
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which further degrades to urea.24 The drug is stable at acid pH, but its solubility is 
compromised and precipitation may occur. The solution is normally colourless to 
faint yellow, due to the presence of free fluorine. A dark yellow colour of the solution 
is indicative of decomposition.128  
5-FU has been classified by the IARC as Group 3 i.e. not carcinogenic to 
humans but mutagenic and teratogenic.9 5-FU contamination has been widely 
reported in pharmacy preparation and administration areas20;26;45;61;62;66;71;125 – see 
Table 1 (page 42). However, to date there is no satisfactory method for the 
degradation of 5-FU in situ with the aim of decontamination. 
1.10.3  Methotrexate  
MTX (4-amino-N-methyl) is a 2,4-diamino-substituted pteridine ring linked to 
a p-aminobenzoyl portion, which is amine bonded to a glutamic acid unit - see Figure 
10 (page 10) for the chemical structure of MTX. MTX is supplied as a clear yellowish 
solution for injection or infusion which may be diluted in NS or 5% glucose.24 Like 5-
FU, sodium hydroxide is added to the formulation to adjust the pH between 8 and 9.24 
MTX is relatively stable in aqueous solution but its solubility is poor and is pH-
dependent. It is more soluble in a solution of mineral acids and in dilute solutions of 
alkali hydroxides and carbonates.24 Maximum stability is observed between pH 6.6 – 
8.2, although it is subject to hydrolysis and photolysis, the rate increasing with 
increasing pH.24;128 For this reason it is recommended that MTX preparations are 
stored between 15ºC to 30ºC, and protected from light.24  
MTX has been classified by the IARC as Group 3 i.e. not carcinogenic to 
humans but mutagenic and teratogenic.9 MTX has increasingly wide clinical 
applications not only in oncology chemotherapy, but also as an immunosuppressive 
agent,130 hence the presence of MTX contamination in the environment. It has been 
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measured on vials, gloves, the handles and doors of storage fridges, shelves, on the 
floor, telephone hand-sets, bench areas, trays and areas inside BSCs26;29;45;108;109 – see 
Table 1 (page 42). 
1.10.4  Doxorubicin  
 DOX (8S,10S)-10-(4-amino-5-hydroxy-6-methyl-tetrahydro-2Hpyran 2-
yloxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10 
tetrahydrotetracene-5,12-dione) consists of an amino sugar (daunosamine) linked 
through a glycosidic bond to a tetracyclic aglycone (doxorubicinone).24 Aqueous 
solutions of DOX are yellow/orange at acid pHs, and violet blues at pHs above pH 
9.131  
 DOX hydrochloride is presented either as a lyophilized product in a rapid 
dissolution formula that requires reconstitution in NS or WFI, or as a 2 mg mL-1 
solution for injection.24 The lyophilized product should be stored at room temperature 
and protected from light. Once reconstituted DOX is stable for up to 48 hrs at room 
temperature under normal light.24 The solution for injection should be stored under 
refrigerated conditions and protected from light.128 DOX exhibits pH-dependent 
stability in solution. Maximum stability has been reported to be in the pH range of pH 
4 to 5.24;128 DOX is unstable at pH outside the range of pH 3 - 7.128 In acidic media 
below pH 3, splitting of the glycosidic bond produces a red-coloured water insoluble 
aglycone, and a water-soluble amino sugar. In alkaline media a colour change from 
red to purple is indicative of rapid degradation.24;132  
1.10.5  Epirubicin  
EPI (10-(4-amino-5-hydroxy-6-methyl-oxan-2-yl) oxy-6,8,11-trihydroxy-8-
(2-hydroxyacetyl)-1-methoxy-9,10-dihydro-7H-tetracene-5,12-dione) is the 4’-epimer 
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of DOX. It consists of the tetracyclic aglycone (doxorubicinone) linked to an amino 
sugar (acosamine) via a glycosidic bond.24  
Similar to DOX, EPI is supplied either as a lyophilized product or as a 
solution for injection, which requires reconstitution in NS or WFI. It also exhibits a 
similar pH stability profile to DOX.24;128 Both DOX and EPI are highly coloured 
fluorescent compounds and are therefore easy to detect i.e. the native fluorescent of 
DOX has been used as a tool to detect contamination of DOX on the skin.116 
The anthracyclines are best represented by DOX or EPI and have been 
classified as Group 2A by the IARC i.e. probably carcinogenic to humans.9 See 
Figures 13 and 14 (page 12) for the chemical structures of DOX and EPI, 
respectively. Analytical methods are numerous for the separation of these compounds 
however, environmental contamination studies of DOX and EPI are limited.64;71 
Soaking in dilute sodium hypochlorite (1% available chlorine), followed by 
water is recommended for the treatment of spillages or leakages of DOX or EPI.133 
1.11  Introduction to this Study 
 There is plentiful evidence in the literature demonstrating that cytotoxic 
contamination released from the manipulation and administration of cytotoxic drugs 
in practice does occur. Even with the improvement of personal protective measures 
recommended by guidelines, measurable levels of cytotoxic drugs have still been 
detected in the urine of personnel and in the facilities where these drugs are prepared 
and administered.25-30;61;63;66;69;108;109;125 There are many sources and routes of 
exposure, not all of which can be avoided in current practice. Contamination of 
cytotoxic drugs is inconsistent and cannot be predicted. Therefore, intervention is 
needed to effectively remove the contamination or to prevent its occurrence.  
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The following research questions were raised during the literature review: 
 
• There is no standard recommended method of decontamination and cleaning after 
the manipulation of cytotoxic drugs, and guidelines are brief. What 
decontamination and cleaning procedures are being used in areas where cytotoxic 
drugs are being manipulated? What methods and products are being used? 
 
• How were these procedures developed? Are they effective? Are they validated? 
Are they just concerned with removing biological contamination e.g. 
microorganisms or is chemical contamination also addressed? 
 
• If cytotoxic contamination is a concern, how deep are these concerns? Do 
managers and operators of cytotoxic reconstitution services recognise these 
concerns? 
 
• Practically, can cytotoxic contamination be removed by current decontamination 
procedures or be broken down into less harmful products? 
 
• How much contamination is actually present in an isolator workstation? Access 
for cleaning the work area of an isolator can sometimes be difficult.134 Can 
cytotoxic contamination be removed by cleaning or is it persistent? The isolator 
may contain the contamination, but when products are removed from the isolator 
is it transferred outside via surface contamination on the finished product, thus 
spreading contamination to other environments? Is there also the risk of product 
cross-contamination occurring in the isolator?  
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• What are the sources of cytotoxic contamination? Can contamination be 
prevented by using a closed-system device i.e. the PhaSeal® device? How 
effective is this device in reducing contamination inside the isolator and on the 
finished product leaving the isolator? 
 
Overall, the aims of this work were to identify deficiencies in current practice, to 
reduce cytotoxic contamination in the working environment and also on the surfaces 
of pharmaceutical dosage forms supplied to wards, clinics and patients.  
1.12  Project Structure 
 In order to investigate systems to reduce the risks of occupational exposure, a 
three-part project was devised. 
 
 The first phase involved researching the current decontamination methods 
applied in cytotoxic reconstitution units in UK hospitals, which manipulate cytotoxic 
drugs. This required sending out a questionnaire to reconstitution service managers in 
NHS hospital to gain information about the decontamination procedures and products 
used. 
 
The second phase involved the evaluation of practical methods to remove and 
degrade cytotoxic contamination on surfaces in an isolator workstation, which could 
be applied as a decontamination protocol. 
 
The third phase investigated the prevention of contamination in an isolator by 
using a closed-system device for fluid-transfer. 
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 It was envisaged that results from these studies could inform the practice of 
cytotoxic reconstitution and manipulation and would encourage the adoption of 
standard, validated techniques to minimise occupational exposure to cytotoxic drugs. 
Although this work is focused on pharmacy reconstitution centres, by reducing 
contamination on the external surfaces of finished products, benefit to personnel 
working in clinics or on hospital wards would also be realised. 
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2.  Investigation into Decontamination Procedures Carried out after the 
Manipulation of Cytotoxic Drugs  
2.1  Introduction 
 Decontamination may be defined as the use of physical and/or chemical 
means to render a surface or item safe for handling, use or disposal.110 This can refer 
to both biological and chemical decontamination, which are paramount in the safe 
preparation of cytotoxic drugs, to maintain product and operator protection. 
Decontamination is, in practice a combination of cleaning and 
disinfection/sterilisation. These are different processes but may be combined, 
although generally they are antimicrobial processes, which do not address chemical 
decontamination. Chemical decontamination may be achieved by physical removal, 
degradation or neutralisation.110  
 It was apparent from the literature that there are no cleaning standards for 
cytotoxic contamination removal; the available guidelines are very brief and not 
definitive.4;47;49-51;135 A review of cleaning procedures is required to find out the 
procedures that are being used in facilities in the UK, which compound cytotoxic 
drugs. 
2.2  Objectives 
The objectives of this study were to investigate the cleaning and disinfection 
procedures that are being applied to decontaminate the areas used for the 
compounding of cytotoxic drugs. To achieve this, a questionnaire was designed and 
sent to NHS hospital pharmacy Aseptic Services Units (ASUs) in England, Wales 
and Scotland where cytotoxic drugs are compounded. 
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2.3  Study Design 
2.3.1  Design of the Questionnaire 
  To achieve the objectives of this study, data would need to be collected from 
a potentially large number of respondents, covering a large geographical area. 
Questionnaire was selected as the tool for collecting data as it has advantages over 
other data collection methods i.e. interviews or focus groups. Questionnaires are 
easier to administer confidentially, and if confidentiality is offered participants are 
likely to respond more honestly. They are also inexpensive to administer, and if the 
questionnaire is distributed via email, potentially the response time may be quicker 
than setting up an interview i.e. arranging the interview and the time taken for travel. 
 The questionnaire was designed after literature review, knowledge of 
practice, visit to an ASU, and consultation with industry manufacturers concerning 
cleaning procedures and products. A pharmacy manager of an ASU, who is a 
member of the Pharmaceutical Aseptic Services Committee, piloted the 
questionnaire. This was to check the relevance of the questions, ascertain if the 
questionnaire was unambiguous, and determine the time taken to complete. 
 The questionnaire comprised of ten questions, of which nine were closed and 
one was an open question. Closed questions gave the respondent a restricted choice 
of answers, and requested the respondent to select an answer from the specified 
response options. These questions were easier and quicker to answer, provided 
consistency, were easier to code, and analyse. Whereas the open question gave the 
respondents the opportunity to answer the question in their own words, allowing the 
respondent to record any issues not covered in the questionnaire. Many of the closed 
questions were also accompanied by a section to record any ‘other’ information, 
which was not covered in the specified response options. The title of the 
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questionnaire was ‘Investigation into the Decontamination (cleaning and 
disinfection) Procedures Carried out after the Manipulation of Cytotoxic Drugs.’  
 Prior to the start of the questionnaire, the name of the hospital was requested. 
The questions and the rationale for inclusion in the questionnaire are given below: 
 
Question 1. In your hospital, what type of workstation do you use for the 
compounding of cytotoxic drugs? 
 This was asked to identify the main type of containment equipment used for 
the compounding of cytotoxic drugs in the hospital facility i.e. in an isolator 
(negative or positive) or in a BSC (ducted internally or externally). The option of 
stating other areas was included. The answers to the following questions 2 to 8 were 
concerned with the main response to this question. 
 
Question 2. How would you describe your concerns about cytotoxic contamination in 
this area? 
 This was designed to ascertain how concerned the participant was about 
cytotoxic contamination. Participants were asked to select only one of the four 
possible responses i.e. 
‘extremely concerned,’ ‘slightly concerned,’ ‘indifferent’ or ‘not concerned at all.’ 
 
Question 3. Do you apply a cleaning and disinfection procedure to this area? 
 Here, the option was given to select ‘a cleaning procedure,’ ‘a disinfection 
procedure,’ or both combined i.e. ‘a cleaning and disinfection procedure.’ The choice 
of answer to this question determined which question the responded should answer 
next - , either question 4 or 5. 
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Question 4. Which of the following do you use for the cleaning of this area? 
 Participants were asked to identify from the list provided which, if any, of the 
water quality or alcohol preparations listed that they used for the cleaning of the area. 
They were also asked to provide details of the type of detergent, if used, for cleaning 
and select from the drop down menu the frequency of use, ‘daily’, ‘weekly’ or 
‘monthly’.  
 
Question 5. Which of the following do you use for the disinfection of this area? 
 Participants were asked to identify from the list provided which liquid 
biocides or gassing/fumigation processes they used for the disinfection of this area. 
The common liquid biocides, according to manufacturers advice and literature 
review were listed i.e. alcohol, stabilised chlorine dioxide, quaternary ammonium 
compounds (QACs), QACs/stabilised chlorine dioxide blends, sodium hypochlorite, 
hydrogen peroxide, stabilised glutaraldehyde and chlorhexidine.110 Formaldehyde, 
hydrogen peroxide, peracetic acid24 and ozone gas were the options given as 
gassing/fumigation processes.24;110 There was the option to include ‘others’, which 
may not have been listed.  
 For any biocides selected, the method of application i.e. impregnated wipes, 
spray with dry wipes, or liquid with dry wipes, was requested from a drop down list. 
The frequency of use of the biocides or the fumigants selected, ‘daily’, ‘weekly’, 
‘monthly’ or ‘yearly’ was also asked for from a drop down list.  
 
Question 6. Does the decontamination procedure for this area differ depending upon 
which drugs have been manipulated? 
 The option of answering ‘yes’ or ‘no’ was provided. If ‘yes’ was chosen 
details were requested. 
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Question 7. In your opinion which of the following best describes the purpose for the 
decontamination procedure which you, have described? 
 The respondents were asked to select only one of four options i.e. ‘to remove 
cytotoxic contamination’; ‘to disinfect/sterilise the area’; ‘to maintain a sterile 
environment and remove some cytotoxic contamination’; or ‘to maintain a sterile 
environment and remove all cytotoxic contamination.’ 
 
Question 8. How was the decontamination procedure you use devised? 
 Information concerning where the procedure had been derived from was 
sought. The options were ‘national/international guidelines’, ‘literature or 
references’, ‘other facilities or manufactures advice’. There was the option of 
including other sources, which were not listed. 
 
Question 9. Have you ever measured for cytotoxic contamination in the following 
areas, and if so was any cytotoxic contamination found? 
 The areas listed were vials, the finished product, airborne, gloves and 
surfaces inside or outside the isolator. There was the option of adding other areas not 
listed. If contamination had been measured for, it was asked to confirm either ‘yes’ 
or ‘no’ if it had been found. 
 
Question 10. Please comment on any concerns you have about manipulating 
cytotoxic drugs and any problems, which you have experienced? 
 This was an open question, which gave the respondents the opportunity to 
describe any concerns, or in their experience, any relevant problems they may have 
encountered.   
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2.3.2  Ethics Committee Approval 
In 1964, the ‘World Association Declaration of Helsinki’ originally outlined 
ethical principles for researchers in medical research. The declaration is the 
definitive code detailing ethical practice in health related research. Included within 
its principles is the freedom of the individual to decide upon participation, the need 
for consent to be informed and minimisation of the risks to the individual balanced 
against the need for research. Within the healthcare environment, these principles are 
assured by NHS Ethics Committee assessment of work before it is conducted. 
Research Ethics Committees (RECs) assess the safety, appropriateness and quality of 
the proposed research in the context of adherence to the ethical principles outlined 
above.  
The taxonomy of the questionnaire was questionable. Classification as a 
‘Service Evaluation’ or as an ‘Audit’ would not require ethical approval. On the 
other hand, classification as ‘Research’ would require ethical review. Guidance was 
sought from the Central Office for Research for Ethics Committee (COREC) as how 
to classify the questionnaire. The response was that the question was classified as a 
Service Evaluation.136 However, their taxonomy is not watertight and conflicting 
opinions were received. Some host organisations i.e. NHS hospital Trusts considered 
an independent ethical review to be essential as NHS staff were involved, and after 
an application was made to an NHS REC, the REC itself considered the 
questionnaire to be classified as ‘Research’, conflicting the opinion of its organising 
body. 
As more than one participant from more than one site would be involved, an 
application was made to a MREC (Multi-centre Research Ethics Committee). The 
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application for Version 1 of the questionnaire was made to the South West Devon 
REC. 
 Ethical opinion was favourable to carry out the research at NHS Hospital 
Trusts in the UK. The Approval Letter (REC reference number: 06/Q2103/120) from 
the South West Devon REC can be found in Appendix 1. The REC suggested that 
the request for the participants’ name and job title were removed from the 
questionnaire to assist in maintaining confidentiality. This was amended and Version 
2 was issued. It should be noted that the questionnaire was designed to be sent 
electronically, therefore some of the options, which were in the form of a drop down 
menu, are not apparent on the paper version, which can be found in Appendix 2. 
2.3.3  Research Governance Approval 
In addition to the MREC application, all activities classified as research 
within the NHS must comply with the Department of Health Research Governance 
Framework and be approved formally by individual Hospital Trust Management 
Committees within the Trust. Such committees review all research carried out in the 
Trusts facilities to ensure NHS resources are used favourably to support research. 
This involves a number of internal authorisation processes and exchanges between 
the R&D manager, principal investigator, participant, finance departments, and data 
protection specialists. 
The NHS in England is managed locally by ten Strategic Health Authorities 
(SHAs), which are separated geographically into the North West, North East, 
Yorkshire and the Humber, West Midlands, East Midlands, East of England, 
London, South Central, South East Coast and South West. The aforementioned 
SHAs, Wales and equivalent departments in Scotland were applied to. Within each 
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SHA, the NHS is split into Trusts, some of which are responsible for managing acute 
NHS hospitals and others are responsible for the primary care sector. 
All relevant acute hospital Trusts within the UK were approached to obtain 
research governance approval prior to commencement of the research. The details of 
the R&D contact for each Trust was obtained from a list provided by the NHS R&D 
forum. This totalled approximately 181 hospital Trusts.137 R&D applications were 
made to comply with the procedures from each Trust. The procedure was different 
for each Trust. R&D applications in the South West and Scotland SHAs operated on 
a Single Point of Entry, where only one application was necessary to cover all Trusts 
in that SHA. In some cases, the committee chair was able to grant approval without 
consultation with the committee, or the questionnaire was classified as a Service 
Evaluation and approval was not required.  
The national standard R&D form, which was the recommended form at the 
time, was accepted by most Trusts. Others would not accept the standard form and 
had their own, often-complicated R&D form.  
2.3.4  Targets and Population Size Selection 
Pharmacy managers in charge of ASUs, which prepare cytotoxic drugs 
centrally in NHS hospitals, were targeted as potential participants for the research. 
The number of NHS hospitals providing this service in the UK determined the 
population size. An accurate figure of the population size could not be obtained, but 
was anticipated to be approximately 181, as this is the approximate number of 
hospital trusts in the UK.137 Willingness to participate was a major factor in 
determining a representative population. To encourage participation the 
questionnaire was designed to take up a short amount of time i.e. approximately 15 
minutes, causing as little inconvenience as possible. 
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A ‘Letter of Invitation’ (see Appendix 3) was included with the questionnaire 
to promote the research, give clear instructions and to express anonymity. Basic 
ethical principles were applied to the NHS staff participants. The questionnaire was 
expressed as being non-compulsory and a response to the questionnaire would be 
taken as consent to participate.  
2.3.5  Method of Distribution 
After careful consideration, the questionnaire was distributed electronically. 
Electronic methods have shown a high degree of acceptance (57%) versus the 
conventional paper version (13%), and the benefits of completeness of data, speed of 
data flow and data handling workload using this method have been demonstrated.138  
There is no central list of NHS aseptic service managers available, and the 
NHS Trust websites were not forthcoming with contact details of the appropriate 
individuals. The Chemist and Druggist Directory provides a register of NHS Hospital 
Trusts,139 however the details given were not specific for ASU pharmacy managers. 
The British Oncology Pharmacy Association (BOPA) was approached, however they 
advised that they would not be an ideal route of circulation as there were too many 
miscellaneous members, and recommended that the relevant targets were identified 
through Specialist Pharmacy Interest Groups concerning cytotoxic and aseptic 
handling procedures.140 The National Pharmaceutical Production Committee was 
approached and agreed to assist in its distribution. The questionnaire was distributed 
via a cascade system. It was sent to the chairs and secretaries of the following local 
groups with the request that it was forwarded to members who were ASU managers; 
Yorkshire Technical Services Group, North-East Quality Assurance Production and 
Preparation Group, South Thames Aseptic Services Managers, London and South 
East Licensed Production Managers, West Midlands Technical Pharmacy Group, 
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Eastern Technical Strategy Group, Eastern Preparative Services Network Group, 
Sussex and Hants Technical Services Group, South and West Technical Group, 
Thames Valley Technical Group, North Thames and Kent Aseptic Managers Group, 
North West Aseptic Services Managers, Welsh Association of Production 
Pharmacists, Scottish Aseptic Specialist Interest Group and Scottish Quality 
Assurance Interest Group. It was also requested that the researcher was copied on all 
emails so that the response rate could be determined.  
2.3.6  Method of Response to the Questionnaire 
The participants were given the option of either completing the questionnaire 
electronically and returning it via email, or printing off a copy, filling it out by hand 
and returning it via FREEPOST.  
The name of the hospital was requested in the questionnaire so that responses 
could be coded. The intention was that after 4 weeks, a reminder would be sent out to 
non-responders using the same method. A second reminder would follow this up to 
non-responders 4 weeks later. The chairs and secretaries of the special interest 
groups would be informed of who had responded to avoid unnecessary follow-up. 
After this time, non-responders were considered as ‘unwilling to participate’ and no 
further contact would be made. 
2.3.7  Data Recording and Analysis  
Electronic responses were stored on a password protected secure computer 
hard drive. Paper responses and a paper copy of the electronic responses were kept in 
a secure cabinet in a locked room. The responses were coded chronologically upon 
receipt and according to each SHA.  
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The results were entered into the computer software SPSS (Statistical 
Package for Social Scientists), Version 14.0 (SPSS Inc. Chicago, Illinois, U.S.). 
Themes and trends from the results were explored and analysed using descriptive 
statistics. 
2.4  Results 
2.4.1  Conduct of Research 
Version 2 (see Appendix 2) of the questionnaire was distributed 
electronically to ASU managers. This kept the handling workload for the Specialist 
Pharmacy Interest Groups, who were distributing the questionnaire, to a minimum 
and enabled rapid distribution. The questionnaire was sent knowingly to 115 ASU 
pharmacy managers however, it was forwarded on to other email addresses without 
copying the researcher, thus the exact number of recipients could not be calculated. 
2.4.2  Participant Response 
 The questionnaire was distributed once, following the decision not to follow 
up to non-responders after 4 weeks. To assist in maintaining confidentiality, it was 
advised by the REC, that the option for the participant to provide their name on the 
questionnaire was removed. This made the participants who responded using the 
paper method and wished to keep the name of the hospital confidential, non-
identifiable. Therefore, details i.e. hospital name or email address could not be given 
to the distributors of the questionnaire to eliminate these responders from the follow-
up list. Resending of the questionnaire may have caused unnecessary distribution to 
responders and to those who had already decided not to participate. In total, 44 
responses to the questionnaire were received, 62.8% of the responses were electronic 
and 37.2% were paper responses.  
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2.4.2.1  Demographics 
 The number of responses from each SHA was determined and is presented in 
Table 2 below. The geographical origin of only one response could not be 
determined. The response rate from the SHAs are also given in Table 2, although 
these data could not be calculated for all SHAs, as the destination of the 
questionnaire in these SHAs was not made available to the researcher.  
 
Table 2. Number of Participants per Strategic Health Authority 
SHA                    Number of Respondents Response Rate (%) 
North West    1    ND 
North East    6    ND 
London    3    33.3 
South Central    4    21.1 
West Midlands   4    ND 
East Midlands    2    ND 
South West    5    ND 
East of England   3    7.70 
Yorkshire and the Humber  2    ND 
South East Coast   5    18.5 
 
Wales     4    18.2 
Scotland    4    44.4 
 
Unknown    1    ND 
 
Total Number of Responses  44    ND 
 
ND = not determined 
 
 
2.4.3  Questionnaire Analysis and Interpretation 
Isolators were used for the compounding of cytotoxic drugs by 44 ASUs 
(100%). None of the ASUs used BSCs or any other areas for this type of work. Of 
these 44 isolators, 95.5% operated under negative-pressure and of this percentage, 
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40.5% were ducted internally and 59.5% were ducted externally. Only 4.5% of the 
isolators used, operated under positive-pressure, all of which were ducted externally. 
2.4.3.1  Concerns Regarding Cytotoxic Contamination 
 In response to concerns regarding cytotoxic contamination, the personal view 
of only one (2.3%) participant was that they were ‘extremely concerned’, 56.8% 
were ‘slightly concerned,’ 15.9% were ‘indifferent’ and 25.0% were ‘not concerned 
at all.’ The results are represented in a pie chart; see Figure 24 below. Each portion 
represents the amount of concern. 
 
Figure 24. Pie Chart Showing Concerns Regarding Cytotoxic Contamination in 
ASUs 
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2.4.3.2  Decontamination Procedures Used 
 After the use of isolators for the compounding of cytotoxic drugs, 6.8% of 
ASUs applied a cleaning procedure only, 4.6% applied a disinfection procedure only, 
and 88.6% applied both a cleaning and a disinfection procedure. 
2.4.3.3  Cleaning and Disinfection Procedure 
 Table 3 below, shows the frequency of usage of water, alcohol, detergents 
and liquid biocides for cleaning and disinfecting the isolator after the compounding 
of cytotoxic drugs.  
 
Table 3. Frequency of Product Usage for Cleaning and Disinfecting the Isolator 
              Number of ASUs 
Product           Cleaning    Disinfection 
Water (all qualities)    8   0 
 
Alcohol (all qualities)    39   20 
 
Detergents 
 Neutral    4   2 
 Amphoteric    3   1 
 
Liquid Biocides 
 QAC/biguanide   6   7 
 QAC/CD    4   11 
 Hydrogen peroxide   1   4 
 QAC     1   13 
 CD     2   5 
 QAC = quaternary ammonium compounds 
CD = stabilised chlorine dioxide 
 
 
Cleaning 
 Water was used for cleaning the isolator only by 8 ASUs (18.2%). WFI and 
water for irrigation were the water qualities used by 7 ASUs. Neither distilled nor 
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deionised water was used for cleaning, one unit did use an ‘other water quality’ once 
a day, five days a week, but they did not specify the quality. Water was used by 6 
ASUs daily, and by 2 weekly. 
 Alcohol was used by 39 ASUs (88.6%) for cleaning the isolator. All used it 
on a daily basis. Denatured ethanol, 70% v/v (IMS) in a spray form (76.9%) was the 
main choice of alcohol and application method, compared to impregnated wipes 
(35.8%), some used both. Isopropyl alcohol (IPA) spray was used in only 1 ASU for 
cleaning the isolator, twice daily. IPA wipes were used for cleaning the isolator in 6 
ASUs. On a daily basis the isolator was cleaned once (13 ASUs), twice (9 ASUs), 
three times (2 ASUs), four times (3 ASUs), five times (2 ASUs) and more than 10 
times by one ASU with IMS spray. ‘Other alcohol’ was used by one ASU; they did 
not specify the type. 
 Detergents, including liquid biocides were used for cleaning by 21 ASUs 
(47.7%). The detergents used for cleaning were either neutral detergent or 
amphoteric surfactant. Neutral detergent was used by more ASUs (4 compared to 3) 
than amphoteric surfactant. The liquid biocides used for cleaning contained QACs, 
QACs/biguanide, QACs/stabilised chlorine dioxide, and hydrogen peroxide. The 
interval of using these products were once a day, once a week, three times week, 
once a month, twice a month and twice a year. The liquid biocide blends of QACs 
/biguanide (6 ASUs) and QACs/stabilised chlorine dioxide (4 ASUs) were also used 
commonly. 
 
Disinfection 
 Alcohol, and the same detergents and liquid biocides, which were used for 
cleaning, were also used for disinfection. Alcohol was used by 20 ASUs (45.5%) and 
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was used commonly for disinfection on a daily basis, sometimes more than 10 times 
a day.  
 Detergents were used by 3 (6.8%) and liquid biocides by 40 ASUs (90.9%) 
for disinfection of the isolator. Again, neutral detergent and amphoteric surfactant 
were the only two detergents mentioned and neutral detergent was the used most 
commonly (2 compared to 1 ASU). QACs were the most common liquid biocide, 
followed by QACs and stabilised chlorine dioxide blends, used by 13 and 11 ASUs, 
respectively. QACs and biguanide blends were also popular; these had not been 
listed on the questionnaire but were used by 7 ASUs. Stabilised chlorine dioxide and 
QACs were used daily, but no more than twice. QACs, and QACs and chlorine 
dioxide blends were more likely to be used as disinfectants on a monthly or yearly 
basis.  
 Sodium hypochlorite was only used by 1 ASU, once a month. Stabilised 
glutaraldehyde and chlorhexidine were not used to disinfect the isolator by any of the 
ASUs.  
 The application method for disinfection of the isolator was only completed by 
17 of the 30 participants who used detergents/liquid biocides. Using a spray and a 
dry wipe was the most common method of detergent/liquid biocide application for 
disinfection. Sprays only, and liquid with dry wipes, were used each by 1 of the 
ASUs. They were used for applying alcohol, and another liquid biocide, the name of 
which was not mentioned. Impregnated wipes were used by 6 of the applications, and 
spray with dry wipes by 16 out of 24 of the respondents. 
 Only 4 ASUs (9.1%) used fumigation/gassing for disinfection of the isolator. 
Peracetic acid was used twice a month in 1 ASU, and formaldehyde was used in 3 
ASUs, once weekly, once yearly, and twice yearly. The process that was described 
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by one participant was to boil off 50% formaldehyde and 50% water in a heated 
mantle placed within the isolator. Hydrogen peroxide and ozone gas were not used 
for fumigation/gassing to disinfect any of the isolators. 
2.4.3.4  Change in Decontamination Procedure Depending on the Drug Manipulated 
 Of the different decontamination procedures described by the participants, 39 
out of 44 (86.6%) of these procedures did not differ according to which drugs had 
been manipulated in the isolator. One reported that the procedure would change if 
there was the occurrence of a cytotoxic antibiotic spillage. 
 A change in these procedures, whether they involved cleaning only, 
disinfection only, or both combined, occurred in 5 ASUs (11.4%), according to 
which drugs had been compounded in the isolator. The reason was due to the 
preparation of MABs i.e. Herceptin and Mylotarg. The procedure was specified for 2 
ASUs. One ASUS, after the preparation of MABs would clean using a biocide 
followed by IMS, the other, would clean with IMS spray followed by IPA wipes. It 
was mentioned by two participants that they have the facilities to use separate 
isolators, one for the preparation of cytotoxics and another for the preparation of 
MABs. In addition, they had extra cleaning procedures in place in the event of only 
one isolator being operational, which in one case was a regular occurrence. None of 
the participants reported that they changed their cleaning procedure according to the 
type, or class, or chemistry of the cytotoxic drugs compounded. 
2.4.3.5  Purpose of the Decontamination Procedure 
 All, except one participant (2.3%) replied to the question, which asked the 
purpose of the decontamination procedure of the isolator. A small percentage, 2.3% 
chose that it was ‘to remove cytotoxic contamination’ or, 9.1% ‘to disinfect/sterilise 
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the area’. The main responses were that the purpose of their decontamination 
procedure had a dual aim i.e. 36.4% said that it was ‘to maintain a sterile 
environment and remove some cytotoxic contamination’; 50.0% said that it was ‘to 
maintain a sterile environment and remove all cytotoxic contamination’. 
2.4.3.6  How the Decontamination Procedure was Devised 
 Information regarding the source of the decontamination procedure was 
provided by 42 of the 44 participants. This question was not responded to by 2 
participants. Of the responses, 54.5% had relied on, and specified, more than one 
source. The main sources of national guidelines were Quality Assurance of Aseptic 
Preparation Services,141 The Cytotoxics Handbook,24 Pharmaceutical Isolators,142 
Aseptic Services Specialist Interest Group (ASSIG) guidelines,143 Rules and 
Guidance for Pharmaceutical Manufacturers and Distributors (MCA).135 
International guidelines had also been used to devise the procedures; however, the 
participants provided no reference to any of the sources of these international 
guidelines. Influence from local ASUs, the regional quality control laboratory, and 
experience from working in other ASUs were also sources. Other sources included 
onsite quality control advice, own collective experience, and advice provided from 
quality assurance, as a result of audits. Advice from manufacturers was also a 
contributor but only one company was mentioned. 
2.4.3.7  Effectiveness of the Decontamination Procedure 
 Few of the ASUs (17) had measured cytotoxic contamination. Out of these, 7 
had found cytotoxic contamination in one of the areas listed in the questionnaire. It 
was commented on by some, that the facilities for measuring levels of cytotoxic 
drugs were not available locally, and that only a limited number of cytotoxics could 
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be tested for. It was also mentioned, referring to the methods, that they are ‘complex 
procedures using expensive equipment and accessibility to them are limited.’  
 Overall, cytotoxic contamination had been measured in all of the areas listed, 
except for airborne levels. Table 4 below, expresses the number (and percentage) of 
ASUs which had measured for cytotoxic contamination in the areas specified in the 
questionnaire, and from those which had measured, the number (and percentage) 
which had found cytotoxic contamination. The frequency of measurement and the 
levels of contamination found were not specified by the ASUs. 
  
Table 4. Number of ASUs and Areas where Cytotoxic Contamination has been 
Measured  
Area      Number (%) of ASUs 
    Contamination Measured    Contamination Found 
Vials     7 (15.9%)   2 (28.6%) 
 
Dispensed product   3 (6.8%)        0 
 
Surfaces inside the isolator 
 before decontamination 10 (22.7%)   4 (40.0%) 
 after decontamination  9 (20.5%)   2 (22.2%) 
 
Surfaces outside the isolator 
 before decontamination 10 (22.7%)   2 (20.0%) 
 after decontamination  5 (11.4%)   1 (20.0%) 
 
Airborne          0         0 
 
Gloves used in the isolator  3 (6.8%)   1 (33.3%) 
 
Gloves used outside the isolator 1 (2.3%)         0 
 
 
 
 The highest number of cases (4 out of 10) when contamination had been 
found was on surfaces inside the isolator. After the decontamination procedure had 
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been carried out, contamination on surfaces inside the isolator was still present in 2 
out of 9 cases (1 ASU did not measure for contamination after decontaminating the 
isolator). In 1 out of 3 cases, the gloves used inside the isolator tested positive for 
contamination, although it had only been measured for in 3 ASUs. Contamination 
had also been found on vials (2 out of 7 cases). One ASU reported heavy 
contaminated of DOX powder observed visibly on the external surface of vials, as 
supplied by the manufacturer. The other contaminating drugs found on the external 
surface of vials were not specified by the ASU. Measurements taken for cytotoxic 
contamination of the dispensed product and the gloves used outside the isolator had 
not tested positive. 
 
 Included in other areas, one ASU had measured for cytotoxic contamination 
in the preparation room as part of an awareness exercise. Low levels were found on 
the telephone and door handles. As a result, the cleaning procedure was reviewed and 
after repeating the exercise, no contamination/low levels were found. The levels of 
contamination found were not provided by any of the ASUs, neither was the LoD of 
the analytical method used. 
 The same facility had also measured for cytotoxic contamination on surfaces 
inside the isolator, interestingly none had been found. Other ASUs had measured for 
contamination on pens, scissors, bench tops, re-usable work trays, transit bags of the 
finished product, work surfaces outside the clean-room, fridges, and the cytotoxic 
floor, where none hand been found.  
 One facility in particular included a risk assessment form with their response. 
The assessment had been carried out after finding cytotoxic contamination present in 
the isolators, and on floors and benches in the checking areas of the isolator room. 
Repeat testing after the introduction of the control measures listed, in the risk 
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assessment, had eliminated contamination in areas outside of the isolator and 
significantly reduced levels in the isolator.  
 In 4 of the ASUs, which had the facilities to test the effectiveness of the 
decontamination procedure applied to the isolator, 2 of the procedures had been 
effective in removing cytotoxic contamination. One procedure was to clean with 
WFI (once a day), and IMS spray and IPA wipes (both 10 times a day), followed by 
disinfection with alcohol spray and dry wipes more than 10 times daily, 
QACs/stabilised chlorine dioxide impregnated wipes (both once a day), and 
fumigation with formaldehyde once a week. The other effective procedure was to 
clean with water for irrigation, IMS spray and wipes, neutral detergent and 
QACs/biguanide daily followed by disinfection with alcohol and QACs (frequency 
not specified). 
2.4.3.8  Concerns and Problems Encountered when Manipulating Cytotoxic Drugs 
 This open question was commented on by 19 (43.2%) of the participants. 
Issues of concern regarding the supply of contaminated vials to the pharmacy were 
mentioned on 3 occasions. One unit had received a visibly very heavily contaminated 
vial of DOX powder, which consequently needed extra cleaning. This contamination 
was visible to the naked eye, but the concern was that contamination on a vial of 
cisplatin would not be visible. The comment was made that the responsibility should 
belong to the manufacturers to provide contamination free vials and packaging, and it 
should not rely so heavily on the individual ASUs to routinely “have to wipe each 
vial 5 times.” 
 The lack of national guidelines, no data on safe low i.e. picogram levels of 
exposure, concern regarding long-term exposure and the lack of biological tests were 
mentioned on several occasions. In particular, one participant expressed their 
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difficultly in reassuring their staff of the safety of long-term exposure. Another 
participant, further questioned “if there was a limit from extensive testing what 
relevance would the results have, how would it relate to personnel exposure, what 
levels of detection and contamination would be considered acceptable, what 
additional means could then be put in place?” 
 One participant explained they are aware of the research carried out in this 
area but that they “have difficulty with projects based on measuring cytotoxic 
contamination levels, given that there is no guidance on what is an acceptable level 
of contamination. Clearly, the approach can only establish a relative reduction in 
contamination, to the lowest level of detection i.e. like radiation; I do not believe that 
a safe level of contamination can be defined. Therefore, the research objectives must 
be to compare different cleaning procedures and establish which are the most 
effective that can be recommended to users.” Another participant suggested that it 
would be interesting to see some “best practice” guidelines for decontamination of 
equipment following the handling of cytotoxics.  
 The opinions of 3 participants were that they had no issues and that they felt 
that the risk to the operators was low. One quoted “operators are suitably trained in 
the safe manipulation of cytotoxic drugs with the correct equipment to reduce the 
risk of aerosol formation and contamination; I feel the risk is low, given that all 
these manipulations are carried out in a contained environment.”  
 One participant only, mentioned that they felt cytotoxics were being handled 
in an inappropriate manner; the reason was attributed to staff shortages and a 
constant increase in workload. 
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2.5  Discussion 
The questionnaire was sent out to explore the procedures which are currently 
used to decontaminate areas where cytotoxic drugs are compounded. It was sent to 
pharmacists who manage ASUs in NHS hospitals in England, Scotland and Wales. 
These hospitals are regulated by the Department of Health and are subjected to 
external audit by the regional Quality Assurance Pharmacist every year, in 
accordance with EL (97) 57, against common standards set by the NHS 
Pharmaceutical Quality Control Committee.141 Private hospitals were excluded from 
this study, as they are not regulated or subject to regular external audit. This results 
in varying standards of aseptic preparation practice between private hospitals, which 
may not always be equivalent to the level of NHS hospitals.   
The number of responses received i.e. the number of participants was 44. 
This was a lower response than anticipated compared to a possible 181 responses. 
Responses were received from hospitals in all twelve SHAs. The highest number of 
responses was from the North East (6 responses) and the South West (5 responses). 
There was only one response from the North West. The response rate could not 
accurately be determined for all areas, i.e. The North West and East, West and East 
Midlands, The South West and Yorkshire and the Humber, as it was not known 
exactly how many people it was sent to in these SHAs. When sending out the 
questionnaire it was requested that the email recipients sent to were copied to the 
researcher, but this was not done for the email recipients in these SHAs. Of those for 
which the response rate could be calculated, Scotland and London gave the highest 
response rates, 44.4% and 33.3%, respectively - see Table 2 (page 67). Although 
national participation in the questionnaire was observed, the results of the 
questionnaire could not be generalised to be representative of current practice in the 
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UK as this would be dependent on obtaining a complete and accurate list of the 
population and a higher and accurate response rate.  
Follow-up reminders to non-responders preceded by two reminders enclosing 
a replacement questionnaire may have facilitated response rates.144 In this present 
study, if follow-up reminders enclosing the questionnaire had been sent to non-
responders, which was the study design (Section 2.3.6), the response rate might have 
been improved. However, the participants of the questionnaire who responded via the 
paper method and chose confidentiality as to the name of the hospital could not be 
identified. This meant that their identity could not be communicated to the chairs and 
secretaries of the National Pharmaceutical Production Committee, who distributed 
the questionnaire, to remove them from the follow-up list. It may have been 
conceived, by those that had already participated, to be a nuisance to receive 
reminders for a questionnaire that they had already completed. Therefore, the 
decision was taken not to follow-up to attempt to enlist non-responders; the trade-off 
being a low response rate.  
On reflection, a higher response rate may have been achieved in this study if 
control of the distribution of the questionnaire had remained with the researcher. This 
was not the case, and the advised method of distribution was to use a Specialist 
Pharmacy Interest Group which operates a communication network through its 
members comprising a representative from each SHA. The researcher could not be 
provided with a list of the contact details of the members of these groups, as it was 
the policy of these specialist groups to protect the identity of its members. Therefore, 
reliance was on the chairs and secretaries of these groups to distribute the 
questionnaire. Although there is no up-to-date list of contact details for pharmacy 
managers of ASUs available, a list of contacts could have been generated using the 
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Chemist and Druggist Directory139 or each individual NHS website to telephone each 
Hospital Trust and ask for the contact details of the relevant ASU pharmacist. A 
higher response rate may also have been observed using an alternative data collection 
method. Face to face interviews are recommended to achieve the best response 
rate.144 However, interviews are time-consuming and costly, and would have been 
impractical in this case due to the large geographical area. They are also suited for 
more complex answers and the collection of a large amount of data. Computer-
assisted telephone interviewing is a rapid method of collecting data145  and may give 
a higher response rate than sending out a questionnaire.144 Using the self-generated 
telephone list of contacts, the pharmacist could have been invited to participate in the 
study via telephone and a convenient time to conduct the computer-assisted 
telephone interview arranged. This would have enabled direct control over the 
recruitment of participants and a quicker and probably higher response rate would 
have been observed. 
The number of participants was adequate to explore this area of research and 
carry out descriptive statistical analysis. Almost twice as many of the responses 
received to the questionnaire were electronic compared to paper versions, 
simplifying data handling procedures. The rate of electronic response to this 
questionnaire (62.8%) was comparable to the rate of acceptability to electronic 
responses (57%), which was observed to be the preferred method of response in a 
study comparing electronic with the conventional paper questionnaire.138 
 
It is very concerning that nearly half of the negative-pressure isolators used in 
ASUs (40.5%) are ducted internally i.e. the air is re-circulated (see Section 2.4.3). It 
is recommended by NIOSH that ducting from the isolator should be to the outside 
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environment, unless the drugs used, do not volatise during manipulation or after 
capture by the HEPA filter.4 It is also concerning that a quarter of the participants 
were ‘not concerned at all’ about cytotoxic contamination in the isolator - see Figure 
24 (page 68). The reason may be that it is not the pharmacy managers’ themselves 
who manipulate cytotoxic drugs, but pharmacy technicians and assistants. It would 
be interesting to learn of the response to this question from the technicians and 
assistants who actually carry out cytotoxic manipulations. It is somewhat reassuring 
that the largest number of participants (56.8%) were ‘slightly concerned’. Only 2.3% 
(1 participant) was ‘extremely concerned’. 
 A large percentage of ASUs (88.6%), apply a cleaning and a disinfection 
procedure for the decontamination of the isolator, after its use for the compounding 
of cytotoxic drugs. Water (18.2%), alcohol (88.6%), and detergent/liquid biocides 
(47.7%) were used for cleaning the isolator – see Table 3 (page 69). The water used 
was WFI or water for irrigation, which is the high quality water recommended for 
cleaning isolators,110 although water was not used commonly for cleaning this area. 
As most cytotoxic drugs are water-soluble (usually salts), water would be a suitable 
solvent for the removal of cytotoxic contamination, more so that alcohol, which is a 
disinfectant; it is not a good cleaner. Water should also be used after cleaning with 
detergent to remove any residue.110  
 
 Alcohol was used less for disinfection (45.5%) compared to cleaning (88.6%) 
of the isolator. IMS spray with dry wipes was the alcohol and application method of 
choice for disinfection of the isolator. IMS, in a spray form, was used twice as much 
as IMS-impregnated wipes. However, spray cleaners run the risk of damaging the 
HEPA filter, and there may be a hazard, if vapours build up and there is inadequate 
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ventilation.49 The frequency of cleaning with IMS spray was generally once or twice 
a day. 
 Gassing/fumigation were only used by 4 (9.1%) ASUs for disinfection of the 
isolator. There is an increasing need for disinfection in hospitals due to the 
emergence of resistant pathogens, especially where pharmaceuticals are aseptically 
prepared. A study carried out to assess biological disinfectant usage in hospitals 
pharmacy ASUs, reported that alcohol was used most commonly by 60.7% to 
disinfect the surfaces of isolators,146 a higher percentage than demonstrated in this 
study. 
 Neutral detergent, QACs and QACs combined with other compounds i.e. 
biguanide and stabilised chlorine dioxide, were the common detergents/liquid 
biocides of choice. Of the two detergents mentioned for cleaning and disinfection 
neutral detergent was used most commonly. QACs/biguanide blends were used most 
commonly for cleaning; QACs/stabilised chlorine dioxide blends were also used 
frequently. QACs were used most commonly for disinfection closely followed by 
QACs/stabilised chlorine dioxide blends. Combining the two processes, 
QACs/stabilised chlorine blends were the liquid biocides used most commonly, and 
were applied as a spray and wiped using a dry wipe (Section 2.4.3.3). Interestingly, 
sodium hypochlorite, which may be sporicidal, was not a common choice for 
decontamination by the ASUs. This may be because there has been a reported 
increase in the use of other halogen-based agents which are also sporicidal, and 
QACs containing added surfactants which may improve cleaning properties.146 
 For disinfection, liquid agents were the choice over gassing/fumigation 
methods (Section 2.4.3.3 - disinfection). The reason may be that they are easier and 
quicker to use and specialised equipment is not required. The gassing or fumigation 
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of an isolator, if performed correctly, can ensure access of otherwise inaccessible 
areas. They are not sterilisation processes but are used to reduce the bio-burden in the 
isolator to a defined level. Fumigation has been used traditionally for many years and 
describes gassing when formaldehyde is the sanitisation agent. Formaldehyde was 
still being used in 3 ASUs, once a week in one ASU, however there are serious 
concerns about its toxicity and it may be potentially carcinogenic.110;147 This may be 
another reason why liquid biocide/detergents were preferred to fumigation/gassing 
methods. Peracetic acid was used only by one ASU, supporting the literature that 
reports its limited use.110 It is heated to produce a vapour, which is harmful but 
decomposes to acetic acid and water, both of low toxicity.  
 The view of 50.0% of the participants, who specified the decontamination 
procedure, was that it was ‘to maintain a sterile environment and remove all 
cytotoxic contamination’ (Section 2.4.3.5). No one specified that it differed 
according to the type of cytotoxic drug manipulated. It is apparent from the 
decontamination procedure described, that the main aim concerns a sterile 
environment, but there appears to be little or no consideration regarding cytotoxic 
chemical removal.  
 Those that are aware of the risks, have only limited information resources, 
with reliance being heavily on national guidelines from a few select books available, 
and advice from quality control staff. The literature is lacking regarding choice of 
disinfection agents for cytotoxic chemical decontamination. Although measurements 
of cytotoxic contamination are well published in the literature, the levels that are 
acceptable have not been defined. This is not surprising since levels causing human 
toxicity are also not defined. 
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 The ASUs which had measured for cytotoxic contamination, had found it on 
vials, gloves used in the isolator, surfaces inside the isolator before and after 
decontamination, and surfaces outside the isolator – see Table 4 (page 74). 
Information regarding the contaminating drug or the levels found were not provided. 
The findings of contamination in one unit had resulted in improved protective 
measures, which were effective. It may have been informative to have asked in the 
questionnaire for the frequency of measurement in each of the areas, the levels of 
contamination found, the contaminating drug and the LoQ of the analytical method 
applied. In any event, there appears to have been little thought given to the design of 
monitoring schedules for cytotoxic contamination. For example, isolator gloves 
would be considered a major area of contamination, yet only 3 out of 17 ASUs who 
monitored contamination included isolator gloves in their schedule. 
 It was apparent that some ASUs have had to introduce and accommodate for 
the production of MABs (Section 2.4.3.4). Those that mentioned that they were 
preparing MABs were aware of the possibility of cross-contamination. A separate 
isolator for the production of MABs was used where available. Decontamination 
procedures were in place with the aim of preventing cross-contamination, if prepared 
in the same isolator as cytotoxic drugs, or after preparation in a separate isolator. 
However, there was little evidence that these procedures were routinely validated, if 
they were validated at all. 
 The questionnaire was designed to ascertain the decontamination procedures, 
which are being carried out in NHS hospitals, which have ASUs. There is no written 
standard for these procedures, against which to evaluate the responses. Concerns 
about cytotoxic contamination ranged from extreme to no concern, and would reflect 
current safety of practice.  
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2.6  Conclusion  
The use of isolators and the preference towards negative-pressure isolators in 
NHS hospital pharmacies is in agreement with the literature.75 The most prevalent 
practice in hospital pharmacies is to decontaminate an isolator after the manipulation 
of cytotoxic drugs according to a protocol, which covers cleaning and disinfection. 
To clean the isolator IMS spray would be used, IMS wipes are also in use, as are IPA 
wipes, and WFI or water for irrigation. Alcohol would also be used for disinfection. 
In addition, detergents/liquid biocides are used for both cleaning and disinfection. 
Neutral detergent, and the liquid biocides i.e. QACs, QACS blends with stabilised 
chlorine dioxide or biguanide are common. These detergents/liquid biocides are 
currently the choice of use over fumigation/gassing methods for disinfection. 
This study indicates that the understanding of mechanisms of cleaning and 
decontamination by ASU managers is currently very low. The lack of structured, 
robust validation and monitoring procedures into the majority of ASUs is a major 
cause of concern, particularly with the increasing use of biological agents such as 
MABs. 
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3.  Development and Validation of Sampling/Quantification Methods 
3.1  Introduction 
 To assess the risk to personnel, cytotoxic marker drugs are selected as the 
most significant analytes. The most toxic, according to the IARC, the drugs used most 
extensively and the availability of suitable sensitive analytical methods are considered 
when selecting marker drugs.8 It was necessary to develop and validate reliable 
analytical methods to identify and quantify the marker drugs after the experimental 
phases in Chapters 4 and 5 of this thesis. 
 
Method 1 was developed and validated to quantify cytotoxic surface contamination 
after the decontamination procedures carried out in Chapter 4. 5-FU, CP, DOX and 
EPI were the cytotoxic marker drugs used. The decontamination procedures were: 
  Phase I    -  physical removal of cytotoxic contamination from a surface by wiping 
 with a) detergents of different pH and b) detergents used commonly
 in hospital practice, 
  Phase IIi -  degradation of cytotoxic contamination by exposure to the same  
  detergents applied in Phase I, 
  Phase IIii -   degradation by oxidation of cytotoxic contamination on a surface from 
 exposure to vaporised hydrogen peroxide (VHP®). 
A recovery method was developed and validated to remove the drug from a surface 
into a desorbing solution after wiping with detergents (Phase I) and exposure to VHP® 
(Phase IIii). HPLC methods were validated to quantify the amount of drug recovered 
from the surface in Phase I and IIii, and quantify the amount of drug degraded after 
exposure to the detergents (Phase IIi). 
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Method 2 was developed and validated to recover multi-drug surface contamination 
into a desorbing solution for analysis by HPLC. EPI, MTX and CP were the drugs 
compounded in an isolator in a two-arm cross-cohort study, as investigated in 
Chapter 5. Two systems for the compounding of cytotoxic drug injections/infusions 
were compared; the traditional open-system and use of a closed-system (PhaSeal®) 
device for fluid-transfer. The multi-drug contamination produced was recovered 
from surfaces inside the isolator, immediate surfaces outside the isolator and syringe 
batches prepared in the isolator. 
    
Recovery Methods – Wipe sampling and Immersion 
 Surface contamination is measured typically by removing the contaminants 
from the surface to an absorbing material and/or solvent and subsequent desorption of 
the drug contamination from that material into another solvent (desorbing solution). 
Wipe sampling and immersion were used to remove and recover the drug from 
various surfaces in this study. 
Wipe sampling is a valuable tool for measuring the residual contaminants in 
the workplace and to assess the effectiveness of personal protective equipment and 
decontamination procedures.148 Many studies have applied this method to evaluate 
surfaces for the presence of cytotoxic contamination.20;28;29;42;58;66;108;109  
Immersion is a method typically used for measuring cytotoxic contamination 
on disposable surfaces of a more complex topology, which are difficult to wipe i.e. 
gloves.28;29 The surface is placed into a desorbing solution which the drug will have 
affinity for, and mechanical methods e.g. mixing, vortexing60;149;150 shaking148 and 
centrifugation60;149;150  have been used to extract contamination from a surface into a 
desorbing solution. 
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High-Performance Liquid-Chromatography 
 HPLC is used commonly for the quantification of pharmaceutical products. It 
provides accurate, precise, selective and robust methods for analysis and is the 
industry standard for this purpose.104 The cytotoxic marker drugs investigated were 
recovered and diluted in aqueous solution. Reverse-phase chromatography involves a 
non-polar stationary phase and a relatively polar mobile phase. Mobile phases are 
usually aqueous-organic solvent mixtures that may be buffered. Mixtures are 
separated by subtle differences in hydrophobicity; the more hydrophobic the analyte 
the longer it is retained on a reverse-phase column.  
 The light absorption of a drug molecule is due to the particular combination of 
auxochromes and chromophores present in its structure.104 UV detection is the most 
commonly used method of detection for pharmaceutical compounds by HPLC,104 
although fluorescence detection is also used and offers greater sensitivity. 
Fluorescence is associated with an extended chromophore/auxochrome and a rigid 
structure.104 When the fluorescent spectrum of a molecule is scanned, two maxima are 
observed, the first maxima is due to the scatter of excitation radiation and the second 
maxima is due to fluorescence emission. 
 
Method Validation 
 Methods must be validated to ensure integrity, and demonstrate that they are 
reliable and reproducible. Validation must be carried out prior to routine use of the 
method, and involves documenting the use of specific tests to provide evidence that 
the method is suitable for application, and does what it is intended to do.151 All the 
variables of the method should be considered, from sample collection and storage, 
sample preparation, the sample diluent (desorbing solution), chromatographic 
  89
separation detection and data evaluation.151 Validation of the analytical method may 
include determining selectivity, precision, accuracy, recovery, LoQ and LoD, and 
stability under study conditions.152  
3.2  Objectives  
3.2.1 Method 1 
The objectives of Method 1 were to: 
i. identify suitable cytotoxic marker drugs which are likely to degrade by different 
mechanisms, 
ii. identify a suitable test surface on which to expose the drugs, 
iii. identify a suitable desorbing solution for each drug, 
iv. develop a recovery method with high and reproducible recovery for the 
quantification of all drugs. 
3.2.2 Method 2 
The objectives of Method 2 were to:  
i. identify suitable cytotoxic marker drugs for compounding in an isolator, 
ii. identify surfaces inside and outside the isolator from which to recover cytotoxic 
contamination of the drugs, 
iii. identify a suitable wipe material and method to remove surface contamination of 
these drugs, 
iv. identify a desorbing solution which the drugs will have affinity for to recover 
contamination of these drugs from the wipe or surface, 
v. identify a recovery method to remove the drug contamination from the wipe or 
surface into the desorbing solution, 
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vi. develop and validate sensitive analytical methods to determine contamination of 
these drugs at low concentrations. 
3.3  Materials 
Cytotoxic Drugs 
5-Fluorouracil 25 mg mL-1 (lot N022669), Doxorubicin Hydrochloride 50 mg 
for Injection (lot N062326) and Methotrexate 25 mg mL-1 Injection (lot R044426) 
were obtained from Mayne Pharma Plc, Leamington Spa, UK. Cyclophosphamide 
500 mg Powder for Injection (lot 3K114A) was obtained from Pzifer Ltd, Kent, UK. 
Pharmorubicin Solution for Injection 2.0 mg mL-1 (lot BD67A) was obtained from 
Pharmacia and Upjohn Ltd, Sandwich, UK. 
 
Diluents 
Normal saline 0.9% (lot MK7209 04) and sterile water for injections (lot 
04C27B25) were obtained from Baxter, Newbury, UK.  
 
Chemicals 
Acetonitrile (lots 0440085, 0553508, 0570049, 0572514, 0584171 and 
0607839), disodium hydrogen orthophosphate (lot 0307261), sodium dihydrogen 
orthophosphate (lot 0389539), methanol (lots 01417856, 0428369, 0432580 and 
0583764), potassium dihydrogen orthophosphate (lot 0398776) and sodium hydroxide 
(lot 0422611), were purchased from Fisher Scientific, Leics, UK.  
Ammonium sulfate (lot A201501), hydrochloric acid (1 M) (lot OC333385), 
perchloric acid (lot B23634917), sodium chloride (lot MK720904) and sulfuric acid 
(lot K29485908) were purchased from BDH, Poole, UK.  
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Potassium permanganate (lot D2.703) was obtained from Sigma Aldrich Co 
Ltd, Dorset, UK, and hydrogen peroxide (lot BN24WD) was obtained from Thornton 
and Ross, Huddersfield, UK. 
All chemicals and reagents used for HPLC were of analytical or HPLC grade. 
 
Equipment 
 The HPLC system comprised an LDC Analytical isocratic constaMetric 3200 
pump (serial no. 048086) from Thermo Separation Products, Stoke on Trent, UK, an 
851-AS autosampler (serial no. C6701589) from Jasco, Great Dunlow, UK, coupled 
with a variable wavelength UV detector 785A (serial no. 9106344) from Applied 
Biosystems, Warrington, UK, or a fluorescent detector FP2020 (serial no. 
B035760869) from Jasco, Great Dunlow, UK. Data analysis was performed using 
Prime software, Version 4.2.0 from HPLC Technology, Herts, UK.  
 Stainless steel column, 150 × 4.6 mm packed with Columbus C18, 5 µm 
particle size (serial no. 414370) was purchased from Phenomenex, Cheshire, UK. 
Stainless steel column 150 × 4.6 mm packed with Techsphere C18, 5 µm particle size 
(serial no. 332-04, 789-04); stainless steel column 250 × 4.6 mm, packed with 
Techsphere C18, 5 µm particle size (serial no. 590-04, 05031778.1) and stainless steel 
column packed with Techsphere CN,
 
250 × 4.6 mm, 5 µm particle size (serial no. 
325-04, 05021707.1, 05040838.2 and 605063021.1) were purchased from HPLC 
Technology, Herts, UK. 
 The glass electrode and pH meter 302 (serial no. 336888) were from Hanna 
Instruments, Bedfordshire, UK. The AE163 balance (serial no. B68994) was from 
Mettler Toledo, Leicester, UK. The BRi4 centrifuge (serial no. 30002493) was from 
Jouan, Winchester, UK and the Class II biological safety cabinet (serial no. MC4607-
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1) was from Medical Air Technology, Oldham, UK. The UV spectrophotometer 
CE5501 (serial no. 84203) & graphic plotter CE5501 (serial no. 85226) was made by 
Cecil Elegant Technology, Cambridge, UK. The water bath with stirrer, model NE4D 
(serial no. 46223) and the vortex FB65000 (serial no. 46998) were made by Nickel 
Electro Ltd, Weston-super-Mare, UK. The Certomat M orbital shaker (serial no. 
886008/4) was made by B.Braun, Sheffield, UK. Variable volume Gilson pipettes, 
P2-P5000, (serial no. X53584G, T55103N, T62823, N55454L, T53730K and 
T60889J) were purchased from Anachem, Bedfordshire, UK, and the vacuum and 
filtration unit were purchased from Millipore, Watford, UK. The Proline PL1218W 
freezer (serial no. 300516015020) was purchased from Comet Group Plc, Bath, UK. 
The Swingwave autoclave Type: S.F.T-lab was from Ilford, Essex, UK.  
 
Consumables 
 Mixed cellulose-ester membrane filters, 0.45 µm pore size, 47 mm diameter 
(lot R4HN57575) were obtained from Millipore, Watford, UK. Polypropylene 
centrifuge tubes (15 mL) and polypropylene containers (250 mL) with screw caps 
were from Sarstedt, Leics, UK. Polypropylene Plastipak syringes (5 mL) were 
obtained from Beckton and Dickinson, Oxford, UK. The HPLC autosampler vials and 
caps were obtained from HPLC Technology, Herts, UK, 
 Cliniwipes IPA 200 and Spiriclens sterile session wipe (lot 14110) were 
obtained from Adams Healthcare, Leeds, UK. Klerwipe™ 70/30 sterile alcohol-
impregnated wipes were from Shield Medicare, Farnham. Stericlean® Flowrap (lot 
W016603) and Stericlean® prep pads (lot 529179) were from Helapet Ltd, 
Bedfordshire, UK. 
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To achieve the objectives described in Section 3.2, two principal methods were 
developed.  
Method 1 to quantify the amount of 5-FU, CP, DOX and EPI remaining or degraded 
after the decontamination procedures described in Chapter 4. 
Method 2 to quantify cytotoxic surface contamination of EPI, MTX and CP after the 
compounding of cytotoxic drugs in an isolator, as described in Chapter 5. 
3.4  Method 1 - Development 
3.4.1  Selection of Drug  
 5-FU, CP, DOX and EPI were the cytotoxic drugs used frequently in the 
treatment of cancer, which were selected as marker drugs for this study. 5-FU, an 
antimetabolite - see Figure 8 (page 8); CP, an alkylating agent - see Figure 2 (page 4); 
and DOX, an anthracycline antibiotic - see Figure 13 (page 12), are structurally 
diverse and are known to be sensitive to degradation by different mechanisms i.e. 
hydrolysis and oxidation.5;24;68;128;153;154 CP is one of the most carcinogenic (Group 1) 
of the cytotoxic drugs according to the IARC.9 5-FU has been used as a marker 
drug8;62;67;124 and methods are plentiful in the literature for the analysis of 5-FU and 
DOX.8;40;44;62;65;124;154-156 EPI was chosen because of its increasing clinical use, and for 
its structural similarity with DOX, and hence a similar stability profile. DOX may be 
degraded by the decontamination procedures carried out in Chapter 4. It exhibits a 
stable pH range between 3 – 7,128 and may be degraded by the detergents of different 
pH formulated outside this narrow range. It is also subject to oxidation153 and may be 
degraded by the oxidising agent VHP®. EPI was investigated to ascertain if it may be 
degraded by the same conditions that may degrade DOX. If the same detergents or 
exposure conditions to VHP® degrade DOX and EPI, then they may be applied to 
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degrade cytotoxic contamination of other anthracyclines i.e. daunorubicin. This may 
allow a prediction of effective decontamination agents for chemical families of 
cytotoxic drugs where there is structural similarity.   
3.4.2  Drug Dilution and Reconstitution 
 5-FU, CP, DOX and EPI were reconstituted or diluted in three diluents. Two 
of the diluents were common to all four drugs, and were the pharmaceutical diluents 
WFI and NS. The third diluent was the aqueous part of the mobile phase specific to 
the HPLC assay used to quantify the drug i.e.   
5-FU: phosphate buffer (0.01 M) pH 7.0, 
CP: ammonium sulfate buffer (0.01 M) pH 3.5, 
DOX: sodium chloride solution (0.01 M) adjusted to pH 2.25 with perchloric acid, 
EPI: phosphate buffer (0.01 M), pH 4.0. 
5-FU (25 mg mL-1) as received was diluted in three diluents to give a working 
concentration of 5.0 mg mL-1.  
CP (500 mg) as received was reconstituted in three diluents to give a working 
concentration of 20 mg mL-1.  
DOX (50 mg) as received was reconstituted in WFI to give a concentration of 2.0 
mg/ml; this was further diluted in three diluents to give a working concentration of 
1.0 mg mL-1. 
EPI (2.0 mg mL-1) as received was diluted in three diluents to give a working 
concentration of 1.0 mg mL-1.  
3.4.3  Test Surface and Test Surface Coating 
A chemically inert polypropylene surface,157 which would not contribute 
towards chemical degradation, was selected on which to carry out the 
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decontamination procedures. This test surface was made by the transverse sectioning 
through the barrel of a 5.0 mL polypropylene syringe at 2.0 cm intervals. The 
resulting rings were cut in half giving rectangular surfaces with dimensions of 2.0 cm 
by 1.2 cm. The mass of the polypropylene pieces ranged from 0.22 to 0.26 g. The 
following were pipetted onto the concave side of the test surface to coat it:  
  5-FU (5.0 mg mL-1 × 10 µL) 
  CP (20 mg mL-1 × 20 µL) 
  DOX (1.0 mg mL-1 × 10 µL) 
  EPI (1.0 mg mL-1 × 20 µL)  
All coated test surfaces were allowed to dry in a BSC. The time taken for the drug 
solution to dry was determined visually. The maximum amount of drying time 
required (until no solvent remained) was approximately 2 hrs. 
3.4.4  Selection of Desorbing Solution 
The aqueous part of the mobile phase specific for each drug assay (which was 
also the third diluent as described in Section 3.4.2) was selected as the desorbing 
solution. This would ensure that the drug had a high affinity for the desorbing 
solution and would be likely to desorb from the test surface into this solution. The 
desorbing solution should also be compatible with the HPLC method, minimising 
disturbance of dynamic equilibrium when the sample is injected, and ensuring total 
and immediate mixing with the mobile phase. Generally, the packaging material in 
reverse-phase HPLC columns is stable within the pH range of 2 to 8 therefore; the 
mobile phase and sample solvent should be formulated within this pH range.  
The desorbing solution for CP was ammonium sulfate buffer (0.01 M, 1.0 
mL) pH 3.5. The basic nitrogen on the heterocyclic ring of CP indicates that CP may 
be fully protonated and soluble at acidic pH. Phosphate buffer (0.01 M, 5.0 mL) pH 
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7.0 was the desorbing solution for 5-FU.155 5-FU is a weak base possessing two 
ionisable nitrogens with pKa values of 7.0 and 13.104 At pH 7.0, these nitrogens 
would be 50% and >99.99% ionised, respectively, and 5-FU would be soluble. The 
desorbing solution for DOX was sodium chloride (0.01 M, 1.0 mL) adjusted to pH 
2.25, and phosphate buffer (0.01 M, 1.0 mL) pH 4.0 was used for EPI. DOX and EPI 
are weak bases with a pKb of 8.2.153 Therefore, they were both >99.9% ionised and 
soluble in the pH of the respective desorbing solution.  
3.4.5  Immersion and Recovery Method of Drug from the Test Surface 
 Immersion methods were developed to remove and recover as much drug as 
possible from the test surface into the desorbing solution. Each test surface 
containing dried drug was placed into a centrifuge tube containing the respective 
desorbing solution specific for each drug (see Section 3.4.4) The tube was inverted 
10 times, vortexed for 30 sec, followed by centrifugation for 5 min at 1500 × g (5ºC). 
An aliquot of the desorbing solution was transferred to autosampler vials for assay by 
HPLC.   
3.4.6  HPLC Methods 
 HPLC methods in use in the Clinical Pharmaceutics Laboratory, Department 
of Pharmacy and Pharmacology, University of Bath, and published methods have 
been used to quantify 5-FU,155 CP,158 DOX,159 and EPI.160  
 The aqueous portion of the mobile phase was prepared using Milli-Q grade 
water, and the pH was measured using a glass electrode and pH-meter. The mobile 
phase was degassed and filtered under negative-pressure through a 0.45 µm pore 
size, 47 mm diameter mixed cellulose-ester membrane filter prior to use. For each 
assay, elution was isocratic, the flow rate was 1 mL min -1 and a sample of 100 µL 
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was injected. Duplicate test injections were bracketed by injections of standard 
solutions. The chromatograms of all samples were processed using Prime software 
(Version 4.2.0). 
 
5-FU was analysed using a 150 × 4.6 mm stainless steel column packed with 
Columbus C18 (5 µm particle size). The mobile phase was phosphate buffer (0.01 M) 
pH 7.0 with 5% methanol (v/v). Detection was by UV at 270 nm. The autosampler 
injection needle was flushed with 2 × 500 µl of methanol:water (50:50) v/v after each 
injection. The final concentration for assay was 10 µg mL-1. 
 
CP was analysed using a 250 × 4.6 mm stainless steel column packed with 
Techsphere CN (5 µm particle size). The mobile phase was ammonium sulfate buffer 
(0.005 M) pH 3.5 with 30% methanol (v/v). Detection was by UV at 210 nm. The 
injection needle of the autosampler was flushed with 2 × 500 µl of methanol:water 
(50:50) v/v after each injection. The final concentration for assay was 400 µg mL-1. 
 
DOX was analysed using a 150 × 4.6 mm stainless steel column packed with 
Techsphere C18 (5 µm particle size). The mobile phase was sodium chloride (0.01 M, 
adjusted to pH 2.25 with perchloric acid) with 40% acetonitrile (v/v). Detection was 
by UV at 254 nm. The injection needle of the autosampler was flushed with 2 × 500 
µl of acetonitrile:water (50:50) v/v after each injection. The final concentration for 
assay was 10 µg mL-1. 
 
EPI was analysed using a 250 × 4.6 mm stainless steel column packed with 
Techsphere CN (5 µm particle size). The mobile phase was phosphate buffer (0.01 M) 
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pH 4.0 with 30% acetonitrile (v/v). Detection was by UV at 276 nm. The injection 
needle of the autosampler was flushed with 2 × 500 µl of acetonitrile:water (50:50) 
v/v after each injection. The final concentration for assay was 20 µg mL-1.  
 
Each column was flushed at the end of the sample run or at the end of the day. The 
flush solution was 10 column volumes of Milli-Q grade water, followed by either 
methanol or acetonitrile:water (50:50) v/v, which was also the storage solution. 
3.5  Method 1 - Validation  
 The recovery method described in Section 3.4.5 was validated for all four 
drugs in three diluents. HPLC was used to quantify the recovered drug as described 
in Section 3.4.6. The following criteria were investigated to ensure a validated 
reliable method. 
3.5.1  Recovery of Drug from the Test Surface 
 The desorption of drug from the test surface into the desorbing solution was 
measured against a standard (taken as 100%), which had not been subjected to 
recovery. Recovery of the analyte with acceptable precision and accuracy was 
considered necessary to obtain a validated method. 
3.5.2  Retention of the Analyte 
 The retention time is the time measured between sample injection and the apex 
of the peak in the chromatogram.161 It is characteristic of a compound but is not 
unique, and was used to provide a tentative identification of the compound within a 
peak window of +/-2%. 5-FU eluted at a retention time of 3.4 min, CP eluted at a 
retention time of 3.8 min, DOX eluted at a retention time of 3.8 min, and EPI eluted at 
a retention time of 4.3 min. 
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3.5.3  Precision, Accuracy and Recovery  
Precision was measured as the coefficient of variation (CV). The CV (%) was 
calculated by dividing the standard deviation by the mean. Five samples were 
prepared and assayed on the same day (intra-day) and one sample was prepared and 
analysed daily on 5 separate days (inter-day) by HPLC. Precision around the mean 
was acceptable if the CV was <+/-15%. The deviation of the mean from the nominal 
value within +/-15% served as the measure of accuracy.162 The precision and accuracy 
around the LoQ was acceptable if it did not exceed a CV of +/-20%.162 
 Precision, accuracy and recovery were evaluated at the experimental sample 
concentration. This was 5-FU (10 µg mL-1), CP (400 µg mL-1), DOX (10 µg mL-1) 
and EPI (20 µg mL-1). The results of precision, recovery and accuracy at the 
experimental sample concentration for each drug assay are shown in Table 5 on the 
following page. Recovery was expressed as a percentage of the standard, precision as 
the CV, and accuracy as the percentage range plus or minus the nominal value. 
Recovery from the drug-coated surfaces was high (≥95%). The methods were 
reproducible and accuracy around the nominal value was within +/-15% for all drugs 
in all diluents. 
3.5.4  Limit of Quantification and Limit of Detection  
The LoQ was the lowest concentration on the calibration plot which could be 
quantitatively determined with reliable precision (CV = +/-20%) and accuracy (+/-
20%).162 The LoD was the smallest concentration that gave a measurable response but 
could not be quantified with reliable accuracy or precision. The LoD and LoQ were 
determined from the analysis of samples of known concentration and by visual 
evaluation. The LoD and LoQ for each drug assay are shown in Table 5 on the 
following page. 
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Table 5. Results of Method Validation for Recovery and HPLC Assay of 5-FU, 
DOX, CP and EPI, as Described in Sections 3.4.5 and 3.4.6 
             Cytotoxic Drug (diluent) 
                5-FU  CP  DOX  EPI 
Limit of  
Detection   0.20 a  2.50 a  0.25 a  1.00 a 
µg mL-1 
     
Limit of          
Quantification   0.50 a  10.0 a  1.00 a  2.00 a  
µg mL-1  
    
   Diluent 
Least-Squares  (WFI)   0.999  0.998  1.000   0.995  
Regression   (NS)    0.999  0.999  0.999  0.990  
Coefficient  (pH) b   0.999  0.997  0.999  0.998  
(R2)  
 
Inter-Day   (WFI)   3.5  3.1  0.4  8.4  
Precision  (NS)   1.9  2.2  2.5  2.6  
CV (%)   (pH) b   1.5  3.9  2.3  9.3  
 
Intra-Day  (WFI)   1.1  5.4  1.7   6.0 
Precision   (NS)    1.3   4.5  0.4  6.4  
CV (%)   (pH) b    3.7   5.0   1.9  4.4  
 
Mean     (WFI)   98.8   96.0  99.8  96.6  
Recovery  (NS)   95.9  100  99.9  96.2 
(%)   (pH) b   98.5  96.3  100  95.0  
 
Range of  (WFI)   98.2 - 101 90.9 - 110 95.2 - 109 87.5 - 108 
Accuracy  (NS)   99.0 - 104 89.3 - 105 92.8 - 101 89.1 - 99.3 
(%)   (pH) b   95.7 - 104 97.6 - 110 92 .0- 98.7 97.6- 106 
 
a applicable to all diluents  
b
 = pH 7.0 for 5-FU, pH 3.5 for CP, pH 2.25 for DOX and pH 4.0 for EPI 
CV = coefficient of variation 
 
 
3.5.5  Linearity 
 Linearity was demonstrated over the concentration range of 0.5 to 30 µg mL-1 
for 5-FU, 10 to 700 µg mL-1 for CP, 1.0 to 20 µg mL-1 for DOX, and 2.0 µg mL-1 to 
150 µg mL-1 for EPI. The average peak area of each concentration was used to 
construct a calibration plot for each drug. The equation for the calibration plot was 
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obtained by linear regression analysis of known drug concentration (x) versus average 
peak area (y). 
 The calibration plots were linear over the selected concentration range with 
least-squares regression analysis giving a correlation coefficient (R2) of >0.99 (see 
Table 5 – previous page), indicating a good dynamic range (x denotes the independent 
variable, in this case the concentration of 5-FU, CP, DOX or EPI, and y denotes the 
dependent variable, in this case peak area). This was confirmed with visual inspection 
of the plot.  
3.5.6  Forced Degradation Studies 
5-FU, CP, DOX and EPI were degraded using forced degradation studies, to 
determine the parent analyte from any degradation products, in terms of retention 
time. 5-FU, CP, DOX and EPI (three diluents) were subjected to stress treatments 
under acidic, alkaline and oxidative conditions at 70+/-1°C for 2 hrs. 5-FU (5.0 mg 
mL-1 × 60 µL) × 5 aliquots, CP (20 mg mL-1 × 250 µL) × 5 aliquots, DOX (2.0 mg 
mL-1 × 100 µL) × 5 aliquots and EPI (2.0 mg mL-1 × 100 µL) × 5 aliquots, were each 
pipetted into 10 mL volumetric flasks, and reacted separately with equivalent volumes 
of the following:-   
a. 1 aliquot × hydrochloric acid (1.0 M) at 70+/-1°C for 2 hrs, 
b. 1 aliquot × sodium hydroxide (1.0 M) at 70+/-1°C for 2 hrs, 
c. 1 aliquot × 6 vol hydrogen peroxide at 70+/-1°C for 2 hrs, 
d. 1 aliquot × distilled water at 70+/-1°C for 2 hrs,  
e. 1 aliquot × distilled water at 4 to 8°C for 2 hrs to act as a control for the effect 
of heating. 
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All solutions were protected from light throughout. After the incubation period, 
each flask was allowed to equilibrate to room temperature. The acidic and alkaline 
solutions were neutralised by the addition of sodium hydroxide (1.0 M, 1.0 mL), and 
hydrochloric acid (1.0 M, 1.0 mL), respectively. Subsequently, each flask was made 
up to volume with Milli-Q grade water to give a final concentration of 5-FU (30 µ g 
mL-1), CP (500 µ g mL-1), DOX (20 µg mL-1), and EPI (20 µ g mL-1). The final 
solutions were assayed by HPLC in duplicate. Peak areas were expressed as the 
percentage of the concentration remaining with respect to the control solution (see 
Table 6 below). 
  
Table 6. Percentage of 5-FU, CP, DOX and EPI Remaining after Forced Degradation  
     Parent Drug Remaining Compared to Control (%) 
Drug (diluent) Acid    Alkali 
   Hydrolysis Hydrolysis Oxidation     Heat (70ºC) 
 
5-FU (NS)  33.2  33.6  79.9  98.2  
5-FU (WFI)  31.7  29.6  75.6  99.2 
5-FU (pH 7.0)  31.7  22.9  79.9  96.8 
 
CP (NS)  2.9  <LoQ  78.7  81.8 
CP (WFI)  22.1  <LoQ  81.9  91.8 
CP (pH 3.5)  <LoQ  <LoQ  54.8  74.1 
  
DOX (NS)  ND  ND  75.7  90.5 
DOX (WFI)  ND  ND  70.3  95.5 
DOX (pH 2.25)  ND  ND  85.0  95.4 
  
EPI (NS)  ND  ND  75.3  97.1 
EPI (WFI)  ND  ND  62.9  97.3 
EPI (pH 4.0)  45.4  ND  49.9  92.3 
ND = none detected 
LoQ = Limit of Quantification 
  
 
Forced stress under acidic and basic conditions and oxidation caused 
degradation of the parent drug for all drug assays in all three diluents. Heating alone 
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had less effect. Any degradation peaks resulting from the stressed conditions were 
well resolved from the parent peak. DOX was sensitive particularly to acid/base-
catalysed degradation, which destroyed the DOX parent peak completely in all three 
diluents. Under basic conditions, EPI was also destroyed completely in all three 
diluents. CP was degraded to below the LoQ of the analytical method by alkali 
hydrolysis. A degradation peak at 2.7 min was observed from CP degradation under 
all forced conditions and in all three diluents. This degradation peak was well 
resolved from the parent peak. Heating alone, had little effect on 5-FU, DOX or EPI 
in all diluents.  
3.6  Method 2 - Development 
3.6.1  Choice of Drug 
 CP, IFOS 5-FU, MTX, paclitaxel and platinum-containing compounds are 
marker drugs which have been used commonly to assess for cytotoxic surface 
contamination.8 Previous studies, with the closed-system (PhaSeal®) device used CP, 
5-FU and IFOS as marker drugs. These drugs are routinely used and there are 
analytical methods available for quantifying the surface contamination of these drugs 
in the environment.8;20;62;65;67;78;124;163 For this study, three cytotoxic drugs, each from 
a different chemical family were selected. Two of the drugs, EPI (Figure 14, page 12) 
and MTX (Figure 10, page 10) were novel to investigation with the closed-system 
(PhaSeal®) device, and were investigated for suitability in this study. CP (Figure 2, 
page 4) has been investigated with the closed-system (PhaSeal®) device 
before,20;62;67;78;124 thus it was investigated for its suitability for comparison with 
previous studies. All of the marker drugs selected for this study are in widespread 
clinical use in the UK. 
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3.6.2  Sensitivity of the Analytical Method  
 The aim was not only to compare the two systems for the compounding of 
cytotoxic drugs, but also to measure the potential risk from contamination that may be 
present on surfaces in an isolator and clean-room. Sensitive analytical methods were 
required to increase the probability of the number of samples that could be quantified 
above the LoD. There are no recommended safe levels of cytotoxic surface 
contamination; therefore, the expected levels could only be anticipated from similar 
studies. Contamination of EPI has not been measured extensively in the environment. 
One study with an LoQ of 2.0 ng mL-1 was sensitive to measure EPI contamination on 
gloves and the base of the BSC.64 The levels of EPI contamination measured in 
Chapter 5 may contribute towards the paucity of EPI surface contamination data. 
Methods with a LoQ of 15 ng mL-1 108 and 50 µg mL-1 109 have been used to measure 
MTX surface contamination. 5-FU was the marker drug in a comparative intervention 
contamination study with the closed-system (PhaSeal®) device but many of the 
samples could not be quantified owing to the lack of sensitivity of the assay. The LoD 
was 20 ng mL-1 and the effectiveness of the device in reducing contamination could 
not be assessed.124 Therefore, a sensitivity of <20 ng mL-1, ideally 2.0 ng mL-1 or 
lower for EPI and MTX should be achieved. 
 Sensitivity of the analytical method at sub-nanogram concentrations was 
unnecessary to measure for CP, as nanogram levels of CP surface contamination have 
already been well documented and routinely measured for with the closed–system 
(PhaSeal®) device.20;62;67;78;124  
3.6.3  Review of Methods for the Quantification of Epirubicin Surface Contamination 
 The majority of methods in the literature quantify EPI in biological matrices 
using reverse-phase HPLC, exploiting its fluorescence. A method using HPLC 
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coupled with fluorescence detection at excitation and emission wavelengths of 254 
nm or 480 nm, and 560 nm, respectively, with an LoQ of 0.4 ng mL-1 in plasma was 
adopted.160 A stainless steel 250 × 4.6 mm column packed with Techsphere CN (5 µm 
particle size) was used. The mobile phase was phosphate buffer (0.05 M, pH 4.0) and 
35% acetonitrile (v/v).160  
3.6.4  Review of Methods for the Quantification of Methotrexate Surface Contamination 
 HPLC coupled with UV detection is a method used commonly for the 
quantification of MTX.130 However, the LoD for one method was only 50 µg mL-1.109 
MTX concentrations in biological samples are monitored very carefully in clinical 
practice and there are a number of different methods, which are used. These methods, 
like environmental levels of contamination, require high sensitivity to detect low 
levels of MTX. The native fluorescence of MTX is low in aqueous media but 
oxidation converts it to a highly fluorescent pteridine-carboxylic acid, which can be 
measured by HPLC with fluorimetric detection. This was the most sensitive detection 
method for MTX.130  
 The method adopted measures the analyte in urine by a pre-chromatographic 
oxidation.164 Potassium permanganate is the oxidising agent and the reaction is 
quenched and the excess destroyed by hydrogen peroxide.164-166 The documented LoQ 
of the highly fluorescent derivative was 10 ng mL-1.164 2,4-diaminopteridine-6-
carboxylic acid (MTX’) is the oxidation product of MTX (see Figure 25 on the 
following page).  
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Figure 25. Scheme Showing the Oxidation of Methotrexate to 2,4-Diaminopteridine-
6-carboxylic acid (MTX’) by Potassium Permanganate 
 
 
 
 
The kinetics of this reaction have been studied regarding pH, temperature and the 
concentration of potassium permanganate, to achieve the maximum oxidation state of 
MTX.165 The method described for the oxidation of MTX to MTX’ and subsequent 
detection was as follows: 
Potassium permanganate (0.01 M, 5.0 mL) and acetic acid (0.005 M, 5.0 mL) 
/sodium acetate buffer (pH 5.0) were added to MTX (100 µL) in urine. The solution 
was vortexed for 30 sec and left to stand for 35 min at room temperature. This was 
the optimal time and pH for the method to achieve the highest oxidation state.164;165 
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The reaction was quenched and the excess potassium permanganate
 
destroyed by the 
addition of aqueous hydrogen peroxide (33%, 0.1 mL). The pH was adjusted to 6.8 
with aqueous sodium hydroxide (1.0 M) and made up to volume with mobile phase 
(25 mL). The mobile phase was tris hydroxymethylamineoethane (15 mM) and 
sodium chloride (1.0 mM) adjusted to pH 6.8 with hydrochloric acid. A stainless 
steel 150 × 3.9 mm column packed with C18 (5 µm particle size) was used, and 
detection was by fluorescent excitation at 280 nm and emission at 444 nm. 
3.6.5  Review of Methods for the Quantification of Cyclophosphamide Surface 
Contamination 
 CP contamination has been quantified as sensitive as 0.1 ng mL-1 (LoD) in 
surface contamination studies using gas-chromatography in tandem with mass-
spectroscopy mass-spectroscopy.20;67;124 However, this method for CP is time-
consuming and complicated extraction, clean-up and derivatisation is required prior to 
analysis. HPLC with UV detection is also used commonly. A method used in-house 
involving no sample pre-treatment to measure CP was adopted.158 The method used 
ammonium sulfate buffer (0.005 M, pH 3.5) and 30% methanol (v/v) as the mobile 
phase. CP was analysed using a stainless steel 250 × 4.6 mm column packed with CN 
(5 µm particle size). Detection was by UV at 210 nm.158 The LoQ for the method 
when used to measure CP diluted in pharmaceutical diluents was 10 µg mL-1, as 
determined in Section 3.5.4. 
3.6.6  Selection of Desorbing Solution 
 Optimal recovery of drug contamination requires the analyte to have a high 
affinity for the desorbing solution and dissolve in it. If the desorbing solution is also 
the storage solution the drug must be stable in it under storage conditions. The 
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desorbing solution for this study must also be suitable to take into a clean-room 
environment i.e. it must be sterile and non-toxic. 
 Desorbing solutions were considered in which all three drugs would be 
soluble, stable at -21°C (the temperature at which the samples would be stored after 
collection and prior to analysis) and be compatible with the mobile phase for the 
respective HPLC assay.  
 The analytical method for EPI was the most sensitive of the three methods, 
and EPI was the least stable of the three drugs. Therefore, to maintain the sensitivity 
of the analytical method and ensure the stability of EPI, a desorbing solution was 
selected which would be optimal for EPI. The methods for MTX and CP were 
modified to accommodate this desorbing solution. The following were considered as 
possible desorbing solutions: 
 
Acetonitrile/Water (10:90) 
 Mixtures of methanol:water (50:50, 60:40 and 70:30) have been evaluated as 
desorbing solutions but desorption of CP from the wipe was low (~50%).148 Mixtures 
of acetonitrile:water (50:50) demonstrated higher recoveries ~100% recovery for 
DOX (which may also be extended to EPI) but did not further improve on the 
recovery of CP.148 A mixture of acetonitrile:water (10:90) recovered almost 100% of 
5-FU.150  
 
Normal Saline 
 EPI demonstrated stability for 43 days, MTX for 3 months and no significant 
loss of CP was observed after 4 weeks when diluted in NS and stored in infusion 
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devices at -20°C.128 Longer term storage has not been investigated but repeated 
freeze-thawing had no significant effect on EPI stored at -20ºC.24  
 
Phosphate Buffer  
 The stability of EPI is pH-dependent and maximum stability was observed at 
pH 4 to 5.128 The HPLC mobile phase in the method adopted to assay for EPI was 
based on a phosphate buffer at pH 4.0.160 MTX is almost insoluble in water but 
dissolves at low pH. Therefore, a desorbing solution comprising a phosphate buffer 
solution within the range of pH 4 to 5 would be compatible with the assay for EPI and 
a possible desorbing solution for both EPI and MTX.  
 It should be noted that phosphate has pKa values of 2.1, 7.2 and 12.3. The 
most effective range of a buffer is 1 pH unit either side of the pKa of the weak acid or 
base.104 Therefore, phosphate is not strictly an effective buffer at pH 4.0. An acetate 
buffer would be a more suitable buffer at pH 4.0 as it has a pKa value of 4.8. 
However, it has a higher UV cut-off wavelength of 210 nm compared to phosphate 
buffer which has a cut-off wavelength of 200 nm. 
 
Phosphate Buffer, Acetonitrile (30%) 
 EPI, MTX and CP are diverse in physical and chemical characteristics. The 
LogP (apparent) values in order of decreasing hydrophobicity are 3.1 (EPI), 0.2 (CP) 
and -0.2 (MTX).167 Tests of various mixtures have shown that the most effective 
solution to desorb several drugs of different polarities from a wipe was a mixture of 
an organic solvent and phosphate buffer (0.01 M) pH 6.0.148 The mobile phase for EPI 
comprises acetonitrile (35%) v/v. Phosphate buffer (0.01 M, pH 4.0) with acetonitrile 
(30%) v/v was investigated as a desorbing solution. 
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 EPI (250 ng mL-1) in each of the four desorbing solutions was assayed by 
HPLC and the detector response (peak area) recorded. The pH of the desorbing 
solution was also noted. The results are shown in Table 7 below. 
 
Table 7. pH and Detector Response of EPI in Desorbing Solutions 
Desorbing Solution     pH    Detector Response  
                (Peak Area)  
 
Acetonitrile:water (10:90)    6.5  2551 
NS       6.5  3202 
Phosphate buffer (pH 4.0)    4.0  2329 
Phosphate buffer (pH 4.0), acetonitrile (30%) 4.0  4050 
 
 
 
 The largest detector response was observed when EPI was assayed diluted in 
phosphate buffer (0.01 M, pH 4.0) with 30% acetonitrile (v/v).  
3.6.7  Stability of Epirubicin in the Desorbing Solution 
 EPI (250 ng mL-1) was placed on storage at -21ºC for up to 12 weeks in a 
temperature monitored laboratory freezer. The percentage of EPI remaining after 
storage at 6 and 12 weeks are shown in Table 8 below.  
  
Table 8. Amount of EPI Remaining after Storage at -21ºC in Desorbing Solutions 
Desorbing  EPI Remaining after Storage at -21ºC (% of initial concentration) 
Solution             6 Weeks       12 Weeks 
Acetonitrile:water 10:90   65.4   63.0 
Normal saline     92.4   83.5  
Phosphate buffer, pH 4.0   99.0   99.2 
Phosphate buffer, pH 4.0, 30% acetonitrile 99.8   99.5 
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The mean value after storage was considered acceptable within +/-5% of the nominal 
concentration.168 After 6 weeks of storage at -21ºC, EPI was most stable in the 
phosphate buffer (0.01 M, pH 4.0) desorbing solutions. Phosphate buffer (0.01M, pH 
4.0) with 30% acetonitrile (v/v) was selected as the desorbing solution for EPI. The 
conditions of the analytical method for MTX and CP were adjusted to include MTX 
and CP, in a single recovery method, for all three drugs using this desorbing solution. 
3.6.8  Methotrexate Method Development 
 The method which measures MTX in urine164 was adopted to measure MTX in 
desorbing solution. The reagent volumes were scaled down by a factor of 25 without 
changing the volume of MTX. Potassium permanganate (0.01 M, 200 µL) and acetic 
acid buffer (0.005 M, pH 5.0, 200 µL) were added to MTX (100 µL) in desorbing 
solution. After 35 mins hydrogen peroxide (30%, 60 µL) was added. The pH was 
adjusted to 6.2 with aqueous sodium hydroxide (1.0 M) and the sample was diluted 
1:20 in mobile phase. 
 MTX’ produces two excitation maxima located close to 280 and 380 nm, and 
one emission maxima at 457 nm.165 The selected excitation wavelength was 380 nm, 
as the background noise recorded by the detector appeared to be visually less noisy at 
this wavelength. The emission wavelength was set at 458 nm (the wavelength settings 
on the fluorescence detector were in increments of 2). 
 Reverse-phase ODS silica gel is the stationary phase employed most 
frequently for the separation of MTX.130 Acetonitrile is the typical organic solvent 
combined with an aqueous buffer ranging from pH 2.5 to 6.7.130 The method adopted 
used a tris-sodium chloride buffer. However, experimentally the MTX’ peak which 
eluted under these mobile phase conditions had a peak symmetry value of 5.49. Peak 
tailing was measured at 20% of the peak height, where A was the distance from peak 
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front to peak maximum and B was the distance from peak maximum to peak end. 
Ideally, chromatographic peaks are Gaussian-shaped,161 and peak symmetry should be 
1 i.e. A = B, but in practice, most peaks show some tailing and are acceptable within 
the peak symmetry range of 0.8 to 1.5.161 The mobile phase was substituted with 
phosphate (0.01 M) pH 6.2 and 5% acetonitrile (v/v). This improved peak symmetry 
(peak symmetry value = 1.1). The scaling down of reagents and the final dilution with 
mobile phase had no effect on the sensitivity of the method.  
3.6.9  Cyclophosphamide Method Development 
 For compatibility with the desorbing solution, the ammonium sulfate buffer 
(0.005 M) of the mobile phase was substituted with phosphate buffer (0.01 M), pH 
3.1. This gave a larger detector response i.e. a 50 µg mL-1 solution of CP diluted in 
desorbing solution gave a detector response, in terms of peak area, of 1154 when 
using phosphate buffer and 316 when using the original ammonium sulfate buffer in 
the mobile phase. 
 The wavelength 210 nm is at the lower end of the UV spectrum and one where 
there is the possibility of other interfering compounds absorbing. To limit the 
absorption of other compounds which may interfere at the CP retention time window, 
the organic portion of the mobile phase i.e. methanol, was substituted with Far UV 
acetonitrile. This has a lower UV cut-off point at 190 nm, compared to methanol, 
which has a cut-off point at 210 nm. The proportion of organic solvent was modified 
to acetonitrile (10%). At 210 nm, absorbing peaks were observed in the recovery 
sample. These peaks were also observed in blank wipe recovery samples but they 
were not observed in the standard samples. 
 Resolution (R) is the measure of the degree of separation between two 
successively eluting components in a chromatogram. A resolution of greater than 1.5 
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was considered acceptable for baseline separation of the two peaks.161 The retention 
time of CP was 4.7 min and the nearest adjacent peak eluted at 3.3 min. The 
resolution between the peak and the CP parent peak was 2.5 at 3.3 min, indicating that 
the peaks were resolved and did not interfere with the integration of CP.  
The parameters of retention time, peak symmetry, resolution of any absorbing peaks, 
and sensitivity (measured as the LoQ) for EPI, MTX and CP are summarised in 
Table 9 below. Examples of chromatograms for each analyte are shown in Appendix 
4 (Figures 55, 56 and 57). 
 
Table 9. HPLC Assay Parameters and Sensitivity of EPI, MTX and CP  
Parameters  EPI   MTX   CP
 
Retention Time 5.7 min  2.2 min  4.7 min 
Peak Symmetry 1.2   1.1   1.5 
 
Resolution from N/A   N/A   2.5@ 3.3 min 
Interfering Peaks        
 
Sensitivity (LoQ) 0.4 ng mL-1  10 ng mL-1  5.0 µg mL-1 
 
N/A = not applicable 
 
 
3.6.10  Selection of Wipe Material and Collection Vessel 
 Wiping and immersion must consider the size of the container to fit the wipe 
or immersed surface. This will influence the volume of desorbing solution required, 
which will ultimately affect the sensitivity of the analytical method. The wipe or swab 
material must be low-linting and sterile. It must also fit into the collection vessel. Dry 
wipes with aqueous sodium hydroxide are used commonly for wipe sampling, 
whereby aqueous sodium hydroxide is pipetted onto the surface then wiped with the 
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dry wipe.20;26;28;29;126 The use of a sterile impregnated wipe rather than a dry wipe was 
investigated. Wipes impregnated with 70% v/v alcohol (IPA or IMS) and 30% v/v 
WFI, are used for cleaning and controlling microorganism levels in a clean-room 
environment. An impregnated wipe is convenient, easier and quicker to use, ensures 
the equal distribution of wetting agent, leaves no residue and would reduce the 
amount of materials taken into the sterile environment.  
In Section 4.5.2, IMS (70%) / WFI (30%) v/v was effective in removing 
cytotoxic contamination of 5-FU, CP, DOX and EPI from a small surface area. IPA 
(70%) / WFI (30%) v/v impregnated wipes have been used successfully to remove 
and recover surface contamination of 5-FU, a very polar molecule, with recoveries of 
84.6%149 and 90.7%.150 Therefore, alcohol-impregnated wipes available commercially 
were investigated for use in this study. They varied according to surface area, weight 
and material - see Table 10 below. 
 
Table 10. Specifications of the Alcohol-Impregnated Wipes Investigated 
Wipe  Wipe Composition           Dry Weight Dimensions 
           (gm-2)        (mm) 
Cliniwipe viscose rayon,  
styrene butadiene synthetic rubber, 22     200 × 220 
surfactant and antifoam    (+/- 2.2g)  
70% v/v IPA (3 mL per wipe) 
 
Spiriclens viscose rayon,    22     200 × 220 
styrene butadiene synthetic rubber   
  70% v/v IPA 
 
Klerwipe™  70/30 polyester cellulose blend  22 or 42   200 × 230 
  70% v/v IPA or IMS 
       
Stericlean®  polyester cellulose blend  66    230 × 230 
Flowrap 70% v/v IPA 
    
Stericlean®   rayon/ polypropylene mix  1.1    67 × 32 
prep pad 70% v/v IPA (+/- 0.08%)   (+/- 0.2g) 
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 The material of the collection vessel (tube) must be able to withstand study 
storage temperatures and be compatible with the drugs and solution stored inside. EPI 
may bind to glass and polyethylene,169 therefore these materials were not considered. 
The study for which this method was developed involved an intense sampling 
protocol and a high volume of wipe samples (see Sections 5.4.7 and 5.4.8), requiring 
960 tubes. Considering the number of tubes required to be taken into the study area, 
transported and stored, they should be as small as possible. Ideally, the volume of 
desorbing solution should be minimal, and to prevent oxidation of the drug the 
headspace in the tube should also be kept to a minimum. Polypropylene centrifuge 
tubes (15 mL) were selected as the collection/storage vessel. Polypropylene is a 
suitable storage material as it can withstand temperatures of -21ºC, it is resistant to 
acidic pH and compatible with EPI and CP.24  
 The wipe must fit into the tube, allowing maximum contact with the desorbing 
solution. Wipes with a mass of 42 gm-2 or 66 gm-2 were too large and would need to 
be folded or rolled to fit into a tube of such a small neck diameter. This may be 
awkward to perform in practice and may cause the spread of cross-contamination by 
unavoidable contact with the wipe.  
 The lower weight wipes (22 gm-2) i.e. Spiriclens, Cliniwipe, Klerwipe™ (IMS 
and IPA) showed significant interference with the HPLC assays. When blank samples 
of drug-free desorbing solution containing these wipes were injected onto the HPLC 
column for each assay, a peak eluted at the EPI (when excited at 254 nm) and MTX 
peak retention time windows. To confirm the interference, each solution was scanned 
using a UV spectrophotometer. A large absorbing peak from each blank wipe solution 
was observed in the UV region of the spectrum. The wavelength of maximum 
absorbance of the scan was 257 nm for the Spiriclens wipe, 268 nm for the 
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Cliniwipes, 271 nm for the Klercide™ wipe, and 254 nm for the Stericlean Flowrap® 
wipe. MTX absorbs at 280 nm,165 EPI absorbs at 254 nm (and also at 480 nm).160 
Blank samples of desorbing solution i.e. containing no wipes or drug contamination, 
showed no interference or absorption across the UV spectrum. This confirmed that the 
interference observed in the chromatograms was from the wipe material. In-house 
studies which have used Cliniwipes to recover 5-FU, required a 1:5 dilution of the 
desorbate to eliminate the interference from this wipe, ultimately this affected the 
sensitivity of the method.150  
 Another requirement for the wipe was to have a constant size and weight to 
ensure consistent performance with respect to the absorption and desorption of 
contaminants. These data were only available for two of the six wipes i.e. the 
Cliniwipes and the Stericlean® prep pads. 
 The small dimensions (6.7 cm × 3.2 cm) of the Stericlean® prep pads (wipes) 
enabled them to be retained in a small collection tube without folding or rolling. The 
size of the wipe required a minimal amount of desorbing solution to cover its surface 
area. This would maximise recovery from the wipe and would not compromise the 
sensitivity of the method. This wipe did not interfere with the drug assays, compared 
with the other proprietary wipes. These wipes are also wrapped individually, 
preventing evaporation and ensuring a consistent volume of IPA.  
3.6.11  Recovery of Cytotoxic Surface Contamination - Wiping and Immersion 
 Methods to extract the drug contamination from the wipe or the immersed 
surface into the desorbing solution were developed. These methods should recover the 
maximum amount of surface contamination with acceptable reproducibility. The 
recovery method was based on a procedure, used in-house, previously to measure 5-
FU surface contamination in the commercial Aseptic Services Unit, Department of 
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Pharmacy and Pharmacology, University of Bath.149;150 This procedure used a wipe 
(Cliniwipe) impregnated with alcohol (70% v/v IPA) for the removal of 
contamination from various surfaces. The wipe was collected into a 50 mL tube 
containing desorbing solution (40 mL) which was a mixture of acetonitrile:water 
(10:90). 5-FU contamination was removed from the wipe by vortexing the tube for 5 
min, followed by centrifugation at 1500 × g for 30 min. 
3.6.12  Surfaces Tested 
 Areas inside (including gloves) and outside of the isolator were selected from 
which to recover cytotoxic contamination after input from technicians, a visit to an 
ASU, literature review and the results presented in Table 4 (page 74). 
 The areas chosen inside the isolator were the base, sleeves, gloves and the 
hatch doors. These are areas of close proximity to the cytotoxic preparation process 
and are likely to be highly contaminated. The surfaces inside the isolator were made 
of stainless steel (base), Perspex™ (screen of the hatch door), Hypalon® (sleeves) and 
latex (gloves).  
 The areas selected in the clean-room to be measured were the floor, trays and 
support gloves. Contamination of CP and MTX has been measured on the floor 
directly in front of the isolator when preparing cytotoxic drugs,26;28 and gloves are 
likely to be highly contaminated.26;28;109 The tray is an object of high use and contact, 
i.e. for collecting and transporting consumables into the clean-room and taking items 
into and out of the isolator. Surfaces outside the isolator were made of vinyl (floor), 
plastic (trays) and nitrile (support gloves). The finished batches of syringes 
(polypropylene) leaving the isolator were also selected to be swabbed to identify if the 
contamination risk originating from the isolator may possibly be transferred to the 
outside environment. 
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 A Perspex™ template with dimensions of 21 cm × 21 cm (441 cm2) was cut 
and used to mark out an area on the floor, and areas of this size on the stainless 
surface of a BSC, the base of which is similar to that of an isolator. Portions of the 
surface materials were obtained; a portion of Perspex™ measuring 31 cm × 23 cm  
(713 cm2) - the same area as the screen of the hatch door of the isolator, a portion of 
vinyl measuring 21 cm × 21 cm (441 cm2) - the same material as the clean-room floor, 
nitrile gloves, latex gloves, syringes, and trays measuring 24 cm × 29 cm (696 cm2) of 
the same type to be used in the study. 
3.7  Method 2 - Optimisation 
 Phosphate buffer (0.01 M, pH 4.0) was autoclaved at 115ºC (15 psi) for 30 
mins and 3.5 mL was pipetted into sterile tubes under aseptic conditions. The wipes 
were collected into this solution, and acetonitrile (1.5 mL) added prior to applying the 
recovery method.  
3.7.1  Swabbing/Wiping Procedure 
 It was important that the designated surfaces were wiped in a methodical way 
to recover consistently the maximum amount of contamination. The method of wiping 
was developed for each individual surface and was carried out in a BSC using tongs, 
IPA wipes (Stericlean® prep pads), 15 mL collection tubes containing desorbing 
solution (3.5 mL) and the 441 cm2 template (floor and isolator base only). 
 To minimise exposure to the researcher, portions of each surface were placed 
in the BSC and contaminated deliberately. The following solutions were pipetted onto 
each surface: EPI (0.1 mg mL-1 × 50 µL), MTX (25 mg mL-1 ×10 µL) and CP (4 mg 
mL-1 1×25 µL), and allowed to dry. Using the tongs, the wipe was placed, unfolded, 
on the surface. Immediately, the surface was wiped by moving the wipe over it (using 
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tongs was safer than touching the wipe and prevented any cross-contamination from 
gloves).  
 
Wiping Method for the Hatch Door, Tray, Isolator Base, and Floor 
 The flat surfaces i.e. hatch door (1 wipe per side), tray (1 wipe), 3 spot areas 
on the isolator base (3 wipes), and the floor (1 wipe) were wiped in a four-step 
parallel overlapping action as shown schematically below and on the following page; 
 
1. The area was wiped using horizontal strokes. Starting in the upper left-hand corner 
the wipe was moved from left to right, and back travelling downwards 
horizontally, covering the whole area with the wipe; 
 
 
 
 
 
 
 
2. When arriving in the lower corner, the edge of the area was wiped around once in a 
clockwise direction; 
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3. The same area was wiped using vertical strokes. The wipe was turned over and 
moved travelling across vertically and covering the whole of the area; 
 
 
 
 
 
4. When arriving in the lower corner, the edge of the area was wiped around once 
again in a counter-clockwise direction.  
 
 
 
 
  
 It was not possible to swab the whole of the isolator base with a wipe of such 
small dimensions. Therefore, three spot areas were identified for wiping totalling 
1323 cm2 (21% of the area of the isolator base). They were 1. the far top left-hand 
corner; 2. the far top centre, and 3. the far top right-hand corner, as shown 
schematically below;  
 
 
1 2 3 
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Wiping Method for the Sleeves 
 It was awkward to wipe the sleeve as it was not flat or rigid. Therefore, only 
the cuff was wiped. The left cuff was wiped with the right hand, and vice versa. The 
wipe was placed on the cuff and wiped around three times. The wipe was turned over 
and again the cuff was wiped around three times. One wipe was used for each cuff. 
 
Wiping Method for the Syringes 
 One wipe was used each for the barrel and plunger of the syringe, and 
combined in the same tube. The wiping method for the syringe is shown in Figure 26 
below. The wipe was moved up and down the syringe barrel three times (a), while 
turning the syringe with the other hand (b). The wipe was turned over and used to 
wipe the hub of the capped syringe. The second wipe was placed in one of the groves 
of the syringe plunger, in contact with both sides of the grove and moved up and 
down each grove three times each grove (c).  
 
Figure 26. Wiping Method for the Syringe Barrel and Plunger 
 
 
Each wipe was placed immediately into a collection tube containing desorbing 
solution (3.5 mL). The tube was sealed tightly with the cap, and the wipe was shaken 
a 
b c b 
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down into the solution. Acetonitrile (1.5 mL) was added and the tubes were inverted 
10 times. 
3.7.1.1  Recovery from the Wipe into the Desorbing Solution  
 Vortexing and centrifugation were investigated to extract the drug from the 
wipe into the desorbing solution. The additional push of the wipe and solution 
through a 10 mL syringe was investigated to further improve on recovery. 
 The following recovery methods were investigated: vortexing vigorously for 1 
min; vortexing vigorously for 1 min followed by centrifugation for 5, 10, 20 or 30 
min (3500 × g at 20°C) and in addition, pushing the solution and wipe through a 10 
mL syringe after 30 min of centrifugation.8;109;130  
 All methods were investigated in triplicate and analysed in duplicate by 
HPLC. The mean value of the triplicate samples was taken and the percentage 
recovery calculated against a standard spiked with the same concentration. The CV 
was determined for each recovery method. A CV within the range of +/-15% was 
considered acceptable.162 The results are presented in Table 11 on the following page. 
 
 Vortexing alone was a very poor method to extract CP from the wipe with 
only 4.9% recovery achieved. Centrifugation, in addition to vortexing greatly 
increased the recovery of CP to approximately 50%. The recovery of MTX increased 
with centrifugation time, with 91.8% recovered after 30 min with good precision (CV 
= 4.5%). In addition to vortexing, centrifugation increased the recovery of EPI, with 
87.3% recovery observed after centrifugation for 30 min with excellent precision 
around this value (CV = 0.2%). This was a slight improvement on vortexing alone 
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Table 11. Amount of Drug Recovered and Reproducibility of the Different Recovery 
Methods for EPI, MTX and CP 
Recovery Method            Mean Recovery of Drug (%)  
      EPI (1 µg mL-1)    MTX (50 µg mL-1)   CP (100 µg mL-1) 
 
vortex for 60 sec  82.9   63.7   4.9 
 CV = 3.2  CV = 14.3  CV = 7.1 
 
vortex for 60 sec,   74.8   64.2   50.0 
centrifuge for 5 min   CV = 2.6  CV = 4.8  CV = 2.4 
 
vortex for 60 sec,  86.8   74.3   52.3 
centrifuge for 10 min  CV = 4.8  CV = 13.8  CV = 1.0 
 
vortex for 60 sec,  84.4   83.3   50.9 
centrifuge for 20 min  CV = 4.8  CV = 6.0  CV = 0.5 
 
vortex for 60 sec,  87.3   91.8   50.7 
centrifuge for 30 min  CV = 0.2  CV = 4.5  CV = 2.3 
 
vortex for 60 sec,   88.7   91.4   100.8 
centrifuge for 30 min,  CV= 3.3   CV = 4.1  CV = 45.1 
push through a 10 mL syringe 
 
CV = coefficient of variation 
  
  
 The additional push of the solution though a 10 mL syringe after vortexing (1 
min) and centrifugation (30 min) did not improve further the recovery of MTX, or 
improve significantly the recovery of EPI from the wipe. The recovery of these two 
drugs was already high i.e. EPI (87.3%) and MTX (91.8%). It did improve the 
recovery of CP significantly; the percentage recovered increased two-fold from 50.7% 
to 100.8%. However, this method could not be used to recover CP with acceptable 
reproducibility, as a CV of 45.1% for the method greatly exceeded the acceptable 
range of +/-15%. This meant that there was a large variation in the spread of the 
results between repeated measures. It was difficult to transfer the samples (wipe and 
desorbing solution) from the collection tube into the barrel of the syringe without any 
spillages. Loss of the desorbing solution would affect the percentage recovery 
calculation, giving a misleadingly higher result. Consequently, reproducibility 
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between samples would not be acceptable. This was also a time-consuming procedure 
and was not pursued further.  
 Centrifugation introduced a constant method with less room for operator 
variability between samples. With centrifugation time, an increasing amount of MTX 
was extracted, and a slight increase in the recovery of EPI was observed, possibly as 
the solution desorbed from the wipe with time by the centrifugal force applied.   
 Methods to increase recovery were not as successful for CP, as for EPI or 
MTX. A summary of analytical procedures, reported drug recoveries from 
environmental matrices, to range from 60 to 100%.8 A higher recovery of CP from 
the wipe may have been achieved at a higher centrifuge speed however, this was the 
maximum safe centrifuge speed for the type of tube used.150 A second wipe from the 
surface was negative for CP contamination (and for EPI and MTX), confirming that 
all the contamination had been removed from the surface by the wipe or at least to a 
level below the LoD. The percentage of CP recovered was approximately 50%, 
depending upon the method. This was considered low,148 but it was reproducible. 
3.7.1.2  Number of Wipes and Volume of Desorbing Solution 
 The feasibility of combining two or three wipes in one tube i.e. the three wipes 
taken from the isolator base, without significantly affecting the recovery from the 
wipes, was investigated. In combination, the probability of a sample above the LoD of 
the analytical method would be greater than the analysis of the samples separately. To 
further improve on sensitivity, smaller volumes of desorbing solution i.e. 2.5 mL and 
2.0 mL were investigated and combined in the same experiment.  
 To investigate one wipe, an aliquot was pipetted equally onto one area of the 
base of the BSC: EPI (0.1 mg mL-1 × 50 µL), MTX (25 mg mL-1 × 10 µL) and CP (4 
mg mL-1 × 125 µL). To investigate two wipes, two aliquots were pipetted equally onto 
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two separate areas of the base, and for three wipes, three aliquots were pipetted 
equally onto three separate areas of the base. One wipe was used for each area and all 
wipes were combined in a centrifuge tube containing the following volumes of the 
aqueous buffer part of the desorbing solution; 3.5 mL (to investigate 5.0 mL), 1.75 
mL (to investigate 2.5 mL) and 1.4 mL (to investigate 2.0 mL). The following 
volumes of acetonitrile were added 1.5 mL, 0.75 mL and 0.6 mL, respectively. The 
tubes were inverted 10 times, vortexed (30 secs) and centrifuged (3500 × g at 20°C). 
An aliquot of the desorbing solution was transferred to autosampler vials for assay by 
HPLC. The tests were carried out in triplicate and analysed by HPLC in duplicate. 
The mean value of the triplicate samples was taken and the percentage recovery 
calculated against a standard spiked with the initial concentration. The reproducibility 
of each test was calculated and quoted as the CV. Again, a CV of +/-15% was used to 
show acceptable reproducibility.162 The results are presented in Table 12 on the 
following page. 
 
 The mean percentage recovery of EPI, MTX and CP was highest in 5.0 mL of 
desorbing solution. There was no significant difference between the recovery of EPI, 
MTX or CP when using one, two or three wipes in this volume. Reducing the volume 
of desorbing solution from 5.0 mL to 2.0 mL caused a significant decrease in the 
amount of CP recovered from one wipe i.e. from 50.7% to 37.4%, respectively, and 
from 48.2% to 27.8%, respectively when three wipes were combined. Recoveries of 
CP into 2.5 mL and 2.0 mL of desorbing solution were not reproducible. The CV was 
greater than +/-15% when using 2 or 3 wipes to recover CP into 2.0 mL of desorbing 
solution, and when using 2 wipes to recover MTX into 2.5 mL of desorbing solution. 
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Table 12. Recovery and Reproducibility of Method Following Variation of Desorbing 
Solution Volume and Number of Wipes 
Desorbing Number               Mean Recovery of Drug (%)      
Volume of Wipes   EPI (1.0 µg mL-1)  MTX (50 µg mL-1)  CP (100 µg mL-1) 
5.0 mL      1  94.4   91.8   50.7 
CV = 0.2%  CV = 4.5%  CV = 2.3% 
 
5.0 mL      2  95.1   98.5   50.2 
CV = 4.7%  CV = 3.2%  CV = 10.3% 
 
5.0 mL      3  91.0   98.5   48.2 
CV = 9.9%  CV = 2.0%  CV = 12.0% 
 
 
2.5 mL      1  91.5   86.8   47.3 
    CV = 3.3%  CV = 9.7%  CV = 19.1% 
 
2.5 mL      2  85.6   79.7   47.4 
    CV = 1.7%  CV = 17.6%  CV = 7.0% 
 
2.5 mL    3  85.1   69.4   43.4 
    CV = 6.9%  CV = 12.0%  CV = 10.9% 
 
 
2.0 mL      1  91.2   84.7   37.4 
    CV = 2.5%  CV = 1.7%  CV = 12.0% 
 
2.0 mL      2  84.6   75.0   37.3 
    CV = 2.8%  CV = 2.2%  CV = 26.1% 
 
2.0 mL      3  85.1   82.8   27.8 
    CV = 12.0%  CV = 11.7%  CV = 18.6% 
 
CV = coefficient of variation 
 
 
3.7.2  Immersion  
 Methods to measure contamination on gloves were based on immersion of the 
gloves in sodium hydroxide solution (100 mL)28 or in ultra-pure water (20 mL)68 with 
continual mixing for 120 min,28 or 180 min.68 In order not to compromise the 
sensitivity of the method, 10 mL of desorbing solution was investigated. The 
following solutions were pipetted onto each type of glove (the latex isolator glove or 
the nitrile support glove) in triplicate, and allowed to dry in a BSC: EPI (0.1 mg mL-1 
× 50 µL), MTX (25 mg mL-1 × 10 µL) and CP (4.0 mg mL-1 × 125 µL). When dry, 
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each glove, contaminated side out was placed into a 250 mL polypropylene container. 
This volume of container was the smallest size available, which would fit the glove 
unfolded with a minimum amount of unexposed surface area. A 10 mL volume of 
desorbing solution i.e. phosphate buffer (0.01 M, 7.0 mL) pH 4.0 and acetonitrile (3.0 
mL), was pipetted over the surface of the glove. The lid of the container was secured, 
and the container vortexed vigorously for 1 min, ensuring the desorbing solution 
made contact with the surface of the glove. The container was agitated continuously at 
300 rpm on an orbital shaker. The variation of recovery of drug from each glove type 
with agitation time was investigated. An aliquot of the desorbing solution was 
removed and transferred to autosampler vials for analysis by HPLC. The results of 
recovery with agitation time are expressed in Table 13 below. 
 
Table 13. Recovery with Agitation Time of EPI, MTX and CP from Gloves  
Agitation Time   Mean Recovery of Drug (%)  
     (min)  EPI (0.5 µg mL-1)  MTX (25 µg mL-1)      CP (50 µg mL-1)
 
Isolator glove  
    30   86.9 (cv = 1.5%) 92.2 (cv = 2.8%) 50.3 (cv = 0.7%) 
    60   85.3 (cv = 0.9%) 93.8 (cv = 1.8%) 52.1 (cv = 1.8%) 
    120   88.4 (cv = 2.6%) 89.5 (cv = 3.2%) 51.9 (cv = 2.5%) 
    180   86.2 (cv = 3.1%) 91.7 (cv = 3.3%) 50.2 (cv = 4.4%) 
 
Support Glove 
    30   86.0 (cv = 2.1%) 89.7 (cv = 4.9%) 50.1 (cv = 4.7%) 
    60   84.3 (cv = 3.8%) 87.4 (cv = 1.5%) 52.5 (cv = 1.1%) 
    120   82.1 (cv = 3.2%) 88.6 (cv = 4.5%) 55.0 (cv = 3.6%) 
    180   86.9 (cv = 2.4%) 86.9 (cv = 6.2%) 51.9 (cv = 2.4%) 
 
CV = coefficient of variation 
 
 
Agitation for 30 min recovered each drug from both glove materials with acceptable 
reproducibility. There was no significant increase in recovery of EPI, MTX or CP 
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with agitation for a longer period of time from either glove material, therefore 30 min 
was selected as the optimal agitation time. 
3.7.3  Summary of the Sampling Procedure and Final Analytical Method for EPI, 
MTX and CP 
 The contaminated areas (isolator base, hatch door, sleeves, trays, floor and 
external surfaces of syringes) were wiped, as described in Section 3.7.1. The wipes 
were placed into tubes containing the desorbing solution i.e. phosphate buffer (0.01 
M, 3.5 mL) pH 4.0. Acetonitrile (1.5 mL) was added and the tubes were vortexed 
vigorously for 1 min, followed by centrifugation for 30 min at 3500 × g (5ºC). 
 Contaminated gloves (isolator and gloves) were placed into 250 mL 
containers. Desorbing solution (10 mL) i.e. phosphate buffer (0.01 M, 7.0 mL) pH 4.0 
and acetonitrile (3.0 mL) was pipetted over the glove. The containers were capped 
and vortexed vigorously for 30 sec, followed by agitation on an orbital shaker at 300 
rpm for 30 min. 
 
The sampling procedure and recovery method used to remove EPI, MTX and CP 
contamination from various surfaces is summarised schematically in Figure 27 on the 
following page. 
After centrifugation or agitation, aliquots of the desorbing solution were transferred 
into autosampler vials for analysis of EPI and CP by HPLC. For MTX, an aliquot of 
100 µL was pipetted into a 7.0 mL tube, for the oxidation procedure of MTX to 
MTX’. Potassium permanganate (0.01M, 200 µL) and acetic acid buffer (0.005 M, 
200 µL) were added. After 35 min, the reaction was quenched by the addition of 
hydrogen peroxide (30%, 60 µL), followed by aqueous sodium hydroxide (1.0 M, 
38.4 µL) to adjust the pH to 6.8. The sample was further diluted 1:20 in mobile phase. 
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Figure 27. Schematic Summary of the Sampling Procedure and Recovery Method 
       
 
 
 
           isolator base (3 wipes)    isolator gloves, right and left (2) 
      hatch door, right (2 wipes, 1 each side)  support gloves, right and left (2) 
      hatch door, left (2 wipes, 1 each side) 
          sleeve, right (1 wipe each) 
          sleeve, left  (1 wipe each)     
            tray (1 wipe per tray)  
                  floor (1 wipe) 
               syringe (2 wipes)   
         
 
 
  
   polypropylene tube (15 mL)     collection bag 
    + phosphate  buffer        
   (0.01 M, 3.5 mL, pH 4.0)      
 
 
 
     
   
 
         add acetonitrile (1.5 mL)        immerse in 250 ml container + 
           phosphate buffer (0.01 M , 7.0 mL,
             pH 4.0) + acetonitrile (3.0 mL)
          
            invert tube × 10        
   vortex vigorously (1 min)    vortex vigorously for 1 min 
   centrifuge (3500 × g, 30 min)   agitate (300 rpm, 30 min) 
 
 
 
 
 
 
 
The final analytical method for each drug was as follows:  
 
EPI was analysed using a 250 × 4.6 mm stainless steel column packed with 
Techsphere CN (5 µm particle size). The mobile phase was phosphate buffer (0.05 
GLOVES 
Collection 
Storage in 
freezer at -21ºC 
 
Thaw 
WIPES 
Removal of aliquot for analysis of EPI, MTX and CP by HPLC 
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M, pH 4.0) with 35% acetonitrile (v/v). Excitation was carried out at 480 nm and 
emission at 560 nm using a fluorescence detector. The gain was set at x1000. EPI 
eluted at a retention time of 5.7 min. The autosampler injection needle was flushed 
with 2 × 500 µL acetonitrile:water (50:50) v/v after each injection.  
 
MTX was analysed using a 150 × 4.6 mm stainless steel column packed with 
Techsphere C18 (5 µm particle size). The mobile phase was phosphate buffer (0.01 
M, pH 6.2) with 5% acetonitrile (v/v). Excitation was carried out at 380 nm, and 
emission at 458 nm using a fluorescence detector. The gain was set at x1000. MTX’ 
eluted at a retention time of 2.2 min. The autosampler injection needle was flushed 
with 2 × 500 µL of acetonitrile:water (50:50) v/v after each injection.  
 
CP was analysed using a 250 × 4.6 mm stainless column packed with CN (5 µm 
particle size). The mobile phase was phosphate buffer (0.01 M, pH 3.1) with 10% 
acetonitrile (v/v). Detection was by UV at 210 nm. CP eluted at a retention time of 
4.7 min. The autosampler injection needle was flushed with 2 × 500 µL of 
acetonitrile:water (50:50) v/v after each injection.  
Each column was flushed at the end of the sample run or at the end of the day. The 
flush solution was 10 column volumes of Milli-Q grade water, followed by either 
acetonitrile:water (50:50) v/v, which was also the storage solution. 
3.8  Method 2 - Validation 
 The recovery method was validated to remove and quantify EPI, MTX and CP 
from eight surfaces of different material and topology i.e. the isolator base, hatch 
door, syringes, floor, tray, sleeves, support gloves and isolator gloves. Portions of 
each type of surface were obtained and cut or marked out to the same size of the areas 
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identified inside and outside the isolator that were to be investigated (see Section 
3.6.12). Each area was contaminated deliberately by pipetting a volume of drug 
solution of known concentration over the surface and allowing it to dry in a BSC. 
3.8.1  Contamination of Surfaces 
 Wiping was used to remove surface contamination from the isolator base, 
hatch door, sleeves, trays, floor and surfaces of syringes, as described in Section 3.7.1. 
Immersion was used to recover surface contamination from the gloves, as described in 
Section 3.7.2. Contamination-free surfaces were wiped or immersed and carried 
through the recovery process to ensure a blank response and no interference from any 
of the surfaces. 
3.8.2  HPLC Assay 
 The mobile phase was prepared as described in Section 3.4.6. For each assay, 
elution was isocratic, the flow rate was 1 mL min-1, and the injection volume was 
100 µL. The recovered solutions were assayed in duplicate and the mean of the peak 
areas calculated. The chromatograms of all samples were processed using Prime 
software (Version 4.2.0). 
3.8.3  Specificity/Selectivity 
 The specificity of each method was determined by measuring for any 
compounds other than the analyte of interest absorbing at the same wavelength under 
the chromatographic conditions for each drug. These compounds may be 
contaminants from the surface material or wipe, or from co-prepared drugs, which 
may absorb at the same wavelength. The response was measured from recovered 
drug-free surface samples, and from solutions spiked with the co-prepared drugs, i.e. 
the specificity of the method for EPI was tested by injecting samples containing only 
  132
MTX and CP, and vice versa for MTX and CP. The selectively of the method to 
resolve any potentially interfering compounds from the analyte peak of interest was 
assessed by calculating the resolution (R) between the retention times of the two 
adjacent peaks.  
 A lack of response above the LoD of the analytical method across the 
retention time window for EPI or MTX was observed in blank wipe samples. The 
presence of compounds absorbing at the same wavelength was observed on the CP 
chromatogram, however these were well resolved from the CP peak i.e. R was greater 
than 1.5, and did not interfere with the analysis of CP (see Section 3.6.9). 
 There was no interference from any co-prepared drugs i.e. there was no 
interference from the presence of MTX or CP across the EPI retention time window, 
and vice versa for MTX and CP.  
3.8.4  Limit of Quantification and Limit of Detection  
 The LoQ of the analytical method was 0.4 ng mL-1 for EPI, 10 ng mL-1 for 
MTX and 5.0 µg mL-1 for CP. The LoD of the analytical method was 0.2 ng mL-1 for 
EPI, 5.0 ng mL-1 for MTX and 2.5 µg mL-1 for CP.      
  
Limit of Quantification and Limit of Detection per Surface 
 The LoQ and the LoD per surface were expressed as mass of drug per unit of 
surface area i.e. ng cm-2. The LoQ and LoD values per surface for each of the three 
drugs are shown in Tables 14 and 15 on the following page. These values per surface 
area could only be calculated for surfaces which were measurable i.e. the isolator 
base, hatch door, floor and tray. The sleeves, gloves and syringes are expressed as 
nanograms (EPI and MTX) or micrograms (CP) per sleeve, glove or syringe. 
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Table 14. Limit of Quantification of EPI, MTX and CP per Surface Sampled 
         Limit of Quantification per Surface 
Surface          EPI         MTX         CP 
Isolator Base  0.002 ng cm-2  0.04 ng cm-2  18.9 ng cm-2 
Hatch Door  0.003 ng cm-2  0.07 ng cm-2  35.1 ng cm-2 
Tray   0.003 ng cm-2  0.07 ng cm-2  35.9 ng cm-2 
Floor   0.005 ng cm-2  0.11 ng cm-2  56.7 ng cm-2 
Sleeve   2.0 ng per sleeve 50.0 ng per sleeve 25.0 µg per sleeve 
Syringe  2.0 ng per syringe 50.0 ng per syringe 25.0 µg per syringe 
Support Glove  4.0 ng per glove 100 ng per glove 50.0 µg per glove 
Isolator Glove  4.0 ng per glove 100 ng per glove 50.0 µg per glove
 
 
 
Table 15. Limit of Detection of EPI, MTX and CP per Surface Sampled 
     Limit of Detection per Surface 
Surface        EPI      MTX         CP 
Isolator Base  0.001 ng cm-2  0.02 ng cm-2  9.50 ng cm-2 
Hatch Door  0.001 ng cm-2  0.04 ng cm-2  17.5 ng cm-2 
Tray   0.001 ng cm-2  0.04 ng cm-2  18.0 ng cm-2 
Floor   0.002 ng cm-2  0.06 ng cm-2  28.3 ng cm-2 
Sleeve   1.0 ng per sleeve 25.0 ng per sleeve 12.5 µg per sleeve 
Syringe  1.0 ng per syringe 25.0 ng per syringe 12.5 µg per syringe 
Support Glove  2.0 ng per glove 50.0 ng per glove 25.0 µg per glove 
Isolator Glove  2.0 ng per glove 50.0 ng per glove 25.0 µg per glove 
 
 
 
3.8.5  Linearity and Range 
 Linearity of recovery was demonstrated over the concentration range of 0.4 ng 
mL-1 to 1500 ng mL-1 for EPI (n= 7), 10 ng mL-1 to 1200 ng mL-1 for MTX (n= 7), 
and 5.0 µg mL-1 to 500 µg mL-1 for CP (n= 6). The calibration plots were linear over 
the selected concentration range with least-squares regression analysis giving a 
correlation coefficient (R2) of >0.99 (see Table 16 on the following page), indicating a 
good dynamic range (x denotes the independent variable, in this case the 
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concentration of EPI, MTX or CP, and y denotes the dependent variable, in this case 
peak area). This was confirmed with visual inspection of the plot.  
 
Table 16. Least-Squares Regression Coefficient (R2) Values for the Recovery of EPI, 
MTX and CP from all Surfaces 
        R2 
Surface  EPI   MTX   CP
 
Isolator Base  0.994   0.997   0.999 
Hatch Door  0.995   0.999   0.995 
Tray   0.995   0.999   0.997 
Floor     0.996   0.999   1.000 
Sleeve   0.990   0.993   0.991 
Syringe  0.996   0.997   0.994 
Support Glove  0.996   0.999   0.996 
Isolator Glove  0.996   0.996   0.998 
 
 
 
The percentage recovery of each concentration from which the calibration plot 
was devised are shown in Table 17 (EPI), Table 18 (MTX) and Table 19 (CP) on the 
following pages. The least squares regression equations given were used to calculate 
the concentration of the drug (x) from the peak area (y), recovered from surfaces in 
Chapter 5. 
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Table 17. Recovery of EPI (%) at Concentrations Covering the Analytical Range 
Nominal         Surface 
Concentration Isolator Floor  Screen  Sleeve  Tray  Syringe Isolator  Support 
(ng mL-1)  Base            Glove  Glove 
 0.4   93.2  84.5  93.2  91.8  97.9  90.2  90.3  89.1 
 1.0   80.4  90.5  91.5  97.8  92.1  87.9  99.8  85.3 
 10   80.5  86.3  84.2  90.4  80.5  81.8  85.5  82.7 
 20   93.5  90.6  88.5  86.7  82.8  76.7  80.4  88.9 
 100   84.0  92.4  79.0  90.9  90.4  94.3  71.3  79.4 
 500   79.4  71.0  74.4  91.4  96.4  70.3  98.3  71.2 
 1500   78.6  72.8  98.6  73.0  90.1  97.8  91.2  77.5 
 
 
Table 18. Recovery of MTX (%) at Concentrations Covering the Analytical Range 
Nominal         Surface 
Concentration Isolator Floor  Screen  Sleeve  Tray  Syringe Isolator  Support 
(ng mL-1)  Base            Glove  Glove 
 10   87.1  93.9  90.4  91.3  98.3  90.4  88.7  92.1 
 20   79.8  83.6  90.9  83.7  74.1  96.9  82.5  87.4  
 50   75.2  96.4  96.2  69.8  95.0  89.2  81.3  85.6 
 100   81.4  93.3  87.9  79.3  94.2  90.3  93.7  90.4 
 250   79.3  79.3  73.7  79.7  82.7  76.5  86.5  87.2 
 500   73.2  78.2  80.5  67.0  89.9  73.5  74.9  82.6 
 1000   84.1  77.9  82.6  80.7  95.4  81.8  87.7  91.3 
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Table 19. Recovery of CP (%) at Concentrations Covering the Analytical Range 
Nominal         Surface 
Concentration Isolator Floor  Screen  Sleeve  Tray  Syringe Isolator  Support 
(µg mL-1)  Base            Glove  Glove 
 5.0   52.6  57.1  54.9  51.7  54.9  52.6  55.1  54.7 
 10   50.9  54.8  56.4  53.2  56.9  52.4  53.8  54.9 
 20   56.9  56.0  54.2  57.8  56.2  50.9  56.3  50.7 
 50   58.2  56.9  53.4  52.1  56.8  50.3  54.2  59.5 
 100   55.8  57.2  53.0  59.4  52.1  50.9  59.9  57.5  
 500   54.9  56.0  55.2  54.0  51.8  53.6  52.4  55.9 
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3.8.6  Precision, Accuracy and Recovery 
The precision, accuracy and recovery of EPI, MTX and CP at three 
concentrations were measured from all surfaces over the linear range of the 
calibration plot. This covered the highest and lowest concentration i.e. the LoQ of the 
calibration plot. EPI was measured at 0.4 ng mL-1, 100 ng mL-1 and at 350 ng mL-1 or 
1500 ng mL-1 (gloves only). MTX was measured at 10 ng mL-1, 250 ng mL-1, and 
1200 ng mL-1 or 900 ng mL-1 (gloves only), and CP was measured at 5.0 µg mL-1, 100 
µg mL-1, and 500 µg mL-1. 
 The results of intra-day and inter-day precision, accuracy and recovery are 
shown in Table 20 (EPI), Table 21 (MTX) and Table 22 (CP) on the following pages. 
Recovery was expressed as a percentage of the standard, precision as the CV, and 
accuracy as a range of the percentage plus or minus the nominal value. 
 
 The CV of the intra-day and inter-day precision for the recovery of each drug 
from all surfaces were within +/-15%, and within +/-20% at the LoQ. The accuracy of 
the assay was within the range from 85.0 to 115%, or from 80.0 to 120% at the LoQ. 
The recovery from each surface was high for EPI and MTX, ranging from 70.2 to 
93.5%, and 74.2 to 98.9%, respectively. The recovery of CP was lower, ranging from 
50.1% to 59.8%, but reproducible. 
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Table 20. Recovery, Precision and Accuracy of EPI Sampled from all Surfaces 
Concentration  Intra-Day (%)  Inter-Day (%) 
          Recovery  CV Accuracy         Recovery  CV Accuracy 
 
Isolator Base: 
 0.4 ng mL-1   86.3 6.8 105.1 - 115.8  80.7 4.3 89.2 - 96.4 
 100 ng mL-1 82.0 3.5 86.4 - 101.3  71.7 12.6 85.0 - 114.3 
 350 ng mL-1 83.5 6.8 92.2 - 101.1  75.5 8.1 91.0 - 106.2 
 
Hatch Door: 
 0.4 ng mL-1 77.7 6.0 85.6 - 99.7  80.3 11.2 89.1 - 100.0 
 100 ng mL-1 81.8 8.7 92.6 - 106.1  76.3 13.9 91.5 - 108.8 
 350 ng mL-1 83.0 11.4 87.7 - 95.3  71.7 14.6 87.7 - 95.6 
 
Sleeve: 
 0.4 ng mL-1 77.0 7.9 101.0 - 115.6  93.5 13.5 93.6 - 110.9 
 100 ng mL-1 84.0 6.3 92.3 - 106.5  81.7 5.2 88.7 - 94.8 
 350 ng mL-1 78.7 10.2 95.0 - 103.1  77.7 11.4 86.8 - 111.3 
 
Syringe: 
 0.4 ng mL-1 75.0 3.0 88.3 - 101.1  86.2 8.2 91.1 - 111.9 
 100 ng mL-1 86.8 11.2 94.7 - 107.3  75.8 11.1 96.8 - 108.5 
 350 ng mL-1 89.7 11.0 98.9 - 100.0  81.3 11.0 87.7 - 114.4 
 
Tray: 
 0.4 ng mL-1 87.7 10.3 89.8 - 110.4  89.0 10.3 89.8 - 110.4 
 100 ng mL-1 87.6 7.4 99.0 - 108.7  82.3 7.4 95.3 -105.6 
 350 ng mL-1 70.2 5.1 97.2 - 104.8  77.1 13.5 89.0 - 107.7 
 
Floor: 
 0.4 ng mL-1 82.3 6.6 103.7 - 110.4  83.8 6.6 86.4 - 93.9 
 100 ng mL-1 84.4 3.9 93.9 - 99.4  80.2 0.8 89.9 - 90.7 
 350 ng mL-1 85.4 3.1 91.4 - 100.0  86.5 3.1 95.6 - 100.6 
 
Isolator Glove: 
 0.4 ng mL-1 85.9 7.7 92.4 -109.7  79.5 4.5 85.2 - 99.1 
 100 ng mL-1 89.7 6.8 90.7 - 112.5  82.4 11.7 89.5 - 104.3 
 1500 ng mL-1 81.3 4.2 95.2 - 109.8  89.7 10.2 90.3 - 106.4 
 
Support Glove: 
 0.4 ng mL-1 82.1 5.3 87.5 - 103.8  80.1 8.1 91.8 - 104.7 
 100 ng mL-1 78.4 6.2 91.5 - 108.3  86.3  5.7 93.7 - 105.6 
 1500 ng mL-1 85.6 8.5 91.8 - 101.3  78.2 13.4 91.5 - 107.2 
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Table 21. Recovery, Precision and Accuracy of MTX Sampled from all Surfaces 
Concentration Intra-Day (%)   Inter-Day (%) 
            Recovery  CV Accuracy                    Recovery  CV    Accuracy 
 
Isolator Base: 
 10.0 ng mL-1  92.6 9.7 86.5 - 91.5  88.6 7.3 101.5 - 115.6  
 250 ng mL-1 98.9 10.2 88.5 - 107.0  92.0 7.0 89.1 - 105.7 
 1200 ng mL-1 98.5 4.4 95.9 - 106.3  93.8 5.6 89.2 - 100.2 
 
Hatch Door: 
 10.0 ng mL-1 86.4 6.4 94.0 - 110.0  88.3 5.3 94.0 - 113.2 
 250 ng mL-1 82.7 2.5 99.0 - 100.2  80.2 12.5 88.5 - 107.3 
 1200 ng mL-1 85.1 4.2 98.6 -106.2  91.3 8.0 98.9 - 104.7 
 
Sleeve: 
 10.0 ng mL-1 78.3 5.3 95.0 - 106.3  84.5 5.9 83.8 - 105.0 
 250 ng mL-1 97.8 7.0 101.5 - 115.5  90.7 0.6 100.7 - 102.2 
 1200 ng mL-1 98.0 4.4 95.8 - 102.4  93.0 4.9 97.0 - 102.3 
 
Syringe: 
 10.0 ng mL-1 74.2 12.0 89.0 - 111.0  87.5 11.6 85.5 - 101.8 
 250 ng mL-1  89.7 4.2 88.8 - 102.9  93.6 10.4 89.5 - 102.2 
 1200 ng mL-1 84.4 10.0 96.8 - 104.2  92.5 1.8 98.1 - 102.1 
 
Tray: 
 10.0 ng mL-1 85.7 4.6 93.5 - 114.0  90.5 12.6 96.5 - 101.9 
 250 ng mL-1 98.1 11.5 90.1 - 111.4  84.5 7.4 89.9 - 107.1 
 1200 ng mL-1  87.5 7.2 96.1 - 106.0  82.9 4.0 94.9 - 102.5 
 
Floor: 
 10.0 ng mL-1 97.0 9.2 93.3 - 114.0  93.9 6.3 96.0 - 108.0 
 250 ng mL-1  88.1 4.4 93.5 - 107.2  91.9 8.9 92.3 - 103.4 
 1200 ng mL-1 84.5 1.0 92.5 - 103.5  87.4 9.3 96.0 - 108.0 
 
Isolator Glove: 
 10.0 ng mL-1 92.1 8.4 92.3 - 104.7  87.2 11.1 98.9 - 113.8 
 250 ng mL-1 88.9 6.9 87.3 - 100.0  85.8 8.5 91.0 - 104.6 
 900 ng mL-1 85.4 10.3 95.2 - 107.6  80.3 7.3 87.5 - 97.2 
 
Support Glove: 
 10.0 ng mL-1 82.5 10.0 82.4 - 101.2  91.0 6.7 91.9 - 103.4 
 250 ng mL-1 87.4 4.5 91.5 - 109.7  87.6 9.2 97.3 - 107.8 
 900 ng mL-1  78.8 5.1 89.4 - 102.4  90.5 5.8 92.1 - 103.5 
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Table 22. Recovery, Precision and Accuracy of CP Sampled from all Surfaces 
Concentration Intra-Day (%)   Inter-Day (%) 
       Recovery CV Accuracy                   Recovery   CV Accuracy 
 
Isolator Base: 
 5.0 µg mL-1 51.3 0.2 90.8 - 92.0  58.0 0.8 99.1 - 101.0 
 100 µ g mL-1 50.5 1.5 97.1 - 99.9  54.8 1.1 96.0 - 98.2 
 500 µ g mL-1 59.5 7.2 87.6 - 102.6  51.3 3.2 98.1 - 105.1 
 
Hatch Door: 
 5.0 µg mL-1 52.2 1.3 98.8 - 101.0  57.2 10.4 92.6 - 100.0 
 100 µ g mL-1 59.7 4.6 92.2 - 103.2  57.9 4.6 87.5 - 97.6 
 500 µ g mL-1 59.5 4.6 8.9 - 100.7  53.3 8.4  91.6 - 111.3 
 
Sleeve: 
 5.0 µg mL-1 51.5 0.5 90.2 - 91.2  52.2 7.9 90.6 - 101.1 
 100 µ g mL-1 59.0 4.2 91.4 - 100.3  58.6 1.3 89.9 - 92.6 
 500 µ g mL-1 59.5 9.1 88.3 - 110.9  52.6 9.7 91.6 - 114.2 
 
Syringe: 
 5 µ g mL-1 56.5 6.6 82.5 - 95.3  51.0 1.0 90.7 - 92.5 
 100 µ g mL-1 54.2 2.7 98.5 - 105.4  55.2 2.7 96.5 - 101.7 
 500 µ g mL-1 53.7 10.0 86.0 - 105.2  58.6 4.0  93.1 - 99.9 
 
Tray: 
 5.0 µg mL-1 59.2 0.6 89.3 - 90.2  53.1 1.3 89.0 - 91.1 
 100 µ g mL-1 51.3 3.1 86.7 - 91.9  50.1 7.6 87.6 - 104.3 
 500 µ g mL-1  54.8 7.1 93.0 - 107.0  52.8 4.5 100.3 - 110.0 
 
Floor: 
 5.0 µg mL-1 51.8 1.0 94.5 - 96.6  57.7 1.9 92.3 - 95.5 
 100 µ g mL-1 53.1 1.5 93.7 - 97.6  53.9 2.9 94.2 - 100.1 
 500 µ g mL-1 59.0 6.1 91.6 - 107.6  55.3 5.0  92.7 - 103.4 
 
Isolator Glove: 
 5.0 µg mL-1 59.8 4.5 93.9 - 100.0  50.9 8.2 87.9 - 100.0 
 100 µ g mL-1 52.4 9.0 85.9 - 99.7  55.1 3.9 97.6 - 99.3 
 500 µ g mL-1 53.6 8.9 88.5 - 106.5  58.4 6.4 90.2 - 100.3 
 
Support Glove: 
 5.0 µg mL-1 56.0 3.4 92.8 - 99.7   51.2 8.0 92.4 - 101.2 
 100 µ g mL-1 51.7 3.9 94.0 - 108.0  51.5 9.2 88.7 - 104.0 
 500 µ g mL-1 53.0 6.1 96.7 - 113.2  56.7 8.0 86.3 - 95.9 
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3.8.7  Stability 
 Stability should be determined over the maximum storage time, under the 
temperature conditions between the time of preparation and the time of sample 
analysis. The amount of drug degradation after storage was considered acceptable 
within +/-5% of the nominal concentration168 and +/-15% if derivatisation had been 
carried out.151 
 The same three concentrations of EPI, MTX and CP investigated in Section 
3.8.6 for precision, accuracy and recovery were investigated in triplicate. A stock 
solution of each concentration was diluted in phosphate buffer, pH 4.0 and transferred 
to 15 mL polypropylene tubes. These solutions were stored at -21ºC in a temperature 
monitored laboratory freezer for defined intervals over 6 months (this was the 
estimated time taken to analyse all of the study samples in Chapter 5). To simulate the 
freeze-thaw and removal of sample for the three different drug assays at each time 
interval, the samples were thawed, an aliquot was removed and transferred into 
another tube and acetonitrile (30%) was added. HPLC assay against freshly prepared 
standards were used to measure the percentage of drug degradation of the storage 
samples. 
 The percentage of EPI, MTX and CP, stored in phosphate buffer (0.01 M, 3.5 
mL), pH 4.0 (the organic portion of the desorbing solution was not added until the 
experimental samples were thawed, prior to the recovery process) remaining with 
time at each drug concentration investigated is shown in Table 23 on the following 
page. 
 EPI was stable in the desorbing solution for up to and including 15 weeks. 
MTX and CP were stable in the desorbing solution for up to and including 36 weeks 
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when stored at -21ºC and carried through the conditions of the study, from collection 
through to analysis. 
 
Table 23. Storage Stability of EPI, MTX and CP in Desorbing Solution at -21ºC over 
36 Weeks  
Storage              Drug Remaining (%) 
Interval       EPI (ng mL-1)        MTX (ng mL-1)      CP (µg mL-1) 
(weeks)  0.4 100 1500  10 250 1250  5.0 100 500 
 
 6 99.5 99.8 101.0  92.4 103.7 90.5  97.8 99.5 99.2 
 9 96.1 99.5 104.4  95.9 107.7 108.5  98.2 96.7 99.8 
 12 98.7 101.7 100.3  103.8 105.1 102.8  97.6 96.9 98.3 
 15 96.1 95.9 99.6  94.0 104.3 106.3  99.4 98.7 98.5 
 18 95.2 94.2 96.1  96.3 101.5 98.9  99.0 98.2 97.3 
 24 94.1 93.4 95.0  91.7 96.2 100.5  98.5 97.0 98.4 
 30 ND ND ND  97.7 92.0 97.4  97.2 97.5 98.6 
 36 ND ND ND  93.5 95.6 94.3  96.0 97.2 95.8 
ND = not determined 
 
  
3.9  Discussion 
3.9.1  Method 1 
 The development of Method 1 required relatively little investigation compared 
to Method 2, which was more complex, requiring the drug removal and recovery of 
three drugs of different chemical and physical properties from several surfaces in a 
single method. For Method 1, HPLC methods regularly used in-house were adapted to 
quantify 5-FU, CP, DOX and EPI, after recovery from a test surface. The analytical 
methods adopted for these drugs were sufficiently sensitive to measure the levels of 
degradation achieved by the decontamination procedures (Chapter 4).  
 The aqueous part of the mobile phase specific for each drug assay was 
selected as the desorbing solution in which to remove and quantify each drug from the 
test surface (Section 3.4.4). Vortexing for 30 sec, followed by centrifugation for 5 min 
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at 1500 × g (5ºC) was sufficient to desorb each drug from the test surface with high 
recovery, and acceptable precision and accuracy (Table 5, page 100). Thus, no further 
investigation concerning the desorbing solution or more rigorous mechanical methods 
to remove the drug from the test surface were required.  
 The four cytotoxic marker drugs were 5-FU, CP, DOX and EPI. These served 
the role of marker drugs, as they are drugs of frequent use, and there were analytical 
methods available for quantification of all four drugs. CP was the most toxic 
(classified as Group 1 i.e. carcinogenic to humans by the IARC), followed by DOX 
and EPI (classified as Group 2A i.e. probably carcinogenic to humans).9 5-FU is not 
carcinogenic, but it is mutagenic and teratogenic, and its presence in the environment 
in pharmacy preparation and administration areas has been documented on numerous 
occasions.20;45;61;62;66;71;125 These cytotoxic drugs were also selected because 
degradation by different mechanisms has been well documented for all four 
drugs.5;128;153;156;170-175  
 The studies that were carried out in Chapter 4, investigated the removal of 
cytotoxic surface contamination and degradation of cytotoxic drugs by methods, 
which are used currently in the pharmaceutical industry. It was important to use a 
chemically inert surface to carry out the tests and recover the drug from, which would 
not contribute towards any degradation. Polypropylene pieces cut from the barrel of 
5.0 mL syringes served this purpose. The methods of degradation investigated were 
oxidation by VHP®, and degradation from exposure to detergents of different pH and 
detergents/cleaning agents of different formulations (Chapter 4).  
 The method was validated for all four drugs in three diluents. Two of the 
diluents were pharmaceutical diluents in which the drugs are likely to be diluted or 
reconstituted in practice i.e. WFI and NS, and in which form cytotoxic surface 
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contamination may be present. The aqueous part of the mobile phase for the 
corresponding drug was additionally included as a diluent. This allowed the effects of 
VHP® to be compared between two pharmaceutical diluents and a diluent of different 
pH. Forced degradation studies under stressed conditions showed that each drug assay 
was stability-indicating (Table 6, page 102). Peak purity measurements would have 
been useful to demonstrate that the HPLC peak was not attributable to more than one 
component i.e. any degradation products. Peak purity may have been determined if 
the spectra of the two peaks were quite different, by comparing the peak areas 
obtained at another wavelength, or using UV diode array detection or mass-
spectrometry.168 
 The objectives of Method 1 (Section 3.2.1) were achieved and it was suitable 
to quantify 5-FU, CP, DOX and EPI, and measure the amount remaining on a test 
surface after the decontamination procedures (Chapter 4). 
3.9.2  Method 2 
 Method 2 qualified to quantify multi-cytotoxic drug contamination from 
surfaces inside an isolator and from surfaces outside the isolator typically found in a 
clean-room (Chapter 5). The recovery method was developed for three cytotoxic 
drugs, each from a different chemical class i.e. an anthracycline antibiotic (EPI), an 
antimetabolite (MTX) and an alkylating agent (CP). These are drugs which pose a risk 
to health as they are extensively used, and are carcinogenic (CP), probably 
carcinogenic (EPI), or mutagenic and teratogenic (MTX).9 The presence of MTX and 
CP in pharmacy preparation and administration areas has been widely 
reported.20;26;58;62;63;67;68;109  
 Detection methods were adopted which were sensitive to nanogram levels of 
EPI and MTX, and microgram levels of CP. A pre-chromatographic step involving 
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oxidation of MTX was necessary to achieve sensitivity as low as nanogram levels of 
MTX. This method required a simple derivatisation reaction and was reproducible 
using scaled-down volumes of reagents (Section 3.6.8).  
 The recovery method for Method 2 was developed to remove cytotoxic 
surface contamination using either wipe sampling or immersion, depending upon the 
type of surface. A wipe impregnated with IPA was considered for the removal of 
multi-surface contamination of EPI, MTX and CP. The small size of this wipe 
allowed a minimum amount of desorbing solution to be used i.e. 5.0 mL, and up to 
three wipes to be combined in one tube without compromising the sensitivity of the 
analytical method adopted. In previous in-house studies where the use of large 
volumes i.e. 40 mL of desorbing solution have been used, the sensitivity of the assay 
was compromised.150  
 A desorbing solution of phosphate buffer (0.01 M, pH 4.0) with acetonitrile 
(30%) v/v, similar to, and compatible with, the mobile phase for the EPI analytical 
method was selected. EPI was stable in this solution – see Table 8 (page 110), thus the 
analytical methods adopted for MTX and CP were modified to accommodate this 
desorbing solution. All three drugs were stable in the desorbing solution, had an 
affinity for it, and it was compatible with the HPLC assay.  
 The surfaces selected from which to recover cytotoxic contamination in the 
isolator were the main surfaces and those that were likely to be highly contaminated. 
Trays and gloves used outside the isolator may also be highly contaminated, as they 
are used to prepare for the compounding process i.e. gathering together the 
consumables and drug vials. Cytotoxic contamination has been reported on the floor 
when using an isolator to prepare CP and MTX.26 Syringe batches were also chosen to 
be swabbed to identify if they may pick-up contamination. Contamination on the 
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external surface of syringe batches would transfer the risk outside of the pharmacy 
environment to other personnel i.e. those working in clinics or on hospital wards e.g. 
nurses who may handle the pharmaceutical dose during administration.  
 The selection of surfaces from which surface contamination was measured 
varied according to material, surface area and topology. The surfaces had to be 
consistently wiped in a methodical way to remove all of the contamination from the 
surface each time. Immersion was used to recover contamination from surfaces i.e. 
gloves, which would otherwise be difficult to wipe methodically. There was no 
significant difference between the recoveries from each surface. A lack of response 
across the retention time window for each parent drug peak was observed from blank 
surface samples (Section 3.8.3). Extra peaks from contaminants absorbing at the same 
wavelength were observed in the CP chromatogram. They may have come from the 
wipe, as they were also observed in blank wipe surface samples; however, they were 
well resolved and did not interfere with the CP assay.  
 A larger container was required for immersion of the gloves to expose as 
much surface area as possible to the desorbing solution to aid recovery. Contact with 
the desorbing solution and surface of the glove was aided by vortexing and agitation. 
An increase in the volume of desorbing solution from 5.0 to 10 mL observed a 2-fold 
decrease in the sensitivity of the assay. The immersion volume (20 mL or 100 mL) 
used in other studies28;68 would have compromised the sensitivity of the assay and 
observed possibly a 4-fold or 25-fold decrease in sensitivity, respectively. Recovery 
of glove contamination into the desorbing solution was achieved after vortexing 
vigorously for 1 min followed by agitation at 300 rpm for 30 min. High recovery of 
EPI (86.9% from isolator gloves and 86.0% from support gloves) and MTX (92.2% 
from isolator gloves and 89.7% from support gloves), and recoveries of 50.3% from 
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isolator gloves and 50.1% from support gloves for CP, were reproducible for the 
recovery of all three drugs into 10 mL of desorbing solution - Table 13 (page 127). 
This gave similar percentage recoveries to the method used for recovery from the 
wipe samples (87.3% EPI, 91.8% MTX, and 50.7% CP) - Table 11 (page 123) 
therefore; a longer agitation time was not investigated. 
 
 It is more of a challenge to remove, recover and quantify the surface 
contamination of three structurally different drugs, than one drug, in a single method. 
Removal, recovery and extraction of the drug, and compatibility with the analytical 
method is influenced by the physical and chemical properties of the drug i.e. 
solubility, ionisation, stability. The development and validation of Method 2 
achieved all the objectives set for the method – Section 3.2.2. However, the recovery 
method, which achieved high recoveries for EPI and MTX, recovered approximately 
50% of CP. All of the CP contamination was removed by the wipe, suggesting the 
low recovery was due to the higher affinity of CP for the wipe and glove surface than 
the desorbing solution, compared to EPI and MTX. Recovery was determined by the 
composition of the desorbing solution, or the method used i.e. vortexing and 
centrifugation or agitation may not have provided sufficient mechanical energy to 
recover CP from the wipe or glove.  
 The impregnated wipe used in this present study was sterile, effective, and 
convenient to take into the clean-room environment, especially as it was already 
being used in the study to swab the bungs of vials. A study investigating different 
desorbing solutions achieved 50% recovery of CP, and 100% recovery of DOX when 
using a desorbing solution of acetonitrile:water (50:50). Recovery of CP was 100%, 
but the recovery of DOX was reduced to 60% when a desorbing solution of 
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acetonitrile (10%), methanol (25%) and phosphate buffer (65%) pH 6.0 v/v, was 
applied.148 These desorbing solutions were pipetted onto the surface to aid recovery 
of the contamination. Taking a separate desorbing solution and wipe into the clean-
room and isolator, and pipetting the solution onto surfaces is less convenient. It is 
also not practical to use this method on vertical surfaces i.e. the hatch door, as the 
solution would run off and equal distribution onto the surface would not be achieved. 
 MTX is a polyelectrolyte carrying two carboxyl groups with pKa values of 
3.36 and 4.70. It also possesses a number of amino groups which may also dissociate; 
the most basic has a pKa of 5.71.130 At pH 4.0 the carbonyl groups would be ~<50% 
ionised and the most basic nitrogen ~90 to 99% ionised. EPI, with a pKb of 8.2 would 
be ~99.99% ionised. Therefore, EPI and MTX surface contamination would be water-
soluble and removed by an aqueous-based solution. In this study, a wipe impregnated 
with 70% IPA and 30% WFI v/v was effective in removing EPI and MTX 
contamination. CP is soluble in water,24;131 and in ethanol.131 Methanol and ethanol 
have a similar polarity index i.e. 5.1 and 5.2,176 respectively, and are less polar than 
water and acetonitrile. Absorbent tissues soaked in methanol have been used to 
remove CP surface contamination successfully.34 In this present study, the wipe was 
impregnated with IPA, which is less polar than methanol i.e. it has a polarity index of 
3.9.176 The addition of methanol to the desorbing solution may have increased the 
affinity of CP for the desorbing solution. However, altering the composition of the 
desorbing solution may have compromised the high recovery of EPI or MTX and may 
not have been as compatible with the mobile phase of the HPLC methods. 
  
 Shaking/agitation has been used to successfully recover drug contamination 
from gloves,28;68 however the recovery of the method was not reported in these 
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studies and cannot be compared with that achieved in this present study. The highest 
percentage recovery of EPI and MTX was observed after 30 min of centrifugation, in 
addition to vortexing. MTX recovery was observed to increase significantly with 
centrifugation time, with 64.2% recovery observed after 5.0 min increasing to 91.8% 
after 30 min - see Table 11 (page 123).  
 Fluorimetry is more sensitive than UV detection and was employed to achieve 
levels of detection for EPI and MTX with an LoQ of 0.4 ng mL-1and 10 ng mL-1, 
respectively. EPI is a brightly coloured compound and exhibits native fluorescent 
properties.160 MTX presents low fluorescence in an aqueous medium.164 Oxidation 
with potassium permanganate converted this analyte into a fluorescent pteridinic 
carboxylic acid. The method for EPI was 5 times more sensitive than the method used 
in a previous surface contamination study in which the LoQ was 2.0 ng mL-1.64 The 
method for MTX was more sensitive (LoQ = 10 ng mL-1) than other methods used for 
surface contamination studies i.e. 15 ng mL-1 108 and 50 µg mL-1.109 The sensitivity 
which was achieved with EPI and MTX was below 20 ng mL-1. In one study, an LoD 
of 20 ng mL-1 was not sensitive enough to detect 5-FU surface contamination. As a 
result, the surface samples could not be quantified for 5-FU, the sampling of 5-FU 
was terminated and the contribution of using intervention in reducing 5-FU 
contamination could not be assessed.124   
 The sensitivity of CP may have been improved using a method that involves a 
complicated multi-step sample clean-up and derivatisation, followed by gas-
chromatography mass-spectroscopy. The LoD reported by this method was 0.1 ng 
mL-1.177 However, the intense sampling schedule of surface samples in Chapter 5 
involves the measurement of 1088 samples, separately for each drug. Using this 
method would involve high reagent usage and specialist equipment. It would also be 
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considerably time-consuming, risking the analysis of all of the CP samples within the 
6 months stability period at -21ºC defined in this study.  
 EPI may be stored at -21ºC in the aqueous buffer part of the desorbing solution 
for up to and including, but no longer than 15 weeks – see Table 23 (page 142). After 
18 weeks, 5.8% degradation of EPI from the initial value was observed at one of the 
concentrations investigated. This change in drug concentration was >+/-5% and was 
not considered acceptable.168 CP and MTX were more stable and may be stored for 
longer i.e. up to and including 36 weeks. During this storage time, a maximum of 
4.4% and 9.5% change in assay from the initial value was observed for CP and MTX, 
respectively. A change in assay of +/-15% was considered acceptable for MTX to 
allow room for manipulation error when oxidising MTX to MTX’. On the basis of 
these studies the samples for EPI are analysed first within the time-frame of 15 weeks 
from storage, followed by the analysis of MTX’ and CP within 36 weeks.  
 EPI and MTX were the most significant contaminants of the three cytotoxic 
drugs selected as marker drugs. Levels of CP contamination are plentiful in the 
literature – see Table 1 (page 42) and the closed-system (PhaSeal®) device has been 
effective in significantly reducing levels of CP contamination.62;67;125;177 The purpose 
of CP was as a marker drug for comparison with other studies. The recovery of CP 
was lower than the other two drugs, but it was reproducible and considered 
acceptable for this method. 
 The amount of contamination produced from the compounding of cytotoxic 
drugs, as investigated in Chapter 5 could not be predicted, but could only be 
anticipated from previous surface contamination studies. Studies of this nature have 
reported a range from 0 to 100% in the number of positive samples.8 Due to 
differences in sensitivity of the analytical methods of the three drugs, the number of 
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positive samples recovered from surfaces may differ. In comparison with other 
studies, the sensitivity of the analytical methods for the three drugs were considered 
acceptable and the results generated using this method satisfied the criteria of the 
study objectives, as described in Section 5.2. This is described in more detail in 
Section 5.6, where the number of positive samples and the amount of contamination 
of each drug recovered from surfaces in Chapter 5, using Method 2 are discussed. 
3.10  Conclusion  
 Two methods were developed and validated to satisfy the objectives of this 
study. Method 1 and Method 2 are suitable to be applied to enable the quantification 
of cytotoxic drugs to support the analytical measurements for Chapters 4 and 5, 
respectively. 
 
Method 1 was successfully developed and validated to enable the very high 
recovery (≥95%) and quantification of 5-FU, CP, DOX and EPI in three diluents, 
from a test surface with acceptable accuracy and precision. The methods were 
reproducible and accurate around the nominal experimental concentration (within +/-
15%), and demonstration of a linear calibration plot enabled quantification of 
cytotoxic drug remaining after the decontamination procedures (Chapter 4).  
 
 Method 2 achieved a sensitive LoQ at nanogram levels to remove and 
quantify the surface contamination of EPI (0.4 ng mL-1) and MTX (10 ng mL-1) and 
microgram levels to remove and quantify the surface contamination of CP (5.0 µg 
mL-1). HPLC coupled with fluorimetric detection was employed as a suitable 
sensitive detection method for EPI and MTX. HPLC coupled with UV detection was 
used to quantify CP. Overall, the results show that it is feasible to remove, recover 
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and analyse EPI, MTX and CP surface contamination from different surfaces in an 
isolator and immediate environment, in single recovery method, by using wipe 
sampling and immersion. Surface samples contaminated with EPI, MTX and CP are 
stable in the desorbing solution and may be stored at -21ºC, but must be analysed 
within 15 weeks for EPI, and 36 weeks for MTX and CP. 
 Multi-surface contamination of EPI, MTX and CP can be recovered and 
quantified with acceptable accuracy and precision (within +/-15%, and +/-20% at the 
LoQ) from the isolator base, hatch door, sleeves, tray and floor using wipe sampling, 
and from the isolator gloves and support gloves using immersion. The recovery was 
high, ranging from 70.2% to 93.5% for EPI, and 74.2% to 98.9% for MTX. Recovery 
of CP from surfaces was lower, ranging from 50.1% to 59.8%. Linear calibration 
plots (R2 = ≥0.99) can be applied to quantify EPI in the range from 0.4 ng mL-1 to 
1500 ng mL-1, MTX from 10 ng mL-1 to 1200 ng mL-1, and CP from 5.0 µg mL-1 to 
500 µg mL-1 from the isolator base, hatch door, sleeves, tray, floor, syringes, isolator 
gloves and support gloves.  
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4.  Decontamination of Surfaces Exposed to Cytotoxic Drugs in an 
Isolator Workstation 
4.1  Introduction 
4.1.1  Decontamination of Isolators  
 An isolator separates the process, which may be the compounding of 
cytotoxic drugs, from the operator and its surroundings. Its purpose is to provide an 
aseptic environment required for product protection and to protect the operator from 
any hazards arising from the process. Therefore, effective decontamination of the 
isolator is paramount to protect the product and the operator. Contamination may be 
in the form of biological or chemical contamination and both need to be addressed 
differently. Bacteria are of a known particle size,24 while cytotoxic contaminants may 
be airborne or surface contamination in the form of droplets or particles. 
Decontamination is a combination of cleaning and disinfection, as described in 
Section 2.1. 
4.1.2  Cleaning with Detergents 
 Cleaning (removal of chemical contamination) needs to be performed 
correctly or it may just spread contamination in the isolator. It should be methodical, 
i.e. move progressively from back to front, top to bottom, in an overlapping parallel 
movement. Circular movements can spread contamination and should be avoided.110 
Detergent cleaners can be either enzymatic or non-enzymatic. Non-enzymatic 
detergents are further classified as alkaline, acidic or neutral cleaners and are 
recommended for cleaning an isolator.110 The importance of detergents is that, unlike 
single chemical solutions, they are composed of a series of components such as 
acid/alkali/neutral base, pH regulators, oxidising agents, chelators, surfactants and 
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solubilising agents. These components work together to clean a specific target soil 
from a surface. WFI is used typically to remove detergent residues/surfaces films 
after detergent application and is the water quality recommended for isolators.110 The 
detergents used in this study were formulated to meet the cleaning demands found in 
the hospital and pharmaceutical industry.178 
4.1.3  Disinfection by Vaporised Hydrogen Peroxide 
Disinfection (removal or elimination of microbiological contamination) can 
be achieved using direct or indirect methods. Direct methods apply a liquid 
disinfectant e.g. biocides, phenolics, alcohols onto a surface by spraying or wiping. 
Indirect methods deliver antimicrobial gas or liquid fumigants indirectly to the 
surfaces of an enclosed area.110  
VHP® is a fumigation method which is more effective at lower concentrations 
than liquid hydrogen peroxide.110;147 It is applied widely in the hospital environment 
where it is used as a surface decontaminant of enclosed areas and for medical device 
sterilization.147 VHP®, a strong oxidising agent, is an odourless, colourless gas 
produced from the vaporisation of liquid hydrogen peroxide. The advantages of 
VHP® over more traditional fumigants such as formaldehyde are that it is safe to use 
and breaks down to non-toxic products i.e. water and oxygen.110 There are two 
hydrogen peroxide vapour processes ‘wet’ and ‘dry’ based on the physical chemistry 
of the hydrogen peroxide applied. The wet process introduces gaseous hydrogen 
peroxide at high concentrations, which on reaching its dew point condenses onto 
surfaces. Condensation of peroxide results in varied non-standard delivery, which is 
difficult to validate. The wet process requires a long cycle time, specifically the 
aeration phase required to remove the condensed peroxide. The dry process 
introduces gaseous hydrogen peroxide and maintains it below its dew point i.e. non-
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condensed. The dry process results in a vapour, which is maintained throughout the 
decontamination phase producing a standard form of VHP® delivery to the surface. 
In addition to this, cycle time is reduced, achieving effective disinfection in less time 
than that required for traditional fumigation methods. The ‘dry’ process has 
demonstrated superior antimicrobial activity compared to the ‘wet’ process and is the 
method of choice for the decontamination of hard surfaces such as in isolators and 
clean-rooms.110 VHP® has a broad spectrum of antimicrobial properties. It has been 
demonstrated to be bactericidal, sporicidal, fungicidal, and efficacious against 
organic molecules i.e. endotoxins and proteinaceous-based toxins.147;179-181 However, 
its effect on cytotoxic drugs is unknown and there are no reported studies. This study 
investigates the effect of VHP® dry process on cytotoxic drugs. 
4.1.4  The VHP® 100P Bio-Decontamination Unit 
 The STERIS VHP® bio-decontamination system generates and delivers 
hydrogen peroxide vapour to sealed enclosures, providing a consistent fumigation 
process. Cycle times vary with initial temperature and humidity, and are calculated 
for a given area to ensure condensation does not occur. The cycle operates in a 
closed-loop configuration consisting of four phases, which are monitored 
continuously by internal sensors and controlled with pre-programmed process 
parameters: 
i. the dehumidification phase reduces the humidity within the enclosure to a pre-
determined level to prevent condensation; 
ii. the conditioning phase involves injecting VHP® into the enclosure so that the 
required VHP® concentration is achieved; 
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iii. the decontamination phase maintains the desired VHP® concentration at a 
constant level, by continually introducing the vapour into the incoming air and 
degrading VHP® catalytically to water vapour and oxygen in the returning air; 
v. the aeration phase evacuates VHP® rapidly. It is complete when the 
concentration of VHP® is at, or below, 1 ppm. 
 
The decontamination of four marker drugs was investigated in this study. 
Three drugs were used initially; they were 5–FU, CP, and DOX. In addition, studies 
were extended to include EPI. The rationale for inclusion of these drugs are 
described in Section 3.4.1. 
4.2  Objectives 
The objectives of this study were to investigate the safe decontamination of 
cytotoxic drugs from surfaces of a pharmaceutical isolator workstation. The effects 
of two decontamination technologies available in the pharmaceutical and healthcare 
environments i.e. liquid detergents/cleaning agents and VHP® were evaluated on 
cytotoxic marker drugs in two phases: 
 
• Phase I investigated the physical removal of the drugs by cleaning with aqueous-
based detergents of different pH and cleaning agents; 
 
• Phase II investigated: 
i. the breakdown of the drugs by the same detergents and cleaning agents, 
ii. the ability of VHP® to degrade the drugs by oxidation. 
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4.3  Materials 
Cytotoxic Drugs 
5-Fluorouracil 25 mg mL-1 (lot N012669) was obtained from Mayne Pharma 
Plc, Leamington Spa, UK. Cyclophosphamide, Doxorubicin and Epirubicin were 
obtained, as described in Section 3.3.  
 
Chemicals 
Liquid hydrogen peroxide (Vaprox®) (lots 0-2021092185-BF, 
02004104135BF and 02021046135BF) was supplied by STERIS, Basingstoke, UK 
 
Detergents/Cleaning Agents 
The detergent concentrates CIP 100 (lot 231630), CIP 150 (lot 233946), 
Criti-Klenz (lot 2318326L3), Renu-Klenz (lot 234091364), NpH-Klenz (lot 236024), 
Cage-Klenz 250 (lot 223611), CIP 200 (lot 232809) and CIP 220 (lot 229960) were 
supplied by STERIS, Basingstoke, UK. 
 Klercide 70/30 sterile denatured ethanol (lot 051005EP), Klerclean sterile 
neutral detergent (lot 060203ND/4) and Klercide CR sterile filtered biocide B (lot 
060310BP/4) were obtained from Shield Medicare, Farnham, UK. 
 
Equipment 
The VHP® 100P generator (serial no. 0135103–29), VHP® 100P High Output 
generator (serial no. 0118705-05), flexible-walled isolator (serial no. 013510-29), 
and exposure chamber were supplied by STERIS, Basingstoke, UK. 
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Consumables 
Chemdi chemical indicators (lot 227519/1/A), hydrogen peroxide detection 
tube and the Accuro® pump (serial no. 8101041) were supplied by STERIS, 
Basingstoke, UK. The Stericlean® low-linting dry wipes (lot W016603) were 
obtained from Helapet Ltd, Bedfordshire, UK. 
4.4  Methods 
Cytotoxic drug preparations, surface coating of test surfaces and Phase I and 
IIi of the study were carried out in a BSC. Exposure of the drugs to VHP® (Phase 
IIii), Cycle 1 was carried out in a flexible-walled isolator, Cycles 2 and 3 were 
carried out in an exposure chamber. HPLC analysis and all tests were carried out at 
the University of Bath, UK, except for VHP® exposure Cycles 2 and 3, which were 
carried out at the University of Cardiff, Wales. 
4.4.1  Drug Dilution/Reconstitution  
 All four-marker drugs were reconstituted or diluted in three diluents; WFI 
and NS, and the aqueous component of the mobile phase specific to the drug assay 
(see Section 3.4.2). The third diluent was included to evaluate the study of the 
decontamination procedure at different pH. Glucose was not used as it has been 
suggested that it may consume some of the oxidising potential of hydrogen 
peroxide.113  
 Phase I, which involved removal by wiping, was carried out on the drugs 
diluted or reconstituted in WFI and NS. Phase IIi, which involved degradation by 
detergents, was carried out on the drugs diluted or reconstituted in WFI. Phase IIii, 
which involved degradation by VHP®, was carried out on the drugs diluted or 
reconstituted in all three diluents.  
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4.4.2  Test Surface Coating 
 The test surfaces were coated (Phase I and IIii), as described in Section 3.4.3, 
by pipetting 10 µL or 20 µL of drug solution onto the concave side of the surface. To 
eliminate the effect of the drying process and the temperature reached inside the BSC 
on drug stability, drug controls were allowed to dry alongside the test samples. 
Surface controls of coating with drug-free diluent only and blank non-coated 
surfaces were also included. All test surfaces (including the controls and blanks) 
were allowed to dry in the BSC for 2 hrs (until no solvent remained). For Phase I, the 
surfaces were treated in the BSC. For Phase IIii, the surfaces were placed 
horizontally in the centre of the isolator or exposure chamber on a flat plastic tray 
elevated at approximately 30 cm or 10 cm above base level, respectively. 
4.4.3  Immersion and Recovery of Drug from the Test Surface 
Immersion methods were used to remove and recover as much drug as 
possible from the test surface for Phase I and IIii tests. The recovery method was as 
described in Section 3.4.5.  
4.4.4  LC Methods for Drug Quantification 
Validated HPLC methods, as described in Section 3.4.6 were used to quantify 
the amount of the parent drug 5-FU, CP, DOX or EPI after all study phases. 
Quantification was conducted using the external standard method; duplicate test 
injections were bracketed by injections of standard solutions. The concentrations of 
the standard solutions were 5-FU (10 µg mL-1), CP (400 µg mL-1), DOX (10 µg mL-
1) and EPI (20 µg mL-1). These were the same concentrations as the initial 
concentration of the experimental samples applied to the test surfaces.  
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4.4.5  Chemical Composition of the Detergents (formulations) 
Eight detergents (acid, alkali and neutral) covering an extreme pH-range 
(referred to as the pH-detergents), and two cleaning agents used commonly in 
hospital pharmacies for the decontamination of isolators, were investigated for the 
purpose of this study. The major components of the formulated detergent/cleaning 
agents are shown in Table 24 below.182 
 
Table 24. Chemical Composition of the Detergents and Cleaning Agents Included in 
this Study 
 
Detergent/Cleaning Agent  pH         Chemical Components of Formulation 
 
pH-detergents 
   CIP 220   acidic  <30% w/v hydroxyacetic acid 
 
   CIP 200   acidic  <50% w/v phosphoric acid  
      <30% w/v citric acid 
 
   Cage-Klenz   acidic  <30% w/v citric acid 
 
   Renu-Klenz   neutral  high levels of surfactants 
 
   NpH-Klenz   neutral  high levels of surfactants 
 
   Criti-Klenz   alkaline  high levels of surfactants 
      <20% w/v EDTA 
 
   CIP 150   alkaline  <10% w/v potassium hydroxide 
      <1% w/v sodium hydroxide 
      <5% w/v sodium hypochlorite 
 
   CIP 100   alkaline  <25% w/v potassium hydroxide 
      <5% EDTA 
 
Cleaning Agents 
   Klerclean neutral detergent  neutral  a non-ionic fatty alcohol ethoxylate 
 
   Klercide CR-B  alkaline  blend of stabilized chlorine dioxide and  
      QACs  
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The acidic detergents were formulated with acids i.e. citric, hydroxyacetic, 
phosphoric. The alkaline detergents were formulated with sodium hypochlorite and 
claimed to have the oxidising properties of chlorine, or were formulated with sodium 
hydroxide and/or potassium hydroxide. Some detergents were formulated with 
surfactants, chelating or sequestering agents to aid the removal of surface soiling. 
They were non-corrosive and formulated at concentrations which were suitable for 
cleaning the surface materials of an isolator.182  
4.4.6  Phase I - Physical Removal by Detergents and Cleaning Agents 
The ability of the detergents and cleaning agents to remove dried cytotoxic 
drug contamination from a coated test surface were investigated. The eight 
detergents of different pH were used in a wipe study to remove 5-FU, CP and DOX 
and the two cleaning agents were applied to remove 5-FU, CP, DOX and EPI. WFI 
and IMS were used as the controls. For each detergent/cleaning agent, 50 µL was 
pipetted onto a cytotoxic-coated surface and control test surface. This was the 
optimal volume to cover the contamination for the size of area to be wiped, 
simulating cleaning in practice. Wiping involved one stroke across the test surface. 
The area was wiped immediately using a dry wipe cut to the dimensions of 2.0 cm × 
6.0 cm. If drug remained on the surface i.e. the amount remaining was above the 
LoD of the method, a second surface treated with the same drug was wiped twice. If 
still above the LoD of the analytical method, a third surface of the same drug was 
wiped three times. Any remaining drug was recovered from the wiped test surface 
and analysed by HPLC.  
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4.4.7  Phase IIi - Deactivation by Detergents/Cleaning Agents 
The ability of the detergents/cleaning agents to degrade cytotoxic drugs was 
investigated using a modification of the suspension test as set out in British Standard 
(BS EN 1656; 2000).183 A liquid hydrogen peroxide (35% v/v) solution (Vaprox®) 
was also included to compare with VHP®. A solution (100 µL) of test drug was 
mixed with an equal volume (100 µL) of detergent/cleaning agent or Vaprox® at 
room temperature. The test drugs for reaction were 5-FU (5 mg mL-1 × 100 µL), CP 
(4 mg mL-1 × 100 µL) - diluted in WFI from the 20 mg mL-1 working concentration, 
and DOX and EPI (1 mg mL-1 × 100 µL). The solution was vortexed for 1 min then 
incubated for up to 60 min at 22 to 23°C. After incubation, the solutions were diluted 
with the aqueous component of the mobile phase (800 µL). 5-FU, DOX and EPI 
were further diluted in the respective mobile phase to achieve the experimental 
sample concentration prior to immediate assay. IMS was used as a control.  
4.4.7.1  pH Measurement of Detergents and Cleaning Agents 
 The pH of the detergents and cleaning agents were measured in-house using a 
glass electrode and pH meter (see Table 25 on the following page). The eight 
detergents of different pH subjected the drugs to extreme levels of pH ranging from 
1.7 to 13.2. The detergents were liquids and were diluted in distilled water according 
to manufacturers’ instructions. The cleaning agents were in the form of liquid sprays, 
which were used as supplied.  
 
 
 
 
 163
Table 25. Dilution and pH of the Detergents, Cleaning Agents, Vaprox® and IMS 
Detergent         Dilution    pH 
 
pH-Detergents 
   CIP 100   0.8    13.2 
   CIP 150    0.8    12.8 
   Criti-Klenz     1.6    11.3 
   Renu-Klenz    1.6    8.0 
   NpH-Klenz    1.6    7.5 
   CIP 220     1.6    2.4 
   Cage-Klenz     1.6    2.3 
   CIP 200     1.6    1.7 
 
Cleaning Agents 
   Klerclean neutral  N/A (as supplied)  4.7 
   Klercide CR-B  N/A (as supplied)  9.5 
 
   Vaprox®   35% v/v (as supplied)  2.6 
   IMS    70% v/v (as supplied)  3.5 
 
N/A = not applicable 
 
 
4.4.8  Phase IIii - Deactivation by VHP® 
VHP® delivery and control systems have been developed to provide a 
consistent fumigation process for a given enclosure. VHP® was generated using 
Vaprox® inside a VHP® 100P bio-decontamination mobile unit, which when 
connected to the isolator or exposure chamber controlled the whole dry fumigation 
process. The conditions for the four phases of each cycle are given in Table 26 on the 
following page. 
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Table 26. VHP® Cycle Conditions for Cycles 1, 2 and 3 
Parameter      Value 
 Cycle 1 Cycle 2 Cycle 3 
Dehumidification 
airflow (m3 h-1)    18  28  28 
absolute humidity (mg L-1)  2.3  2.3  2.3 
time (min)    10  10  10 
 
 Conditioning 
airflow (m3 h-1)   12  18  18 
injection rate (g min-1)  2.5  1.0  1.6 
time (min)   3.0  1.0  1.0 
  
Decontamination 
airflow (m3 h-1)   12  18  30 
injection rate (g min-1)  1.6  1.2  1.6 
time (min)   25  120  120 
 
 Aeration  
airflow (m3 h-1)   18  28  28 
time (min)   90  120  120 
 
 
  
 Cycle 1 was carried out in a flexible-walled isolator with an area of 1 m3. 5-
FU, CP and DOX were exposed to 1.6 g min-1 of VHP® for 25 mins during this 
cycle. The parameters of Cycle 1 were modified to give a longer exposure time 
during Cycles 2 and 3. This was possible using an exposure chamber and a High 
Output Unit, which were able to operate to maintain the concentration of VHP® 
during a longer period of time. 
 Exposure time was increased from 25 min to 2 hrs, and VHP® was applied at 
a concentration of 1.2 g min-1 (Cycle 2). Cycle 2 was applied only to CP to determine 
the extent of CP susceptibility to oxidation with time.  
 The concentration of the 2 hr cycle (Cycle 2) was increased from 1.2 to 1.6 g 
min-1 (Cycle 3) and applied to 5-FU, CP, DOX and EPI. Cycle 3 determined the 
extent of susceptibility of 5-FU to oxidation with a longer exposure time, and CP 
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with increased VHP® concentration in comparison with Cycle 2. DOX was exposed 
to investigate further degradation with a longer exposure time. In addition, EPI was 
exposed to extend oxidative susceptibility to a drug from the same chemical family 
as DOX.  
Prior to each cycle, a leak test was carried out to ensure that the flexible-
walled isolator or exposure chamber were leak-proof. During the leak test and three 
exposure test cycles, regular VHP® gas measurements were carried out using a hand 
held hydrogen peroxide detection tube in the vicinity of the equipment, to ensure the 
absence of VHP® leakage. Chemical indicators were placed evenly within the inside 
of the isolator or exposure chamber to confirm the semi-quantitative presence of 
VHP® throughout the enclosure. The indicators were printed with blue-grey indicator 
ink, which is responsive to VHP®, and a strip of control ink identical in colour to the 
unexposed ink. Once exposed to VHP® the indicator ink turned to a beige colour 
within 15 mins, for comparison with the control ink which did not change colour.184 
A printer readout from the VHP® generator recorded the cycle parameters and 
injection concentration of VHP® in the enclosure, at 1 min intervals, during the 
course of each cycle. In addition, room temperature and the temperature inside the 
enclosures were recorded and signs of condensation monitored. If condensation had 
appeared, the cycle would have been aborted. The study was set up and carried out in 
a standard dry laboratory with good natural lighting. To eliminate the effect of light 
on drug stability, control samples were placed outside the isolator/exposure chamber 
during the cycles. To eliminate the effect of the temperatures reached inside of the 
isolator or exposure chamber on drug stability, control samples were exposed to a 
blank cycle minus VHP®. After exposure to VHP®, the drugs were recovered from 
the test surfaces (Section 3.4.5) and quantified by HPLC (Section 3.4.6 and 4.4.4).  
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4.5  Results 
4.5.1  Test Surface Coating 
 The drying process, applied after coating the test surfaces with drug in the 
BSC, had no effect on the drug controls. In addition, no effect was observed on 
surface controls coated with drug-free diluent only, or on blank non-coated surfaces. 
4.5.2  Phase I - Physical Removal by Detergents and Cleaning Agents 
 Table 27 below, shows the number of wipes required to remove the drug 
contamination from the surfaces by the various detergents and cleaning agents.  
   
Table 27. Physical Removal of 5-FU, CP, DOX and EPI by the pH-Detergents and 
Cleaning Agents 
                   Number of Wipes Required to Remove Drug 
 
Test   5-FU  5-FU  CP CP DOX DOX EPI EPI 
   (WFI) (NS) (WFI) (NS) (WFI) (NS) (WFI) (NS) 
 
   WFI   1 3 1 1 1 1 1 1 
   IMS   1 1 1 1 1 1 1 1 
 
pH-Detergents 
   CIP 100  1 1 1 1 2 2 - - 
   CIP 150   1 1 1 1 3 3 - - 
   Criti-Klenz  1 1 1 1 2 2 - - 
   Renu-Klenz  1 1 1 1 1 1 - - 
   NpH-Klenz  1 1 1 1 1 1 - - 
   Cage-Klenz  1 1 1 1 1 1 - - 
   CIP 220  1 1 1 1 1 1 - - 
   CIP 200  1 1 1 1 1 1 - - 
 
Cleaning Agents 
   Klercide CR-B 1 1 1 1 1 1 1 1 
   Klerclean neutral 1 1 1 1 2 1 1 1 
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 5-FU and CP were easily removed from the test surface when using a dry 
wipe, with acid, neutral or alkaline detergent. DOX was removed easily by acid or 
neutral detergent, but was more persistent to removal by alkaline detergents, 
requiring more than one wipe to remove all traces (not quantifiable but above the 
LoD of the analytical method). An immediate colour change from red to purple was 
evident when DOX was exposed to the three alkaline detergents. The depth of purple 
increased with increasing alkalinity of the detergents. This colour change was not 
observed with the controls (WFI and IMS).  
  Wiping with WFI and IMS was effective in removing 5-FU, CP and DOX. 
All detergents were superior to WFI when removing 5-FU diluted in NS. 
The cleaning agents easily removed 5-FU, CP, DOX and EPI. Only one wipe 
across the surface was required, except for DOX (WFI), which was slightly more 
persistent and required two wipes with Klerclean neutral detergent. 
4.5.3  Phase IIi - Deactivation by Detergents and Cleaning Agents 
5-FU and CP were not susceptible to chemical decomposition across the pH 
range of 1.7 - 13.2, after 60 min of exposure to all detergents and liquid hydrogen 
peroxide. DOX was not susceptible to degradation at acid and neutral pH for up to 
and including 60 min. However, significant degradation of DOX was observed with 
alkaline detergents. Exposure for 15 min to CIP 100 caused 66.5% degradation, CIP 
150 caused 44.2% degradation and Criti-Klenz caused 28.5 % degradation. Exposure 
of DOX for 60 min caused 81.0% degradation by CIP 100 (pH 13.2) and 62.3% by 
CIP 150 (pH 12.8). The rate increased with increasing alkalinity of the detergent 
formulation. The rate of degradation of DOX by alkaline detergents is shown in 
Figure 28 on the following page. 
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Figure 28. Semi-Log Plot Showing the Amount of DOX Remaining with Time after 
Exposure to the Alkaline Detergents CIP 100, CIP 150 and Criti-Klenz 
 
 
 The rate of degradation of DOX when exposed to Criti-Klenz can be 
described by the equation y = -0.0089x + 1.9773 (R2 = 0.934) with a half-life of 31.2 
min. The rate of degradation of DOX by CIP 150 can be described by the equation y 
= -0.0055x + 1.8847 (R2 = 0.904) with a half-life of 33.6 min. The rate of 
degradation of DOX by CIP 100 can be described by the equation y = -0.009x + 
1.7485 (R2 = 0.847) with a half-life of 5.4 min. All three drugs demonstrated no 
degradation after exposure to liquid hydrogen peroxide for 60 min. 
 5-FU, CP, DOX and EPI were not susceptible to degradation by the cleaning 
agents. Klerclean neutral detergent, although branded a ‘neutral’ detergent, measured 
a weakly acidic pH. Temperatures, which did not exceed 24ºC throughout the study, 
had no effect on the controls and therefore did not contribute towards the degradation 
of DOX observed. 
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4.5.4  Phase IIii - Deactivation by VHP® 
All three decontamination cycles with the VHP® were completed 
successfully. The chemical indicators changed colour from blue-grey to beige within 
15 mins confirming the semi-quantitative presence of VHP®. This was evident 
throughout the flexible isolator and the exposure chamber, and indicated a successful 
validated cycle. During Cycle 1, internal isolator temperature readings averaged 
30ºC, and external air temperature did not rise above 28ºC. During Cycle 2, the 
internal temperature of the exposure chamber averaged 42.3ºC, and the external air 
temperature readings did not exceed 25ºC. During Cycle 3, the internal temperature 
inside the exposure chamber averaged 46.7ºC (range 43.6 to 48.7°C). The 
temperature recorded throughout Cycle 3 is shown graphically in Figure 29 below. 
External air temperature readings did not exceed 26°C.  
 
 
Figure 29. Graph Showing Internal Temperature (°C) Recorded in the Exposure 
Chamber during Cycle 3 
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No condensation occurred inside the isolator or the exposure chamber at any point 
throughout the duration of the three exposure cycles. VHP® had no effect on the 
blank surfaces or drug-free diluent controls in the study. Table 28 below shows the 
amount of 5-FU, CP and DOX remaining after exposure to Cycle 1, expressed as a 
percentage of the initial concentration, plus or minus the standard deviation. The 
results are from the exposure of triplicate samples and subsequent analysis by HPLC 
in duplicate.  
 
Table 28. Assay Results for 5-FU, CP and DOX after Exposure to VHP® at 1.6 g 
min-1 for 25 Minutes (Cycle 1) 
Drug (diluent) Exposure  Drug Remaining (%) after Exposure +/-SD 
 
5-FU (WFI)  VHP®    97.9 +/- 0.5 
 
5-FU (NS)  VHP®    96.5 +/- 1.2 
 
5-FU (pH 7.0)  VHP®    99.1 +/- 0.2 
  
 
CP (WFI)  VHP®    98.7 +/- 9.2 
  
CP (NS)  VHP®    97.7 +/- 15.2 
 
CP (pH 3.5)  VHP®    94.1 +/- 10.4 
 
 
DOX (WFI)  VHP®    56.6 +/- 0.4  
   control (light)   102.4 +/- 0.1 
   control (temperature)  101.0 +/- 0.5 
 
DOX (NS)  VHP®    44.0 +/- 0.4 
   control (light)   98.9 +/- 0.6  
   control (temperature)  100.0 +/- 0.6 
 
DOX (pH 2.25)  VHP®    8.1 +/- 0.4 
   control (light)   90.1 +/- 0.3 
                  control (temperature)  97.9 +/- 0.5 
 
SD = standard deviation 
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 Under the conditions of Cycle 1, VHP® had little or no effect on 5-FU. The 
concentration of 5-FU remaining after VHP® exposure was 97.9% (WFI) and 96.5% 
(NS) of the initial concentration. This was slightly lower than the range of accuracy 
of the method i.e. the range of accuracy for 5-FU (WFI) was from 98.2 to 101%, and 
99.0 to 104% for 5-FU (NS) - see Table 5 (page 100). This was not considered 
significant since no degradation products or significant decreases in analyte peak 
height were observed. 
Similarly, VHP® had no significant effect on CP. The amount of CP (pH 3.5) 
remaining after VHP® exposure was 94.1% which was slightly lower than the range 
of accuracy of the method i.e. the range of accuracy for CP (pH 3.5) was from 97.6 to 
110% - see Table 5 (page 100). Again, this was not considered significant as no 
degradation products or significant decreases in peak height were observed. 
VHP® did cause significant degradation of DOX. The amount of degradation 
was dependent on the diluent used i.e. 43.4% degradation with WFI (pH 5.9), 56.0% 
with NS (pH 6.5) and 91.9% with sodium chloride (0.01 M, pH 2.25). No colour 
change of DOX was observed with VHP® exposure. Furthermore, there was no 
evidence of degradation of DOX in the controls from the effect of temperature, or any 
significant effects from natural light throughout the cycle duration. The concentration 
of the light control of DOX (pH 2.25) after exposure was 1.9% lower than the 
accuracy of the method – see Table 5 (page 100). This may be due to limited 
degradation of DOX from light exposure throughout the duration of the cycle. 
However, in comparison to the amount of degradation caused by VHP® (91.9%), this 
was not considered to be significant. A significant reduction was observed in the 
parent DOX peak, which eluted at 3.8 min. There were also additional peaks eluting 
at 2.3 min and at 4.7 min. These eluting peaks were degradation products of DOX. 
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They were not identified or quantified. See Appendix 4, Figures 58 and 59, for 
chromatograms showing of the degradation of DOX (buffer) following exposure to 
Cycle 1. 
 
 Under the conditions of Cycle 2, CP was not susceptible to oxidation after 2 
hrs exposure, at a concentration of 1.2 g min-1. Table 29 below shows the amount of 
CP remaining, expressed as a percentage of the initial concentration, plus or minus 
the standard deviation after exposure to Cycle 2. The results are from the exposure of 
triplicate samples and subsequent analysis by HPLC in duplicate.  
 
Table 29. Assay Results for CP after Exposure to VHP® 1.2 g min-1 for 2 Hours 
(Cycle 2) 
Drug (diluent) Exposure CP Remaining (%) after Exposure +/-SD 
 
CP (WFI)   VHP®    104.4 +/- 4.2 
 
CP (NS)  VHP®    104.7 +/- 1.2 
 
CP (pH 3.5)  VHP®    105.7 +/- 6.1
SD = standard deviation 
 
 
The conditions of Cycle 3, caused the degradation of three out of the four 
drugs when exposed in all diluents, and of 5-FU when exposed diluted in NS or 
buffer (pH 7.0). Table 30 on the following page shows the amount of 5-FU, CP, DOX 
and EPI remaining after exposure to Cycle 3, expressed as a percentage of the initial 
concentration plus or minus the standard deviation. The results are from the exposure 
of triplicate samples and subsequent analysis by HPLC in duplicate.  
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Table 30. Assay Results for 5-FU, CP, DOX and EPI after Exposure to VHP® at 1.6 g 
min-1 for 2 Hours (Cycle 3) 
Drug (diluent) Exposure      Drug Remaining (%) after Exposure +/-SD 
 
 
5-FU (WFI)  VHP®    98.5 +/- 3.8 
   control (light)   102 +/- 7.5 
   control (temperature)  99.8 +/- 0.3 
 
5-FU (NS)  VHP®    70.7 +/- 5.9 
   control (light)   95.1 +/- 2.2 
   control (temperature)  103.7 +/- 3.2 
 
5-FU (pH 7.0)  VHP®    84.9 +/- 0.2 
   control (light)   98.1 +/- 6.6 
   control (temperature)  95.7 +/- 6.7 
 
CP (WFI)   VHP®    1.1 +/- 0.17 
   control (light)   87.5 +/- 1.2 
   control (temperature)  97.0 +/- 6.1 
  
CP (NS)  VHP®    6.8 +/- 1.1   
   control (light)   89.4 +/- 0.3 
   control (temperature)  90.5 +/- 0.4 
 
CP (pH 3.5)  VHP®    25.4 +/- 0.2  
   control (light)   98.2 +/- 0.1 
   control (temperature)  100.2 +/- 6.4 
 
DOX (WFI)  VHP®    30.4 +/- 1.4 
   control (light)   96.8 +/- 3.1 
   control (temperature)  96.2 +/- 1.2 
 
DOX (NS)  VHP®    29.0 +/- 6.0 
   control (light)   92.3 +/- 4.9 
   control (temperature)  93.3 +/- 4.7 
 
EPI (WFI)  VHP®    34.1 +/- 0.4 
      control (light)   106.5 +/- 0.8 
   control (temperature)  104.8 +/- 3.3 
  
EPI (NS)  VHP®    69.0 +/- 2.1   
   control (light)   98.3 +/- 1.6 
   control (temperature)  98.8 +/- 3.2 
  
EPI (pH 4.0)   VHP®    45.5 +/- 4.5 
   control (light)   103 +/- 4.2 
   control (temperature)  99.2 +/- 5.3 
SD = standard deviation 
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VHP® had little or no effect on 5-FU (WFI) under the conditions of Cycle 3. 
Exposure of 5-FU (NS) caused 29.3% degradation and 15.1% when diluted in buffer 
(pH 7.0).  
 The longer exposure time of Cycle 3, caused significant degradation of CP. 
CP (WFI) was slightly more susceptible to degradation, with only 1.1% of drug 
remaining i.e. VHP® caused 98.9% degradation, followed by CP diluted in NS (6.8% 
remaining) and CP diluted in pH 3.5 buffer (25.4% remaining).  
 An increase in the degradation of DOX (WFI) from 43.4% (Cycle 1) to 69.6% 
(Cycle 3) was as a result of the longer exposure time. Furthermore, 56.0% 
degradation of DOX (NS) during Cycle 1 increased to 71.0% during Cycle 3. The 
effect of Cycle 3 on DOX (pH 2.25) was not determined as DOX demonstrated 
limited stability at pH 2.25. DOX was stable i.e. within +/- 5%168 for up to and 
including 5 hrs of storage in sodium chloride (0.01 M, pH 2.25); at 6 hrs 6.1% 
degradation was observed. Due to the logistics of the study i.e. the time taken for 
transport after a 4 hr cycle, the results in Table 30 (page 173) show exposure of DOX 
in the pharmaceutical diluents only.  
 EPI was also degraded by VHP®. During Cycle 3, 65.9% degradation of EPI 
(WFI) was observed, a similar effect was observed on DOX in WFI (69.6%). EPI 
(NS) compared to DOX (NS) was less susceptible to oxidation with only 31.0% 
degradation occurring compared to 71.0%, respectively. When EPI was exposed 
diluted in buffer (pH 4.0) 54.5% degradation was observed.  
There was no evidence of degradation of CP, or EPI in the control test 
surfaces from the effect of temperature or natural light throughout the cycle duration. 
The concentration of the light control for 5-FU (NS) was slightly lower (95.1%) than 
the range of accuracy of the method (99.0 to 104% - see Table 5, page 100). VHP® 
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caused 29.3% degradation of 5-FU (NS) in the test samples therefore, the contribution 
of natural light towards degradation was minimal. VHP®, light or temperature had no 
effect on blank surfaces or on any of the diluents used as blank controls. 
  No significant degradation products, observed as additional peaks, were 
present in the chromatograms showing the degradation of 5-FU or CP. A small peak 
at 3.6 min present in a chromatogram representing the degradation of EPI may be a 
degradation product of EPI. It was not identified or investigated further. There was no 
evidence of degradation of EPI diluted in WFI, NS or pH 4.0 buffer in the controls 
from the effect of natural light or temperature throughout the cycle duration.  
4.6  Discussion 
This study was set up initially as a pilot study, to investigate the effect of 
current decontamination technologies (liquid detergents/cleaning agents and VHP® 
fumigation) as potential agents, which could reduce the risk to the operator by 
reducing or eliminating drug contamination from a surface. 
Three cytotoxic marker drugs (5-FU, CP and DOX) were exposed to 
detergents of different pH and cleaning agents (Phase I and IIi), and VHP® (Phase 
IIii). Based on the results, these tests were further extended to EPI, another drug 
likely to be pH sensitive and susceptible to degradation by oxidation. 
 
Preliminary wipe tests with strong alkaline, acid, or neutral detergents, and 
wiping with a dry wipe removed all drugs tested from a contaminated surface – see 
Table 27 (page 166). WFI and IMS, the controls, were also as efficient. 5-FU (NS) 
was more persistent to removal by WFI than 5-FU (WFI), requiring 3 wipes 
compared to 1 wipe, respectively. 5-FU is formulated with sodium hydroxide to 
prevent precipitation which may occur at pH <8.128 Effectively, the 5-FU is present as 
 176
a sodium salt. The presence of sodium ions in the formulation and in the diluent (NS), 
could have reduced the solubility of 5-FU sodium salt in solution, as a result of the 
common-ion effect. The reduced solubility would make 5-FU (NS) more persistent to 
removal than 5-FU (WFI).   
 The solubility of a drug depends upon the extent to which it is ionised. This is 
determined by the pKa of any acidic and basic groups and the pH of the 
environment. Drugs are more soluble and likely to be taken up by a wipe at the pH at 
which they are 100% ionised. DOX has a pKa value of 8.2171 and would have been 
ionised and very water-soluble at the pH it was subjected to by the acidic detergents 
(pH 1.7 to 2.4) and not at the pH of the alkaline detergents (pH 11.3 - 13.2). This 
could explain why it was easier to remove from the surface with acid rather than 
alkali detergents; although, alkaline detergents played a part in the degradation of 
DOX. Persistency to removal at alkaline pH, indicates that surfaces contaminated 
with DOX would need to be cleaned twice with detergents/cleaning agents of 
alkaline pH, or extra pressure applied to remove all of the contamination from the 
surface.   
Wipe tests with the two cleaning agents used currently to decontaminate 
isolators and a dry wipe were also effective in removing all drugs, including EPI. 
DOX was slightly more persistent to one of the cleaning agents. 
 
Exposure of drug solution for up to 1 hour in strong acid and alkali and 
neutral-based detergents caused no degradation of 5-FU or CP. Degradation of DOX 
occurred when it was subjected to detergents of alkaline pH after 1 hour of exposure. 
The exposure of DOX to alkaline-based detergents resulted in an immediate colour 
change of DOX from red to purple, which is indicative of alkaline decomposition.24 
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CIP 100 (pH 13.2) caused the most degradation of DOX, 81% after 1 hour, with 50% 
occurring after 5.4 min - see Figure 28 (page 168). CIP 100 is formulated with 
potassium hydroxide and is 0.4 of a pH unit more alkaline than CIP 150, which is 
formulated with potassium hydroxide, sodium hydroxide, and sodium hypochlorite 
(<5% w/v). DOX has been reported to be degraded completely by sodium 
hypochlorite (5.25% w/v) after 1 hour of exposure.115;185 The strong alkalinity of the 
detergent appeared to be the dominant factor in determining degradation of DOX 
rather than oxidation i.e. by sodium hypochlorite, indicating that hydrolysis was pH-
dependent. DOX was also susceptible to VHP®, indicating that the degradation of 
DOX occurred through two different mechanisms, oxidation being one method and 
alkali hydrolysis being the other. No colour change was observed with oxidation. 
Exposure for up to 1 hour to the cleaning agents which are used for the 
decontamination of isolators after the compounding of cytotoxic drugs caused no 
degradation of 5-FU, CP, DOX or EPI. Klercide CR-B would be used in cleaning for 
its biocidal properties but it would not be effective in degrading cytotoxic 
contamination of any of the four drugs tested in this study. 
 
5-FU and CP were not susceptible to the initial VHP® parameters applied in 
Cycle 1 – Table 26 (page 164). DOX was subject to oxidation by VHP®. The degree 
of degradation was dependent on the diluent used, with significant degradation 
observed when DOX was exposed following dilution in a strongly acidic diluent (pH 
2.25) – see Table 28 (page 170). Further studies carried out to investigate the effects 
of VHP® over a longer exposure time subjected the drugs to harsher conditions. To 
maintain the concentration of VHP® for Cycles 2 and 3, it was necessary to use an 
exposure chamber, as flexible-walled isolators leak with time.186 As a result, the 
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drugs were also subjected to higher temperatures. VHP® penetration of the target 
increases with temperature and it would be expected to be significantly more effective 
at higher temperatures. Drug controls exposed in the isolator/exposure chamber to a 
blank cycle subjected the drugs to the same temperatures minus VHP® exposure. 
These controls confirmed stability to the temperatures reached during the cycles. 
Initial exposure to VHP® carried out at 1.6 g min-1 for 25 min (Cycle 1) had no 
significant effect on 5-FU or CP, which was expected, as these are drugs not likely to 
undergo oxidation. Increasing the length of exposure from 25 min to 2 hrs at a lower 
concentration of 1.2 g min-1 (Cycle 2) was not effective against CP – see Table 29 
(page 172). The increase in VHP® from 1.2 to 1.6 g min-1 (Cycle 3) under the same 
conditions, i.e. time and temperature, had a significant effect – see Table 30 (page 
173). CP was susceptible to degradation by this small increase in concentration. The 
longer exposure time and increase in concentration of Cycle 3 compared to Cycle 1 
increased the amount of degradation of DOX. It may appear from Table 30 (page 
173) that VHP® Cycle 3 had a greater effect on CP compared to the other drugs. 
However, quantification of the drugs cannot be compared between methods due to the 
difference in sensitivity of the HPLC assays. The method for DOX was a 10-fold 
more sensitive assay compared to the method for CP – see Table 5 (page 100). 
Although the CP peak was almost degraded completely the measurement was only 
slightly above the LoD of the CP assay, which was 2.5 µg mL-1, compared to 0.25 µg 
mL-1 for DOX. Cycle 3 also caused degradation of EPI. 5-FU was the least 
susceptible to oxidation of the four drugs. However, degradation (29.3%) of 5-FU 
was observed when it was exposed diluted in NS. When exposed diluted in WFI the 
drug solution was not susceptible to oxidation. A significant difference in the amount 
of degradation was also observed between the pharmaceutical diluents when DOX 
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was exposed diluted in NS, compared to WFI (Cycle 1). An increase in ionic strength 
by the addition of sodium chloride to a solution has been demonstrated to increase the 
rate of degradation of DOX.171 The rate of degradation of DOX by VHP® in this 
study may have been increased by the influence of the ionic strength of NS as the 
diluent. This may have also influenced the rate of degradation of 5-FU, and would 
explain why more degradation of DOX and 5-FU was observed when exposed diluted 
in NS compared to WFI.  
DOX and EPI were the least stable to oxidation. Cycle 3 further increased the 
degradation of DOX in the pharmaceutical diluents by 26.2% when exposed diluted 
in WFI and by 15% when exposed diluted in NS. However, DOX was not degraded 
completely to below the LoD for the analytical method. The susceptibility of DOX to 
oxidation is reported in the literature,116;153 DOX and EPI are also unstable at pH 
values less than 3 or greater than 7.128 In this study, DOX was susceptible to 
oxidation by VHP®, and its instability at a pH lower than pH 3 was confirmed. 
 
This study confirms the superior stability of 5-FU and CP compared to DOX, 
since no decomposition occurred during exposure to liquid hydrogen peroxide or 
even when exposed to the extreme pH conditions (pH 1.7 to 13.2) applied. 5-FU and 
CP were not susceptible to oxidative stress during initial exposures to VHP® but CP 
was more susceptible to the harsher exposure conditions.  
EPI was less susceptible to oxidation than DOX. Cycle 3 caused more than 
twice as much degradation of DOX (71.0% degradation) compared to EPI (31.0% 
degradation) when exposed diluted in NS. When exposed diluted in WFI the amount 
of degradation between the two drugs was similar. Between the three diluents, EPI 
was most stable in WFI (pH 5.9) and not at pH 4.0. The amount of degradation 
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between the drugs when exposed at different pHs values cannot be compared. DOX 
was exposed in a pH at which it was unstable after a certain period of time, and EPI, 
CP and 5-FU would demonstrate some stability at the respective pH of the aqueous 
part of the mobile phase. Comparisons could have been made if the drugs had all been 
exposed in standard buffers covering a range of pH values. However, surface 
contamination of these drugs in an isolator would only be found in the pharmaceutical 
diluents and further work should investigate these more relevant diluents only. 
The gaseous form of hydrogen peroxide is advantageous over the liquid form 
as it contacts all the surfaces that it is exposed to, even those of complex 
topographies, ensuring a uniform decontamination. The gaseous form of hydrogen 
peroxide was demonstrated to be a more effective oxidising agent than liquid 
hydrogen peroxide, which in this present study had no effect on the decomposition of 
DOX. The ineffectiveness of liquid hydrogen peroxide in degrading DOX has already 
been reported.115  
Liquid hydrogen peroxide (35%) and CIP 150 formulated with sodium 
hypochlorite (<5%) had no effect on CP. These results are not in total agreement with 
the literature.113;115 Sodium hypochlorite (5.25%) and ≤30% liquid hydrogen peroxide 
have been reported to exhibit >98% efficiency in inactivating CP to non-mutagenic 
residues after 1 hour of exposure,113 with complete disappearance of the parent peak 
when assayed by HPLC. However, the method used was not as sensitive; any 
contribution to cytotoxicity could only be measured from residues equivalent to 20 µg 
of degraded CP tested per plate in the Ames mutagenicity tests, and the LoD of the 
analytical method was 20 µg mL-1, compared to an LoD of 2.5µg mL-1 in this present 
study. 
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Exposure to potassium hydroxide (0.2 M) in methanol solution for one hour is 
recommended for the chemical destruction of CP.24 The detergent formulations CIP 
150 and CIP 100 contain <10 % w/v (<0.02 M) and <25% w/v (<0.04 M) potassium 
hydroxide, respectively. Detergents formulated with a higher concentration of 
potassium hydroxide may have been more effective in degrading CP.  
Phase I was carried out following a review of drug structures. Alkaline 
hydrolysis above pH 9.0 appears to be the likely method of degradation of 5-FU in 
solution.5 The range of alkaline-based detergents had no effect on 5-FU after 1 hour. 
Certainly, the alkaline hydrolysis of 5-FU is a slow process.5 The degradation of 5-
FU by alkaline hydrolysis is shown schematically in Figure 30 below.5  
 
Figure 30. Scheme Showing the Hydrolysis of 5-Fluorouracil at Alkaline pH5 
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(iv).5 Thermal and photo degradation also lead to this end product,24 which is not 
cytotoxic. In this study, the thermal and photo stability of 5-FU was confirmed with 
the temperature and light controls.  
Although, CP mainly degrades by hydrolysis in vitro,172;173;187;188 chemical 
degradation by oxidation has also been reported. Oxidation of CP by Fenton’s reagent 
produced acrolein,175 which is one of the cytotoxic metabolites produced from the 
enzymatic oxidation of CP in the liver.1 The rate of CP hydrolysis in aqueous solution 
is constant over the pH range of 2 to 10. Specific acid and specific base catalysis 
occurs at extreme pH.5 Initial acidic hydrolysis may occur in one of three ways to 
produce intermediate products which are alkylating agents: i. cleavage of the 
exocyclic N-P bond to release nor-nitrogen mustard; ii. cleavage of the endocyclic N-
P bond to produce cytoxylamine or iii. cleavage of the endocyclic O-P bond to 
produce cytoxyl alcohol.5;173 This is shown schematically in Figure 31 below.5  
 
Figure 31. Scheme Showing the Three Possible Hydrolysis Pathways of 
Cyclophosphamide at Acidic pH5 
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Subsequent hydrolysis of these intermediate products produces phosphoric acid (iv), 
propanolamine (v) and nor-nitrogen mustard (vi).  
The scheme for the degradation of CP at neutral or alkaline pH is shown in 
Figure 32 below.5 Under neutral or basic conditions, CP (i) hydrolysis occurs by an 
initial intra-molecular N-alkylation with the loss of a chloride ion that forms 
hydrochloric acid, and a bicyclic product (ii).187 This compound is very labile in 
aqueous solution and undergoes a series of hydrolytic cleavages of amide (N-P) and 
ester (P-O) bonds to produce the main product iii. N-(2-hydroxyethyl)-N’(3-
hydroxypropyl)ethylenediamine and iv. a minor product from a second 
alkylation.173;187  
 
Figure 32. Scheme Showing the Hydrolysis of Cyclophosphamide at Neutral or 
Alkaline pH5 
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CP is temperature sensitive and hydrolysis may occur rapidly at temperatures 
above 30°C. The disappearance of the CP parent peak indicates degradation of CP, 
but further work would be needed to identify degradation products and assess any 
contribution to cytotoxicity. 
 
 DOX and EPI have a similar stability profile. They exhibit pH-dependent 
stability in solution, with maximum stability observed at pH 4, and are sensitive to 
light and temperature.24 The acid hydrolysis of DOX is shown schematically in 
Figure 33 below.171 In solutions of pH less than 4, the glycosidic bond is cleaved and 
both release a water-insoluble tetracyclic aglycone (ii. doxorubicinone) and a red 
water-soluble amino sugar. The amino sugar released by DOX is daunosamine (iii)171 
and EPI releases acosamine.24 The aglycone is cytotoxic but less so than the parent 
drug.128  
 
Figure 33. Scheme Showing the Hydrolysis of Doxorubicin at Acidic pH171 
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 In alkaline solution a colour change from red to deep purple is due to the rapid 
degradation of DOX and EPI.24 This is thought to reflect cleavage of the amino sugar 
and the formation of other degradation products such as 7,8-dehydro-9,10 desacetyl-
daunorubicnone.153 The proposed reaction scheme is shown in Figure 34 below. The 
colour change also occurs with other anthracyclines antibiotics which are structurally 
similar.128  
 
Figure 34. Scheme Showing the Degradation of Doxorubicin at Alkaline pH153 
 
 
 Mechanical removal by detergents was restricted to a small surface area where 
the contamination was visible. Scaling-up the procedure to remove surface 
contamination from an isolator would be more complex to undertake. The inside of an 
isolator covers a larger surface area of more complex topography. Some areas are not 
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accessible easily via the glove port system, making it difficult to wipe in a methodical 
way and apply pressure consistently over the whole area. 
   
 Exposure of the drugs to VHP® at different pH demonstrated the pH-
dependent oxidation of DOX. Degradation between drugs was not comparable as the 
drugs demonstrate different stability profiles at various pH. For practical significance, 
further studies should explore cytotoxic decontamination on drugs exposed diluted in 
the standard pharmaceutical diluents only.  
4.7  Conclusion 
 Mechanical removal by acidic, neutral and alkaline pH-based detergents was 
effective on 5-FU, CP and DOX surface contamination. The alkaline detergents, 
particularly CIP 100 which caused 81% degradation after 1 hour of contact with 
DOX, could be applied as part of a cleaning protocol for the removal and breakdown 
of DOX surface contamination. However, further studies would be required to 
identify the breakdown products and to establish whether these were still cytotoxic. 
 Two cleaning agents (Klerclean neutral detergent and Klercide CR-B) used 
currently in hospital pharmacies, IMS and WFI, were also effective in removing 5-
FU, CP, DOX and EPI contamination. These cleaning agents have the potential of 
surface wipe cleaning only, as they were not effective in the breakdown of the 
cytotoxic drugs.  
 Exposure to VHP® at 1.6 gmin-1 for 25 min caused the oxidative degradation 
of DOX. The effect was pH-dependent and the maximum amount of degradation 
from this exposure was 91.9%. 5-FU and CP were not susceptible to oxidation from 
VHP® under these conditions. A longer exposure time to VHP® for 2 hrs caused 
 187
degradation of CP, some degradation of 5-FU, and in addition caused the degradation 
of EPI.  
 VHP® is effective against microbial contamination. It also has the potential, 
with further investigation of cycle parameters to cause the degradation and maybe 
inactivation of surface cytotoxic contamination inside an isolator. However, to be 
applied successfully as a method for cytotoxic decontamination a guarantee would be 
required that the drug was completely degraded and that any degradation products 
would not contribute towards cytotoxicity. The breakdown products of 5-FU would 
not be expected to contribute any cytotoxicity, but CP, an oxasophosphorine prodrug 
which degrades to produce other alkylating cytotoxic compounds would need to be 
investigated thoroughly. 
 
 In conclusion, decontaminating an isolator using mechanical removal of 
cytotoxic residues with detergents is the method of most importance to hospital 
pharmacy practice. Using technology for chemical breakdown is less practical and 
would be more costly to implement into the daily running of a hospital pharmacy. If 
the products used for removal also cause chemical decomposition of the 
contamination, this could be potentially beneficial, depending on the extent of 
decomposition and the nature of the breakdown products   
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5.  Comparative Contamination Study in an Isolator: traditional open-
system versus a closed-system 
5.1  Introduction 
 Although there have been comparative studies on effectiveness between the 
closed-system PhaSeal® device and traditional ‘open’ reconstitution methods,67;78;124 
no data have been reported on its effectiveness in an isolator under UK standards of 
practice. In the UK, drug reconstitution and administration is a pharmacy-based 
activity carried out in purpose designed facilities, which normally use isolators in 
preference to BSCs. Studies have been carried out in positive-pressure isolators under 
French standards of practice.59;61 However, the need to investigate drug contamination 
found in pharmacies where negative-pressure isolators are normally used in the UK is 
apparent. In fact, apart from one recent study which carried out environmental 
monitoring in two UK hospital pharmacy units,26 there appears to be a paucity of 
current UK data on occupational exposure.  
Elimination of the primary contamination event would not only prevent 
potentially harmful exposure but would also prevent the occurrence of secondary 
contamination of areas outside the immediate drug environment.20 Two systems for 
the compounding of cytotoxic drug injections/infusions were compared: the traditional 
‘open-system’ using syringes, needles and venting needles, and a closed-system 
device, which is a special closed containment device for fluid-transfer.  
5.1.1  The Traditional Open-System 
 The traditional open-system uses Luer-Lok syringes and needles, and 
hydrophobic filter needles as air vents. It is classified as an ‘open-system’ as it is well 
known that droplets can be liberated during manipulations using this method.32;67  
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5.1.2  The PhaSeal® Device - A Special Closed Containment Device  
 The PhaSeal® device prevents cytotoxic aerosols/droplets from contaminating 
the outside environment.32 This was the closed-system device used during the 
Intervention period of this present study. The PhaSeal® system was an assembly of the 
following three main components;127  
  
The Protector 
 The protector is a protective cover, which fits over the top of the vial (see 
Figure 35 below). It has a flexible expansion bulb which accommodates air pressure 
equalization when increased i.e. filling the vial with diluent, injecting air into the vial, 
or when a vacuum is created i.e. aspiration of a liquid. It contains a hydrophobic 
PTFE/polypropylene filter, which prevents vapour leakage.  
 
Figure 35. Image of the Protector, and a Protector and Vial Assembled127 
 
 
   (reproduced with permission from Carmel Pharma) 
 
 
 The Injector 
 The injector (see Figure 36 on the following page) contains an encapsulated 
single lumen cannula, which locks into a disposable syringe via a Luer-Lok fitting. 
When the protector and injector are assembled, a double, tightly sealed, elastomeric 
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membrane is created. These membranes, made of elastomers are self-sealing and fit 
tightly together through a bayonet fitting which locks tightly with a twist. The cannula 
perforates the double membranes for the transfer of liquid, ensuring the tip of the 
cannula is never exposed, preventing needle-stick injuries. When the needle is 
retracted, the membranes seal off preventing leakage to the environment. This ensures 
a dry connection with only ‘wet’ retained behind each membrane. It also comprises a 
safety latch, which has to be released before the injector can be depressed.  
 
Figure 36. Image of the Injector, and an Injector and Luer-Lok Syringe Assembled127 
 
 
 
 
   (reproduced with permission from Carmel Pharma) 
 
 
The Infusion Adaptor 
 The infusion adaptor (see Figure 37 on the following page) connects via a 
puncture spike to the infusion bag. Transfer into the infusion bag from an Injector-
fitted syringe is via a membrane-infused bayonet fitting on the infusion adaptor, 
allowing closed transfer into and out of the bag.  
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Figure 37. Image of the C71 Infusion Adaptor127 
 
(reproduced with permission from Carmel Pharma) 
 
 
A 2-arm cross-cohort study was designed to collect data during the 
compounding of cytotoxic drugs in an isolator. A cohort study was used to collect 
contamination data from the same surfaces, at a large number of sampling points, so 
that contamination produced from batch preparation could be assessed. An intense 
sampling schedule was applied to generate a large amount of data and assess the time 
sequence of events. A cross-over design was used to make individual comparisons 
between contamination measured on the same surfaces using the two different 
methods over the same period of time, one after another. 
The compounding process was a simulated process and the test infusions 
produced were not administered to the patient. Baseline data were collected using 
existing standard practice (open-system) and intervention data were collected during 
implementation of a closed-system transfer (PhaSeal®) device. The effectiveness of 
intervention was investigated with two drugs novel to testing with the device; EPI and 
MTX, and also with CP. CP has been used frequently as a marker drug and the 
effectiveness of the closed-system (PhaSeal®) device in reducing CP contamination 
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when it was prepared in a BSC or on a bench top in the U.S and in continental Europe 
has been documented.20;67;78;124 Methods developed and validated for these drugs as 
described in Chapter 3 (Method 2) were used to quantify the amount of contamination 
from surfaces and achieve the objectives as described below. 
5.2  Study Objectives 
  The primary objectives were to investigate the following during the 
compounding of cytotoxic drugs in an isolator workstation: 
i. determine the frequency and amount of contamination in an isolator workstation; 
ii. determine if this contamination is persistent, or if it can be removed by cleaning; 
iii. determine how much contamination is transferred to the outside environment via 
the external surface contamination of products leaving the isolator; 
iv. determine the effectiveness of intervention (PhaSeal®) in reducing  
a. the frequency and level of this contamination in the isolator workstation and 
b. the frequency and level of surface contamination of finished syringe batches 
leaving the isolator. 
 
 The secondary objectives were to determine operator acceptance of using this 
intervention in the isolator setting. 
5.3  Materials 
Cytotoxic Drugs 
Methotrexate 25 mg mL-1 Injection (lot R084426) was obtained from Mayne 
Pharma Plc, Leamington Spa, UK. Cyclophosphamide 500 mg Powder for Injection 
(lot 44139) was obtained from Pzifer Ltd, Kent, UK. Pharmorubicin Solution for 
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Injection 2.0 mg mL-1 (lot BF87B) was obtained from Pharmacia and Upjohn Ltd, 
Sandwich, UK. 
 
Cleaning Agents 
Klercide 70/30 sterile denatured ethanol (lot 051005EP), Klerclean sterile 
neutral detergent (lot 060203ND/4) and Klercide CR (lot 060310BP/4) sterile filtered 
biocide B were obtained from Shield Medicare, Surrey, UK. 
 
Equipment 
 The closed-system (PhaSeal®) device components: protector 50 (lot 607217), 
injector N31 (lot 612705) and infusion adapter C100 (lot 509034) were supplied by 
Carmel Pharma, Gotёborg. Sweden. The negative-pressure isolator, ducted externally, 
model CDC-B (2-glove) was manufactured by Envair, Rossendale, UK. 
 
Consumables 
 Luer-Lok Plastipak syringes, 3.0 mL (lot 04K03A), 10 mL (lot SC050314), 20 
mL (lot SD060115), and 60 mL (lot SF050117), and microlance™ 3 syringe needles, 
19G × 2” (lot 050416) were obtained from Becton Dickinson, Oxford, UK. Syringe 
tip caps (lot 6023D) and 0.2 µm hydrophobic filter needles, 20G (lot 181703) were 
obtained from Baxa Ltd, Berkshire, UK. Berner cytostatic protection gloves (lot 
507452780), cytostatic protection gowns (lot 5914), cytotoxic workmats, BioClean 
100 nitrile gloves, Stericlean® dry wipes (lot W016603) and Stericlean® prep pads (lot 
529179) were obtained from Helapet Ltd, Bedfordshire, UK. Freeflex® 500 mL 
polyolefin intravenous infusion bags (lot MK72094) containing sodium chloride 0.9% 
were obtained from Baxter Healthcare Ltd, Berkshire, UK. Polypropylene 250 mL 
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containers and 15 mL polypropylene tubes were obtained from Sarstedt Ltd, Leics, 
UK. 
5.4  Study Design 
5.4.1  Pharmacy Staff and Equipment 
 Two technicians were involved in cytotoxic batch preparation. Technician One 
(a pharmacy technician) with 3 years experience of working with cytotoxic drugs in a 
hospital pharmacy, and Technician Two (a pharmacist), were trained in use of the 
closed-system (PhaSeal®) device over a period of two weeks.  
 The study was undertaken in a controlled GMP-compliant clean-room 
environment in an academic setting at the Department of Pharmacy, Kingston 
University, London. The environment in the clean-room was tested to EU grade Class 
B.135 Work was carried out to simulate the compounding of cytotoxic drugs in one 
isolator by following the Standard Operating Procedures (see Appendix 5 for list of 
SOPs), according to current practice at Plymouth Hospitals NHS Trust, Derriford. 
This is an acute university hospital with a specialised MHRA licensed pharmacy 
aseptic unit producing in excess of 50,000 dose units of chemotherapy per year, 
shared between five isolator workstations. Throughout the study, standard safety 
precautions were adhered to and personal protective equipment was used. 
The study was restricted to an isolator operating under negative-pressure, with 
air ducted to the external environment. It was designed with two glove ports and two 
interlocking hatches with a 2 min time delay. The selected isolator and the clean-room 
it was situated in were used only for the compounding of cytotoxic drugs for the 
purpose of this study. Neither the clean-room or the isolator had previous exposure to 
cytotoxic drugs prior to this study. 
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5.4.2  Work Schedule 
The study was divided into 4 data collection periods, each of 1-week duration. 
Data were collected using the open-system to establish a Baseline (Baseline periods 1 
and 2), and using the closed-system (PhaSeal®) device (Intervention periods 1 and 2). 
The open-system was the existing standard practice of the model study site 
(Plymouth). Baseline and Intervention data were collected over two one-week periods 
in each case. This included an initial one-week period for familiarisation with the 
closed-system (PhaSeal®) device as follows; 
 
Week 1 Baseline 1 
Week 2 Closed-system (PhaSeal®) device familiarisation 
Week 3 Intervention 1 
Week 4 Baseline 2 
Week 5 Intervention 2 
 
 The study was conducted so that data were captured each day of a four 
consecutive day working week for the Baseline and the Intervention arms of the study. 
During the Intervention arm of the study, all manipulations were carried out using the 
closed-system (PhaSeal®) device. No data were collected during the familiarisation 
period.  
5.4.3  Training of the Technicians 
 The technicians had two weeks of training prior to the start of the study, one 
with the open-system and one with the closed-system (PhaSeal®) device. The second 
week of the study was used as another training week with the device (closed-system 
device familiarisation).  
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 A professional from Carmel Pharma, Gotёborg, Sweden, undertook training of 
the technicians and competency assessment with the closed-system (PhaSeal®) device. 
Both technicians achieved competence prior to implementation of the device. The 
technicians documented any leakages or spillages during all study weeks, and any 
problems, observations or difficulties during implementation with the closed-system 
(PhaSeal®) device.  
 The technicians rotated between batch preparation in the isolator and support 
work on a daily basis. Technician One prepared batches on days 1 and 3, and 
Technician Two prepared batches on days 2 and 4. This arrangement was the same for 
each study week. The technician who was not preparing batches on a particular day 
would act as the support, and would also carry out the Sampling Procedure, as 
described in Section 5.4.8. Both technicians were trained with the Sampling Procedure 
prior to the start of the study.  
5.4.4  Test Drugs and Batch Production 
 EPI, MTX and CP were the cytotoxic drugs compounded. Table 31 on the 
following page shows details of the batches produced during the four-day week. Each 
day was divided into Session 1 and Session 2. In total, 25 batches of chemotherapy 
(201 dose units) were prepared on each four-day week. This was equivalent to a total 
throughput in one isolator of 10,452 dose units per year, representing 21% of the 
workload of the ‘model’ unit at Plymouth. The total amount of drug prepared weekly 
was made up of 370 mg of EPI (10.5%), 493mg of MTX (14.0%), and 2,650 mg of 
CP (75.4%). This workload was the same for each week of the study to remove bias in 
workload variation during the study. A log of each batch of chemotherapy prepared 
was produced, recording the date, infusion name, number of devices filled, volume of 
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fill, total amount of cytotoxic drug in each batch, type of container, time to prepare the 
batch and the name of the technician involved in batch production.  
 
Table 31. Schedule of Batch Production of EPI, MTX and CP for Each Study Week 
Day and Session    Drug         Volume        Infusion         Number of      Batch  
     (mL)           (mL)  Units     Number 
 
Day 1, Session 1 CP, 150 mg  7.5     10.0 mL syringe 10  1 
   CP, 500 mg  25.0     60.0 mL syringe 10  2 
   EPI, 15.0 mg  7.5     10.0 mL syringe 15  3 
 
Day 1, Session 2 EPI, 50.0 mg  25.0    60.0 mL syringe 10  4 
   EPI, 75.0 mg  37.5    60.0 mL syringe 1  5 
   MTX, 15.0 mg  0.6    3.0 mL syringe 10  6 
   MTX, 200 mg  500    500 mL bag  1  7 
 
Day 2, Session 1 CP, 200 mg  10.0    10.0 mL syringe 10  8 
   EPI, 50.0 mg  25.0    50.0 mL syringe 10  10 
   EPI, 40.0 mg  20.0    20.0 mL syringe 10  11 
 
Day 2, Session 2 MTX, 20.0 mg  0.8    3.0 mL syringe 10  9 
   MTX, 20.0 mg  0.8    3.0 mL syringe 10  12 
   MTX, 40.0 mg  1.6    3.0 mL syringe 1  13 
 
Day 3, Session 1 CP, 400 mg  20.0    20.0 mL syringe 10  14 
   CP, 500 mg  25.0    60.0 mL syringe 10  15 
   EPI, 20.0 mg  10.0    10.0 mL syringe  10  16 
   EPI, 50.0 mg  25.0    60.0 mL syringe  10  17 
 
Day 3, Session 2 MTX, 100 mg  500    500 mL bag  1  18 
   MTX, 40.0 mg  1.6    3.0 mL syringe 1  19 
 
Day 4, Session 1 CP, 400 mg  20.0    20.0 mL syringe 10  20 
   CP, 500 mg  25.0    60.0 mL syringe  10  21 
   EPI, 30.0 mg  15.0    20.0 mL syringe  10  22 
   EPI, 40.0 mg  20.0    20.0 mL syringe 10  23 
 
Day 4, Session 2 MTX, 17.5 mg  0.7    3.0 mL syringe 10  24 
   MTX, 40.0 mg  1.6    3.0 mL syringe 1  25 
 
 
 
5.4.5  Standards of Practice 
 The Plymouth Hospitals Standard Operating Procedures followed included 
use of the isolator (SOP CH7) and glove changing (SOP CH8), reconstitution of 
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cytotoxics and preparation of cytotoxic syringes (SOPs ASG8, ASG17, and CH1), 
dealing with cytotoxic spillages (SOP CH9), entering the isolator room (SOP CG6) 
and hatch transfer (SOP ASG2). The preparation of all batches was carried out in a 
similar manner. The following describes batch preparation on a day when Technician 
One would be preparing batches in the isolator.  
Technician Two wiped all items with a wipe impregnated with IMS, and placed them 
into trays sprayed with IMS, prior to transfer into the clean-room. The technicians 
changed into their personal protective clothing i.e. overshoes, barrier hats, nitrile 
support gloves and chemotherapy gowns, and transferred items via the trolley 
transfer hatch into the clean-room. Technician Two gathered the appropriate supplies 
for the preparation of one batch at a time. The tray used to take items/consumables 
into the isolator though the right-hand hatch (when facing the isolator) was referred 
to as the ‘tray in’. The ‘tray in’ was sprayed with IMS and the items sprayed into the 
tray. The outer door of the right hatch was opened and the ‘tray in’ placed inside. 
Technician One was seated and placed each arm and hand into the isolator sleeves 
and gloves. After 2 minutes, the right inner hatch door was opened, contents of the 
tray were removed and placed into the isolator main chamber. Prior to, during, and 
after the preparation of each batch, the isolator gloves were sprayed with IMS. When 
batch production was complete, the finished product was placed into a plastic bag in 
the left hatch. A different tray referred to as the ‘tray out’ was used to take any 
waste/items to be removed from the isolator via the left-hand hatch. The bag 
containing the finished product was removed from the left hatch via the outer door 
alongside the ‘tray out’. Plastic backed absorbent mats were used for all preparations 
and changed at the end of each session, alongside with the gloves used in the isolator. 
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At the end of the session, Technician One cleaned the isolator and Technician Two 
carried out the Sampling Procedure as described in Section 5.4.8. 
5.4.6  Cleaning Procedure 
 The isolator was cleaned twice daily. Prior to the start of Session 1 of each 
day, the right hatch was sprayed with Klercide CR-B (a blend of stabilized chlorine 
dioxide and a QAC), left for 5 min then wiped clean with IMS and a low lint swab. 
The procedure was repeated for the left hatch. The cleaning agents were transferred 
into the isolator and all accessible surfaces of the main chamber, including the sleeves 
were cleaned using the same method. All surfaces were then sprayed with IMS. Prior 
to the start of Session 2, the process was repeated except Klerclean neutral detergent 
(a non-ionic fatty alcohol ethoxylate), was used in place of Klercide CR-B. The tray 
was cleaned after each batch by spraying the inner and outer surfaces using Klercide 
CR-B and wiping with a sterile low lint wipe. At the end of the week, the floor was 
cleaned with distilled water and Klercide CR-B. A log was maintained of the cleaning 
procedures used and the time/date of cleaning. 
5.4.7  Sampling Strategy 
 Sampling involved the removal of drug contamination from the specified areas 
of each surface, and was undertaken on four occasions (a, b, c and d) daily.  
 
Sampling a was carried out at the beginning of each day prior to the start of 
Session 1 and loading of the isolator; 
Sampling b was carried out at the end of Session 1, prior to cleaning;  
Sampling c was carried out at the end Session 1 after cleaning, and prior to the 
start of Session 2 and loading of the isolator; 
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Sampling d was carried out at the end of Session 2 prior to the end of session 
cleaning. 
 
This is outlined in the scheme below; 
 
i.e.   Day 1     sampling a  
   Session 1 (batch preparation) 
       sampling b  
         cleaning 
       sampling c 
   Session 2 (batch preparation) 
       sampling d 
         cleaning 
Day 2     sampling a   etc 
 
Sampling was also carried out prior to the start of the study and before any cytotoxic 
drugs had entered the room or isolator. 
5.4.8  Sampling Procedure 
 Each sampling time point (a-d) involved wiping/swabbing predefined surfaces 
by wiping with an 70% IPA-impregnated wipe (Stericlean® prep pad). Validated 
methods, as described in Section 3.7.3 were used to wipe and remove the multi-drug 
contamination of EPI, MTX and CP from eleven surfaces. The contaminated wipes 
were collected and retained into 15 mL centrifuge (collection) tubes containing 
desorbing solution (3.5 mL) i.e. phosphate buffer (0.01 M) pH 4.0. Gloves used in the 
isolator (isolator gloves) and gloves used outside the isolator (support gloves) were 
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retained at the end of each session. The following areas were swabbed at each 
sampling point; 
 
Isolator Base  
 Swabs were taken from three spot areas on the isolator base (see Section 
3.7.1). A template measuring 21 cm × 21 cm was placed on the stainless steel surface 
and the swabs were taken within this area. The top left-hand side, top right-hand side, 
and the top centre were swabbed, using one wipe for each. The three-swabbed areas, 
in combination covered 21% of the area of the isolator base. All three swabs were 
combined in one collection tube. 
 
Isolator Hatch Door 
 The hatch on the right-hand side of the isolator was used for the introduction 
of consumables into the isolator, and the hatch on the left was used for removal from 
the isolator. Each hatch door was made of a clear Perspex™ screen surrounded by a 
black rubber seal. Both sides of the screen of the right and left door leading directly 
into the isolator were swabbed i.e. the inner side of the hatch door in contact with the 
isolator (see Figure 38 on the following page); and the outer side of the door in 
contact with the hatch (see Figure 39 on the following page).  
 
Isolator Sleeves  
 The isolator sleeves were made of Hypalon®. The cuffs of both the left and 
right sleeves were swabbed.  
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Figure 38. Image of the Isolator Base and Inner Hatch Doors 
 
 
 
 
 
inner hatch door, left    isolator base         inner hatch door, right 
                      
 
Figure 39. Image of the Right-Hand Outer Hatch Door and 'Tray In' 
 
 
 
 
outer hatch door, right  tray in  
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Tray 
 The same type and size of tray was used as the ‘tray in’ (see Figure 39 on the 
previous page) and the ‘tray out’. The inside surface of both of the trays was swabbed.  
 
Clean-room Floor  
 A square area was marked out on the blue vinyl floor of the clean-room, 
directly in front of the isolator and behind where the operator was positioned (see 
Figure 40 below). The marked area of the floor covered 21 cm × 21 cm. Special care 
was taken not to walk in this area during the study. 
 
Figure 40. Image of the Marked Out Floor Area in Relation to the Isolator 
Workstation 
 
 
 
marked out floor area 
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Finished Product (syringes) 
 One third of the syringe batches produced were swabbed i.e. eight of the 
twenty-five batches prepared per week. In each case, these were all batches containing 
ten syringes, and all syringes from the batch were swabbed. The swabbed syringes 
were predetermined to be from batches 2, 4, 8, 12, 14, 16, 22, and 24 (three batches of 
EPI, three batches of CP, and two batches of MTX) - Table 31 (page 197). The 
syringe barrel and the plunger of the syringe were swabbed separately – see Figure 26 
(page 121), using one wipe for each. The two wipes were combined into one 
collection tube.  
5.4.9  Treatment of Samples 
 The contaminated wipe samples were placed into collection tubes, which 
were secured tightly and shaken to move the wipe down to be exposed to the 
desorbing solution. 
The isolator gloves and support gloves were retained when they were 
changed at the end of each session. Each glove was removed inside out, carefully so 
as not to contaminate one with the other, and placed into a pre-labelled grip-top bag. 
The air was squashed out of the bag and it was sealed tightly. 
The collection tubes containing the wipes and the bags containing the gloves 
were stored at -21ºC. When due for transfer they were packed in dry ice and 
transported to the University of Bath where they remained in a temperature 
monitored laboratory freezer at -21ºC until recovery and analysis. 
5.4.10  Analysis of Samples 
A validated method, as described in Section 3.7.3 to recover the multi-drug 
surface contamination of EPI, MTX and CP from the wipes into a desorbing solution 
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was applied. A validated immersion method, as described in Section 3.7.3 was 
applied to recover multi-drug contamination of EPI, MTX and CP from the isolator 
gloves and the support gloves into a desorbing solution.  
The performance of the analytical method was monitored throughout by the 
analysis of freshly prepared quality control samples for each drug. Also, quality 
control samples which had been transported and stored alongside the surface 
contamination samples, carried through the recovery process and subjected to the 
same laboratory conditions i.e. temperature and time waiting in the autosampler prior 
to analysis, were analysed together with the surface contamination samples. 
Levels of contamination of each drug were quantified in both the Baseline 
and Intervention arms of the study using HPLC methods, as described in Section 
3.7.3. Responses below the LoQ of the analytical method (see Section 3.8.4) were 
reported as being present but not quantifiable i.e. <LoQ. Response below the LoD of 
the method was stated as ‘not detected’ i.e. ND.  
5.4.11  Statistical Evaluation 
 Levels of contamination and site-specific frequencies were compared for each 
test drug in both arms of the study. Significance was established using descriptive 
statistical methods. Potential variables of contamination data for each system were 
explored. 
5.4.12  Acceptance of the Closed-System (PhaSeal®) Device – A Questionnaire 
 Acceptance of the closed-system (PhaSeal®) device in the isolator setting was 
determined by questionnaire. The questionnaire comprised three parts (see Appendix 
6 - Questionnaire to Determine Operator’ Opinion on the Use of the Closed-System 
(PhaSeal®) Device). This was designed after literature review, consultation with a 
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professional from the manufacturers (Carmel Pharma), and a pharmacy manager of 
an ASU. It was piloted in the commercial ASU, Department of Pharmacy, University 
of Bath, by pharmacy technicians, to check the relevance and clarity of the questions. 
 
Part 1 was administered to the technicians and completed prior to start of the study 
and training with the closed-system (PhaSeal®) device. It consisted of three closed 
questions, with the option of including comments, to learn from the experience of the 
technicians and how worried or safe they felt about working with cytotoxic drugs.  
 
Part 2 was administered and completed by the technicians after training with the 
closed-system (PhaSeal®) device and prior to the start of the Intervention 1. It 
consisted of four questions. Three closed questions asked to select from a list how 
adequate the training they had been given with the closed-system (PhaSeal®) device 
was and how confident they felt using the device and that it was protecting them. A 
fourth open question asked to describe any reservations they might have with using 
the closed-system (PhaSeal®) device.  
 
Part 3 was administered and completed by the technicians at the end of Intervention 2. 
It consisted of four questions. Two closed questions asked to select from a list how 
confident the technician was using the closed-system (PhaSeal®) device and if the 
same amount of care was applied regardless of the method. Two open questions asked 
the technicians to describe any problems encountered when using the device and if it 
hindered work in any way.  
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5.5  Results - Data Analysis and Interpretation 
5.5.1  Surface Contamination Recovered from the Isolator 
Over the duration of the four-week study, 960 wipe samples, 64 isolator gloves 
and 64 support gloves were collected. Prior to the start of the study, all wipe samples 
were negative for cytotoxic contamination. Therefore, the amount recovered during 
Baseline 1 can be attributed only to the batch production during this week - see Table 
31 (page 197). A total amount of EPI (16,311 ng), MTX (10,988 ng) and CP (180,000 
ng) were recovered from surfaces inside the isolator, cumulative of all the sampling 
points during Baseline 1. Figures 41, 42 and 43 (below and on the following page) 
show the amount of EPI, MTX and CP contamination, respectively, recovered from 
the isolator surfaces after one week of production. The results are shown in a pie chart 
for each drug, and are expressed in nanograms or nanograms per isolator glove or 
sleeve, cumulative of the week. Each coloured portion represents an area from where 
contamination was recovered.  
 
Figure 41. Amount of EPI (ng, or ng per sleeve/glove) Recovered from Isolator 
Surfaces (Baseline 1) 
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EPI was recovered from all surfaces inside the isolator, with the highest 
amounts found on the isolator gloves and the base. MTX was recovered from the 
isolator base, gloves, left sleeve and both sides of the right-hand hatch door. CP was 
only recovered from the hatch door, both sides in contact with the hatch. 
 
Figure 42. Amount of MTX (ng, or ng per sleeve/glove) Recovered from Isolator 
Surfaces (Baseline 1) 
 
 
 
Figure 43. Amount of CP (ng) Recovered from Isolator Surfaces (Baseline 1) 
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 This surface contamination recovered from the isolator during Baseline 1 was 
from the compounding of EPI (370 mg), MTX (493 mg) and CP (2,650 mg) - Table 
31, page 197. Each mg of EPI, MTX and CP prepared contributed 44.1 ng, 22.3 ng 
and 67.9 ng of contamination, respectively. The mass of drug recovered (nanograms) 
directly after the corresponding session, and prior to any cleaning was normalised per 
mg of drug prepared in the session. The results of EPI and MTX recovered from areas 
inside the isolator per mg prepared during Baseline 1 are expressed in Table 32 below, 
and Table 33 on the following page, respectively. 
 
Table 32. Amount of EPI Contamination Recovered (Baseline 1) 
                Amount of EPI Recovered (ng per mg prepared)  
Area       Day 1 1 (Session 2)  2   3   4   
 
Isolator base  51.6 1.12     ND  1.40  0.76 
Door: outer right 3.32 0.31     ND  ND  ND 
Door: outer left  0.70 0.31      ND  ND  ND 
Door: inner right 4.07 0.43      0.48  ND  ND 
Door: inner left  3.80 0.40     0.55  ND  ND 
Sleeve, right  47.4 0.72     0.46  0.61  ND 
Sleeve, left  26.5 0.65      ND  ND  ND 
Isolator glove, right 32.5 2.93     3.12  10.7  1.71 
Isolator glove, left 28.6 3.35     3.53  7.81  1.56 
 
Total   199 10.2      8.14  20.5  4.03
 
ND = none detected 
 
 
 EPI was only prepared in the morning session (Session 1) during the week, 
except on day 1 when two of the three batches were prepared in the afternoon session 
(Session 2). Batch preparation on Day 1, during Session 1 contributed the most EPI 
contamination to surfaces in the isolator per mg prepared. Batch 3 was the only batch 
of EPI prepared during this session therefore, the contamination recovered could be 
attributed only to this batch. The base and the right sleeve were the most highly 
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contaminated from the preparation of this batch. In total, on Day 1, 199 ng per mg of 
EPI prepared was recovered, a significant amount compared to sessions on other days. 
 
Table 33. Amount of MTX Contamination Recovered (Baseline 1) 
             Amount of MTX Recovered (ng per mg prepared)   
Area   Day   1     2     3     4
 
Isolator base   ND  ND  1.75  2.05 
Door: outer right  ND  ND  ND  ND 
Door: outer left   ND  ND  ND  ND 
Door: inner right  ND  ND  ND  2.65 
Door: inner left   ND  ND  ND  ND 
Sleeve, right   ND  ND  ND  ND 
Sleeve, left   ND  ND  ND  ND 
Isolator glove, right  1.74  8.92  5.57  13.1 
Isolator glove, left  1.99  4.98  0.48  2.60 
 
 Total    3.73  13.9  7.80  20.4 
 
ND = none detected 
  
  
MTX was prepared on each day but always during Session 2. MTX was 
recovered from the isolator gloves on every day of the working week and from the 
isolator base on days 3 and 4. Batches (24 and 25) prepared on day 4 (Table 31, page 
197) contributed the most contamination per mg prepared. 
 CP was only prepared during Session 1. No CP was recovered from samples 
taken directly after batch preparation for the corresponding session during Baseline 1, 
although CP was recovered after sessions in which it was not prepared. Therefore, the 
results in Table 34 on the following page are expressed as the amount of CP recovered 
from areas in the isolator per mg prepared during Baseline 2. No CP was recovered 
from batches prepared during Day 1, 2 or 4 during Baseline 2. 
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Table 34. Amount of CP Contamination Recovered (Baseline 2) 
   Amount of CP Recovered (ng per mg prepared)            
Area  Day 1   2    3  4  
 
Isolator base  ND  ND  ND  ND  
Door: outer right ND  ND  213  ND  
Door: outer left  ND  ND  151  ND  
Door: inner right ND  ND  239  ND  
Door: inner left  ND  ND  188  ND  
Sleeve, right  ND  ND  338  ND  
Sleeve, left  ND  ND  308  ND  
Isolator glove, right ND  ND  ND  ND  
Isolator glove, left ND  ND  ND  ND  
Total   ND  ND  1,436  ND 
 
ND = none detected  
 
 
5.5.2  Effectiveness of the Closed-System (PhaSeal®) Device in Reducing Isolator 
Surface Contamination  
The percentage of positive samples recovered for each drug during the 
Baseline (B1 and B2) weeks and Intervention (I1 and I2) weeks of the study are 
shown graphically in Figure 44 on the following page.  
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Figure 44. Graph Showing the Percentage of Positive Samples (EPI, MTX and CP) 
Recovered during the Baseline and Intervention Periods 
 
 
  
  
 The effect of the closed-system (PhaSeal®) device in reducing contamination 
in the isolator was investigated by comparing sampling data from Baseline and 
Intervention. Table 35 (Baseline 1 and 2), Table 36 (Intervention 1 and 2), and Table 
37 (Baseline 1 + 2 combined, and Intervention 1 + 2 combined) on the following 
pages show the amount of contamination (median and range) and the frequency of 
positive samples recovered from all surfaces in the isolator during all weeks of the 
Study Week 
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study. All data have been normalised per square centimetre of the area sampled, 
except for gloves and sleeves, which are in ng or µg per isolator glove or sleeve. The 
LoD is also expressed in the same units, as the surfaces sampled from, varied in size.  
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Table 35. Surface and Glove Contamination Recovered from the Isolator during 
Baseline 1 and 2  
   Median, Range and Frequency of Positive Samples above the LoD 
Area   Baseline 1    Baseline 2  
             median    range             frequency            median   range         frequency 
Isolator base, ng cm-2 
  EPI          0.06 <0.002 - 0.59 16/16  ND  ND - <0.002  3/16    
  MTX  ND ND - 0.33 9/16  ND ND -  0.60   4/16        
  CP  ND  all ND  0/16  ND all ND   0/16   
 
Door: outer right, ng cm-2 
  EPI  ND  ND - 0.07  6/16  ND ND - <0.003  2/16      
  MTX  ND  ND - 0.07  3/16  ND ND - 0.34  7/16  
  CP  ND  ND - 117  1/16  ND ND - 426  3/16        
 
Door: outer left, ng cm-2 
  EPI  ND  ND - 0.07  7/16  ND ND - <0.003 2/16      
  MTX  ND  ND - <0.07   2/16  ND  ND - 0.24  7/16        
  CP  ND  ND - 135 1/16  ND  ND - 393  3/16        
 
Door: inner right, ng cm-2 
  EPI  ND  ND - 0.08   8/16  ND  ND - 0.05 3/16       
  MTX  ND ND - 0.22  3/16  ND ND - 8.04  6/16        
  CP  ND all ND    0/16  ND  ND - 982  3/16        
 
Door: inner left, ng cm-2 
  EPI  ND  ND - 0.08   9/16  ND  ND - <0.003   5/16         
  MTX  ND ND - <0.07  3/16  ND  ND - 0.15   5/16         
  CP  ND all ND    0/16  ND  ND - 2,034 3/16               
 
Sleeve, right, ng per sleeve (EPI, MTX), µ g per sleeve (CP) 
  EPI  41.5 ND - 711   11/16  ND  ND - <2.0  3/16  
  MTX  ND ND - <50.0   1/16  ND  ND - 216  5/16        
  CP  ND all ND    0/16  ND ND - 304  2/16         
 
Sleeve, left, ng per sleeve (EPI, MTX), µ g per sleeve (CP) 
  EPI  ND  ND - 398   12/16  ND ND - <2.0  3/16         
  MTX  ND ND - 282  5/16  ND ND - 716  7/16         
  CP  ND all ND   0/16  ND ND - 278  3/16        
 
Isolator glove, right, ng per glove (EPI, MTX), µ g per glove (CP) 
 EPI  486 239 - 1,506   8/8  217 ND - 409   5/8         
 MTX  653  ND - 1,559   6/8  ND ND - 748   1/8         
 CP  ND all ND    0/8  ND  ND - 192   1/8         
 
Isolator glove, left, ng per glove (EPI, MTX), µ g per glove (CP) 
  EPI  737  218 - 1,932   8/8  206 ND - 1,830  5/8         
  MTX  226  ND - 856   6/8  ND ND - 750  1/8          
  CP  ND all ND    0/8  ND all ND   0/8          
 
ND = none detected below the LoD 
EPI LoD (ng cm-2) = 0.001 (base, hatch door, tray), 0.002 (floor), 1.0 ng per sleeve/syringe, 2.0 ng per glove   
MTX LoD (ng cm-2) = 0.02 (base), 0.04 (hatch door, tray), 0.06 (floor), 25.0 ng per sleeve/syringe,  
50.0 ng per glove   
CP LoD (ng cm-2) = 9.50 (base), 17.5 (hatch door), 18.0 (tray), 28.3 (floor), 12.5 µg per sleeve/syringe,  
25.0 µg per glove   
 215
Table 36. Surface and Glove Contamination recovered from the Isolator during 
Intervention 1 and 2  
    Median, Range and Frequency of Positive Samples above the LoD 
Area   Intervention 1   Intervention 2 
          median    range             frequency            median   range         frequency 
Isolator base, ng cm-2 
  EPI  ND ND - <0.002   1/16  ND  all ND    0/16  
  MTX  ND all ND    0/16  ND  all ND    0/16  
  CP  ND all ND    0/16  ND all ND    0/16 
  
Door: outer right, ng cm-2 
  EPI  ND all ND   0/16  ND  all ND    0/16  
  MTX  ND all ND    0/16  ND  all ND    0/16  
  CP  ND all ND   0/16  ND  all ND    0/16 
  
Door: outer left, ng cm-2 
  EPI  ND ND - 0.11   2/16  ND  all ND   0/16  
  MTX  ND ND - <0.07 1/16  ND all ND  0/16  
  CP  ND all ND   0/16  ND  all ND   0/16 
  
Door: inner right, ng cm-2 
  EPI  ND ND - <0.003  1/16  ND  all ND   0/16  
  MTX  ND ND - 0.07   1/16  ND  all ND    0/16  
  CP  ND all ND    0/16  ND  all ND    0/16 
  
Door: inner left, ng cm-2 
  EPI  ND all ND    0/16  ND  all ND   0/16  
  MTX  ND all ND   0/16  ND  all ND    0/16  
  CP  ND all ND    0/16  ND  all ND    0/16 
  
Sleeve, right, ng per sleeve (EPI, MTX), µ g per sleeve (CP) 
  EPI  ND ND - 41.0 1/16  ND  all ND    0/16  
  MTX  ND all ND    0/16  ND  ND - <50.0   1/16  
  CP  ND all ND  0/16  ND  all ND    0/16 
  
Sleeve, left, ng per sleeve (EPI, MTX), µ g per sleeve (CP) 
  EPI  ND all ND   0/16  ND  all ND   0/16  
  MTX  ND all ND   0/16  ND  all ND    0/16  
  CP  ND all ND   0/16  ND  all ND  0/16 
  
Isolator glove, right, ng per glove (EPI, MTX), µ g per glove (CP) 
  EPI  ND ND - 171  1/8  ND  all ND   0/8  
  MTX  ND all ND    0/8  ND  all ND   0/8  
  CP  ND all ND   0/8  ND  ND - 138  1/8  
 
Isolator glove, left, ng per glove (EPI, MTX), µ g per glove (CP) 
  EPI  ND ND - 164 2/8  ND  ND - 161  1/8 
  MTX  ND all ND   0/8  ND  all ND   0/8  
  CP  ND all ND   0/8               ND ND - 192  1/8             
 
ND = none detected below the LoD 
EPI LoD (ng cm-2) = 0.001 (base, hatch door, tray), 0.002 (floor), 1.0 ng per sleeve/syringe, 2.0 ng per glove   
MTX LoD (ng cm-2) = 0.02 (base), 0.04 (hatch door, tray), 0.06 (floor), 25.0 ng per sleeve/syringe, 
50.0 ng per glove   
CP LoD (ng cm-2) = 9.50 (base), 17.5 (hatch door), 18.0 (tray), 28.3 (floor), 12.5 µg per sleeve/syringe,  
25.0 µg per glove   
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Table 37. Surface and Glove Contamination Recovered from the Isolator during 
Baseline 1 and 2 Combined, and Intervention 1 and 2 Combined  
    Median, Range and Frequency of Positive Samples above the LoD 
Area                Baseline 1 + 2                      Intervention 1 + 2  
            median    range             frequency            median   range         frequency 
Isolator base, ng cm-2 
  EPI  ND ND - 0.59 19/32  ND ND - <0.002 1/32 
  MTX  ND  ND - 0.60   13/32  ND  all ND    0/32 
  CP  ND all ND    0/32  ND all ND    0/32 
  
Door: outer right, ng cm-2 
  EPI  ND  ND - 0.07  8/32  ND all ND    0/32 
  MTX  ND  ND - 0.34   10/32  ND all ND   0/32 
  CP  ND  ND - 426   4/32  ND all ND    0/32 
 
Door: outer left, ng cm-2 
  EPI  ND ND - 0.07   9/32  ND  ND - 0.11   2/32  
  MTX  ND ND - 0.24   9/32  ND  ND - <0.07  1/32 
  CP  ND  ND - 393   4/32  ND all ND    0/32 
  
Door: inner right, ng cm-2 
  EPI  ND ND - 0.08  11/32  ND  ND - <0.003  1/32 
  MTX  ND ND - 8.04   9/32  ND  ND - 0.07  1/32  
  CP  ND ND - 982  3/32  ND all ND    0/32 
 
Door: inner left, ng cm-2 
  EPI  ND ND - 0.08   14/32  ND all ND    0/32 
  MTX  ND ND - 0.15   8/32  ND all ND    0/32 
  CP  ND  ND - 2,034   3/32  ND all ND   0/32 
 
Sleeve, right, ng per sleeve (EPI, MTX), µ g per sleeve (CP) 
  EPI  ND ND - 711   14/32  ND  ND - 41.0   1/32 
  MTX  ND  ND - 216   6/32  ND  ND - <50.0  1/32 
  CP  ND  ND - 304  2/32  ND all ND    0/32  
 
Sleeve, left, ng per sleeve (EPI, MTX), µ g per sleeve (CP) 
  EPI  ND  ND - 398   15/32  ND all ND   0/32  
  MTX  ND  ND - 716   12/32  ND all ND    0/32  
  CP  ND ND - 278  3/32  ND all ND    0/32  
 
Isolator glove, right, ng per glove (EPI, MTX), µ g per glove (CP) 
  EPI  272  ND - 1,506   13/16  ND ND - 171  1/16 
  MTX  ND ND - 1,559   7/16  ND all ND    0/16 
  CP  ND  ND - 192   1/16  ND  ND - 138  1/16 
 
Isolator glove, left, ng per glove (EPI, MTX), µ g per glove (CP) 
  EPI  737 ND - 1,932  13/16  ND  ND - 164  3/16 
  MTX  ND  ND - 856   7/16  ND all ND   0/16 
  CP  ND all ND    0/16  ND ND - 192  1/16 
 
ND = none detected below the LoD 
EPI LoD (ng cm-2) = 0.001 (base, hatch door, tray), 0.002 (floor), 1.0 ng per sleeve/syringe, 2.0 ng per glove   
MTX LoD (ng cm-2) = 0.02 (base), 0.04 (hatch door, tray), 0.06 (floor), 25.0 ng per sleeve/syringe, 
50.0 ng per glove   
CP LoD (ng cm-2) = 9.50 (base), 17.5 (hatch door), 18.0 (tray), 28.3 (floor), 12.5 µg per sleeve/syringe,  
25.0 µg per glove   
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The complete tables of results showing the amount of drug recovered at each 
sampling point during the study period are shown in Appendices 7 (EPI), 8 (MTX) 
and 9 (CP). 
 Surface contamination data (ng cm-2, or ng or µg per glove/sleeve) for the 
Baseline and Intervention methods were not normally distributed. Therefore, to 
compare the data using the two different methods, a non-parametric test; the Wilcoxon 
matched-pairs, signed ranks test (two-tailed) was used. The significance level of the 
test was p ≤0.05, which meant there was sufficient evidence to reject the null 
hypothesis. The hypothesis were:  
 
Ho – intervention with the closed-system (PhaSeal®) device does not reduce levels of 
cytotoxic surface contamination in the isolator, 
 
H1 – intervention with the closed-system (PhaSeal®) does reduce levels of cytotoxic 
surface contamination in the isolator. 
 
Comparing Baseline 1 and Intervention 1 suggested significantly reduced levels of 
EPI and MTX surface contamination, (both p = 0.001) when the closed-system  
(PhaSeal®) device was implemented. 
 
Comparing Baseline 2 and Intervention 2 suggested significantly reduced levels of 
EPI (p = 0.003), MTX (p = 0.001) and CP (p = 0.002) contamination when the closed-
system (PhaSeal®) device was implemented. 
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There were an insufficient number of valid cases for comparison of CP contamination 
between Baseline 1 and Intervention 1. Combining data from Baseline 1 + 2, and 
Intervention 1 + 2 suggests significantly (p = 0.001) reduced levels of CP 
contamination when using the closed-system (PhaSeal®) device. 
  
 No problems were encountered with the closed-system (PhaSeal®) device, 
except on one occasion when a small spillage occurred while preparing EPI. The 
incident occurred on Day 2, during Session 1 of Intervention 1. The protector came 
away from the vial whilst separating the protector from the injector, spilling 3 drops of 
EPI onto the mat. The spillage was dealt with immediately; the syringe and vial were 
put into a plastic bag and transferred out of the isolator. The three remaining syringes 
from the batch were prepared away from the contamination on the mat. The isolator 
was cleaned down afterwards using the normal procedure. No surface contamination 
was recovered anywhere in the isolator after this session. Apart from this one incident, 
no leakages or spillages were reported which could have influenced levels of 
contamination during the study. There were also no recorded deviations from standard 
practice, so the levels of contamination, which were measured, were a result of the 
defined practice. 
5.5.3  External Surface Contamination and Surface Cross-Contamination of Batches 
It was evident that the external surfaces of batches prepared in the isolator are 
contaminated during the preparation process. The results of the median and range (ng 
or µg per syringe), and frequency of positive samples of EPI, MTX and CP 
contamination recovered from batches during Baseline 1 and 2, and Intervention 1 and 
2 are expressed in Tables 38 – 43 on the following pages. Each batch was made up of 
ten syringes.  
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Table 38. EPI Contamination Recovered from External Surface of Syringe Batches during Baseline 1 and 2, and Baseline 1 and 2 Combined 
            Median and Range (ng per syringe), and Frequency of Positive Samples above the LoD 
Batch            Baseline 1                Baseline 2        Baseline 1 + 2  
 
             median    range            frequency             median   range         frequency   median   range         frequency  
EPI batches:  
4   49.5  42.0 - 78.5   10/10   ND  ND - <2.0  7/10   21.0 ND - 78.5 17/20 
16   20 .0 ND - 64.5   9/10   ND all ND    0/10    ND ND - 64.5 9/20          
22   51.3  <2.0 - 99.0   10/10   45.0 40.5 - 1,807  10/10   50.0 <2.0 - 1,807 20/20  
 
MTX batches: 
12   ND  all ND   0/10   ND all ND    0/10   ND all ND    0/20  
24   ND ND - 696 1/10   <2.0 <2.0 - 40.5   10/10   ND ND - 696 11/20 
  
CP batches: 
2   ND  all ND    0/10   ND all ND    0/10   ND all ND    0/20  
8   ND  ND - 41.5  6/10   ND ND - <2.0  3/10   ND ND - 41.5 9/20 
14   52.3  ND - 61.5  9/10   ND all ND    0/10   ND ND - 61.5 9/20  
 
ND = none detected below the LoD 
EPI LoD = 1.0 ng per syringe  
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Table 39. EPI Contamination Recovered from External Surface of Syringe Batches during Intervention 1 and 2, and Intervention 1 and 2 Combined 
            Median and Range (ng per syringe), and Frequency of Positive Samples above the LoD 
Batch               Intervention 1            Intervention 2     Intervention 1 + 2  
             median    range            frequency             median   range         frequency   median    range            frequency  
 
EPI batches:   
4   ND all ND    0/10   ND all ND    0/10   ND all ND    0/20 
16   ND all ND    0/10   ND all ND    0/10   ND all ND    0/20 
22   ND all ND   0/10   ND ND - <2.0 1/10   ND ND - <2.0 1/20 
 
MTX batches: 
12            ND all ND    0/10   ND all ND    0/10   ND all ND    0/20 
24    ND all ND    0/10   ND all ND    0/10   ND all ND    0/20 
  
CP batches: 
2             ND ND - <2.0  2/10   ND all ND    0/10   ND ND - <2.0 2/20 
8   ND all ND    0/10   ND all ND    0/10   ND all ND    0/20 
14           ND all ND   0/10   ND all ND    0/10   ND all ND    0/20 
 
ND = none detected below the LoD 
EPI LoD = 1.0 ng per syringe  
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Table 40. MTX Contamination Recovered from External Surface of Syringe Batches during Baseline 1 and 2, and Baseline 1 and 2 Combined  
           Median and Range (ng per syringe), and Frequency of Positive Samples above the LoD 
Batch    Baseline 1               Baseline 2               Baseline 1 + 2  
 
              median  range             frequency           median   range             frequency     median    range            frequency      
EPI batches: 
4   ND ND - 205   1/10   ND all ND    0/10   ND ND - 205 1/20 
16   ND all ND    0/10   ND ND - <50.0   3/10   ND ND - <50.0 3/20 
22   ND ND - <50.0   1/10   ND ND - <50.0  1/10   ND ND - <50.0 2/20 
 
MTX batches 
12   ND  ND - 73.0   1/10   ND all ND   0/10   ND ND - 73.0 1/20        
24   ND  ND - 259   1/10   ND ND - <50.0   3/10   ND ND - 259 4/20 
 
CP batches: 
2   ND all ND    0/10   ND all ND    0/10          ND all ND    0/20 
8   ND all ND    0/10   ND all ND    0/10      ND all ND    0/20      
14   ND ND - <50.0   1/10   ND all ND   0/10   ND ND - <50.0  1/20 
 
ND = none detected below the LoD 
MTX LoD = 25.0 ng per syringe 
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Table 41. MTX Contamination Recovered from External Surface of Syringe Batches during Intervention 1 and 2, and Intervention 1 and 2 Combined 
           Median and Range (ng per syringe), and Frequency of Positive Samples above the LoD  
Batch              Intervention 1         Intervention 2           Intervention 1 + 2 
 
                      median  range             frequency           median   range             frequency          median    range            frequency 
EPI batches: 
4   ND    all ND    0/10   ND all ND    0/10   ND all ND    0/20 
16   ND all ND    0/10   ND all ND    0/10   ND all ND    0/20 
22   ND all ND    0/10   ND all ND   0/10   ND all ND    0/20 
 
MTX batches: 
12   ND all ND    0/10   ND all ND    0/10   ND all ND    0/20 
24   ND all ND   0/10     ND ND - 81.5   1/10   ND ND - 81.5   1/20 
 
CP batches: 
2   ND all ND  0/10   ND all ND   0/10   ND all ND    0/20  
8   ND all ND  0/10   ND all ND   0/10   ND all ND    0/20 
14   ND all ND   0/10   ND all ND  0/10   ND all ND    0/20 
 
ND = none detected below the LoD 
MTX LoD = 25.0 ng per syringe 
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Table 42. CP Contamination Recovered from External Surface of Syringe Batches during Baseline 1 and 2, and Baseline 1 and 2 Combined 
            Median and Range (µg per syringe), and Frequency of Positive Samples above the LoD 
Batch    Baseline 1               Baseline 2     Baseline 1 + 2          
 
                         median  range             frequency           median   range             frequency           median    range            frequency 
EPI batches: 
4   ND all ND    0/10   ND all ND    0/10   ND all ND   0/20 
16   ND all ND    0/10   ND all ND   0/10   ND all ND   0/20 
22   ND all ND    0/10   ND ND - 75.0   4/10   ND ND - 75.0  4/20 
 
MTX batches: 
12   ND all ND    0/10   ND all ND   0/10    ND all ND   0/20 
24   ND all ND    0/10   ND all ND    0/10    ND all ND   0/20 
 
CP batches: 
2   ND all ND   0/10   ND all ND    0/10   ND all ND   0/20 
8   ND ND - 41.5   2/10   ND all ND    0/10   ND ND - 41.5  2/20 
14  ND all ND   0/10   ND  all ND    0/10   ND all ND   0/20 
 
ND = none detected below the LoD 
CP LoD = 12.5 µg per syringe 
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Table 43. CP Contamination Recovered from External Surface of Syringe Batches during Intervention 1 and 2, and Intervention 1 and 2 Combined 
            Median and Range (µg per syringe), and Frequency of Positive Samples above the LoD 
Batch            Intervention 1              Intervention 2     Intervention 1 + 2 
 
                       median  range             frequency            median   range             frequency           median range             frequency 
EPI batches: 
4   ND all ND    0/10   ND all ND   0/10   ND all ND   0/20 
16   ND all ND    0/10   ND all ND    0/10   ND all ND   0/20 
22   ND all ND    0/10   ND all ND    0/10   ND all ND   0/20 
 
MTX batches: 
12   ND all ND   0/10   ND all ND   0/10   ND all ND   0/20 
24   ND all ND    0/10   ND all ND    0/10   ND all ND   0/20 
 
CP batches: 
2   ND all ND    0/10   ND all ND    0/10   ND all ND   0/20 
8   ND all ND   0/10   ND all ND    0/10   ND all ND   0/20  
14  ND all ND    0/10    ND all ND    0/10   ND all ND   0/20 
 
ND = none detected below the LoD 
CP LoD = 12.5 µg per syringe 
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The complete tables of results showing the amount of drug recovered per 
syringe for each batch during the study period are shown in Appendices 7 (EPI), 8 
(MTX) and 9 (CP).  
 EPI was recovered from all EPI batches during Baseline 1 (Table 38, page 
219). A total of 29 of the 30 (96.7%), and 17 out of 30 (56.7%) of the syringes 
swabbed during Baseline 1 and 2, respectively, were positive for EPI contamination 
on the external surface of the syringe. The highest amount of EPI was 1,807 ng 
recovered from a syringe (batch 22) of the corresponding drug infusion during 
Baseline 2. No EPI contamination of the corresponding drug infusion was recovered 
during Intervention, except during Intervention 2, when trace was observed on one 
syringe from batch 22 (Table 39, page 220). 
 A total of 2 out of 20 (10%), and 3 out of 20 (15%) syringes swabbed during 
Baseline 1 and 2, respectively, which were filled with MTX, tested positive for MTX 
(Table 40, page 221). During Intervention, MTX contamination was only observed 
on one occasion when 81.5 ng was recovered from one syringe (batch 24) of the 
corresponding drug infusion during Intervention 2 (Table 41, page 222). Although 
this was a positive event, the amount recovered was less than the amount recovered 
from one syringe (259 ng) of the same batch prepared during Baseline 1. 
 The external contamination of CP on batches of CP was recovered less 
frequently. Of the 30 syringes, which were filled with CP during Baseline 1, 2 
(6.7%) of the syringes swabbed tested positive for CP. The highest amount of CP 
was 41.5 µg recovered from a syringe (batch 8) of the corresponding drug infusion 
during Baseline 1 (Table 42, page 223). There were no positive cases of CP 
contamination on syringes of CP recovered during Baseline 2, Intervention 1 or 2 
(Table 43, page 224). 
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 It was evident that surface cross-contamination on the external surfaces of 
batches of syringes also occurs. Cross-contamination of EPI was recovered on 1 out 
of 20 (5%) syringes filled with MTX, and 15 out of 30 (50%) filled with CP during 
Baseline 1. The highest amount of EPI cross-contamination recovered was 696 ng on 
a single syringe of MTX (batch 24) and 61.5 ng on a batch of CP (batch 14), during 
Baseline 1. During Baseline 2, cross-contamination of EPI was recovered on 10 out 
of 20 (50%) syringes filled with MTX, and 3 out of 30 (10%) filled with CP (Table 
38, page 219). No cross-contamination of EPI on batches of MTX was observed 
during Intervention 1 or 2, but trace amounts were recovered from two syringes of a 
batch of CP during Intervention 1 (Table 39, page 220).  
 Cross-contamination of MTX was recovered on 2 out of 30 (6.7%) of syringes 
filled with EPI, and 1 out of 30 (3.3%) filled with CP during Baseline 1. The largest 
amount of MTX cross-contamination was 205 ng recovered from a single syringe of 
EPI (batch 4) during Baseline 1. During Baseline 2, cross-contamination of MTX was 
recovered on 4 out of 30 (13.3%) syringes filled with EPI, and none filled with CP 
(Table 40, page 221). No cross-contamination of MTX on batches of EPI or CP was 
recovered during Intervention 1 or 2 (Table 41, page 222). 
 No cross-contamination of CP was observed on batches of EPI or MTX 
during Baseline 1 or on MTX batches during Baseline 2. Cross-contamination of CP 
on 4 out of 30 (13.3%) batches of EPI was recovered during Baseline 2. The highest 
amount of CP cross-contamination was 75.0 µg recovered from a syringe of EPI 
(batch 22) during Baseline 2 (Table 42, page 223). No CP cross-contamination on 
batches of EPI or MTX was recovered during Intervention 1 or 2 (Table 43, page 
224). 
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5.5.4  Effectiveness of the Closed-System (PhaSeal®) Device in Reducing External 
Surface Contamination and Cross-Contamination of Batches 
  External surface contamination recovered from syringe batches (ng or µg per 
syringe) for the Baseline (1 + 2 combined) method versus the Intervention (1 + 2 
combined) method was compared using the Wilcoxon matched-pairs, signed ranks test 
(two-tailed). The significance level of the test was p ≤0.05, which meant there was 
sufficient evidence to reject the null hypothesis. The hypothesis were: 
 
Ho – intervention with the closed-system (PhaSeal®) device does not reduce levels of 
external cytotoxic surface contamination on the batches of syringes, 
 
H1 – intervention with the closed-system (PhaSeal®) does reduce levels of external 
cytotoxic surface contamination on the batches of syringes. 
 
 The closed-system (PhaSeal®) device significantly reduced levels of EPI 
contamination (p = 0.000) on the outside surfaces of EPI batches, and on the surface 
of CP syringes (p = 0.012). The frequency of the occurrence of positive measurable 
cases of EPI cross-contamination on batches of MTX was insufficient for statistical 
comparison between the two techniques. However, implementation of the closed-
system (PhaSeal®) device reduced the number of positive cases of EPI cross-
contamination on syringes of MTX from 11 to 0 cases during the Baseline and 
Intervention periods, respectively. 
 The frequency of the occurrence of positive measurable cases of MTX 
contamination was insufficient to compare statistically between the two techniques in 
reducing contamination of MTX on batches of the corresponding drug infusion, and 
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cross-contamination on batches of EPI or CP. However, it was effective in reducing 
the number of positives cases of MTX contamination on syringes of the 
corresponding drug infusion from 5 to 1, on syringes of CP from 1 to 0, and 6 to 0 
positive cases on syringes of EPI during the Baseline and Intervention periods, 
respectively. 
 There were an insufficient number of measurable positive cases to 
statistically assess the effectiveness of the closed-system (PhaSeal®) device in 
preventing the contamination of CP on batches of the corresponding drug infusion, 
and CP cross-contamination on batches of EPI and MTX. However, the closed-
system (PhaSeal®) device was effective in reducing the number of positive cases of 
CP contamination on syringes of the corresponding drug infusion from 2 to 0, and 
the cross-contamination of CP on syringes of EPI from 4 to 0, during Baseline and 
Intervention, respectively. There were no positive cases of CP contamination on any 
syringes filled with MTX during the Baseline or Intervention periods. 
 
 The amount of contamination of the corresponding drug infusion recovered 
from the surfaces of syringes was normalised to explore relationships between the 
number of dose units prepared; the amount of drug prepared (mg) and the volume 
prepared (mL). The results of the calculations from Baseline 1 data are shown in 
Table 44 on the following page. 
 Batches 4 and 22 were the most contaminating per unit prepared to the 
exterior of syringes of the corresponding EPI batch. Batch 22 was the most 
contaminating per mg or per mL prepared. Batch 4 was prepared in 60 mL syringes, 
batch 16 in 10 mL syringes, and batch 22 in 20 mL syringes. Overall EPI, batch 22 
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prepared in 20 mL syringes appeared to be the most contaminated on the outer 
syringe surface. 
 Both batches (12 and 24) of MTX were prepared in 3.0 mL syringes. MTX, 
batch 24 was the most contaminating (approximately a 4-fold increase) per unit mass 
and volume prepared compared to batch 12. 
 
Table 44. Amount External Syringe Contamination Recovered from Batches of the 
Corresponding Drug Infusion during Baseline 1, Normalised per Number of 
Units/Mass of Drug Prepared/Volume of Drug Prepared 
  Amount of Contamination Recovered from Batches during Baseline 1 
Batch  ng per unit prepared ng per mg prepared ng per mL prepared 
EPI, batch 4     53.2   10.6   2.13  
EPI, batch 16      23.1   11.6       2.31  
EPI, batch 22      47.9   16.0       3.19 
      
MTX, batch 12  7.30   3.65       9.13  
MTX, batch 24   25.9   14.8       37.0 
     
CP, batch 2  ND   ND   ND 
CP, batch 8  7,700   385   770 
CP, batch 14  ND   ND   ND 
 
ND = none detected 
 
 
 Of the three batches of CP prepared, contamination was only recovered on 
syringes from one batch (batch 8). CP was prepared in 60 mL syringes (batch 2), 10 
mL syringes (batch 8) and 20 mL syringes (batch 14). Batch 8, prepared in the 
smallest syringe was the most contaminated compared to all the batches prepared 
during Baseline 1.  
5.5.5  Contamination Recovered from Surfaces Outside the Isolator 
 Contamination was also recovered from areas outside the isolator i.e. the 
floor, the ‘tray in’ and ‘tray out’, and the support gloves. Tables 45, 46 and 47 on the 
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following pages show the amount of contamination (median and range) and the 
frequency of positive samples recovered outside the isolator during Baseline 1 and 2, 
Intervention 1 and 2, Baseline 1 + 2 combined, and Intervention 1 + 2 combined, 
respectively. The complete tables of results are shown in Appendices 7 (EPI), 8 
(MTX) and 9 (CP). 
  
Table 45. Surface Contamination Recovered from Surfaces Outside the Isolator 
during Baseline 1 and 2  
   Median, Range and Frequency of Positive Samples above the LoD  
Area   Baseline 1    Baseline 2      
 
            median    range             frequency            median   range         frequency 
Floor, ng cm-2 
  EPI  ND ND - 0.11   7/16  ND ND - <0.005   1/16       
  MTX  ND ND - <0.11  3/16  ND ND - 11.3   4/16      
  CP  ND all ND    0/16  ND ND - 128   3/16      
 
Tray in, ng cm-2 
  EPI  0.07 ND - 0.19   13/16  ND all ND    0/16      
  MTX  ND ND - 0.19   4/16  ND ND - 0.08 3/16      
  CP  ND all ND    0/16  ND ND - 384 5/16      
 
Tray out, ng cm-2 
  EPI  0.06 ND - 0.07  13/16  ND ND - <0.003  3/16      
  MTX  ND ND - 0.21  6/16  ND ND  - <0.07  2/16      
  CP  ND all ND    0/16  ND ND - 137   4/16      
 
Support glove, right, ng per glove (EPI, MTX), µg per glove (CP) 
  EPI  1,037 165 - 12,823  8/8  ND all ND   0/8   
  MTX  ND all ND   0/8  ND all ND   0/8       
  CP  910 ND - 1,216   6/8    790 97.6 - 1,111 8/8       
 
Support glove, left, ng per glove (EPI, MTX), µ g per glove (CP) 
  EPI  1,248 178 - 13,268  8/8  ND  ND - 172  2/8      
  MTX  ND all ND   0/8  ND all ND    0/8      
  CP   819 ND - 1,356  7/8  870 612 - 946 8/8          
 
ND = none detected 
EPI LoD (ng cm-2) = 0.002 (floor), 0.001 (tray), 2.0 ng per glove   
MTX LoD (ng cm-2) = 0.06 (floor), 0.04 (tray), 50.0 ng per glove   
CP LoD (ng cm-2) = 28.3 (floor), 18.0 (tray), 25.0 µg per glove   
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Table 46. Surface Contamination Recovered from Surfaces Outside the Isolator 
during Intervention 1 and 2  
   Median, Range and Frequency of Positive Samples above the LoD 
Area   Intervention 1           Intervention 2 
  
                    median    range             frequency            median   range         frequency 
Floor, ng cm-2 
  EPI  ND all ND   0/16  ND all ND    0/16  
  MTX  ND all ND    0/16  ND all ND    0/16  
  CP  ND all ND    0/16  ND all ND   0/16 
  
 Tray in, ng cm-2 
  EPI  ND all ND    0/16  ND all ND    0/16  
  MTX  ND all ND   0/16  ND all ND    0/16  
  CP  ND ND - 214  3/16  ND ND - 91.2   4/16  
 
Tray out, ng cm-2 
  EPI  ND  ND - <0.003  1/16  ND all ND    0/16   
  MTX  ND  ND - 0.14   1/16  ND ND - 0.39   2/16   
  CP  ND  ND - 183 2/16  ND all ND   0/16                
 
Support glove, right, ng per glove (EPI, MTX), µg per glove (CP) 
  EPI  ND ND - 189   1/8  ND ND - 172 2/8    
  MTX  ND all ND   0/8  ND all ND    0/8  
  CP      455 96.0 - 1,146  8/8    568 46.0 - 865  8/8                
 
Support glove, left, ng per glove (EPI, MTX), µ g per glove (CP) 
  EPI  ND ND - 1,046  2/8  ND ND - 177   2/8   
  MTX  ND all ND    0/8  ND all ND    0/8  
  CP     590 199 - 873 8/8    588 1,027 – 1,476  8/8     
 
ND = none detected 
EPI LoD (ng cm-2) = 0.002 (floor), 0.001 (tray), 2.0 ng per glove   
MTX LoD (ng cm-2) = 0.06 (floor), 0.04 (tray), 50.0 ng per glove   
CP LoD (ng cm-2) = 28.3 (floor), 18.0 (tray), 25.0 µg per glove   
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Table 47. Surface Contamination Recovered from Surfaces Outside the Isolator 
during Baseline 1 and 2 Combined, and Intervention 1 and 2 Combined 
 
  Median, Range and Frequency of Positive Samples above the LoD 
 Area  Baseline 1 and 2 Combined  Intervention 1 and 2 Combined 
 
                     median    range             frequency            median   range         frequency 
Floor, ng cm-2   
  EPI  ND ND - 0.11 8/32  ND all ND   0/32 
  MTX  ND ND - 11.3 7/32  ND all ND   0/32 
  CP  ND ND - 128 3/32  ND all ND   0/32 
 
Tray in, ng cm-2 
  EPI  ND ND - 0.19 13/32  ND all ND   0/32 
  MTX  ND ND - 0.19 7/32  ND all ND   0/32 
  CP  ND ND - 384 5/32  ND ND - 214 7/32  
 
Tray out, ng cm-2 
  EPI  ND ND - 0.07 16/32  ND  all ND    1/32 
  MTX  ND ND - 0.21 8/32  ND ND - 0.39 3/32 
  CP  ND ND - 137 4/32  ND  ND - 183 2/32 
 
Support glove, right, ng per glove (EPI, MTX), µg per glove (CP) 
  EPI  1037 ND - 12,823   8/16  ND ND - 189 3/16 
  MTX  ND all ND   0/16  ND all ND    0/16 
  CP          790 400 - 1,216  14/16  455 46.0 - 1,146 16/16 
 
Support glove, left, ng per glove (EPI, MTX), µ g per glove (CP) 
  EPI  175 ND - 13,268 10/16  ND ND – 1,046 4/16 
  MTX  ND all ND   0/16  ND all ND  0/16 
  CP   870 ND - 1,356 15/16  950 199 - 1,476 16/16 
 
ND = none detected 
EPI LoD (ng cm-2) = 0.002 (floor), 0.001 (tray), 2.0 ng per glove   
MTX LoD (ng cm-2) = 0.06 (floor), 0.04 (tray), 50.0 ng per glove   
CP LoD (ng cm-2) = 28.3 (floor), 18.0 (tray), 25.0 µg per glove   
 
 
During the Baseline periods, EPI and CP were recovered from all surfaces 
outside the isolator. The largest amounts were recovered from the support gloves 
during Baseline 1 for EPI and during Baseline 2 for CP. Contamination of the support 
gloves with CP were consistently high during all weeks of the study, regardless of the 
system used. In fact, similar amounts of CP were recovered during the Intervention 
periods combined (1,476 µg) compared to the Baseline periods combined (1,356 µg) - 
Table 47. The trays ‘in and out’ were also found to be contaminated with similar 
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levels of CP during the Baseline periods compared to the Intervention periods. There 
appears to be a relationship between the ‘tray in’ and areas in the isolator testing 
positive for CP during Baseline 2, since contamination was recovered from the 
isolator only when the ‘tray in’ was also found to be contaminated. No MTX 
contamination was recovered from the support gloves during either the Baseline or 
Intervention periods, but it was present on the ‘tray in and out’ and on the floor during 
the Baseline periods. 
 During Intervention, there was no cytotoxic contamination of any of the three 
drugs recovered from the floor, and no EPI or MTX contamination was recovered 
from the ‘tray in.’ Contamination of all three drugs was recovered from the ‘tray out’ 
during the Intervention periods. More MTX was recovered from the ‘tray out’ during 
the Intervention periods than during the Baseline periods, however, the frequency of 
positive cases of contamination of all three drugs was less than during the Baseline 
periods.  
5.5.6  Effectiveness of Cleaning in Removing Surface Contamination during Baseline 
 The amount of contamination recovered before and after cleaning the isolator 
during Baseline 1 and 2 determined the effectiveness of the cleaning protocol used. 
Sampling point’s b (prior to cleaning) and c (after cleaning) determined the 
effectiveness of cleaning after Session 1. Sampling points d (prior to cleaning) and 
sampling a of the following day (after cleaning) determined the effectiveness of 
cleaning after Session 2. Tables 48 (EPI), 49 (MTX) and 50 (CP) on the following 
pages show the amount contamination recovered before, and after, each cleaning 
procedure was applied. 
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Table 48. Amount of EPI Contamination Recovered from the Isolator before and after Session Cleaning (Baseline 1 and 2)  
    End of Session 1 Clean        End of Session 2 Clean   
Area  Baseline 1       Baseline 2            Baseline 1            Baseline 2 
Isolator base, ng cm-2 
  b 0.59      <0.002 0.07 0.04  ND <0.002  ND ND  0.11 0.08     <0.002 0.06  ND ND ND ND 
  a 0.17 0.09 0.05 0.07  ND <0.002  ND ND  0.20 0.08 0.05 ND  ND   <0.002 ND ND 
Door, outer right, ng cm-2 
  b 0.07      <0.003 ND ND  ND ND ND ND  0.05 ND ND ND  ND ND     <0.003 ND 
  a 0.07 ND ND 0.07  ND <0.003 ND ND  0.06 ND ND ND  ND ND ND ND 
Door, outer left, ng cm-2 
  b 0.01 ND     <0.003 ND  ND ND ND ND  0.05 ND ND ND  ND ND ND ND 
  a         <0.003  <0.003  ND 0.07  ND       <0.003 ND ND              <0.003 ND ND ND          <0.003 ND ND ND 
Door, inner right, ng cm-2 
  b 0.08 0.06 ND ND  ND <0.003 ND ND  0.07 ND ND ND  ND ND 0.05 ND 
  a         <0.003 ND ND 0.07  ND ND ND ND            <0.003   <0.003 ND ND             <0.003 ND ND ND 
Door, inner left, ng cm-2 
  b 0.08 0.07     <0.003 <0.003  ND    <0.003 ND ND  0.07 ND ND ND  ND  ND ND   <0.003 
  a ND ND       <0.003 <0.003  ND    <0.003 <0.003 ND  0.05 ND ND ND  <0.003  ND ND ND 
Sleeve, right, ng per sleeve 
  b 711 41.0 42.5 ND  ND ND ND ND  90.5 ND ND ND  ND <2.0 <2.0 ND 
  a 89.5 41.5 45.0 49.0  ND <2.0 ND ND  106 41.5 ND ND  ND ND ND ND 
Sleeve, left, ng per sleeve 
  b 398 <2.0 <2.0 <2.0  ND ND ND <2.0  81.0 ND ND 53.5  ND <2.0 ND ND 
  a 86.0 <2.0 ND 49.5  ND <2.0 ND ND  44.0  <2.0 <2.0 ND  ND ND ND ND 
 
b = before cleaning          EPI LoD (ng cm-2) = 0.001 (base, hatch door), 1.0 ng per sleeve 
a = after cleaning           
ND = none detected          
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Table 49. Amount of MTX Contamination Recovered from the Isolator before and after Session Cleaning (Baseline 1 and 2)  
       End of Session 1 Clean           End of Session 2 Clean   
Area  Baseline 1       Baseline 2                   Baseline 1            Baseline 2 
Isolator base, ng cm-2 
  b. ND ND 0.26 <0.04  ND ND ND ND  <0.04 ND 0.19 0.09  ND ND ND 0.24 
  a ND ND 0.18 <0.04  ND ND ND 0.27  ND 0.33 0.13 ND  ND 0.60 0.24 ND 
Door, outer right, ng cm-2 
  b ND ND ND 0.07  <0.07 ND <0.07 <0.07  <0.07 ND ND ND  ND ND ND 0.15 
  a ND ND ND <0.07  <0.07 ND ND ND  ND ND ND ND  ND ND 0.11 ND 
Door, outer left, ng cm-2 
  b ND ND ND <0.07  <0.07 ND <0.07 0.16  ND ND ND ND  ND ND ND 0.24 
  a ND ND ND <0.07  ND ND ND 0.19  ND ND ND ND  ND ND 0.14 ND 
Door, inner right, ng cm-2 
  b ND ND ND 0.10  ND ND ND 0.19  ND ND ND 0.22  ND 8.04 ND 0.08 
  a <0.07 ND ND ND  ND ND ND <0.07  ND ND ND ND  ND ND 0.20 ND 
Door, inner left, ng cm-2 
  b ND ND ND <0.07  ND ND <0.07 <0.07  ND ND ND ND  ND ND ND      <0.07 
  a ND ND ND <0.07  ND ND ND <0.07  ND ND <0.07 ND  ND ND 0.15 ND 
Sleeve, right, ng per sleeve  
  b ND ND ND <50.0  ND ND <50.0 ND  ND ND ND ND  ND ND ND ND 
  a ND ND <50.0 ND  ND ND 102 <50.0  ND ND ND ND  ND ND 198 ND 
Sleeve, left, ng per sleeve 
  b ND ND <50.0 <50.0  <50.0 ND <50.0 ND  <50.0 ND ND ND  ND ND ND 716 
  a ND ND ND 282  ND ND 158 211  ND ND <50.0 ND  ND ND <50.0 ND 
 
b = before cleaning          MTX LoD (ng cm-2) = 0.02 (base), 0.04 (hatch door), 25.0 ng per sleeve 
a = after cleaning           
ND = none detected          
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Table 50. Amount of CP Contamination Recovered from the Isolator before and after Session Cleaning (Baseline 1 and 2)  
   End of Session 1 Clean                             End of Session 2 Clean   
Area  Baseline 1     Baseline 2      Baseline 1            Baseline 2 
Isolator base, ng cm-2 
  b. ND ND ND ND  ND ND ND ND  ND ND ND ND  ND ND ND ND 
  a ND ND ND ND  ND ND ND ND  ND ND ND ND  ND ND ND ND 
Door, outer right, ng cm-2 
  b ND ND ND ND  ND ND 269 ND  ND ND ND ND  ND ND ND ND 
  a ND ND 117 ND  426 ND 174 ND  ND ND ND ND  ND ND ND ND 
Door, outer left, ng cm-2 
  b ND ND ND ND  ND ND 190 ND  ND ND 135 ND  ND ND 393 ND 
  a ND ND ND ND  ND ND 215 ND  ND ND ND ND  ND ND ND ND 
Door, inner right, ng cm-2 
  b ND ND ND ND  ND ND 302 ND  ND ND ND ND  ND ND 982 ND 
  a ND ND ND ND  ND ND 368 ND  ND ND ND ND  ND ND ND ND 
Door, inner left, ng cm-2 
  b ND ND ND ND  ND ND 237 ND  ND ND ND ND  ND ND 2,034 ND 
  a ND ND ND ND  ND ND 221 ND  ND ND ND ND  ND ND ND ND 
Sleeve, right, µg per sleeve 
  b ND ND ND ND  ND ND 304 ND  ND ND ND ND  ND ND ND ND 
  a ND ND ND ND  ND ND 264 ND  ND ND ND ND  ND ND ND ND 
Sleeve, left, µg per sleeve 
  b ND ND ND ND  ND ND 278 ND  ND ND ND ND  ND ND ND ND 
  a ND ND ND ND  134 ND 266 ND  ND ND ND ND  ND ND ND ND 
 
b = before cleaning          CP LoD (ng cm-2) = 9.5 (base), 17.5 (hatch door), 12.5 µg per sleeve 
a = after cleaning           
ND = none detected          
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 The effectiveness of the cleaning protocol applied in Baseline periods of the 
study was assessed by comparing surface contamination in the isolator (ng per square 
centimetre, or ng or µg per sleeve) before and after cleaning during Baseline 1 and 2. 
The frequency of cases when contamination was removed was determined using the 
Chi Squared Test. The significance level of the test was p ≤0.05, which meant there 
was sufficient evidence to reject the null hypothesis. The hypothesis were: 
 
Ho – cleaning does not remove cytotoxic contamination in the isolator  
 
H1 – cleaning does remove cytotoxic contamination in the isolator 
  
 The cleaning procedure applied after Session 1 did not significantly reduce 
contamination of EPI (p = 0.853), MTX (p = 0.655) or CP (p = 0.317) from areas in 
the isolator.  
 The cleaning procedure applied after Session 2 did not reduce contamination of 
EPI (p = 0.371) or MTX (p = 0.827) from areas in the isolator. There were insufficient 
valid occurrences of an ineffective cleaning procedure for CP to enable statistical 
assessment, as CP was removed completely (at least to below the LoD of the analytical 
method) in all four cases.  
 There was only one occasion when contamination was recovered at the end 
of the week to assess the cleaning procedure applied to clean the floor. On this one 
occasion, the cleaning procedure was effective in removing MTX contamination. 
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5.5.7  Acceptance of the Closed-System (PhaSeal®)Device - Questionnaire 
 The questionnaire (see Appendix 6) was completed by both technicians and 
consisted of open and closed questions. Feedback on parts 1, 2 and 3 is expressed in 
Tables 51, 52 and 53, respectively, below and on the following pages. 
 
Table 51. Results of Part 1 of the Questionnaire to Determine Operators Opinion on 
the Use of the Closed-System (PhaSeal®) Device 
Part 1. Prior to the Start of the Study
 
Question 1.a.  How long have you been working with cytotoxic drugs?  
Answer T1. 3 years 
  T2. A few days  
     
Question 1.b.  How worried are you about working with cytotoxic drugs?  
Answer T1. Quite happy 
  T2. Slightly bothered      
 
Question 1.c.  How safe do you feel with the current methods you have been using 
   when working with cytotoxic drugs?   
Answer T1.  Very safe - “very competent and well trained” 
  T2.  Safe 
 
T1 = Technician One     
T2 = Technician Two 
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Table 52. Results of Part 2 of the Questionnaire to Determine Operators Opinion on 
the Use of the Closed-System (PhaSeal®) Device 
Part 2. Prior to the Start of the Intervention Period 
 
Question 2.a.  I found the training for the closed-system device adequate 
Answer T1.  Strongly agree    
  T2.  Strongly agree  
 
Question 2.b.  I felt confident using the closed-system device after the training given 
Answer T1. Strongly agree    
  T2. Strongly agree   
 
Question 2.c.  Do you have any reservations about using the closed-system device? 
Answer T1.  Packaging waste       
  T2. “No, we were trained well enough to allow us to fix a problem if 
         one occurs”. 
 
Question 2.d.  How confident do you feel that the closed-system device is protecting 
  you? 
Answer T1.  Confident      
  T2.  Very confident 
 
T1 = Technician One     
T2 = Technician Two 
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Table 53. Results of Part 3 of the Questionnaire to Determine Operators Opinion on 
the Use of the Closed-System (PhaSeal®) Device 
Part 3. End of the Intervention Period 
 
Question 3.a.  How confident are you in using the closed-system device now? 
Answer T1. Very confident 
  T2. Very confident 
 
Question 3.b.  I was more careful when using the closed-system device than when 
  using the traditional ‘open’ method 
Answer T1.  Disagree 
  T2.  Disagree 
 
Question 3.c.  Did you have any problems when using the device? 
Answer T1.  Time to unwrap individual product 
 T2.  “Only once when I separated the injector from the vial with the 
protector on it. I realised I was pushing down on the injector at the 
same time I was pulling it apart. This caused them to come apart”. 
 
Question 3.d.  Did the device hinder work in any way? 
Answer T1.  “No, made it easier to draw up, less strain on hands” 
  T2.  “Not at all, I looked forward to the weeks when using PhaSeal®” 
 
Question 3.e.  After using the closed-system device which method would you prefer to 
  continue working with? 
Answer T1.  PhaSeal® device – “Quicker and easier to use” 
 T2. PhaSeal® device – “Although it is a little time consuming 
unwrapping all of the individually wrapped PhaSeal® parts. I found it 
was actually quicker to produce the end product. I felt a lot safer using 
PhaSeal® especially when drawing up liquid from vials. It was a lot 
easier to manoeuvre the vials whilst manufacturing. There was also less 
strain on the thumbs when using the PhaSeal® compared to the 
traditional method”. 
 
T1 = Technician One 
T2 = Technician Two 
 
 
5.6  Discussion  
 This study was designed as a short-term study simulating the compounding of 
cytotoxic drugs in an isolator under UK standards of practice. The intense sampling 
schedule enabled a large amount of data to be collected over the whole 4-week study 
period. The three drugs of interest were the only ones manipulated, thereby 
eliminating interference from any other drugs. The method (Chapter 3, Method 2) 
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employed to remove cytotoxic surface contamination was novel compared to wipe 
sampling methods applied previously. It used a wipe impregnated with 70% (v/v) 
IPA, in a single recovery method, to remove the multi-surface contamination of three 
cytotoxic drugs. It was sensitive to measure surface contamination at nanogram 
levels of two of the drugs of interest. Prior to its application, it was validated for 
recovery from each surface (Section 3.8). All of the samples collected were assayed 
for all three drugs. 
 The data generated from the sampling schedule enabled the quantification of 
contamination of surfaces inside the isolator, the finished product leaving the isolator 
and the immediate surfaces outside the isolator. It enabled conclusions to be drawn 
about the effectiveness of the closed-system (PhaSeal®) device and of the cleaning 
protocol used. 
 
 The presence of cytotoxic contamination, particularly during the Baseline 
periods, on the gloves and sleeves, the base of the isolator, the hatch doors and the 
batches prepared, demonstrates that contamination does occur from the compounding 
of cytotoxic drugs in an isolator workstation. However, this study showed that the 
levels of contamination vary, are inconsistent, and are not predictable. There was a 
clear difference in the amount of contamination and the frequency of positive 
samples between the three drugs recovered from the surfaces inside the isolator. The 
frequency of EPI contamination, in terms of the number of positive samples 
recovered from the isolator during Baseline was the highest, followed by MTX, then 
CP (Figure 44, page 212). This reflects the different LoD and LoQ of the analytical 
method for each drug (Section 3.8.4); the method applied to quantify EPI was the 
most sensitive, followed by MTX then CP. A review of environmental studies 
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reported the positive number of wipe samples taken from hospital pharmacies to 
range between 0 - 100%.8 Other studies have reported a range of positive samples for 
CP from surfaces i.e. 29%, 21%, 95% and 94%;124-126 and 2%, 56%, and 60% for 
MTX.108;109;189 These samples were taken from established hospital pharmacies 
where baseline levels of contamination may possibly be higher and there were longer 
intervals between sampling points i.e. the end of the working day over a year,20 twice 
weekly,62 every 4 weeks,78 at various monthly intervals.124 The Baseline levels in the 
isolator and clean-room in this present study were zero prior to the start of the study 
i.e. completely free from cytotoxic contamination and ideal for research purposes. 
The frequency of monitoring was very intense over a short period of time i.e. four 
times daily over a period of 4 weeks (Section 5.4.7 and 5.4.8), not allowing much 
time for the potential build-up of contamination between monitoring. 
 The levels of contamination in this study were sufficient to make 
comparisons between the two different methods for the reconstitution and dilution of 
the three drugs. For each drug, a significant reduction in the number of samples, 
which tested positive during Baseline compared to Intervention, was observed 
(Figure 44, page 212). Although the frequency of the number of positive samples of 
CP was the lowest of the three drugs, the total amount of CP recovered during 
Baseline 1 was the highest for the study, indicating that CP was the most 
contaminating drug. This was supported by the fact that CP contributed more 
cumulative contamination to isolator surfaces per mg prepared over the whole week 
(67.9 ng), than EPI (44.1 ng) or MTX (22.3 ng) during Baseline 1. This may reflect 
the way in which CP was prepared i.e. it is a lyophilised powder, and requires an 
extra manipulation i.e. reconstitution prior to dilution, compared to EPI and MTX 
which were presented in solution form and simply diluted. The lower frequency of 
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the number of positive samples may be due to the lack of sensitivity of the CP assay 
method; contamination may have been present but it was not measurable. On 
occasions when CP was recovered, the amount measured was well above the LoQ of 
the analytical method i.e. there were no samples that were positive for CP, but could 
not be quantified. If a more sensitive method had been employed or if higher 
recoveries had been achieved to give a lower LoD, it is likely that a higher frequency 
of positive samples would have been recorded. 
 Interestingly, no CP contamination was recovered from the isolator base, 
despite this being a positive source of contamination of EPI and MTX. In the 
isolator, most CP contamination was recovered from the hatch doors (both sides) - 
Table 35 (page 214), and the ‘tray in’ and ‘tray out’ - Table 45 (page 230). 
Worryingly, the highest amounts of CP contamination were recovered from the 
support gloves used outside the isolator. Levels on these gloves tested positive during 
both the Baseline and Intervention weeks of the study, indicating a pre-contaminated 
source of CP prior to any manipulations being carried out in the isolator. It is known 
that high external contamination on drug vials as received from the manufacturer, are 
a source of pre-contamination, and have been previously reported for CP.41;43;45 In 
Section 2.4.3.7 of this thesis, contamination was reported on vials, when measured in 
2 out of 7 cases in hospital pharmacies in the UK. Cytotoxic drug contamination has 
also been found on packaging40;63 and contaminated vials have been suggested to be 
an influencing factor on data from other surface contamination studies.26;126 The 
likelihood of external contamination on the vial may explain contamination on the 
‘tray in’ where high quantities of CP were recovered on several occasions.  
 The high quantities of CP found on the support gloves is of great concern as 
this is a potential source of dermal exposure. Typically, the same pair of gloves 
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would be worn for the whole session, unless glove integrity was visibly 
compromised, and the gloves would be changed. However, in this study, double 
gloving was practiced when working in the isolator. The outer gloves used in the 
isolator were made of latex, a thick glove especially designed for handling 
cytotoxics, and underneath a thinner nitrile glove was worn (contamination was only 
measured for on the thicker, latex isolator, gloves). However, even these thick latex 
gloves would have a finite breakthrough time. Certainly, the practice of double 
gloving and the higher temperatures achieved from the running of the isolator would 
cause the hands to sweat and this may influence the permeation of gloves.38 The 
support gloves were made of nitrile but they were considerably thinner and possibly 
offered less protection. The high levels of CP contamination found on these support 
gloves used outside the isolator would pose the risk of dermal exposure. A session 
may have lasted a number of hours and OSHA recommends that gloves are changed 
every hour.79 Studies have shown breakthrough times through latex gloves for CP 
and MTX as rapid as 10 min and 62 min.30 Unlike the isolator gloves, the support 
gloves were worn in the clean-room, a larger area in which to transfer contamination. 
Contaminated support gloves would potentially transfer contamination onto any 
areas touched and cause a secondary contamination event i.e. areas in the clean-room 
or, on items sprayed in for subsequent batch preparation in the same session.  
 Significant levels of CP were recovered from the ‘tray in’ during Day 3 of 
Baseline 2. The positive testing of the ‘tray in’ for CP contamination and 
corresponding contamination recovered in the isolator during the same sessions, may 
also be a consequence of external contamination on vials.  
 The liberal spraying of IMS on vials prior to transfer into the isolator may 
also be a method of transferring contamination. The wetting with IMS on heavily 
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contaminated vials may act as a medium to carry any contamination into the tray or 
onto the base when transferred into the isolator. Significant amounts of CP were also 
recovered during sessions when CP was not manipulated. Airborne levels of CP have 
periodically been reported when CP was not the drug being manipulated.34 It has 
been suggested that CP may vaporise as it has a low vapour pressure,34 and diffuse 
through the HEPA filter. 
 Anomalous results have been previously reported before when large 
quantities of CP were found on gloves used for handling vials which did not contain 
CP. It was suggested that the cross-contamination of vials may occur during the 
manufacturing process. This may be prevented or reduced by washing the vials after 
the manufacturing process and would also reduce the levels of pre-contamination 
provided by the corresponding drug.45 The importance of CP in this study was as a 
marker drug for comparison with other studies. Although it was not detected 
frequently, a reduction in contamination when using the closed-system (PhaSeal®) 
device was observed, as with other studies.20;67;78;124  
  
 The first Baseline week, using the open-system, showed high levels of EPI 
contamination (Table 35, page 214). The largest amount of EPI contamination was 
recovered on Day 1, and the amount and frequency of contamination decreased 
throughout the week. The amount of EPI recovered from the base, right sleeve and 
both gloves, and also the frequency of contamination, was lower during Baseline 2. It 
may be suggested that the technicians, after using the closed-system (PhaSeal®) 
device for one week, were more careful when using the open-system. However, this 
suggestion cannot be supported by the fact that the amount of MTX and CP 
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contamination recovered was higher during the second Baseline week. Certainly, on 
Day 3 of Baseline 2, a large amount of CP was recovered.  
 The median surface levels recovered of EPI and MTX contamination were 
highest on the gloves and sleeves, and on the inner right hatch door (Table 35, page 
214). During Baseline 1, EPI was recovered consistently from the isolator gloves, 
which would explain the frequent contamination recovered from the syringes. On 
several occasions, especially during Baseline 2, the levels of EPI were below the 
LoD of the analytical method and traces, which were not measurable, were found 
frequently on the hatch doors where less contamination would be expected. No MTX 
was recovered from the support gloves during any week of the study (Table 47, page 
232). The size and the number of MTX vials was smaller than the size and number of 
EPI and CP vials required for the study, resulting in a smaller potentially pre-
contaminated surface area. EPI, MTX and CP were all supplied by different 
manufacturers, and variations in washing could explain differences in external 
contamination on vials of different drugs and between manufactures.41 None of the 
vials of EPI, MTX or CP were supplied with a coating shrunk around the vial to 
contain any contamination, and there is no standardised cleaning procedure between 
manufacturers. It is possible that the MTX vials received may not have been as 
contaminated as the CP vials because of the filling process. The process of filling 
vials with lyophilised powder (i.e. CP) may cause dusting, which may be more 
contaminating than filling a vial with a liquid i.e. EPI or MTX. It was not anticipated 
that such high levels of CP would be recovered from areas outside of the isolator i.e. 
support gloves in this study. Including vials as part of the wipe sampling schedule 
would have confirmed if the vials were the source of pre-contamination. Cleaning of 
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the vials prior to the start of the study may have removed this potential pre-
contaminating source. These options should be considered in future studies. 
 Isolators are designed for containment, and any contamination generated or 
taken into the isolator should pose no threat to operators. However, isolators do leak 
to some extent110 and this may partly explain the presence of contamination on the 
floor. Floor contamination recovered when cytotoxic drugs were compounded in a 
negative-pressure isolator (also recovered when a positive-pressure isolator was 
used) was found by another study. The levels of CP and MTX recovered were 117 ng 
m-2 (median) ranging from 22.0 ng m-2 to 290 ng m-2, and 58 ng m-2 (median) 
ranging from 40.0 ng m-2 to 674 ng m-2 respectively.26 These levels are considerably 
higher than the levels of CP and MTX recovered from the floor in this present study 
(Table 47, page 232). 
 It is evident that the external contamination of syringes occurs during 
preparation and this is highly variable. Syringes making up the batch were sometimes 
contaminated infrequently e.g. 1 syringe from a batch of MTX was found to be 
contaminated with 259 ng of the corresponding drug. In other cases contamination 
was frequent and consistent e.g. all the syringes from EPI batch 4 during Baseline 1 
were contaminated (range = 42.0 to 78.5 ng). The bagging of each batch of syringes 
would retain the contamination until the bag was re-opened, but any highly 
contaminated syringes may potentially contaminate other, non-contaminated 
syringes, in the batch, unless packaged as individual units. The external cross-
contamination of batches was also found to occur, although less frequently than the 
contamination of syringes from the corresponding drug. Cross-contamination is 
likely to occur from handling with contaminated gloves or placing the syringes onto 
contaminated surfaces. EPI was the most frequent contaminant and cross-
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contaminant recovered from batches i.e. 9 of the 10 syringes of CP (batch 14) were 
cross-contaminated with similar amounts of EPI during Baseline 1, day 3. This cross-
contamination is difficult to explain as the CP batch was made prior to any EPI 
preparation that day. In fact, the last batch of EPI was prepared in the morning 
session of the previous day, and since then the isolator had been cleaned twice and 
the gloves changed. 
 During the Intervention weeks, there was no positive presence of CP on any 
of the syringes (Table 43, page 224). EPI was positive on 3 syringes but could not be 
quantified as it was below the LoQ of the analytical method. During Intervention 2, 
81.5 ng of MTX was recovered from one syringe, on the last batch prepared that 
week. There was no other MTX contamination recovered from the surfaces in the 
isolator during the whole week of Intervention 2, except for a trace on the right 
sleeve at the beginning of the week, therefore implying the isolator was free from 
MTX contamination. This anomalous result could potentially be explained by a 
contaminated vial. However, no contamination was recovered from the support or 
isolator gloves to support this. The syringe may have been placed on a surface of the 
isolator, which had not been sampled from, as wipe samples were taken only from 
21% of the isolator base. In previous studies with the PhaSeal® device, the occasional 
positive sample has been reported.125 In this present study, the occasional positive 
sample during Intervention may be carryover from Baseline due to the 
ineffectiveness of the cleaning procedure.  
 The closed-system (PhaSeal®) device, used in conjunction with an isolator 
was able to contain and control the environment inside the isolator during drug 
preparation and reduce contamination on the finished product leaving the isolator. 
Although control could only be exerted in the isolator, the reduced contamination 
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found on batches would also reduce exposure to personnel involved in the 
transportation, handling and administration of the finished product. 
 The results suggest that the cleaning protocol applied in this study was not 
fully effective in removing surface contamination of all three drugs. The two 
cleaning agents (Klercide CR-B and Klerclean neutral detergent) and IMS are used 
commonly for cleaning after the manipulation of cytotoxic drugs in the facilities 
which responded to the survey (Chapter 2). Wipe studies carried out with these two 
cleaning agents in Chapter 4, demonstrated that these two agents and IMS have the 
potential to be effective in removing cytotoxic contamination, where EPI and CP 
were two of the contaminating drugs investigated (Table 27, page 166). However, 
these studies were applied to a small surface area and the contamination was visible 
to the naked eye. The task of cleaning an isolator is very different. An isolator is 
awkward to clean manually, using the sleeve/glove port access makes it a clumsy 
task, some areas are inaccessible, and it is difficult to be methodical and apply the 
same amount of pressure over the whole surface. It may be possible that some areas 
were not reached or that the procedure applied was simply spreading the 
contamination around. The sampling procedure did not cover all of the surface area 
of the isolator therefore, cleaning would overlap swabbed and un-swabbed areas and 
if contamination was being spread, it is possible that it could have been transferred 
onto the swabbed areas. This would explain the findings of drug contamination when 
the corresponding drug had not been prepared in the preceding session. In most 
cases, cytotoxic contamination was not visible to the naked eye and decontamination 
was dependent on the cleaning procedure. 
 It may also be possible that the contamination was persistent and that the 
cleaning agents applied in this study were not appropriate to collect or degrade these 
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cytotoxic molecules. Studies on these two cleaning agents in Chapter 4 showed that 
they were not effective in degrading cytotoxic drugs, once more EPI and CP were 
two of the drugs investigated (Section 4.5.3). It must be noted that taking swabs 
during sampling points c and a would have removed some of the contamination prior 
to cleaning. As a result, the number of positive occasions when the cleaning 
procedure was effective may be an over-estimation, as the removal of contamination 
may have been due to the removal by the sampling procedure and not by cleaning.  
5.6.1  Levels of Cytotoxic Contamination Recovered – A summary 
 Table 54 on the following page summarises the range of contamination 
recovered from the isolator, areas outside the isolator and syringe batches during the 
combined Baseline 1 and 2, and Intervention 1 and 2 periods.  
 The range of MTX contamination recovered in this study is in agreement 
with levels which were recovered from a positive-pressure isolator i.e. ND to 8.61 ng 
cm-2 under French standards of practice.59 This supports the conclusion that there is 
no distinction in terms of risk to the operator between the differential operating 
pressure of the isolator in relation to the pharmacy atmosphere.26 Although, contrary 
to this, the levels of CP are significantly higher i.e. ND to 2,034 µg cm-2 in this 
present study, compared to the range of CP contamination recovered from a positive-
pressure isolator i.e. 0.16 to 6.55 ng cm-2.59  
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Table 54. Summary of the Range of Contamination Recovered During the Baseline 
and Intervention Periods  
Area   Baseline    Intervention
Isolator EPI ND - 0.59 ng cm-2        ND - 0.11 ng cm-2 
   ND - 1,932 ng per sleeve/glove       ND - 171 ng per sleeve/glove 
 
  MTX ND - 8.04 ng cm-2         ND - 0.07 ng cm-2 
   ND - 1,559 ng per sleeve/glove        ND - <50.0 ng per sleeve/glove 
 
  CP ND - 2,034 ng cm-2           ND  
   ND - 304 µg per sleeve/glove         ND - 192 µg per sleeve/glove 
 
Outside EPI ND - 0.19 ng cm-2            ND  
Isolator  ND -13,268 ng per glove         ND - 1,046 ng per glove 
 
  MTX ND - 11.3 ng cm-2               ND - 0.39 ng cm-2 
    ND            ND  
 
  CP ND - 384 ng cm-2                ND - 214 ng cm-2 
   ND - 1,356 µ g per glove         46.0 - 1,476 µ g per glove 
  
Batches EPI ND - 1,807 ng per syringe          0 - <2.0 ng per syringe 
 
  MTX ND - 259 ng per syringe                     ND - 81.5 ng per syringe 
 
  CP ND - 75.0 µ g per syringe          ND
 
ND = none detected 
 
 
5.6.2  Effectiveness of the Closed-System (PhaSeal®) Device – A summary 
 Statistical tests comparing the Baseline and Intervention weeks of the study, 
demonstrated the closed-system (PhaSeal®) device to be significantly effective in 
preventing the release of contamination from the compounding of all three drugs in 
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the isolator (Section 5.5.2). A summary of the outcome of the effectiveness of the 
closed-system (PhaSeal®) device is shown in Table 55 below. Where there were a 
sufficient number of statistical cases the p value was quoted (p values equal to or 
below <0.05 were considered to be significant). Where there were not enough 
statistical cases the reduction in the number of positive cases is shown. 
  
Table 55. Effectiveness of the Closed-System (PhaSeal®) Device in Preventing 
Cytotoxic Contamination  
      Statistical Outcome 
Area    EPI   MTX   CP
Isolator B1 vs I1 p = 0.000  p = 0.000       a 
  B2 vs I2 p = 0.003  p = 0.000  p = 0.002 
  B1+2 vs I1+2 ND   ND   p = 0.001 
 
Batches of 
Corresponding   p = 0.000  5 → 1 a   2 → 0 a 
Drug  
 
Batch      11→0 a  (MTX)  6 → 0 a (EPI)            4→0 a (EPI) 
Cross-Contamination  p = 0.012 (CP)  1 → 0 a (CP)            ND b (MTX) 
 
Cleaning 
 Session 1  p = 0.853  p = 0.655  p = 0.317 
 Session 2  p = 0.371  p = 0.827  4 → 0 a 
 Floor   ND b   1→ 0 a      ND b 
 
a 
= Insufficient number of positive cases above the LoD to carry out statistical test 
b
 = No positive cases 
B1 vs I1 = Baseline week 1 versus Intervention week 1 
B2 vs I2 = Baseline week 2 versus Intervention week 2 
B vs I = Baseline (week 1+2) versus Intervention (week 1+2) 
ND = not determined  
 
 
There were incidences when statistical analysis could not be carried out i.e. 
due to the lack of positive samples. It may be possible that the contamination was not 
present, or that it was below the LoD of the analytical method. Nethertheless, there 
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was a significant reduction in the levels of contamination recovered from the isolator 
between the two systems for the reconstitution and preparation of cytotoxic drug 
containing syringes and infusion bags. This was true for two drugs (EPI and MTX), 
novel to usage with the closed-system (PhaSeal®) device, and was supported by the 
results for CP found by other investigators.20;62;67;78;124;125 It should be noted that the 
closed-system device would not be effective in reducing contamination arising from 
the exterior wall of drug vials. 
5.6.3  Acceptance of the Closed-System (PhaSeal®) Device 
 Feedback from the technicians in this study supported acceptance of the 
closed-system (PhaSeal®) device and preference of its usage to the ‘open’ technique 
– see Tables 52 and 53 (pages 239 and 240). This was true for an experienced 
technician and a technician new to the role. Technician One had 3 years of 
experience of working with cytotoxic drugs. She was quite happy working with 
cytotoxic drugs and felt very safe using the open-system, which she has always used 
in previous employment. She considered herself very competent and well trained in 
her technique. Technician Two was a pharmacist who had less experience of working 
with cytotoxic drugs. She was slightly bothered about working with these drugs but 
felt safe with the open-system and the safety protection provided. However, after 
seeing how the closed-system (PhaSeal®) device worked, she was no longer keen on 
using the open-system.  
 Prior to the start of the Intervention period, both technicians found the 
training given before use of the device adequate, and afterwards felt confident in 
using the closed-system (PhaSeal®) device. Technician One felt confident that the 
device was protecting her from contamination, but found the packaging problematic 
when opening it to remove the device. Technician Two felt very confident that the 
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device was protecting her from contamination, she did not have any reservations 
about the device as the training given also covered troubleshooting and felt that if a 
problem did occur it would be ‘fixable’. 
 After two weeks of usage with the closed-system (PhaSeal®) device, both 
technicians felt very confident with using it and preferred this method to the open-
system. Again, the only drawback was the individual packaging which was 
problematic when many vials were used requiring the removal of many protectors 
from packaging. Opening of the packaging in the isolator was hindered by the 
wetting of the packaging caused by IMS saturation when spraying in. This problem 
was referred to the manufacturer. 
 Both technicians found it quicker to produce the end-product when using the 
device (apart from the unwrapping of the components) and found it easier to draw up 
liquid, relieving strain on the hands. Technician Two actually looked forward to the 
Intervention weeks when using the device. She felt safer using the device, especially 
when drawing up liquid from the vials, and it made the vials much easier to 
manoeuvre during compounding.   
5.6.4  Potential Surface Contamination Risk Assessment for Pharmacy Technicians - 
A Theoretical Projection of Data 
 When data have been lacking because of the time it would take to collect, 
short-term available data have been extrapolated to calculate a long-term risk.22 The 
modelling of data in such a way enabled a cancer risk from exposure to CP to be 
determined.22 This information otherwise would only have been generated from 
observation over a long period of time.  
 The total amount of drug compounded (Table 31, page 197) and the amount 
of surface contamination generated by EPI, MTX and CP (Appendices 7, 8 and 9, 
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respectively) over the two Baseline weeks using the open-system was aggregated. 
The data was projected to estimate a short-term risk i.e. over 1 year (the data from 2 
weeks was multiplied by 24, assuming a working year of 48 weeks) and a long-term 
risk i.e. over 40 years (the data from 1 year was multiplied by 40, assuming a 
working life of 40 years). The calculation was performed for EPI, MTX and CP, 
grouping contamination recovered from the different surfaces into three areas of risk: 
 
area a contamination recovered from surfaces inside the isolator only; 
area b contamination recovered from all surfaces outside the isolator; 
area c contamination and cross-contamination recovered from the external 
  surfaces of batches of infusions. 
 
The same calculation was performed comparatively alongside Intervention data to 
calculate an estimated potential reduced risk over the same time points. The results 
of these calculations are shown in Table 56 below, and Tables 57 and 58 on the 
following page.  
 
Table 56. Amount of EPI, MTX and CP Compounded over 2 Weeks, and Estimated 
over 1 Year and 40 Years 
    Amount of Drug Compounded 
Drug  2 Weeks  1 Year   40 Years 
 
EPI  0.74 g   17.8 g   710 g 
MTX   0.99 g   23.6 g   947 g 
CP  5.3 g   127 g   5,088 g 
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Table 57. Amount of Drug Contamination Produced during Baseline over 2 Weeks, 
and Amount Estimated over 1 Year and 40 Years 
Drug     Amount of Drug Recovered from Surfaces in Area 
   2 weeks  1 year   40 years 
 
EPI 
 area a   21,750 ng  0.52 mg  20.9 mg 
 area b   20,006 ng  0.48 mg  19.2 mg 
 area c   4,657 ng  0.11 mg  4.47 mg 
  
MTX 
 area a   23,252 ng  0.56 mg  22.3 mg 
 area b   6,057 ng  0.15 mg  5.81 mg 
 area c   537 ng   0.01 mg  0.52 mg 
 
CP 
 area a   1,170 µg  28.1 mg  1,123 mg 
 area b   25,087 µg  602 mg  24,084 mg 
 area c   343 µg   8.23 mg  329 mg 
 
 
 
Table 58. Amount of Drug Contamination Produced during Intervention over 2 
Weeks, and Amount Estimated over 1 Year and 40 Years 
Drug           Amount of Drug Recovered from Surfaces 
   2 weeks  1 year   40 years 
 
EPI 
 area a   510 ng   0.01 mg  0.49 mg 
 area b   1,411 ng  0.03 mg  1.35 mg 
 area c   ND   ND   ND 
 
MTX 
 area a   1,499 ng  0.04 mg  1.44 mg 
 area b   611 ng   0.15 mg  0.59 mg 
 area c   81.5 ng  0.002 mg  0.08 mg 
 
CP 
 area a   ND   ND   ND     
 area b   23,768 µg  570 mg  22,817 mg 
 area c   ND   ND   ND 
 
ND = none detected 
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 Implementation of the closed-system (PhaSeal®) device would reduce the risk 
of surface contamination (>LoD) in area a of EPI and MTX contamination by 97.7% 
and 93.6%, respectively, and would eliminate CP contamination. 
 Although the closed-system (PhaSeal®) device would not exert any direct 
control over the environment outside of its immediate use, EPI contamination was 
reduced by 92.9%, MTX contamination by 90.0%, and CP contamination by 5.3% in 
area b. 
 Implementation of the closed-system (PhaSeal®) device would eliminate 
external surface contamination (>LoD) on batches of syringe infusions of EPI and 
CP, and reduce MTX contamination by 84.8%.  
 The approach of short and long-term projection of the data from this study 
would be of importance to those who would consider an occupation of working with 
cytotoxic drugs either short-term or long-term. It was recognised that this can only be 
an estimate, and there were some drawbacks in this estimation due to the following 
assumptions that were made: 
 
i. batches of the same size and of the same quantities of these three drugs were 
prepared week in, week out; firstly over 1 year, then over a 40 year period;  
ii. no effect of other drugs used in the unit over this time was considered; 
iii. the technician worked everyday for 40 years, with only 4 weeks of holidays 
per year; 
iii. there was no change in the compounding method, use of personal protective 
 equipment, cleaning procedure or facilities where the cytotoxic drugs were 
 compounded;  
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iv.   the contamination was consistently produced, and there were no influences 
such as reported spillages. 
  
 In this study, the areas swabbed, represented 21% of the isolator base, a small 
area of the floor, the cuffs of the sleeves, and one third of the batches leaving the 
isolator. Therefore, this contamination risk is likely to be an under-estimation of the 
actual risk in practice. Furthermore, it may be possible that the results from this study 
are a slight under-indication of those that may be recovered from an established 
hospital environment after long-term continued use of the facilities for the 
compounding of cytotoxic drugs. However, for comparative purposes, the projection 
is useful in estimating the effect of new technology in the form of the closed-system 
(PhaSeal®) device. It demonstrates how the implementation of measures such as a 
closed-system (PhaSeal®) device in comparison with current practice may reduce or 
eliminate the potential risk in three main areas. The Baseline data calculates a 
potential risk if no successful changes were made and was necessary to highlight the 
potential risk if current practice does not improve. Of course, there will be the 
influence of changes in practice, which might include among others, improved 
personal protective equipment, less use of cytotoxics and the increased use of oral 
drugs and biological agents.  
5.7  Conclusion  
 Contamination was recovered from all surfaces inside the isolator after the 
compounding of cytotoxic drugs when using the open-system. The first 
contaminating event of a cytotoxic contamination-free isolator occurred rapidly i.e. 
after the first session on the first day of batch production. The cytotoxic 
contamination recovered from the isolator base, sleeves, hatch doors and gloves was 
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found to be inconsistent, and was not as the result of any spillages or visible leakages. 
Once present, it was resistant to removal by the cleaning protocol employed.  
 The contamination of the external surface of the finished product also occurs 
in an isolator. Contamination may not only arise from the corresponding drug 
prepared in the batch, but from the cross-contamination of other drugs prepared in the 
previous sessions or in the same session.  
 High levels of surface contamination recovered from areas outside the isolator 
indicated a pre-contaminated source. The suggested source was the supply of drug 
vials with external surface contamination. Use of a closed-system fluid-transfer 
device would not reduce contamination from this source. 
 The implemented closed-system (PhaSeal®) device exerted control in its 
immediate environment i.e. in an isolator, significantly reducing the levels of 
contamination on all surfaces. It also eliminated contamination on the external surface 
of batches of two of the three drugs analysed, and reduced the frequency of surface 
cross-contamination on batches leaving the isolator. This was true for all of the test 
drugs, including two drugs (EPI and MTX), which were novel to usage with the 
closed-system (PhaSeal®) device, and also for CP where results were in accordance 
with previous studies.20;62;67;124;125 Operators of the closed-system (PhaSeal®) device 
preferred it to the open-system. 
 Isolators have the capacity of protecting immediate external areas from multi-
cytotoxic drug surface contamination. When used in conjunction with a closed-
system (PhaSeal®) device, the frequency and magnitude of cytotoxic drug 
contamination inside the isolator and the surface of prepared infusions leaving the 
isolator were diminished. 
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6.  Effectiveness of a Closed-System (PhaSeal®) Device in Reducing 
Product Cross-Contamination of Batches in an Isolator 
6.1  Introduction 
 There has been speculation about the possible product cross-contamination 
that may occur in an isolator.190 Regulatory authorities advise against sharing an 
isolator where cross-contamination may present a risk, and expect to see the use of 
separate dedicated facilities.110;135 However, it is not mandatory for an already 
financially stretched NHS to dedicate one isolator/BSC for the preparation of 
potentially infectious or biological agents, and another for chemotherapeutic agents in 
all pharmacies. Increasingly, a number of clinical trials with agents of biological 
origin (protein, viral drug-delivery vectors) are ongoing in the UK. Consequently, 
cytotoxics may share isolators with other drugs i.e. MABs and gene therapy agents, 
presenting the potential risk of product cross-contamination occurring. The 
occurrence of drug solution cross-contamination has already been suggested. It was 
implied that bacille Calmette-Guérin (BCG) contaminated MTX, after the sequential 
preparation of both in a BSC on the same day. The inadvertent inoculation of BCG 
during the administration of intrathecal MTX resulted in two children developing 
BCG-associated meningitis.191 
 Results reported in this thesis have shown that the hospital pharmacies, which 
responded to the questionnaire, are already preparing MABs, occasionally in the same 
isolator as cytotoxic drugs, if separate facilities are not available (see Section 2.4.3.4). 
It has also been demonstrated that cross-contamination on the external surfaces of 
batches prepared in the same isolator can occur. Implementation with the closed-
system (PhaSeal®) device was successful in preventing the occurrence or reducing the 
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number of positive cases of external surface cross-contamination on pharmaceutical 
dosages of all of the cytotoxic drugs compounded (see Section 5.5.4). 
 Fluorescent indicator solutions have been used to identify the sources and 
routes of contamination when evaluating the techniques used to reconstitute and 
dilute cytotoxic drugs.32;60 These compounds fluoresce in UV light, highlighting 
spillages or poor operator technique. Pre-prepared test kits containing these 
fluorescent dyes are useful to train, evaluate and improve operator skills.11;192  
 Fluorescence spectrophotometry is a selective detection method, which can be 
used to quantify strongly fluorescent compounds in the presence of a non-fluorescent 
medium.104 Quinine sulfate (QS) is a strongly fluorescent molecule due to its 
extended chromophore and rigid structure. Its chemical structure is shown in Figure 
45 below. It is a stable compound and due to its fluorescent properties can be 
measured at low concentrations of 1.0 to 2.0 ng mL-1.104;193 QS was selected as the 
contamination indicator in this study as it exhibits UV absorption and fluorescence 
emission spectra.104  
 
Figure 45. Chemical Structure of Quinine Sulfate 
 
 
 This study was carried out simulating the dilution of two different drug 
solutions i.e. WFI and QS, sequentially in the same isolator. Batches were prepared 
N
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using the closed-system (PhaSeal®) device and the workload was repeated using the 
traditional open-system syringe/needle technique. QS was used as an indicator to 
identify surface contamination in the isolator, and solution cross-contamination of the 
finished product. 
6.2  Objectives 
The objectives of this study were to achieve the following: 
i. to determine if there is a significant risk of product cross-contamination 
occurring when different products are made in the same isolator,  
ii. to identify the main areas, and the frequency and point of surface 
contamination when preparing batches in an isolator, and 
iii. to evaluate the effectiveness of a closed-system (PhaSeal®) device for fluid-
transfer in reducing this risk.  
 6.3  Materials  
Chemicals 
 Quinine sulfate powder (lot 439257CM) was obtained from BDH, Poole, UK. 
 
Consumables 
 Macoflex® 100 mL polyolefin intravenous infusion bags, containing 0.9% 
sodium chloride isotonic solution (lot 06J12D) were obtained from Maco Pharma, 
Twickenham, UK. Viaflo® polyolefin infusion bags, containing water for injections 
(lot 06116E1J) were obtained from Baxter Healthcare Ltd, Berkshire, UK. 
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Equipment 
 A UV scanning lamp with settings at 254 nm and 365 nm was from P.W 
Allen, London. The fluorescence spectrophotometer, model 204-S (serial no. 813-07), 
and 150-xenon power supply (serial no. 002) were manufactured by Perkin Elmer 
Instruments, Beaconsfield, UK. The digital camera was a Nikon Coolpix 3200 (serial 
no. 4486420). 
6.4  Study Design 
 The study (batch preparation and the scanning of surfaces) was undertaken in 
a controlled GMP-compliant clean-room environment tested to EU Class Grade B135 
in an academic setting at the Department of Pharmacy, Kingston University, London, 
UK. The study was restricted to an isolator operating under negative-pressure relative 
to external atmospheric pressure with external ducting to the outside environment. 
The environment and the setup was the same as described in Section 5.4.1. Cross-
contamination of the product was measured at the Department of Pharmacy and 
Pharmacology, University of Bath. UK.  
 The manipulations investigated were the piercing of a vial and the withdrawal 
of solution from the vial and its transfer to an I.V infusion bag. All manipulations, by 
both methods i.e. the closed-system (PhaSeal®) method (see Section 5.1.1) and the 
open-system (see Section 5.1.2) were carried out on the same day by an operator with 
basic training in aseptic manipulations. A professional from Carmel Pharma, 
Gotёborg, Sweden undertook training and competency assessment with the closed-
system (PhaSeal®) device. Competency was achieved prior to the start of the study, 
and the professional trainer was present and observant during all of the closed-system 
manipulations of the study. 
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6.5  Methods 
6.5.1  Filling of Vials 
 Empty 100 mL vials were filled with either 55.0 mL of WFI or QS solution. 
The filling process was carried out in a room separate from the clean-room where the 
isolator was situated. The vials filled with WFI and QS were kept segregated from 
each other to ensure no contact throughout all stages of the study. 
 
WFI 
 Firstly, the vials were filled with WFI to avoid the cross-contamination of 
WFI with QS. These vials were then segregated from the QS vial filling process. 
 
Quinine Sulfate 
 QS powder was dissolved in WFI to give a standard concentration of 1.0 mg 
mL-1. The vials were filled carefully with QS solution, avoiding any contact of the QS 
with the external surface of the vial or any immediate surfaces. The external surface 
of the vials and the bungs were cleaned with WFI and a dry wipe, followed by IMS 
70% v/v impregnated wipes. After the vials were cleaned, the external surface of each 
vial was scanned for QS contamination, as described in Section 6.5.2, to confirm a 
clean external surface. 
6.5.2  Scanning of Surfaces  
 A UV lamp was used to scan surfaces for QS. It had two settings at 
wavelengths of 254 nm or 365 nm. QS has excitation and emission wavelengths at 
350 nm and 450 nm, respectively.104 QS was observed visually to absorb more 
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strongly at 365 nm therefore, it was used for the scanning of all surfaces throughout 
the study. 
 All surfaces were scanned prior to the start of the study to confirm a clean 
environment. Glove contamination in the form of a fluorescent marker has been 
reported as being difficult to visualise on glove material,32 however information 
regarding the type and make of glove used was not reported. To check for the 
visibility of QS, a latex glove of the same type to be used in the isolator for this 
study, was deliberated contaminated with QS. This was undertaken in a room outside 
the clean-room environment. 
 The external surface of the vials filled with QS were scanned at 365 nm 
immediately after cleaning. There was no visible QS contamination on the external 
surface of the vials, to confirm this; the vials were immersed in 250 mL of distilled 
water for 1 min. The immersion water was retained, and tested for fluorescent 
emission to verify the external surfaces were free from QS contamination.  
6.5.3  Quantification of Cross-Contamination  
 Cross-contamination was identified as the presence of QS in infusion bags 
prepared with WFI. Fluorescence spectrometry was employed to quantify any QS 
cross-contamination. A fluorescence spectrophotometer, model 204-S with a 150 
xenon power supply was used. The sensitivity was set at 0.1 and the gain was 1 p.m. 
6.5.3.1  Linearity 
 Linearity was evaluated across the dynamic range of the spectrophotometer. 
The excitation wavelength of the spectrophotometer was set at 317 nm and the 
emission wavelength was set at 390 nm. These wavelengths were determined 
experimentally by measuring the excitation and emission wavelengths, which 
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achieved the maximum response. Standard solutions of 0.1 ng mL-1, 1.0 ng mL-1, 2.0 
ng mL-1, 5.0 ng mL-1, 10 ng mL-1, and 100 ng mL-1 QS diluted in NS were prepared. 
The average fluorescence response of duplicate measurements at each concentration 
was calculated and used to construct a calibration plot of emission intensity against 
the concentration of the standard solution (ng mL) of QS. Emission was measured on 
a scale of 0 to 110. The equation of the calibration plot was obtained by linear 
regression analysis of known drug concentration (x) versus average fluorescence 
response (y). 
 Fluorescence emission plotted against concentration (ng mL-1) was linear over 
the measured concentration range of 1.0 ng mL-1 to 100 ng mL-1. This is shown 
graphically in Figure 46 below. 
 
Figure 46. Graph Demonstrating the Linear Relationship between the Concentration 
of Quinine Sulfate (ng mL-1) and Fluorescence Response 
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Regression analysis using the least-squares method gave the equation Y = 1.979x + 
0.0903, with a correlation coefficient (R2) of 1, indicating a good linear dynamic 
range (x denotes the independent variable i.e. the concentration of QS, and y denotes 
the dependent variable i.e. fluorescence response). This was supported by visual 
inspection of the plot. 
 
6.5.3.2  Limit of Quantification and Limit of Detection  
 The LoD and LoQ were determined by the analysis of samples of known 
concentration and the level measured by visual evaluation. The LoD (i.e. the smallest 
concentration that gave a measurable response162) was 0.1 ng mL QS. The LoQ was 
1.0 ng mL-1. It was the lowest concentration on the calibration plot, which could be 
quantitatively determined with reliable precision and accuracy i.e. CV = 4.3 %, and 
the range of accuracy was from 96.5% to 106%. 
6.6.  Experimental 
 A series of manipulations were carried out requiring dilution of QS, 
alternating with identical manipulations of WFI. 
6.6.1  Batch Preparation 
 The batch preparation of WFI and QS was carried out in an isolator, closely 
simulating the dilution of two different drug solutions under actual working 
conditions. All personnel protective measures were undertaken. Overshoes, barrier 
hats, gloves and gowns were worn to simulate actual practice with the exception that 
an absorbent mat was not placed on the isolator base so that surface contamination on 
the base could be observed. Batches were initially prepared using the closed-system 
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(PhaSeal®) device, then the isolator was cleaned and the process was repeated using 
the ‘open-system’. 
 Using a 20.0 mL syringe, 10.0 mL of solution was drawn up from a 100 mL 
vial, and added to a Macoflex bag containing 100 mL of NS. This was repeated four 
times, to give a batch size of five infusion bags. Batches of infusions were prepared 
sequentially, alternating between batches of WFI and batches of QS. Six batches of 
each solution were prepared to give thirty infusions per solution. Operator technique 
was monitored throughout and any spillages or equipment failure was documented. 
This process is illustrated schematically in Figure 47 on the following page. 
6.6.2  Monitoring of Surface Contamination 
 The manipulations were carried out under normal room lighting. After the 
preparation of each batch of QS, the lights were switched off and the surfaces of the 
isolator, hatch area and doors, gloves and sleeves in the isolator, and the infusion bags 
were scanned with UV light (365 nm). Areas of contamination were photographed 
using a digital camera. Prior to batch preparation using the open-system the isolator 
was cleaned and all surfaces were scanned to ensure an environment free from QS 
contamination. 
 The point was established during manufacture, when surface contamination of 
QS was first observed on the exterior surface of infusion bags, and in the isolator. 
From this point onwards, the frequency and level of QS surface contamination when 
using the open-system was compared when using the closed-system (PhaSeal®) 
device. 
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Figure 47. Flow Chart Showing the Process and Manipulations Carried out for the 
Preparation and Testing of QS and WFI Batches 
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6.6.3  Measurement of Product Cross-Contamination  
 All infusions from each batch of WFI prepared were retained and transported 
to the University of Bath to measure for the presence of any QS cross-contamination. 
A fluorescence spectrophotometer with a xenon power supply was used to measure 
fluorescence emission from the contents of the infusion bags. The excitation 
wavelength was set at 317 nm and the emission wavelength was set at 390 nm. To 
measure for QS, approximately 3.0 mL of solution was removed from each infusion 
bag and transferred into a cuvette for measurement of fluorescent intensity. The 
measurements were carried out in duplicate. 
   
 It was intended to establish the point during manufacture when the cross-
contamination of infusion bags occurred for comparison with the closed-system 
(PhaSeal®) method. 
6.7  Results 
 There were no spillages reported from the manipulations carried out using 
both methods for the production of all batches of WFI and QS. There were no 
problems with the closed-system (PhaSeal®) device except on one occasion during 
the preparation of a batch of QS when the injector was separated from the protector 
before the needle was fully retracted into the injector. This exposed the needle tip; 
immediately the needle was withdrawn back into the injector and secured with the 
safety latch. There were no droplets of contamination on the tip or released into the 
isolator that were visible to the naked eye. Batch preparation was temporarily halted 
and all areas were scanned with the UV lamp. There was no contamination observed 
on any of the surfaces concluding that this incidence had no effect on the study.       
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 The same manipulations were carried out 30 times with WFI and QS using the 
closed-system (PhaSeal®) device. The isolator was cleaned and a clean environment 
confirmed prior to repeated manipulations using the open-system. The distilled water, 
in which the vials filled with QS were immersed in, showed no fluorescence emission 
response, confirming that the outside of the vials were clean. QS contamination was 
visible on the latex material of gloves used in the isolator. All surfaces scanned prior 
to the start of the study were negative for the presence of QS contamination.  
6.7.1  Surface Contamination 
 After the preparation of each batch of QS, surface contamination was made 
visible by scanning the surfaces with a UV lamp. Absorbance of QS was scanned for 
at a wavelength of 365 nm.  
6.7.1.1  The Open-System 
 Surface contamination was clearly visible when using the open-system. The 
first occurrence of surface contamination was a small spot observed on the metal rim 
of a vial containing QS (see Figure 48 on the following page). This was observed 
after the production of QS batch 1, therefore it is not known at which point during the 
production of the batch 1 that it occurred. It was not a requirement of the study 
protocol to scan the vials. This contamination was observed inadvertently when 
scanning the batches after removal from the isolator. Its presence was considered 
important in this study and so it was photographed.  
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Figure 48. Image of a Vial with a Spot of Contamination on the Rim 
 
 
 The following incidences of surface contamination were observed only on the 
base of the isolator when using the open-system. No surface contamination was 
observed on the gloves, sleeves or hatches, or on the external surfaces of any of the 
infusion bags.  
 
The first occurrence was in the centre of the base to the right-hand side of the area 
where batch manipulations were carried out. Contamination in the form of 4 large 
spots (see Figure 49 on the following page) were photographed. These were produced 
from the manipulations carried out to prepare 10 infusion bags of QS (2 batches). 
 
The second occurrence of surface contamination on the isolator base was from the 
manipulations carried out to prepare 20 infusion bags (4 batches). Surface 
contamination was observed in two areas on the isolator base. Firstly, a ‘splash’ was 
photographed towards the left-hand corner of the base closest to the operator (see 
Figure 50 on the following page).  
 
spot of contamination 
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Figure 49. Image of Contamination after the Preparation of Two Batches of QS with 
the Open-System 
 
 
  
  
Figure 50. Image of a 'Splash' of Contamination after the Preparation of Four Batches 
of QS with the Open-System (left-hand corner of the isolator base closest to the 
operator) 
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Secondly, contamination was observed in the top left-hand side of the base furthest 
from the operator; a collection of small spots are observed and a trail of leakage from 
the syringe (see Figure 51 below).  
 
Figure 51. Image of Contamination after the Preparation of Four 
Batches of QS with the Open-System (top left-hand corner of the 
isolator base)  
 
  
 At the end of batch production i.e. after the production of 6 batches of QS (30 
infusions), another leakage contributed towards the contamination observed on the 
isolator base. The leakage was a trail of large spots of contamination (see Figure 52 
on the following page).   
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Figure 52. Image of Contamination after the Preparation of Thirty Batches of QS 
with the Open-System 
 
  
 No contamination was observed on any other surfaces in the isolator i.e. the 
walls and ceiling of the isolator chamber, sleeves, hatches or gloves, or on any of the 
infusion bags when prepared using the open-system.  
6.7.1.2  The Closed-System 
 No contamination was observed on any of the surfaces in the isolator i.e. the 
base, walls and ceiling of the isolator chamber, gloves, sleeves or hatches, or on the 
external surfaces of any of the infusion bags when prepared using the closed-system 
(PhaSeal®) device.  
Figure 53 on the following page shows an image of an infusion bag with no external 
surface contamination. This infusion bag was diluted with QS using the closed-
system (PhaSeal®) device. 
Figure 54 on the following page shows an image of the injector component of the 
closed-system (PhaSeal®) device after batch preparation of QS. It was photographed 
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to show droplets of QS inside the injector contained behind the membrane of the 
PhaSeal® injector component. 
 
Figure 53. Image of an Infusion Bag (0.01 mg mL-1 QS) with no External Surface 
Contamination 
 
 
Figure 54. Image of a Closed-System (PhaSeal®) Assembled Syringe with QS 
Retained Inside the Injector 
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6.7.2  Product Cross-Contamination 
 All infusions from all batches of WFI prepared using both the open and the 
closed-system (PhaSeal®) methods were measured for fluorescence response. The 
initial concentration of the QS solution for dilution was 1.0 mg mL-1 and the 
sensitivity of the analytical detection method was 0.1 ng mL-1 of QS. Therefore, to 
identify a positive presence of QS in the infusion bags at the LoD of 0.1 ng mL-1, 
1/100,000th of a millilitre of QS cross-contamination would need to be detected. None 
of the infusions tested positive for fluorescence above the LoD of the analytical 
method i.e. there was no cross-contamination of the fluorescent marker QS. 
6.8  Discussion 
 The manipulations carried out in this study as shown schematically in Figure 
47 (page 269) were the piercing of a vial with a syringe/needle, the withdrawal of 
solution and its transfer to an I.V infusion bag. Repetitive dilutions carried out, 
alternating between the preparation of batches of WFI and batches of QS, simulated 
the sequential handling of two different drug solutions in the same isolator. 
 The first objective of this study was to identify surface contamination 
occurring in an isolator after the dilution of batches containing a highly fluorescent 
indicator. After the manipulation of each batch, surfaces were scanned and 
photographed under UV lighting to visualise any leaks and spillages.  
 A small spot of contamination was observed on a vial used to prepare the first 
batch of QS (Figure 48, page 272). This is likely to have occurred when removing the 
syringe needle from the vial. Otherwise, contamination was only observed on the 
isolator base, which was contaminated frequently when using the open-system. The 
first point of leakage occurred during the preparation of the second batch of QS, as 
contamination was observed at the end of production of batch 2. The 4 large spots 
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observed in Figure 49 (page 273) are possibly due to drips from the syringe needle 
when moving it towards the I.V. bag. The contamination observed in the lower left 
corner in Figure 50 (page 273) appears to be leakage from the removal of a syringe 
from the vial; drops from the needle of the syringe or leakage from the port of an I.V. 
bag when removing the syringe. The trail of smaller droplets in Figure 51 (page 274) 
observed in the top left corner after the preparation of batch 4 appears to be small 
droplets/aerosol released from the syringe, possibly when placing it down onto the 
base. The largest leakage was observed at the end of batch production after 30 
manipulations had been carried out (Figure 52, page 275). This leakage was in the 
working zone of the operator and was visible to the naked eye. Nethertheless, when 
contamination is not visible it is difficult to avoid, thus it is easy to see how the 
inadvertent transfer of secondary contamination onto other surfaces may occur. 
 
 No surface contamination was observed on the gloves, sleeves, the surfaces of 
the isolator chamber or on any of the surfaces in the hatch. There were no pre-
contaminating sources to influence the results of this study. All vials used in this 
study were clean and confirmed to be free from QS contamination prior to transfer 
into the isolator, eliminating a main pre-contaminating source. This would have 
prevented any initial glove contamination through contact with the vial, and 
subsequent contamination of surfaces touched by the gloves prior to batch 
preparation. Conclusively, any surface contamination found was as a result of batch 
preparation in the isolator.  
 When using the closed-system (PhaSeal®) device to prepare infusions, no 
leakage was observed after the preparation of any of the six batches. Scanning the 
surfaces at 365 nm showed no contamination on the gloves, sleeves, isolator chamber 
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surfaces, surfaces of the hatches or on the surface of the infusion bags. The function 
of the closed-system (PhaSeal®) device to contain contamination was further 
confirmed when an injector was scanned after use (Figure 54, page 276). QS 
contamination was observed inside the end of the injector, demonstrating that 
contamination would have been released into the environment either during the 
piercing or the withdrawal of QS solution from the vial. This contamination was 
contained safely inside the injector, fulfilling its role as a closed-system and 
preventing the release of contamination into the outside environment. Furthermore, 
the components of the closed-system (PhaSeal®) device are disposable and it does not 
need to be disassembled from the vial or syringe. Therefore, the benefits of 
containment would also continue through the disposal process.    
 
 It would be expected that the isolator base would be one of the main areas 
contaminated in an isolator when carrying out dilutions. The first contamination event 
occurred early on i.e. during the preparation of the second batch and increased with 
batch preparation, contaminating different areas of the isolator base around the 
preparation area. The surface contamination made visible in this study supports 
findings that the traditional open-system has the potential to allow the release of 
contamination into the surroundings. It also supports the effectiveness of the closed-
system (PhaSeal®) device in preventing the release of contamination when the 
dilution of batches was carried out.32  
 
 The second objective of this study was to determine if the cross-contamination 
of batches does occur after the sequential dilution of different solutions in an isolator. 
A method using the native fluorescence emission of QS was sensitive to measure and 
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quantify cross-contamination as low as 1.0 ng mL-1 in the infusions of batches 
prepared with WFI. Cross-contamination may not have occurred, or it may have been 
present in lower concentrations but was not detectable. Mass-spectroscopy in 
conjunction with either gas-chromatography or liquid-chromatography is a more 
sensitive method of detection. However, a more sensitive method than the method 
using the native fluorescence of QS in this study (LoD = 0.1 ng mL-1) could not be 
found when searching the literature. The references retrieved were methods for the 
quantification of QS from biological samples. The methods were solid-phase 
extraction and gas-chromatography/mass-spectrometry,194 capillary liquid-
chromatography with native fluorescence,195 and chemiluminescence,196 reporting 
LoDs of 12.2 ng mL-1, 5.0 ng mL-1, and 1.5 ng mL-1, respectively. It is expected that 
the presence of contamination on surfaces would increase the possibility of batch 
cross-contamination occurring. However, contamination observed on the base of the 
isolator did not influence the cross-contamination of batches, suggesting that the 
cross-contamination of batches does not occur, certainly for this size of batch 
production, and does not pose a risk in isolators.  
6.9  Conclusion  
 This study visually confirms the release of contamination onto surfaces in the 
immediate environment when carrying out dilutions using the open-system, and the 
containment of contamination when using the closed-system (PhaSeal®) method. 
When using the open-system the base of the isolator was the surface contaminated the 
most highly and frequently. There was no surface contamination observed on any 
surface in the isolator when using the closed-system (PhaSeal®) device.  
 No cross-contamination of QS was detected in any of the infusions prepared 
using the open-system or when using the closed-system (PhaSeal®) method. 
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Consequently, it was not possible to compare the two methods or assess the 
effectiveness of the closed-system (PhaSeal®) device in reducing or preventing the 
cross-contamination of batches after preparation in the same isolator, although 
intuitively the risk of this occurring should be reduced with the closed-system 
(PhaSeal®) device. 
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7.  Concluding Discussion and Conclusion 
7.1  Concluding Discussion 
 Under the Health and Safety Act 1974 and the Management of Health and 
Safety at Work Regulations 1999 the employer has a duty to protect the health of its 
employees. The simulated compounding of cytotoxic drugs in an isolator under UK 
standards of practice (Chapter 5) demonstrated that immediate surfaces in the isolator 
and the finished product become contaminated from this process. This was supported 
where surface contamination was visually observed on the isolator base (Figures 48 - 
52, pages 272 - 275) when using the open-system for the preparation of syringe 
doses. Surface contamination has the potential for inhalation, glove penetration and 
subsequent dermal contact. It may also be potentially transferred to other 
environments, posing a risk to personnel working in the clean-room and nurses who 
would administer the infusion dose.  
 Pharmacy technicians and assistants are the main subjects of occupational 
exposure in centralised hospital pharmacies. The lack of concern from pharmacists 
managing ASUs (Section 2.4.3.1) suggests that they do not appear to be aware of 
their responsibilities. They may be more concerned if it was the role of the 
pharmacist to carry out cytotoxic manipulations. COSHH regulations specify that 
regular monitoring of the work environment must be undertaken when employees are 
exposed to substances hazardous to health. Many hospital pharmacies do not have 
the facilities to measure the low levels of contamination that are likely to be present. 
Further, measuring for cytotoxic surface contamination is limited and no airborne 
monitoring of cytotoxic contaminants is being carried out (Section 2.4.3.7). This is of 
great concern, as nearly half of the isolators in use re-circulate air that may be 
contaminated back into the clean-room. 
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 Not all drugs can be measured at sensitive levels, as a result, only a fraction of 
cytotoxic drugs have been monitored in the workplace. It is important to measure 
more than one marker drug as contamination may be influenced by various factors, 
particularly the nature of the product i.e. volatility, pharmaceutical form - liquid or 
powder, different preparation modalities and the quantities of drug handled.189   
 The levels of multi-drug surface contamination measured in this thesis 
(Section 5.5) were influenced by the chemical properties of the marker drugs used. CP 
does not possess a strongly absorbing chromophore, unlike EPI and MTX’, thus the 
same level of sensitivity could not be achieved for all three drugs in one single 
recovery method (Chapter 3). CP contributed more cumulative contamination to 
isolator surfaces during the Baseline period using the open-system. This is of great 
concern, as there are no safe established levels, and CP is one of the most potent 
cytotoxic drugs. The significance of including CP was as a marker drug for 
comparative measurement with other studies of the closed-system (PhaSeal®) device. 
 The closed-system (PhaSeal®) device was accepted and preferred by pharmacy 
technicians to the open-system (Tables 51 - 53, pages 238 - 240). The projection of 
data (Table 58, page 256), demonstrated how effective such intervention would be in 
reducing the potential long-term risk to surface contamination. There are other 
devices available commercially claiming a closed-system (Section 1.9) which should 
be investigated and compared. However, the NIOSH definition of a closed-system 
device gives no performance standard or test system for such a device, or acceptable 
levels of contamination when using the device.4  
 
 Testing marker drugs with different stability profiles from different chemical 
classes (Chapters 4 and 5), demonstrated the need to approach and treat cytotoxic 
 284
contamination of different drugs selectively. Decontamination procedures that are 
effective for one drug may not be so effective for another, and a more stringent 
application may be required for more stable drugs.  
 One participant of the questionnaire (Chapter 2) expressed that “the research 
objectives must be to compare different cleaning procedures and establish which are 
the most effective that can be recommended to users”. The products chosen for 
decontamination primarily have maintenance of the bio-burden level inside the 
isolator in mind, to protect product sterility (Section 2.4.3.5). It should be considered 
that surface contamination may consist of multi-drug chemical contamination, as 
many different cytotoxic drug batches are handled simultaneously inside an isolator, 
increasing the risk of surface cross-contamination (Section 5.5.1 and 5.5.3). The 
solvent basis of the formulation of the cleaning agent should be considered carefully, 
and a combination of agents may be required to cover complete removal.  
 The pH-detergents, cleaning agents, IMS and WFI were effective in 
removing cytotoxic contamination on a small scale (Table 27, page 166). However, 
the cleaning agents, WFI and IMS, when combined in a cleaning protocol (Section 
5.4.6 – Cleaning Procedure) were not always effective in removing cytotoxic 
contamination in an isolator (Tables 48 – 50, pages 234 - 236). In some incidences, 
an increase in contamination was observed after cleaning, on other occasions a 
reduction or no change in surface contamination was observed. The reason for the 
ineffectiveness of this procedure when put into practice may be that the cleaning 
action was not consistent in pressure or in coverage of the areas, or the contamination 
was redistributed by the wiping action onto other areas of the surface with which the 
wipe may have had contact. 
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 The only degradation effect observed by the pH-detergents and cleaning 
agents, was on DOX, by the alkaline detergents. Limited success was observed when 
applied to drugs representing the other classes i.e. the alkylating agents (CP) and the 
antimetabolites (5-FU). A longer reaction time may have lead to eventual 
degradation, but ideally, the detergents would need to act within a quick contact 
time. The pH-detergents applied in this study were formulated for specific target soil 
(biological control). It may be necessary; to vary the formulation to target the more 
chemically stable structures of 5-FU or CP.  
 Applying a safe controlled gassing/fumigation of the internal workspaces of 
an isolator enables the even decontamination of areas otherwise inaccessible 
manually.110 The advantages of gaseous hydrogen peroxide versus liquid hydrogen 
peroxide were observed experimentally (Section 4.5.4). It can be appreciated from 
the VHP® exposures carried out in this study that an increase in exposure time can 
make a significant difference. The duration time of the most effective VHP® cycle in 
the decontamination studies (Cycle 3) was 4 hrs and 11 mins. Fumigation/gassing 
methods are more time consuming and the cycle time would be too long to apply in-
between batch preparation or sessions during a working day. This cycle would be 
more suitable for application at the end of a working day, and left to run overnight to 
decontaminate an isolator from biological and chemical contamination. 
     
 The questionnaire demonstrated that hospital pharmacies in the are already 
preparing MABs in a separate isolator if available (Section 2.4.3.4), but this may not 
be an option for all pharmacies. The effectiveness of the closed-system (PhaSeal®) 
device in preventing cross-contamination could not be ascertained in this study, as the 
cross-contamination of infusions was not observed in the batches prepared (Section 
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6.7.2). Surface contamination recovered from the isolator (Section 5.5.1), the positive 
occurrence of external surface cross-contamination on batches of different drugs 
prepared previously in the same isolator (Section 5.5.3), and the ineffectiveness of the 
cleaning procedure (Section 5.5.6) would be expected to increase the probability of 
solution cross-contamination occurring. The effectiveness of the closed-system 
(PhaSeal®) device in reducing both surface and surface cross-contamination in the 
environment would reduce the potential risk of drug solution cross-contamination 
occurring.  
 The supply of pre-contaminated vials has been suggested to be a significant 
factor in influencing cytotoxic surface contamination results in previous studies, and 
was suggested to be as a result of the high levels of CP recovered in the clean-room 
in this present study (Table 47, page 232).26;126 Surface contamination was found on 
vials in 2 out of 7 cases when measured in ASUs (Table 4, page 74). The receipt of 
pre-contaminated vials was also a criticism, which was expressed by some 
participants of the questionnaire. The consensus was that it is the manufacturers’ 
responsibility to ensure the supply of cytotoxic contamination-free vials, and busy 
hospital pharmacies should not have the additional task of cleaning every vial, 
supplied to the pharmacy. Methods have been published addressing a simple vial 
cleaning procedure which could be adopted by manufacturers.45 It may be suggested 
that manufacturers are required to provide a written guarantee that the vials they 
supply have been cleaned according to a validated process and are contamination-
free. Hospital pharmacies should then only purchase from these manufacturers, 
encouraging other manufactures to follow suit. 
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7.1.1  Implications of the Project for Practice 
 This study has several implications for the practice of cytotoxic drug 
reconstitution and manipulation, which would gain an overall improvement in safety 
for those who manipulate these drugs. It should inform the managers of hospital 
pharmacies in the UK of the levels of contamination that can occur in an isolator and 
in the immediate environment as a result of the compounding of cytotoxic drugs. For 
staff pursuing a short or long-term career of working with cytotoxic drugs, this study 
shows the amount of surface contamination they would have the potential to be 
exposed to, unless changes in practice take place.  
 Current practice should reassess the agents that are being used for cleaning 
and take into consideration chemical decontamination in addition to biological 
decontamination. It should be considered that one agent will not be suitable for all 
cytotoxic drug contamination, and cleaning agents should be chosen based on the 
physical chemistry of the contaminating drug. Selection would be based on whether 
the drug contamination is water-soluble, the pH at which the contaminating drug 
would be ionised and therefore be solubilised and removed from the surface by the 
cleaning agent. This should encourage the adoption of standard, validated techniques 
to minimise occupational exposure to chemical contamination from cytotoxic drugs. 
 The results from the studies carried out in this thesis have presented 
additional methods which should be implemented in hospital pharmacies to further 
reduce the levels of cytotoxic surface contamination which personnel may potentially 
be exposed to. The implementation of these methods would also reduce 
contamination on the external surfaces of the finished product, benefiting personnel 
working in clinics or on hospital wards. Action taken by manufacturers to use 
validated cleaning procedures and supply cytotoxic contamination-free drug vials 
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may also significantly reduce the levels of pre-contamination in the pharmacy 
environment. 
 Use of a closed-system device such as the PhaSeal® device to prepare syringe 
batches and infusions in an isolator would significantly reduce levels of surface 
contamination. However, this would incur a cost (~$10 a dose),197 and financial 
constraints may be a limiting factor for its implementation into NHS hospital 
pharmacy practice. These costs and risks need to be considered by hospital Trust 
managers. 
7.1.2  Key Limitations of the Work 
 A large number of different drug infusions of varying cytotoxicity are 
prepared in hospital pharmacies; it was therefore practical to select a small number of 
representative marker drugs for the purpose of this work. They were chosen for the 
following reasons; they are compounded in relatively large amounts, represent 
different chemical classes of cytotoxic drug, and are relatively well established. 
Nethertheless, it must be considered that physical and chemical properties and 
metabolic pathways are different for each drug and the determination of a larger 
number of compounds would provide a wider representative for risk assessment. 
 The decontamination study was a pilot study and demonstrated visible 
cytotoxic contamination to be removed easily from a small surface. In practice, the 
surfaces of the interior of the isolator to be decontaminated would be a much larger 
area, manufactured of several materials and be of a more complex topology.  
 The compounding of batches of cytotoxic drugs was carried out in an isolator 
situated in a clean-room environment in an academic setting. The study simulated 
actual practice, which would be carried out in a hospital environment. One of the 
important aspects of this situation was that it enabled the batches of cytotoxic drugs 
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prepared, which would otherwise be administered to the patient, to be retained for 
sampling. 
 Prior to the start of the study, the isolator and the clean-room environment 
were clean i.e. free from cytotoxic contamination. Although ideal for research 
purposes, this would not be true of an isolator used in a busy hospital environment 
for the multi-drug batch preparation of cytotoxic drugs and other cancer treatments. 
It is therefore likely that the results of this simulated study may be an under-
estimation of the amount of surface contamination that would actually be present on 
the equivalent surfaces in a hospital pharmacy environment. The situation did 
however enable the compounding of the three marker drugs to be restricted to one 
isolator, eliminating the risk of interference of the drug assays from other co-
prepared drugs. 
7.1.3  Future Work 
 Further investigations into VHP® exposure cycle parameters would be 
essential to develop decontamination cycles to achieve the chemical breakdown of 
cytotoxic drugs other than the marker drugs investigated in this thesis. VHP® injected 
under vacuum would achieve direct contact and greater penetration of VHP® into the 
target. The vacuum is created prior to injection and the number of pulses per cycle 
can be controlled, thus increasing and controlling the amount of VHP® in an 
exposure. Under vacuum, the impediment of air is removed and the enclosed area 
fills with VHP® only. This method has already been demonstrated to be effective 
against resistant spores, which were resistant to oxidation by VHP® under normal 
atmospheric conditions.186 This is a more rapid process than the VHP® exposure 
cycles carried out in this thesis. The samples can be removed from the exposure 
vessel at certain time intervals, without the aeration time-consuming phase of the 
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cycle. Exposure and removal of several samples at certain time intervals would allow 
the rate constant of the reaction to be calculated and the optimal conditions of 
temperature and VHP® exposure time for the degradation of the drug to be 
determined. The cycle conditions could be optimised to cover a wide spectrum of 
drugs. 5-FU, a drug that is unsusceptible to degradation by VHP® may be applied as 
the worse case marker for the optimisation process. This could be determined for 
DOX and EPI and extended to daunorubicin, and other cytotoxic drugs likely to 
undergo oxidation i.e. mitoxantrone, bleomycin etoposide, mitomycin C, teniposide, 
MTX, cisplatin.24 It could also be determined for CP and extended to other members 
of the same chemical family i.e. IFOS, although parameters that are more stringent 
may be required. In addition, it may be extended to biological treatments for cancer 
which are also prepared in hospital pharmacies and carry the risk of biological cross-
contamination e.g. BGC, a microorganism and immunotherapeutic agent, prepared 
by many pharmacies for the treatment of superficial bladder cancer.191 The 
contribution to toxicity of any degradation products would need to be investigated 
thoroughly and identified. Methods that are more sensitive would also be required if 
further degradation effects of VHP® were to be further investigated. Sensitivity may 
be achieved by using liquid-chromatography mass-spectroscopy, or HPLC coupled 
with fluorescence detection for DOX and EPI.  
 The preliminary decontamination studies with the pH-detergents and cleaning 
agents also leaves open the possibility for future work. The cleaning system used 
should be explored to find cleaning agents more suitable to the chemistry of EPI, 
MTX and CP. The alkaline detergents, which were effective in the degradation of 
DOX, may also be effective for EPI. These should be investigated on a larger surface 
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area and on surfaces of different material i.e. stainless steel. This may include 
increasing and ultimately optimising, the ratio of detergent to surface area.  
 The cleaning agents that were effective in removing cytotoxic surface 
contamination on a small scale should also be extended to larger surfaces. The role of 
other cleaning agents that are used commonly in ASUs and available formulations 
containing sodium hypochlorite (5.25%) should also be investigated for the removal 
and degradation of cytotoxic contamination. 
 There are other devices available commercially claiming to be closed-
systems, which are designed for cytotoxic containment. These claims should be 
assessed in similar studies as investigated in Chapter 5 of this thesis. Testing should 
be carried out in a clinical setting or simulating actual practice to provide a valid 
comparison between devices, and ascertain whether the system used under practice 
conditions is closed or not. Scientific proof that the device is closed must be 
published in peer-reviewed journals before the integrity and validity of the device 
can be ensured. Other similar devices would make the market more competitive and 
possibly reduce the financial burden.  
7.1.4  Horizons 
 As the number of cancer cases increase, the amount of chemotherapy doses 
prepared and administered will also increase, resulting in an even greater potential 
for occupational exposure of health-care professionals. Novel drugs and therapeutic 
approaches are still being discovered and introduced into clinical practice. Some are 
analogues of agents that have already proven to be effective chemically and 
pharmacologically, some are natural products isolated from plants or microorganisms 
and others are designed based on biological approaches e.g. potential inhibitors of 
enzymes or essential cellular components. The conventional cytotoxic drugs are not 
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specific to cancer cells. As cellular pathways become more understood, future 
cytotoxic drugs will be developed based on more rational and mechanism-based 
approaches. There have already been moves towards therapies that target cancer cells 
specifically. Currently, the major classes of targeted therapies, which reflect these 
new directions and mechanisms of action are the MABs, tyrosine kinases and cell-
cycle specific agents.198;199 Many of the tyrosine kinases that have emerged are for 
oral administation.198  
The upward trend in the number of oral chemotherapy agents, which are 
suitable for home administration, is likely to continue.200 Although this route of 
administration has advantages and disadvantages, patient preference is likely to be 
towards the oral route for convenience, the preference of administration in the home 
setting, or due to the fear of needles.198 The use of oral chemotherapy could potentially 
reduce the use of healthcare resources and ancillary support personnel such as nurses 
and technicians.198 This would engage patient involvement outside the healthcare 
environment and non-adherence by the patient may be an issue. Reliance from the 
healthcare practitioner on educating the patient in managing their oral chemotherapy 
would be required. It has been suggested that guidelines specific to safe handling of 
oral chemotherapy in the non-conventional setting i.e. the home environment are 
developed.201  
 There is little information available as to how hospital pharmacies should 
manipulate viral and genetic material. It has been acknowledged that information is 
lacking as to which decontamination procedures should be used for viral products,202 
and suggested that there need to be separate facilities for the manipulation of these 
products.203 This could also be a key role for closed fluid-transfer systems. 
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The risks of drug toxicities may be justifiable to patients undergoing treatment 
for a life-threatening disease but such risks, even at a reduced level are not acceptable 
to healthcare professionals involved in drug preparation or administration. It should be 
recognised that technicians may be facing a long career of exposure to cytotoxic drugs 
and novel drugs developed in the future of unknown toxicity. Future breakthroughs 
will almost certainly occur and influence practice in this area. Instead of preparing 
each dose on a bespoke basis after receipt of the prescription, dose-banded syringes 
pre-filled by industry may be supplied. The prescribing of standard doses prepared 
based on calculations from the body surface area of patients would require no further 
manipulation in the pharmacy.203 Novel formulations are already entering into clinical 
trials and some are available commercially. These changes will make prediction of 
future occupational risks very difficult to define. 
7.2  Conclusion  
 Isolators are used in hospital pharmacies for the compounding of cytotoxic 
drugs. In the facilities which responded to the survey, 17 out of 42 (40.5%) isolators 
are ducted internally. They are decontaminated according to a protocol, which 
considers cleaning and disinfection. ASU managers of these facilities were not 
profoundly concerned regarding cytotoxic contamination. The purpose of the 
decontamination products used was to address the removal of biological and not 
chemical cytotoxic contamination. The products used for decontamination of the 
isolator were limited to proprietary products, mostly supplied by the same 
manufacturer. These decontamination procedures were developed from information 
provided by national guidelines and books, quality control and assurance, other 
ASUs and manufacturers’ advice. The effectiveness of these procedures for the 
removal of cytotoxic contamination were not often validated or tested due to the lack 
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of on-site equipment and expertise to analyse cytotoxic contamination. The current 
protocol used most widely for decontamination of the isolator would be to clean 
using IMS spray with dry wipes. A detergent/liquid biocide i.e. neutral detergent or 
QACs/biguanide or QACs/stabilised chlorine dioxide may also be used. For 
disinfection, again alcohol and/or detergents/liquid biocides i.e. QACs, 
QACs/stabilised chlorine dioxide, QACs/biguanide would be used.    
Decontamination methods can be used to reduce, if not eliminate, the risk 
posed by cytotoxic drugs to the operator and environment. The extent of risk 
reduction or elimination will vary depending on the structure of the drug, but may be 
extended to drugs of the same family. Alkaline-based detergents CIP 100, CIP 150 
and Criti-Klenz have resulted in the breakdown of DOX, and oxidation by VHP® has 
resulted in the breakdown of DOX and EPI. CP was susceptible to degradation by 
VHP® under the more stringent oxidative conditions, but 5-FU was less susceptible. 
VHP® decontamination may be considered for drugs, which are prone to oxidation 
such as the anthracyclines, and also for CP, for routine biological and cytotoxic 
contamination within isolators.  
 
 The compounding of cytotoxic drugs contaminates surfaces within the 
isolator when using the open-system. The first contaminating event occurs rapidly. 
Once present, surface contamination in the isolator was resistant to removal by 
cleaning agents (Klercide CR-B and Klerclean neutral detergent) used currently in 
ASUs. Isolators have the capability of protecting immediate areas from multi- 
cytotoxic drug surface contamination when used in conjunction with a closed-system 
(PhaSeal®) device. The closed-system (PhaSeal®) device evaluated in this study 
exerted control on contamination in the surrounding environment i.e. in an isolator. 
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This was true for two drugs (EPI and MTX), novel to usage with the closed-system  
(PhaSeal®) device, and was supported by the results for CP which are in accordance 
with previous studies found by other investigators.20;62;67;124;154 Operators of the 
closed-system device preferred it to the traditional open-system method. 
 
 If no further changes occur or no further methods are introduced to protect 
the worker, implementing a closed-system (PhaSeal®) device over 1 year or 40 years 
would significantly reduce the potential risk of occupational exposure to pharmacy 
personnel from surface contamination. This risk reduction would not only include 
personnel who work in the isolator and clean-room, but those who work in clinics or 
on wards.  
 The risk of drug cross-contamination of the injection solution from batches 
prepared previously during the same session was not evident. For this reason, the 
effectiveness of the closed-system (PhaSeal®) device in reducing solution cross-
contamination could not be determined. 
 High levels of surface contamination were recovered from surfaces in the 
clean-room. The high levels of CP were influenced possibly by the supply of pre-
contaminated vials. Pharmaceutical manufacturers should be encouraged to improve 
their decontamination procedures and to guarantee the supply of vials free of 
cytotoxic contamination. 
Universally, pharmacy managers of hospital pharmacies should recognize 
their responsibilities and use decontamination procedures that have been validated 
and proven to remove not only biological contamination but also cytotoxic 
contamination. These procedures should be validated and defined intervals of 
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environmental monitoring implemented. Only then, can levels of environmental 
contamination be established and a safe level of exposure be determined.  
 
The risk posed by cytotoxic drugs to the operator and the environment may 
be reduced, if not eliminated by considering additional approaches. Firstly, the 
application of effective decontamination methods; and secondly, by using a closed-
system drug transfer device such as the PhaSeal® device in a controlled environment, 
such as in an isolator.  
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7.3  Papers and Abstracts 
The listed below can be found on pages 298 to 311: 
 
• Journal of Oncology Pharmacy Practice Publication (2006) 12; 95 - 104. Studies 
on the decontamination of surfaces exposed to cytotoxic drugs in chemotherapy 
workstations. 
 
• Hospital Pharmacy Europe Publication (2007) 33; 17 - 19 Safe handling of 
cytotoxics. 
 
• ISOPP Abstract - Studies on the Decontamination of Cytotoxic Drugs on 
Surfaces in Chemotherapy Workstations. Journal of Oncology Pharmacy Practice 
(2006) 12; 1; 34. 
 
7.4  Conference Presentations 
The listed below can be found on page 312: 
 
 
• ISOPP Poster - Studies on the Decontamination of Cytotoxic Drugs on Surfaces 
in Chemotherapy Workstations. 
 
7.5  Award 
The listed below can be found on page 313: 
 
 
• ISOPP Travel Award. 
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ISOPP Abstract 
 
Studies on the Decontamination of Cytotoxic Drugs on Surfaces in Chemotherapy 
Workstations. 
S. Roberts, N.Khammo, G.McDonnell, M.Bernado, G.J.Sewell. 
 
Objectives: Evaluate the effect of decontamination methods currently used in the 
pharmaceutical industry to degrade 3 cytotoxic drugs. 
 
Methods: Study was completed in three phases: Phase I investigated the ability of 
three alkaline detergents to remove physically cytotoxic drugs from a surface (this 
could be incorporated into a cleaning protocol); Phase II investigated the ability of 
eight water-soluble detergents (acidic, alkaline and neutral), and liquid hydrogen 
peroxide to degrade cytotoxic drugs; and Phase III investigated the ability of 35% 
Vaporized Hydrogen Peroxide (VHP®) to degrade cytotoxic contamination on an inert 
surface by oxidation. VHP® technology is based on a dry process and drug exposure 
was carried out at a rate of 1.6g/min for 25 min. The amount of drug after each phase 
was quantified by high recovery HPLC methods. 5-Flurouracil, doxorubicin and 
cyclophosphamide were removed by wiping the surface with alkaline detergents. 
 
Results: Degradation of doxorubicin was observed after 1 hour of exposure to 
alkaline detergents, with 81% observed at pH 13.2. Doxorubicin changed colour from 
red to purple under alkaline conditions, which is indicative of degradation. 
Doxorubicin was chemically stable in neutral and acid detergents. VHP® and alkaline 
detergents caused degradation of doxorubicin. The effect was diluent and pH 
dependent; 43.4% degradation occurred in water for injections (pH 5.9), 56.0% in 
0.9% sodium chloride (pH 6.5), and 91.9% in buffer (0.01 M, pH 2.25). 
 
Conclusion: 5-Flurouracil and cyclophosphamide were not susceptible to chemical 
degradation by both technologies, at the concentrations and contact times tested. 
Alternative methods need to be explored. 
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Studies on the Decontamination of Cytotoxic Drugs on Surfaces in Chemotherapy Workstations 
      
During the  preparation of cytotoxic infusions, a varie ty of drug manipulations are 
performed resulting in the production of aerosols and drople ts, which are  known to 
contaminate  the  areas which they disperse  into including isolators and surrounding 
surfaces (1-6). This increases the  risk of occupational exposure  to these  drugs.  The  health 
e ffects resulting from the ir exposures are well documented (7-10). 
Chemical and biological decontamination are both important in the safe  dispensing of 
cytotoxic drugs. However, the e ffectiveness of removing cytotoxic residues from surfaces 
during cleaning is not often considered. Ideally, removing contamination should involve 
the physical removal of drug from a surface and breakdown into less cytotoxic compounds.  
91.9 2.25 Buffer 
43.3 5.9 Water for Injections 
56.0 6.5 0.9% Sodium Chloride 
Percentage Degradation pH of Diluent Diluent 
   Sarah Roberts1, Nancy Khammo2,  Gerald McDonnell2,  Mildred Bernado3 and Graham Sewell4  
1Department of Pharmacy and Pharmacology, University of Bath, Bath. UK. 2Steris Ltd, Basingstoke .UK. 3Steris Corp, USA. 4Department of Pharmacy, Kingston University. London. UK.                    
The  aims of this study were  to investigate  the  safe  decontamination of cytotoxic drugs by 
removal and breakdown into safe  by-products. This was investigated by two 
decontamination technologies currently used in various hospital and pharmaceutical 
applications.  
The  study was carried out in three  phases on three  marker cytotoxic drugs; 5-fluorouracil 
(5-FU; an antimetabolite ), cyclophosphamide (CP; an alkylating agent) and doxorubicin 
(DOX; an anthracycline ). 
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6.   
Phase II  
5-FU and CP demonstrated resistance  to degradation across the  pH range  following 1 hour of exposure 
to all de tergents. 
DOX was resistant to degradation at acidic and neutral pH following 1 hour of exposure. Significant 
degradation of DOX occurred when it was exposed to alkaline detergents (Criti-klenz, CIP 150 and CIP 
100). This resulted in 81% degradation at pH 13.2, with 50% occurring after 5.5 minutes (Figure  2). 
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Conclusions and Discussion 
Strong acid, alkaline, or neutral de tergents removed all three  drugs from a contaminated 
surface. DOX was more resistant to removal by alkaline detergents, but less resistant to 
breakdown.  
The  stability of 5-FU and CP to oxidative  stress was demonstrated, since  no degradation 
occurred following exposure  to VHP. In addition, no degradation occurred under the 
extreme pH conditions (1.7 - 13.2) applied.  
 DOX was, however, found to be  less stable, with 81% degradation occurring after 1 hour 
of exposure  to the alkaline detergent, CIP 100. Oxidation, aided by acid hydrolysis also 
caused significant degradation of DOX, as observed when exposed to VHP; interestingly, 
unlike  the VHP results, degradation was not observed with liquid/condensed hydrogen 
peroxide  at 30%v/v (results not shown).  
 This study has demonstrated the  breakdown of DOX (an anthracycline  antibiotic) by two 
different mechanisms (oxidation and alkaline  hydrolysis), however limited success was 
observed on drugs representing other classes i.e. 5-FU and CP. The  results of this study 
demonstrate that current decontamination methods can be  used to reduce, if not eliminate 
the  risk posed by cytotoxic drugs to the  operator and environment. The  liquid detergents 
used in this study were formulated for specific target soil. Future  studies may include 
varying the  formulation of the detergent to target the  more stable  structures of 5-FU or 
CP. Alternative ly, removal by the  use  of a  wipe  incorporating an agent which binds the 
target drug could be  a compromise. DOX was susceptible  to VHP; further studies with 
VHP may include longer exposure times with DOX and other cytotoxic drugs.   
In both phases I and II a  colour change  of DOX from red to purple  was observed. The  depth of 
purple increased with increasing alkalinity. This is indicative  of alkaline  degradation of  DOX. 
 
Phase III 
VHP had no e ffect on 5-FU or CP, but caused degradation of DOX. The  amount of 
degradation was dependent on the  diluent used (Table 1). 
 
 
Figure 1. Front view of a mobile VHP® 
100P Biodecontamination unit. 
 
 Methods 
    
 Eight liquid detergents (pH 1.7 – 13.2), diluted as 
per manufacturers instructions were 
investigated as cleaning agents (phase I and II); 
 Phase I 
 Detergent was pipetted onto a contaminated 
surface. The surface  was wiped and the ease  of 
removal evaluated. 
 Phase II  
 Equal volumes of drug + detergent were  mixed, 
incubated together, and the  reaction terminated 
at time intervals up to and including 1 hour. 
 
 
Determination of Vaporised Hydrogen Peroxide  (VHP®) to oxidise cytotoxic 
contamination was investigated (phase III); 
Phase III 
Drugs were exposed to VHP in a flexible  walled isolator. VHP was generated from a VHP® 
100P biodecontamination system (Figure  1) that, when connected to a given area, controls 
the  whole   dry fumigation process. The  VHP is a  dry gas that is generated in the  system 
from a liquid peroxide  solution (Vaprox®). The  full VHP cycles consists of 4 phases: 
dehumidification, conditioning, decontamination and aeration (11). Exposure  to VHP in 
test cycles was for 25 minutes. 
Recovery coupled with HPLC methods were deve loped and validated to quantify the 
amount of drug remaining on the  surface  (phase  I and III ), and degradation of the  parent 
drug (phase II). 
 
 
T able 1. Percentage Degradation  of  DOX by VHP. 
 
  Significant degradation (91.9%) was obtained when DOX was exposed diluted in a strongly acidic buffer             
  (Figure  3). 
 
Results 
 
Phase I 
5-FU and CP were  easily removed from the test surface when wiped using a dry wipe  and 
acid, neutral or alkaline detergents. 
DOX was easily removed with acid and neutral de tergent but was more resistant to removal 
by alkaline detergents.  
 
 
7. Se levan, S. G.; Lindbohm, M.-L.; Hornung, R. W.; Hemminki, K. New England J.  
Med . 1985, 313, 1173-1177.  
8. Shortridge , L. A.; Lemasters, G. K.; Valanis, B. Cancer Nurs. 1995, 18, 439-444. 
9 Skov, T.; Maarup, B.; Olsen, J.; Rorth, M.; Winthere ik, H.; Lynge E. Br. J. Int. Med. 
1992, 49, 855-861.  
10.  Valanis, B.; Vollmer, W. M.; Steele . P. J. Occup. Environ. Med. 1999, 41, 362-368. 
11.  Meszaros, J. E.; Antloga, K.; Justi, C.; Plesniche, C.; McDonnell, G. Appl.  Biosafety 
2005, 10, 91-100.  
 
 
References 
I would like to acknowledge Steris Ltd for an unrestricted research grant, and the   
University of Bath for its financial support. 
Figure 2. Degradation of DOX by Alkaline Detergents.  
Figure 3. Chromatogram of DOX diluted in buffer, pre (upper) and post (lower) exposure 
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Appendix 2 – Questionnaire to Investigate Decontamination 
Procedures Carried out after the Manipulation of Cytotoxic Drugs 
 
 
 
The purpose of this questionnaire is to learn about the current decontamination 
(cleaning and disinfection) procedures which take place in hospitals in the U.K. 
where cytotoxic drugs are compounded. 
 
 This questionnaire should take approximately 10-15 mins to complete. 
 
Please click and type in the boxes below 
 
Hospital  
      
 
 
Question 1. 
In your hospital what type of workstation do you use for the compounding 
 of cytotoxic drugs? 
Please click in the box either yes or no 
         Yes No 
 
a. in an internally-ducted positive-pressure isolator    
 
b. in an externally-ducted positive-pressure isolator    
 
c. in an internally-ducted negative-pressure isolator    
  
d. in an externally-ducted negative-pressure isolator    
 
e. in an internally-ducted biological safety cabinet    
 
f. in an externally-ducted biological safety cabinet    
        
 
g. other, please specify by clicking in the top left corner and typing in the box  
  below  
  
 
 
 
 
 
 
 
 
The following questions 2-8 concern the main area answered in question 1 
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Question 2. 
How would you describe your concerns about cytotoxic contamination in this  
area? Please click in the appropriate box 
 
a. extremely concerned        
 
b. slightly concerned         
 
c. indifferent          
     
d. not concerned at all         
 
 
Question 3. 
Do you apply a ‘cleaning’ and a ‘disinfection’ procedure to this area? 
Please click in the appropriate box 
 
a. a cleaning procedure only    go to question 4 
   
b. a disinfection procedure only   go straight to question 5 
     
c. a cleaning and a disinfection procedure  go to question 4 
 
Question 4. 
Which of the following do you use for the cleaning of this area? 
Please specify frequency of use either daily, weekly or monthly 
(click and select from the drop down menu in the appropriate box) 
         daily     weekly     monthly 
a. water                            
water for injections         0       0                0 
 
water for irrigation         0       0             0 
  
distilled water          0       0             0 
  
deionised water         0       0             0 
  
other water quality         0       0             0 
 
b. 70/30 alcohol                           
 IMS spray          0       0             0 
       
IPA spray          0       0             0 
  
IMS impregnated wipes        0       0             0 
  
IPA impregnated wipes        0       0             0 
 
other alcohol          0       0             0 
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c. detergents, please list product and manufacturer 
please list product and manufacturer by clicking and typing in the box below 
                      
       daily     weekly     monthly 
      0                 0                 0 
 
      0                 0                 0 
  
      0                 0                 0 
  
      0                 0                 0 
  
      0                0                  0 
 
 
           
Question 5. 
Which of the following do you use for the disinfection of this area? 
Please specify application and frequency of use either daily, weekly or monthly? 
(click and select from the drop down menu in the appropriate box) 
 
Part 1. Liquid Biocides         application   daily   weekly   monthly   yearly 
 
a. 70/30 alcohol    none         0           0    0     0 
 
b. stabilised chlorine dioxide   none         0          0              0     0 
  
c. quaternary ammonium   none         0          0              0     0 
           
d. quaternary ammonium/stabilised  none         0          0              0      0 
    chlorine dioxide 
            
e. sodium hypochlorite   none             0          0             0     0 
              
f. hydrogen peroxide    none         0          0             0     0  
 
g. stabilised glutaraldehyde   none         0          0             0     0 
   
h. chlorhexidine    none         0          0             0     0 
 
i. other      none         0          0             0     0  
 
please specify by clicking in the top left corner and typing in the box below 
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Part 2. Gassing/Fumigation   daily weekly   monthly   yearly 
         
a. formaldehyde     0      0         0            0 
 
b. hydrogen peroxide     0      0         0            0 
if applicable please give details of the system by clicking and typing in the box below 
 
 
c. peracetic acid vapour    0      0          0            0 
 
d. ozone gas      0      0          0            0 
 
e. other     0      0          0            0 
please specify by clicking in the top left corner and typing in the box below 
 
 
 
 
 
 
Question 6. 
Does the decontamination procedure for this area differ depending upon which 
drugs have been manipulated? 
Please click either yes or no   
 
Yes    No  
 
If yes please give details by clicking in the top left corner and typing in the box below 
Question 7. 
In your opinion which one of the following best describes the purpose of the 
decontamination procedure which you have described? 
Please click in one of the boxes below 
             
 
a. to remove cytotoxic contamination               
  
b. to disinfect/sterilise the area                
 
c. to maintain a sterile environment and remove some cytotoxic contamination    
  
d. to maintain a sterile environment and remove all cytotoxic contamination        
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Question 8. 
How was the decontamination procedure you use devised? 
Please click either yes or no 
If yes please give details by clicking in the top left corner and typing in the box below 
 
 
a. from national guidelines  Yes   No    
  
 
 
 
 
 
b. from international guidelines    Yes       No    
  
 
 
 
 
 
 
c. literature/references        Yes       No    
 
 
 
 
 
 
 
 
d. other facilities      Yes       No    
  
 
 
 
 
 
 
e. manufacturers advice     Yes       No  
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f. other, please specify     Yes       No    
  
 
 
 
 
 
 
 
 
Question 9. 
Have you ever measured for cytotoxic contamination in the following areas, and 
if so was any contamination found? 
Please click either yes or no 
     Yes   No    Yes   No 
           
a. vials           contamination found?         
 
b. the dispensed product        contamination found?         
 
c. surface inside the BSC/isolator  
    i. before decontamination         contamination found?         
    ii. after decontamination         contamination found?               
 
 
d. surface outside the BSC/isolator   
    i. before decontamination         contamination found?         
    ii. after decontamination         contamination found?         
 
e. airborne            contamination found?         
 
f. gloves used in the BSC/isolator         contamination found?         
 
g. gloves used outside the BSC 
    /isolator            contamination found?         
 
h. other areas            contamination found?         
 
if yes, please give details by clicking in the top left hand corner and typing in  
the box below 
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Question 10. 
Please comment on any concerns you have about manipulating cytotoxic  
drugs and any problems which you have experienced. 
Please click in the top left corner and type in the box below 
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Appendix 3 – Letter of Invitation 
 
 
 
     Letter of Invitation 
 
 
Dear Sir/Madam, 
 
 I am a research student at the University of Bath and as part of my PhD I am 
researching the current practice of decontamination procedures carried out in hospital 
pharmacies where cytotoxic drugs are compounded. 
  
 Please find enclosed a research questionnaire titled “Questionnaire to Investigate 
Decontamination Procedures Carried out after the Manipulation of Cytotoxic Drugs”. I 
have sent this questionnaire to you because information from your hospital pharmacy would 
make a valuable contribution to this research.  
(If this is not applicable to you please would you pass it on to the appropriate person). 
  
 The questionnaire is not compulsory and I appreciate that you are busy, but it would be 
very much appreciated if you would take the time to complete it.  If you would like to take 
part in this research click on the questionnaire to open it and 
 
EITHER 
1. save it to the desktop, fill it out by following the instructions and email back it to me at 
s.roberts@bath.ac.uk   OR 
2. print off a copy, fill it out by hand  and return to me at the freepost address below 
  
Sarah Roberts 
Department of Pharmacy and Pharmacology 
FREEPOST (SN1548) 
Bath. BA2 7LZ  
  
The information will remain anonymous and will be used for research purposes only. 
 
Any questions or queries please do not hesitate to contact me 
s.roberts@bath.ac.uk 
Tel: 01225 384423 
  
Many thanks 
  
Sarah 
  
Research Student 
Pharmacy 
University of Bath 
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Appendix 4 – Chromatograms 
 
 
Figure 55. Example of a Chromatogram of Cyclophosphamide Recovered from a 
Wipe 
 
 
Figure 56. Example of a Chromatogram of EPI Recovered from an Isolator Glove 
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Figure 57. Example of a Chromatogram of MTX Recovered from a Wipe 
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Figure 58. Example of a Chromatogram of DOX (buffer) Standard (no exposure to 
VHP®) 
 
Figure 59. Example of a Chromatogram of DOX (buffer) Post Exposure to VHP® 
Cycle 1 
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Appendix 5 – List of Standard Operating Procedures 
 
 
Pharmacy Technical Services Department 
Plymouth Hospitals NHS Trust, Derriford 
 
 
 
SOP CG6 (Version 2) Changing Procedure- To Enter Isolator Rooms 
 
 
SOP ASG2 (Version 3) Aseptic Suite Transfer Hatch Procedure 
 
 
SOP ASG8 (Version 1) Reconstitution Procedure 
 
 
SOP ASG17 (Version 3) Assembly and Manufacture of Syringes Produced Under 
         the Specials Manufacturing License 
 
 
SOP ASG30 (Version 2) Tray Cleaning Procedure 
 
 
SOP CH1 (Version 3) Procedure for the Preparation of Cytotoxic Injectables Under 
      Section 10 Exemption of Medicines Act 
 
 
SOP CH7 (Version 3) Cytotoxic Envair Isolator Procedure for Use 
 
 
SOP CH8 (Version 3) Envair Cytotoxic Isolator Glove and Sleeve Changing  
   Procedure 
 
 
SOP CH9 (Version 2) Procedure for Dealing with Cytotoxic Spillages 
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Appendix 6 – Questionnaire (closed-system device) 
 
Questionnaire to Determine Operators’ Opinion on the Use of the 
Closed-System (PhaSeal®) Device 
 
Name of Operator …………………………………………..Date:……………. 
 
Part 1. To be completed by the operator: 
Q1.a. How long have you been working with cytotoxic drugs? Describe experience 
 
…………………………………………………………………………………………. 
 
…………………………………………………………………………………………. 
 
…………………………………………………………………………………………. 
 
Q1.b. How worried are you about working with cytotoxic drugs? Please circle 
 
 Very worried  
 
 Worried 
 
 Slight bothered 
 
 Not bothered at all 
 
 Quite happy 
 
 
Q1.c. How safe do you feel with the current methods you have been using when 
working with cytotoxic drugs? Please circle 
 
 Very safe 
 
 Safe 
 
 Neither safe nor unsafe 
 
 Unsafe 
 
 Very unsafe 
 
Comments……………………………………………………………………………... 
 
…………………………………………………………………………………………. 
 
…………………………………………………………………………………………. 
 
…………………………………………………………………………………………. 
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Part 2.  To be completed by the operator at the start of intervention period (1): 
Q2.a. I found the training for the closed-system device adequate. Please circle 
 
 Strongly agree 
 
 Agree 
 
 Neither agree or disagree 
 
 Disagree 
 
 Strongly disagree 
 
Q2.b. I feel confident using the closed-system device after the training given. Please 
circle 
 Strongly agree 
  
 Agree 
 
 Neither agree or disagree 
 
 Disagree 
 
 Strongly disagree 
 
Q2.c. Do you have any reservations about using the closed-system device? If so 
please describe 
 
 …………………………………………………………………………………………. 
 
 …………………………………………………………………………………………. 
 
 …………………………………………………………………………………………. 
  
Q2.d. How confident are you that the closed-system device is protecting you? Please 
circle 
 
 Very confident 
 
 Confident 
 
 Neither confident nor unconfident 
 
 No confidence 
 
 Not confident at all 
 
 
Signature of operator:………………………………………. Date:…………...
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Part 3. To be completed by the operator at the end of intervention period (1): 
Q3.a.  How confident are you in using the closed-system device now?  Please circle 
  
 Very confident 
 
 Confident 
 
 Neither confident nor unconfident 
 
 No confidence 
 
 Not confident at all 
 
 
Q3.b. I was more careful when using the closed-system device than when using the 
open-system. Please circle 
 
 Strongly agree 
 
 Agree 
 
 Neither agree nor disagree 
 
 Disagree 
 
 Strongly disagree 
 
 
Q3.c. Did you have any problems when using the closed-system device? If so please 
describe 
 
…………………………………………………………………………………………. 
 
…………………………………………………………………………………………. 
 
…………………………………………………………………………………………. 
 
…………………………………………………………………………………………. 
 
 
Q3.d. Did using the closed-system device hinder work in any way? Please describe 
 
…………………………………………………………………………………………. 
 
…………………………………………………………………………………………. 
 
…………………………………………………………………………………………. 
 
…………………………………………………………………………………………. 
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Q3.f. After using the closed-system device which method would you prefer to 
continue working with? Please circle 
 
 Open-system 
 
 Closed-system 
 
and explain why 
 
…………………………………………………………………………………………. 
 
…………………………………………………………………………………………. 
 
…………………………………………………………………………………………. 
 
…………………………………………………………………………………………. 
 
…………………………………………………………………………………………. 
 
 
Signature of operator:……………………………………….  Date:……………. 
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Appendix 7 – Epirubicin Surface Contamination Data 
 
Table 59. Amount of EPI Recovered from Isolator Surfaces during Baseline 1 and 2 
Area         Day and Sampling Point 
   1a 1b 1c 1d 2a 2b 2c 2d 3a 3b 3c 3d 4a 4b 4c 4d 
 
Baseline 1 (ng cm-2, or ng per sleeve) 
 Base   0.03 0.59 0.17 0.11 0.20 <0.002 0.09 0.08 0.08 0.07 0.05 <0.002 0.05 0.04 0.07 0.06 
 Door, outer (R)  ND 0.07 0.07 0.05 0.06 <0.003 ND ND ND ND ND ND ND ND 0.07 ND 
 Door, outer (L)  ND 0.01 <0.003 0.05 <0.003 ND <0.003 ND ND <0.003 ND ND ND ND 0.07 ND 
 Door, inner (R)  <0.003 0.08 <0.003 0.07 <0.003 0.06 ND ND <0.003 ND ND ND ND ND 0.07 ND 
 Door, inner (L)  0.003 0.08 ND 0.07 0.05 0.07 ND ND ND <0.003 <0.003 ND ND <0.003 <0.003 ND 
 Sleeve (R)  <2.0 711 89.5 90.5 106 41.0 41.5 ND 41.5 42.5 45.0 ND ND ND 49.0 ND 
 Sleeve (L)  ND 398 86.0 81.0 44.0 <2.0 <2.0 ND <2.0 <2.0 ND ND <2.0 <2.0 49.5 53.5 
 
Baseline 2 (ng cm-2, or ng per sleeve) 
 Base   ND ND ND ND ND <0.002 <0.002 ND <0.002 ND ND ND ND ND ND ND 
 Door, outer (R)  ND ND ND ND ND ND <0.003 ND ND ND ND <0.003 ND ND ND ND 
 Door, outer (L)  ND ND ND ND <0.003 ND <0.003 ND ND ND ND ND ND ND ND ND 
 Door, inner (R)  ND ND ND ND <0.003 <0.003 ND ND ND ND ND 0.05 ND ND ND ND 
 Door, inner (L)  ND ND ND ND <0.003 <0.003 <0.003 ND ND ND <0.003 ND ND ND ND <0.003 
 Sleeve (R)  ND ND ND ND ND ND <2.0 <2.0 ND ND ND <2.0 ND ND ND ND 
 Sleeve (L)  ND ND ND ND ND ND <2.0 <2.0 ND ND ND ND ND <2.0 ND ND
 
EPI LoD (ng cm-2) = 0.001 (base, hatch door), 1.0 ng per sleeve  
ND = not detected 
(R) = right 
(L) = left 
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Table 60. Amount of EPI Recovered from Isolator Gloves during Baseline 1 and 2 
Area        Collection Point (Day and Session) 
   1.1  1.2  2.1  2.2  3.1  3.2  4.1  4.2 
Baseline 1 (ng per glove) 
 Isolator glove, right 975  733  562  404  1,506  274  239  409 
 Isolator glove, left 857  837  636  1,932  1,094  321  218  423 
 
Baseline 2 (ng per glove) 
 Isolator glove, right ND  269  209  409  242  224  ND  ND 
 Isolator glove, left  ND  219  ND  1,591  210  1,830  ND  201 
 
EPI LoD = 2.0 ng per glove         ND = not detected 
 
Table 61. Amount of EPI Recovered from Surfaces Outside the Isolator during Baseline 1 and 2 
Area        Day and Sampling Point 
1a 1b 1c 1d 2a 2b 2c 2d 3a 3b 3c 3d 4a 4b 4c 4d 
 
Baseline 1 (ng cm-2) 
 Floor  <0.005 0.11 ND ND 0.09 0.09 0.10 <0.005 ND ND ND ND ND ND <0.005 ND 
 Tray in  0.06 0.07 0.06 0.19 0.06 0.06 ND ND 0.10 0.07 0.07 0.08 0.06 ND 0.08 0.07 
 Tray out <0.003 0.01 0.06 0.06 0.06 0.06 ND ND 0.06 0.07 0.06 0.06 0.05 ND 0.07 <0.003 
 
Baseline 2 (ng cm-2) 
 Floor  ND ND ND ND ND ND ND ND ND ND ND <0.005 ND ND ND ND 
 Tray in  ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND  
 Tray out ND ND ND ND ND ND ND ND ND <0.003 ND <0.003 <0.003 ND ND ND 
 
EPI LoD (ng cm-2) = 0.002 (floor), 0.001 (tray)     ND = not detected
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Table 62. Amount of EPI Recovered from Support Gloves during Baseline 1 and 2 
Area        Collection Point (Day and Session)  
   1.1  1.2  2.1  2.2  3.1  3.2  4.1  4.2  
 
Baseline 1 (ng per glove) 
 Support glove, right 3,600  926  1,319  205  12,823  1,148  225  165 
 Support glove, left 1,268  1,227  1,488  341  13,268  1,727  178  192 
 
Baseline 2 (ng per glove) 
 Support glove, right ND  ND  ND  ND  ND  ND  ND  ND 
 Support glove, left  ND  ND  172  168  ND  ND  ND  ND 
 
EPI LoD = 2.0 ng per glove         ND = not detected 
 
 
 
Table 63. Amount of EPI Recovered from Support Gloves during Intervention 1 and 2 
Area        Collection Point (Day and Session) 
 1.1  1.2  2.1  2.2  3.1  3.2  4.1  4.2  
 
Intervention 1 (ng per glove) 
 Support glove, right ND  ND  ND  ND  189  ND  ND  ND 
 Support glove, left 186  ND  ND  ND  1,046  ND  ND  ND  
 
Intervention 2 (ng per glove) 
 Support glove, right ND  ND  172  ND  82.0  ND  ND  ND 
 Support glove, left  177  ND  ND  ND  ND  167  ND  ND  
 
EPI LoD = 2.0 ng per glove         ND = not detected 
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Table 64. Amount of EPI Recovered from Isolator Surfaces during Intervention 1 and 2 
Area         Day and Sampling Point 
 1a 1b 1c 1d 2a 2b 2c 2d 3a 3b 3c 3d 4a 4b 4c 4d 
 
Intervention 1 (ng cm-2, or ng per sleeve) 
 Base   ND ND ND ND ND ND ND ND ND ND ND ND <0.002 ND ND ND 
 Door, outer (R)  ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
 Door, outer (L)  ND ND ND ND ND ND ND ND 0.09 ND 0.11 ND ND ND ND ND 
 Door, inner (R)  ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND <0.003 
 Door, inner (L)  ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
 Sleeve (R)  ND 41.0 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
 Sleeve (L)  ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
 
Intervention 2 (ng cm-2, or ng per sleeve) 
 Base   ND ND ND ND ND ND ND ND ND ND ND ND  ND ND ND ND 
 Door, outer (R)  ND ND ND ND ND ND ND ND ND ND ND ND  ND ND ND ND 
 Door, outer (L)  ND ND ND ND ND ND ND ND ND ND ND ND  ND ND ND ND 
 Door, inner (R)  ND ND ND ND ND ND ND ND ND ND ND ND  ND ND ND ND 
 Door, inner (L)  ND ND ND ND ND ND ND ND ND ND ND ND  ND ND ND ND 
 Sleeve (R)   ND ND ND ND ND ND ND ND ND ND ND ND  ND ND ND ND 
 Sleeve (L)   ND ND ND ND ND ND ND ND ND ND ND ND  ND ND ND ND  
 
EPI LoD (ng cm-2) = 0.001 (base, hatch door), 1.0 ng per sleeve  
ND = not detected 
(R) = right 
(L) = left 
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Table 65. Amount of EPI Recovered from Isolator Gloves during Intervention 1 and 2 
Area        Collection Point (Day and Session) 
   1.1  1.2  2.1  2.2  3.1  3.2  4.1  4.2 
 
Intervention 1 (ng per glove) 
 Isolator glove, right ND  ND  ND  ND  ND  171  ND  ND 
 Isolator glove, left ND  ND  ND  ND  ND  162  164  ND 
 
Intervention 2 (ng per glove) 
 Isolator glove, right ND  ND  ND  ND  ND  ND  ND  ND 
 Isolator glove, left  ND  ND  ND  161  ND  ND  ND  ND 
 
EPI LoD = 2.0 ng per glove         ND = not detected 
 
 
Table 66. Amount of EPI Recovered from Surfaces Outside the Isolator during Intervention 1 and 2 
Area        Day and Sampling Point 
1a 1b 1c 1d 2a 2b 2c 2d 3a 3b 3c 3d 4a 4b 4c 4d 
 
Intervention 1 (ng cm-2) 
 Floor  ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
 Tray in  ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
 Tray out ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND <0.003 
 
Intervention 2 (ng cm-2) 
 Floor  ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
 Tray in  ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
 Tray out ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
 
 
EPI LoD (ng cm-2) = 0.002 (floor), 0.001 (tray)     ND = not detected
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Table 67. Amount of EPI Recovered from Batches during Baseline 1 and 2 
      Syringe  
Batch  1 2 3 4 5 6 7 8 9 10
Baseline 1 (ng per syringe) 
 batch 2  ND ND ND ND ND ND ND ND ND ND 
 batch 4  54.5 66.0 43.0 43.0 47.0 78.5 52.0 60.0 42.0      46.0 
 batch 8  <2.0 ND <2.0 ND <2.0 ND <2.0 ND 41.5      <2.0 
 batch 12 ND ND ND ND ND ND ND ND ND ND 
 batch 14 <2.0 59.5 61.5 46.5 52.5 52.0 57.5 53.5 ND       <2.0 
 batch 16 40.0 ND <2.0 64.5 45.0 41.5 40.0 <2.0 <2.0    <2.0 
 batch 22 <2.0 <2.0 99.0 62.0 59.5 56.0 52.0 50.5 49.5      50.5 
 batch 24 ND ND ND 696 ND ND ND ND ND ND 
Baseline 2 (ng per syringe) 
 batch 2  ND ND ND ND ND ND ND ND ND ND 
 batch 4  <2.0 <2.0 <2.0 <2.0 <2.0 ND <2.0 ND ND       <2.0 
 batch 8  ND ND ND ND <2.0 <2.0 <2.0 ND ND ND 
 batch 12  ND ND ND ND ND ND ND ND ND ND 
 batch 14  ND ND ND ND ND ND ND ND ND ND 
 batch 16 ND ND ND ND ND ND ND ND ND ND 
 batch 22 1,807 53.0 46.0 44.0 49.0 41.0 41.0 40.5 40.5      92.0 
 batch 24 40.5 <2.0 <2.0 <2.0 <2.0 <2.0 <2.0 <2.0 <2.0     <2.0 
 
EPI LoD = 1.0 ng per syringe     ND = not detected 
 
Table 68. Amount of EPI Recovered from Batches during Intervention 1 and 2 
      Syringe  
Batch  1 2 3 4 5 6 7 8 9 10
Intervention 1 (ng per syringe) 
 batch 2  ND ND ND ND ND ND ND <2.0 <2.0 ND 
 batch 4  ND ND ND ND ND ND ND ND ND ND 
 batch 8  ND ND ND ND ND ND ND ND ND ND 
 batch 12 ND ND ND ND ND ND ND ND ND ND 
 batch 14 ND ND ND ND ND ND ND ND ND ND 
 batch 16 ND ND ND ND ND ND ND ND ND ND 
 batch 22 ND ND ND ND ND ND ND ND ND ND 
 batch 24 ND ND ND ND ND ND ND ND ND ND 
 
Intervention 2 (ng per syringe) 
 batch 2  ND ND ND ND ND ND ND ND ND ND 
 batch 4  ND ND ND ND ND ND ND ND ND ND 
 batch 8  ND ND ND ND ND ND ND ND ND ND 
 batch 12  ND ND ND ND ND ND ND ND ND ND 
 batch 14  ND ND ND ND ND ND ND ND ND ND 
 batch 16 ND ND ND ND ND ND ND ND ND ND 
 batch 22 ND ND ND ND <2.0 ND ND ND ND ND 
 batch 24 ND ND ND ND ND ND ND ND ND ND 
 
EPI LoD = 1.0 ng per syringe     ND = not detected 
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Appendix 8 – Methotrexate Surface Contamination Data 
 
Table 69. Amount of MTX Recovered from Isolator Surfaces during Baseline 1 and 2 
Area         Day and Sampling Point 
 1a 1b 1c 1d 2a 2b 2c 2d 3a 3b 3c 3d 4a 4b 4c 4d 
 
Baseline 1 (ng cm-2, or ng per sleeve)  
 Base   ND ND ND <0.04 ND ND ND ND 0.33 0.26 0.18 0.19 0.13 <0.04 <0.04 0.09 
 Door, outer (R)  ND ND ND <0.07 ND ND ND ND ND ND ND ND ND 0.07 <0.07 ND 
 Door, outer (L)  ND ND ND ND ND ND ND ND ND ND ND ND ND <0.07 <0.07 ND 
 Door, inner  (R)   ND ND <0.07 ND ND ND ND ND ND ND ND ND ND 0.10 ND 0.22 
 Door, inner (L)  ND ND ND ND ND ND ND ND ND ND ND ND  <0.07 <0.07 <0.07 ND  
 Sleeve (R)  ND ND ND ND ND ND ND ND ND ND <50.0 ND ND ND ND ND 
 Sleeve (L)  ND ND ND <50.0 ND ND ND ND ND <50.0 ND ND <50.0 <50.0 282 ND 
 
Baseline 2 (ng cm-2, or ng per sleeve) 
 Base   ND ND ND ND ND ND ND ND 0.60 ND ND ND 0.24 ND 0.27 0.24 
 Door, outer (R)  0.34 <0.07 <0.07 ND ND ND ND ND ND <0.07 ND ND 0.11 <0.07 ND 0.15 
 Door, outer (L)  0.11 <0.07 ND ND ND ND ND ND ND <0.07 ND ND 0.14 0.16 0.19 0.24 
 Door, inner (R)    <0.07 ND ND ND ND ND ND 8.04 ND ND ND ND 0.20 0.19 <0.07 0.08 
 Door, inner (L)  ND ND ND ND ND ND ND ND ND <0.07 ND ND 0.15 <0.07 <0.07 <0.07 
 Sleeve (R)  216 ND ND ND ND ND ND ND ND <50.0 102 ND 198 ND <50.0 ND 
 Sleeve (L)  191 <50.0 ND ND ND ND ND ND ND <50.0 158 ND  <50.0 ND 211 716 
 
MTX LoD (ng cm-2) = 0.02 (base), 0.04 (hatch door), 25.0 ng per sleeve  
ND = not detected 
(R) = right 
(L) = left 
 
 
 355
Table 70. Amount of MTX Recovered from Isolator Gloves during Baseline 1 and 2 
Area        Collection Point (Day and Session) 
   1.1  1.2  2.1  2.2  3.1  3.2  4.1  4.2  
 
Baseline 1 (ng per glove) 
 Isolator glove, right ND  748  ND  1,427  558  1,559  141  1,507 
 Isolator glove, left ND  856  ND  797  715  133  153  298  
 
Baseline 2 (ng per glove) 
 Isolator glove, right ND  ND  ND  ND  ND  ND  ND  748 
 Isolator glove, left  ND  ND  ND  ND  ND  ND  ND  750 
 
MTX LoD = 50.0 ng per glove        ND = not detected 
  
Table 71. Amount of MTX Recovered from Surfaces Outside the Isolator during Baseline 1 and 2 
Area        Day and Sampling Point 
  1a 1b 1c 1d 2a 2b 2c 2d 3a 3b 3c 3d 4a 4b 4c 4d 
 
Baseline 1 (ng cm-2) 
 Floor  ND ND ND ND ND ND <0.11 ND ND ND <0.11 ND ND ND ND <0.11 
 Tray in  ND ND ND ND ND ND ND ND ND ND ND <0.07 ND 0.19 <0.07 0.10 
 Tray out ND ND ND ND ND ND ND ND 0.14 0.21 <0.07 <0.07 ND ND <0.07 0.16 
 
Baseline 2 (ng cm-2) 
 Floor  11.3 ND ND <0.11 ND ND ND ND 0.68 ND ND ND ND ND <0.11 ND 
 Tray in  ND ND ND ND ND ND ND ND 0.08 <0.07 ND ND ND ND 0.07 ND 
 Tray out ND ND ND ND ND ND ND ND ND <0.07 ND ND ND ND <0.07 ND  
 
MTX LoD (ng cm-2) = 0.06 (floor), 0.04 (tray)     ND = not detected 
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Table 72. Amount of MTX Recovered from Support Gloves during Baseline 1 and 2 
Area        Collection Point (Day and Session) 
 1.1  1.2  2.1  2.2  3.1  3.2  4.1  4.2 
 
Baseline 1 (ng per glove) 
 Support glove, right ND  ND  ND  ND  ND  ND  ND  ND 
 Support glove, left ND  ND  ND  ND  ND  ND  ND  ND  
 
Baseline 2 (ng per glove) 
 Support glove, right ND  ND  ND  ND  ND  ND  ND  ND  
 Support glove, left  ND  ND  ND  ND  ND  ND  ND  ND 
 
MTX LoD = 50.0 ng per glove        ND = not detected 
 
 
Table 73. Amount of MTX Recovered from Support Gloves during Intervention 1 and 2 
Area        Collection Point (Day and Session) 
 1.1  1.2  2.1  2.2  3.1  3.2  4.1  4.2 
 
Intervention 1 (ng per glove) 
 Support glove, right ND  ND  ND  ND  ND  ND  ND  ND 
 Support glove, left ND  ND  ND  ND  ND  ND  ND  ND 
  
Intervention 2 (ng per glove) 
 Support glove, right ND  ND  ND  ND  ND  ND  ND  ND 
 Support glove, left  ND  ND  ND  ND  ND  ND  ND  ND 
 
MTX LoD = 50.0 ng per glove        ND = not detected 
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Table 74. Amount of MTX Recovered from Isolator Surfaces during Intervention 1 and 2 
Area         Day and Sampling Point 
 1a 1b 1c 1d 2a 2b 2c 2d 3a 3b 3c 3d 4a 4b 4c 4d 
 
Intervention 1 (ng cm-2, or ng per sleeve) 
 Base   ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
 Door, outer (R)  ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
 Door, outer (L)  ND ND ND ND ND ND ND ND ND ND ND ND <0.07 ND ND ND 
 Door, inner (R)  ND ND ND ND ND ND ND ND ND 0.07 ND ND ND ND ND ND 
 Door, inner (L)  ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
 Sleeve (R)  ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
 Sleeve (L)  ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
 
Intervention 2 (ng cm-2, or ng per sleeve) 
 Base   ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
 Door, outer (R)  ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
 Door, outer (L)  ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
 Door, inner (R)  ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
 Door, inner (L)  ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
 Sleeve (R)  ND ND ND <50.0 ND ND ND ND ND ND ND ND ND ND ND ND 
 Sleeve (L)   ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
 
MTX LoD (ng cm-2) = 0.02 (base), 0.04 (hatch door), 25.0 ng per sleeve 
ND = not detected 
(R) = right 
(L) = left 
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Table 75. Amount of MTX Recovered from Isolator Gloves during Intervention 1 and 2 
Area        Collection Point (Day and Session) 
   1.1  1.2  2.1  2.2  3.1  3.2  3.3  3.4  
 
Intervention 1 (ng per glove) 
 Isolator glove, right ND  ND  ND  ND  ND  ND  ND  ND 
 Isolator glove, left ND  ND  ND  ND  ND  ND  ND  ND 
 
Intervention 2 (ng per glove) 
 Isolator glove, right ND  ND  ND  ND  ND  ND  ND  ND 
 Isolator glove, left  ND  ND  ND  ND  ND  ND  ND  ND 
 
MTX LoD = 50.0 ng per glove        ND = not detected 
 
 
Table 76. Amount of MTX Recovered from Surfaces Outside the Isolator during Intervention 1 and 2 
Area        Day and Sampling Point 
1a 1b 1c 1d 2a 2b 2c 2d 3a 3b 3c 3d 4a 4b 4c 4d 
 
Intervention 1 (ng cm-2) 
 Floor  ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
 Tray in  ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
 Tray out ND ND ND ND ND ND ND ND ND ND ND ND 0.14 ND ND ND 
 
Intervention 2 (ng cm-2) 
 Floor  ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
 Tray in  ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
 Tray out  ND 0.39 0.35 ND ND ND ND ND ND ND ND ND ND ND ND ND 
 
MTX LoD (ng cm-2) = 0.06 (floor), 0.04 (tray)     ND = not detected 
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Table 77. Amount of MTX Recovered from Batches during Baseline 1 and 2 
      Syringe  
Batch  1 2 3 4 5 6 7 8 9 10 
Baseline 1 (ng per syringe) 
 batch 2  ND ND ND ND ND ND ND ND ND ND 
 batch 4  ND ND ND ND 205 ND ND ND ND ND 
 batch 8  ND ND ND ND ND ND ND ND ND ND 
 batch 12 ND ND 73.0 ND ND ND ND ND ND ND 
 batch 14 ND ND <50.0 ND ND ND ND ND ND ND 
 batch 16 ND ND ND ND ND ND ND ND ND ND 
 batch 22 ND ND ND ND ND <50.0 ND ND ND ND 
 batch 24 259 ND ND ND ND ND ND ND ND ND 
 
Baseline 2 (ng per syringe) 
 batch 2  ND ND ND ND ND ND ND ND ND ND 
 batch 4  ND ND ND ND ND ND ND ND ND ND 
 batch 8  ND ND ND ND ND ND ND ND ND ND 
 batch 12  ND ND ND ND ND ND ND ND ND ND 
 batch 14  ND ND ND ND ND ND ND ND ND ND 
 batch 16 ND ND ND ND ND <50.0 <50.0 ND <50.0 ND 
 batch 22 ND ND ND ND ND ND ND <50.0 ND ND 
 batch 24 ND ND ND ND ND ND <50.0 ND <50.0  <50.0 
 
MTX LoD = 25.0 ng per syringe   ND = not detected 
 
Table 78. Amount of MTX Recovered from Batches during Intervention 1 and 2 
      Syringe  
Batch  1 2 3 4 5 6 7 8 9 10 
Intervention 1 (ng per syringe) 
 batch 2  ND ND ND ND ND ND ND ND ND ND 
 batch 4  ND ND ND ND ND ND ND ND ND ND 
 batch 8  ND ND ND ND ND ND ND ND ND ND 
 batch 12 ND ND ND ND ND ND ND ND ND ND 
 batch 14 ND ND ND ND ND ND ND ND ND ND 
 batch 16 ND ND ND ND ND ND ND ND ND ND 
 batch 22 ND ND ND ND ND ND ND ND ND ND 
 batch 24 ND ND ND ND ND ND ND ND ND ND 
 
Intervention 2 (ng per syringe) 
 batch 2  ND ND ND ND ND ND ND ND ND ND 
 batch 4  ND ND ND ND ND ND ND ND ND ND 
 batch 8  ND ND ND ND ND ND ND ND ND ND 
 batch 12  ND ND ND ND ND ND ND ND ND ND 
 batch 14  ND ND ND ND ND ND ND ND ND ND 
 batch 16 ND ND ND ND ND ND ND ND ND ND 
 batch 22 ND ND ND ND ND ND ND ND ND ND 
 batch 24 ND ND 81.5 ND ND ND ND ND ND ND
 
MTX LoD = 25.0 ng per syringe   ND = not detected 
 
 360
Appendix 9 – Cyclophosphamide Surface Contamination Data 
 
Table 79. Amount of CP Recovered from Isolator Surfaces during Baseline 1 and 2 
Area         Day and Sampling Point 
 1a 1b 1c 1d 2a 2b 2c 2d 3a 3b 3c 3d 4a 4b 4c 4d 
 
Baseline 1 (ng cm-2, or µg per sleeve) 
 Base   ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
 Door, outer (R)  ND ND ND ND ND ND ND ND ND ND 117 ND ND ND ND ND 
 Door, outer (L)  ND ND ND ND ND ND ND ND ND ND ND 135 ND ND ND ND  
 Door, inner (R)   ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND  
 Door, inner (L)  ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND  
 Sleeve (R)   ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND  
 Sleeve (L)  ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND  
 
Baseline 2 (ng cm-2, or µg per sleeve) 
 Base   ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
 Door, outer (R)  ND ND 426 ND ND ND ND ND ND 269 174 ND ND ND ND ND  
 Door, outer (L)  ND ND ND ND ND ND ND ND ND 190 215 393 ND ND ND ND 
 Door, inner (R)  ND ND ND ND ND ND ND ND ND 302 368 982 ND ND ND ND  
 Door, inner (L)  ND ND ND ND ND ND ND ND ND 237 221 2,034 ND ND ND ND 
 Sleeve (R)   ND ND ND ND ND ND ND ND ND 304 264 ND ND ND ND ND  
 Sleeve (L)  ND ND 134 ND ND ND ND ND ND 278 266 ND ND ND ND ND  
 
CP LoD (ng cm-2) = 9.50 (base), 17.5 (hatch door), 12.5 µg per sleeve  
ND = not detected 
(R) = right 
(L) = left 
 
 
 361
Table 80. Amount of CP Recovered from Isolator Gloves during Baseline 1 and 2 
Area        Collection Point (Day and Session) 
   1.1  1.2  2.1  2.2  3.1  3.2  4.1  4.2  
 
Baseline 1 (µg per glove)  
 Isolator glove, right ND  ND  ND  ND  ND  ND  ND  ND 
 Isolator glove, left ND  ND  ND  ND  ND  ND  ND  ND  
 
Baseline 2 (µg per glove) 
 Isolator glove, right ND  ND  ND  192  ND  ND  ND  ND 
 Isolator glove, left  ND  ND  ND  ND  ND  ND  ND  ND  
 
CP LoD = 25.0 µg per glove        ND = not detected 
 
 
Table 81. Amount of CP Recovered from Surfaces Outside the Isolator during Baseline 1 and 2 
Area        Day and Sampling Point 
1a 1b 1c 1d 2a 2b 2c 2d 3a 3b 3c 3d 4a 4b 4c 4d 
 
Baseline 1 (ng cm-2) 
 Floor  ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
 Tray in  ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
 Tray out ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND  
 
Baseline 2 (ng cm-2) 
 Floor  ND ND ND ND ND ND ND ND ND 128 113 119 ND ND ND ND 
 Tray in  ND 383 72.6 384 ND ND ND ND ND 155 137 ND ND ND ND ND  
 Tray out ND ND 131 118 ND ND ND ND ND 137 74.7 ND ND ND ND ND 
 
CP LoD (ng cm-2) = 28.3 (floor), 18.0 (tray)     ND = not detected 
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Table 82. Amount of CP Recovered from Support Gloves during Baseline 1 and 2 
Area        Collection Point (Day and Session) 
 1.1  1.2  2.1  2.2  3.1  3.2  4.1  4.2 
 
Baseline 1 (µg per glove) 
 Support glove, right 756  410  1,063  1,125  1,216  1,186  ND  ND 
 Support glove, left 754  623  108  1,339  1,262  1,356  884  ND 
 
Baseline 2 (µg per glove) 
 Support glove, right 578  823  946  635  913  195  97.6  1,111 
 Support glove, left  946  893  843  874  678  944  612  866  
 
CP LoD = 25.0 µg per glove        ND = not detected 
 
 
Table 83. Amount of CP Recovered from Support Gloves during Intervention 1 and 2 
Area        Collection Point (Day and Session) 
 1.1  1.2  2.1  2.2  3.1  3.2  4.1  4.2 
 
Intervention 1 (µg per glove) 
 Support glove, right 96.0  315  724  1,146  694  453  456  385 
 Support glove, left 693  199  815  873  596  488  584  470  
 
Intervention 2 (µg per glove) 
 Support glove, right 334  395  812  728  407  46.0  865  788 
 Support glove, left  1,251  1,086  1,342  1,099  1,076  1,027  1,431  1,476 
 
CP LoD = 25.0 µg per glove   
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Table 84. Amount of CP Recovered from Isolator Surfaces during Intervention 1 and 2 
Area         Day and Sampling Point 
 1a 1b 1c 1d 2a 2b 2c 2d 3a 3b 3c 3d 4a 4b 4c 4d 
 
Intervention 1 (ng cm-2, or ng per sleeve) 
 Base   ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND  
 Door, outer(R)    ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND  
 Door, outer (L)  ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND  
 Door, inner (R)  ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND  
 Door, inner (L)  ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND  
 Sleeve (R)  ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND  
 Sleeve (L)  ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
 
Intervention 2 (ng cm-2, or ng per sleeve) 
 Base   ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
 Door, outer (R)    ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
 Door, outer (L)  ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
 Door, inner (R)  ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
 Door, inner (L)  ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND  
 Sleeve (R)  ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND  
 Sleeve (L)  ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
 
CP LoD (ng cm-2) = 9.50 (base), 17.5 (hatch door), 12.5 µg per sleeve  
ND = not detected 
(R) = right 
(L) = left 
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Table 85. Amount of CP Recovered from Isolator Gloves during Intervention 1 and 2 
Area        Collection Point (Day and Session) 
   1.1  1.2  2.1  2.2  3.1  3.2  4.1  4.2 
 
Intervention 1 (µg per glove)   
 Isolator glove, right ND  ND  ND  ND  ND  ND  ND  ND 
 Isolator glove, left ND  ND  ND  ND  ND  ND  ND  ND  
 
Intervention 2 (µg per glove) 
 Isolator glove, right ND  ND  ND  ND  138  ND  ND  ND 
 Isolator glove, left  ND  ND  ND  192  ND  ND  ND  ND 
 
CP LoD = 25.0 µg per glove       ND = not detected 
 
 
Table 86. Amount of CP Recovered from Surfaces Outside the Isolator during Intervention 1 and 2 
Area        Day and Sampling Point 
1a 1b 1c 1d 2a 2b 2c 2d 3a 3b 3c 3d 4a 4b 4c 4d 
 
Intervention 1 (ng cm-2) 
 Floor  ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND  
 Tray in  ND ND ND ND ND ND ND ND ND ND ND ND 64.7 65.5 214 ND 
 Tray out ND ND ND ND ND ND ND ND ND ND ND ND ND 66.1 183 ND 
 
Intervention 2 (ng cm-2) 
 Floor  ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
 Tray in  ND ND ND ND ND ND ND ND ND ND 66.1 91.2 ND 68.2 66.8 ND 
 Tray out ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND  
 
CP LoD (ng cm-2) = 28.3 (floor), 18.0 (tray)     ND = not detected
 365
Table 87. Amount of CP Recovered from Batches during Baseline 1 and 2 
      Syringe  
Batch  1 2 3 4 5 6 7 8 9 10 
Baseline 1 (µg per syringe) 
 batch 2  ND ND ND ND ND ND ND ND ND ND 
 batch 4  ND ND ND ND ND ND ND ND ND ND 
 batch 8  ND ND ND 35.5 41.5 ND ND ND ND ND 
 batch 12 ND ND ND ND ND ND ND ND ND ND 
 batch 14 ND ND ND ND ND ND ND ND ND ND 
 batch 16 ND ND ND ND ND ND ND ND ND ND 
 batch 22 ND ND ND ND ND ND ND ND ND ND 
 batch 24 ND ND ND ND ND ND ND ND ND ND 
 
Baseline 2 (µg per syringe) 
 batch 2  ND ND ND ND ND ND ND ND ND ND 
 batch 4  ND ND ND ND ND ND ND ND ND ND 
 batch 8  ND ND ND ND ND ND ND ND ND ND 
 batch 12  ND ND ND ND ND ND ND ND ND ND 
 batch 14  ND ND ND ND ND ND ND ND ND ND 
 batch 16 ND ND ND ND ND ND ND ND ND ND 
 batch 22 ND ND ND ND ND 57.5 59.5 74.0 75.0 ND 
 batch 24 ND ND ND ND ND ND ND ND ND ND 
 
CP LoD = 12.5 µg per syringe   ND = not detected 
 
 
Table 88. Amount of CP Recovered from Batches during Intervention 1 and 2 
      Syringe  
Batch  1 2 3 4 5 6 7 8 9 10 
Intervention 1 (µg per syringe) 
 batch 2  ND ND ND ND ND ND ND ND ND ND 
 batch 4  ND ND ND ND ND ND ND ND ND ND 
 batch 8  ND ND ND ND ND ND ND ND ND ND 
 batch 12 ND ND ND ND ND ND ND ND ND ND 
 batch 14 ND ND ND ND ND ND ND ND ND ND 
 batch 16 ND ND ND ND ND ND ND ND ND ND 
 batch 22 ND ND ND ND ND ND ND ND ND ND 
 batch 24 ND ND ND ND ND ND ND ND ND ND 
 
Intervention 2 (µg per syringe) 
 batch 2  ND ND ND ND ND ND ND ND ND ND 
 batch 4  ND ND ND ND ND ND ND ND ND ND 
 batch 8  ND ND ND ND ND ND ND ND ND ND 
 batch 12  ND ND ND ND ND ND ND ND ND ND 
 batch 14  ND ND ND ND ND ND ND ND ND ND 
 batch 16 ND ND ND ND ND ND ND ND ND ND 
 batch 22 ND ND ND ND ND ND ND ND ND ND 
 batch 24 ND ND ND ND ND ND ND ND ND ND
 
CP LoD = 12.5 µg per syringe   ND = not detected 
 
 
